<SEC-DOCUMENT>0001711279-22-000047.txt : 20220808
<SEC-HEADER>0001711279-22-000047.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808075049
ACCESSION NUMBER:		0001711279-22-000047
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220808
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		221142594

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krys-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77,d:7e672fe7391d467f924465926b4c2682--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:krys="http://www.krystalbio.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV8zLTEtMS0xLTI3MjM0_6fdd4a15-d3c7-449f-80f0-9a5cf15182c1">false</ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV81LTEtMS0xLTI3MjM0_559ce2e8-bcfc-47be-818b-23bfca94262d">2022</ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV82LTEtMS0xLTI3MjM0_8eafcea0-782a-4e32-b64e-f220cb90eee5">Q2</ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV85LTEtMS0xLTI3MjM0_7bb98eaf-b1ab-4aac-9873-4be85914cea1">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV8xMC0xLTEtMS0yNzIzNA_b4bd065c-4b11-4559-aece-cc5ef63cc560">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i83a3fd81529e4a88b0a3828660a59f92_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68056f7be4b3479a8698326d9f76b95b_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id9e4439435f24487b699ba4fbdccaff9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e3e5b1d1904de1ab6caf2253008d57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5ffa4369814ee099cdeb5c269a22a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i167177dab94c4db6a7199e7c88c61883_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96d0e39fa84848fd83a65fbedcbd9193_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4776963ce5424903852057d81548f3d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id292fcdfa2ec483991762030cda62567_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd501c8dcab465e8865f8990e84b682_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4799c83f8064ebaa62e85e4da5639e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab00efeb6ef4be2900da03084a5a9d4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ebd4532229468281c822de2a5e657c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f1e0e5c44a4cfe96d8a13d20f90db7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f8ca7c434f4946a365bbaa9a9d8bce_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22db7b29d7e4ece89a75e653bd2115f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id814f4669c3d4394a7130b5293e3c8a6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775cfbfdc6864e3cb405ab41f9c0eb16_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb89f313eb14a259062ad4a9df63ca2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c29c2ed7724e3f9034ecf0a95d902e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076da2ca9712409eb1f14f99f5da94d6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dbf9c0f040d4dc69fe77d188302bf6b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e05fc289824b83b4328d58ee1c1b1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bdfa279d35d4560b16eb6696604d967_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e70fa1b51374c78acd66828c63b4cee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d42d81e0d64f339007558ceec6d457_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025425ccecb5443b909699e65613a02c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia784962b1a35445abaf692d9da0f8b7c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472f7c3bc8534d648bd470f561540a57_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb9d19bc36946b7a2b39686906270ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia88065ac15b8425ba0dc82f5b062b440_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996e16354ef64539bf61d8bc11b8baf6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60d5bf962dba470ab3a4481875ff9d28_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da18ba1fb574a9c80c2ef998e02b45b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6eeb4e61f234a01a966fc80ccd9a356_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7a3cc2b19144a7acff545065372722_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74ef1968bb10424d945aad572a1eebe8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83b183ffa7240659fcc27d5a7aa5c0e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c755555716244b396f922347ef2dc75_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4702597e5e480a9bc82eb00ce29108_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7198d64a2d734ca3839ec28f8cc1be55_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40e7fd3b4ff64b319e3403886234d050_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7496fd6b01444da889610d00b68a0e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="iab27a23368df44c0b545b31a362ffad0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72afdcf0cb6547a990fc6bb8f48b7521_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5d94d6062c49e2b1db8c7414a71a7e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69cd7bb89554aa38e45742bc5b22eb2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice52f49beadd49d5861085be75f4b8a0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b630056ae3492b8a0991e9b5343757_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8721aeb105fc4c238df1588239e9c101_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f2c361f936d4f35898fb47c6618dcf8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39c1f1d7ae6452eabc0f676318ed72a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0b896d15f540bd9cd89d793a7b3dd9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e86db60e52a433cabc5c934bf137fd1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d892ea64f341f094f64a0244811282_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4680df6fdb6448fe89234b2525155c51_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b201c5d548540d7bff79745cf60be1d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic54be4b4a31245cfa953f2ed8fcbabb1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0408fc3248f94e58a9239a4ddda6b92c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ffb971f777745b180e887cf34cc8df6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc97aeb2c0514e00a399738e538f2fe7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f691466f4f4614820d160aeb87931d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14b5c1cb46b44daa8d2c7200a170896_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10ba9e6940c4bcab91bee5cdf0f1577_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15568dc832834ddaaefabea39a936bcb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89e6376ee9b402191dd9c876f00ffd1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685fdfb571504f15be2ba3d2c639db0d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f864a31b3d847e786f7d911b5e088ba_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4792758104f47bfbfdd2f1ff6cc0f56_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id87854e9024645be88d96e81c1d80ce7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if698ad0c6a754e11892e9ad283a72091_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ae7de2a25e4d8f9c91182ae7bd789a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8f78f72c5f44daa3c018883cf88bc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea1041fd3974f6cbd157670806fb0b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7652f0186854d3eb2df5a9678980d1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5248a77fa14049cf940a8cd1b7fef935_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56331706bfb4519876ce6149c9d3899_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4757de934847a3b5d4eb65e4f812c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef97546d258466e8f022a081bfec632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ebc1166b3d48708f5ffd968b17c9cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ac529d98474127860b5706cc0a4e57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19f873a9b5ad47d6bb38039da03ea567_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7253ed7785a94823a46ec4162da143ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5f33620a0044aaaa5c0668e4413da8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075af6a44d40468781a120b2d5467942_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe24770e30b4ee5b669d117e9f452b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4223978e6e4043b43792467895392c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02db18a6f9842168a740bb3825c2f42_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1d4e05d43f4749b3b95a6990387f23_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dbf144cc1344bc88a90e137beec2ff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5474e41a39a4279ada916abbc519671_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6353eacee0474f88b8a107b02b1652_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aa852ef45a845dda2da256ef25ae970_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e9dbd4ee4e647aeaa50ea67ae6bab6a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if59b699ffbf74fb6b067fb3fd3d26948_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f288e08976b441381de343a114c23bc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id831f855902e4ca8a26e06da3c94f9ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0781359c8a514003ad12a9168fd9fc32_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a061e6cc0574956ae21bc486e71b175_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5217315fdc425a8f055a9896bfb0af_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ieb2b2a6f833a41e0b4880780fe93e686_I20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i119efa4588394a448de123d82168c14b_I20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i827059c44d894d608fa87db88be3f1d6_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d8365f8ec064a42b301d193885831a0_I20220516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26a85807415641c1bbd4c16458db46d6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4c19202a764797b2b092b8f85d150c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibef597c9a74640cfae1769e2be78cba6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eac4d8ff1bc4caf99aefef1cdf232b8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3195ecfb794e2588cdb48c9b9e1fab_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f4b750dd5b41018b6987ded07fec01_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7bff06aaa0b4172b5a7fc7c324cb8d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbfc5ceb794438b99f03eab41975dd2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd330d2d7b434eadb065cd5a8d7e8433_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a8f2da70c8489bbe7c8d73255d7a0e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88eeda34427444d59f2632f3fe3ce3c3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fac24ea1814a04a46df8a1f2b0307d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbc1d20961ac429694a43623cb59dc7f_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8396aa2f370f4359935ac37bbca1ca43_D20220428-20220428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-28</xbrli:startDate><xbrli:endDate>2022-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>krys:milestone</xbrli:measure></xbrli:unit><xbrli:context id="ic0a6b6780e2744a78177e645108c3643_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec561b9438fc47fa9736b2ab0dfa6e25_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93ab2eb0c5b47bea0598419ed1fce33_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8283d8f8c4374e57ae8f04c23b4b7428_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c54249f9c4e49ee9c88d0b3e52be617_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec04e4bd030243cd8732d95021dd1a4a_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb2ca34f0ed04200a5c092337ff47225_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic988cc831aa04c98a4a7c73bda3df147_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie404abea35ec4537a1e5ce4db74c5ab6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c43b6d200f4a04b123151eded83516_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a266617fb74011b52795116bde11a2_D20220405-20220405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74bd7dcda88044e8bdc02d6eb3e42a31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if777d493610b46fea5b70595880f2427_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eb9b132e2e8429691c1fde0ba1c9948_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e198d54f3db4e3e9cc8a6aa406b6115_I20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214b57f548b54a76aea79ee58885eda6_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb77696fe7a4014a844960177bee7df_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9051ae2ee8f6429e8c5caaf5ba0b9a3b_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a3fd81529e4a88b0a3828660a59f92_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa739c94f7e4421b824446b65ca0970b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5e85dd3f394163a17aa2a7a2882596_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf15c469b0c14c2b8d582745c8548a55_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9562a91cca5a4feeabc3e61cfce17db9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63b754f6b02141f7aeffcecd25d8ee9f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ecba4f425444fab5675e6879c78727_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3cd2503a6d4c0d87ab6c13960cd2bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0801eb6aaac14234813d62b72db774ad_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49480057f2645a7bdae78e27c951b23_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67d27acccab4cc7b6215d625269df36_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43306d588f4a45bab466ead6783424bc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97b468c91f394f3982302387c06cb4bb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58302432af964373a1478c96983fa353_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idced79ac55904d99a6ebfa0dcd88778a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8924a2fba7e24e789eae274f8598c078_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f7d144aaf64425a30d562e60e9c259_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218c57c0818b4e67b3e40d185226720b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia77dada28a724687b986b05a7dc8d862_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0203af48a23c4ada819dd5d73122c9e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75647732fba42e284fe467cf75d3e9e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c44a0f0edbf4e42a4210967f72907b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12dcce19b02242d3a86e91bf7df20519_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i973bbe15b2c641d79452fafa91f79ca3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232a7ab61f1e47368c74babe3c12332d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503211a1f9354a229ff0440c90d6d24f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f7b33d629c41b8a67324d2e7bb83ff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f6fa04b56749b38d5db99c77ee8cf9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic087ec71aa444b14b0f99f1a179b4d7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7e672fe7391d467f924465926b4c2682_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY4_5c167b63-6ddc-41b1-8049-053543e3d104">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YTBjNTY2MzM2MjFmNGI4M2ExZmM0YWUyZWZhNmY4N2QvdGFibGVyYW5nZTphMGM1NjYzMzYyMWY0YjgzYTFmYzRhZTJlZmE2Zjg3ZF8wLTAtMS0xLTI3MjM0_f611a45f-6fa1-4004-b573-aa438fc390b4">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDI_74116ef6-6b07-4445-9fa7-6c2310b98f34">June&#160;30, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MzIxNWEyZDMyMGVjNDViN2IwOGNhMzhkODhhMDg5NWIvdGFibGVyYW5nZTozMjE1YTJkMzIwZWM0NWI3YjA4Y2EzOGQ4OGEwODk1Yl8wLTAtMS0xLTI3MjM0_7b25fbe2-f830-4b8b-b584-8b6dc3e3201d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY5_8d75484b-6cd3-4c59-bfdb-e0beca2bca8a">001-38210</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcw_20018c02-8098-4ad0-8273-19496b0812c7">Krystal Biotech, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YmM3NDczOWI4MDRkNGFmMTg5YjgwNTBhMWRmYmYyOGEvdGFibGVyYW5nZTpiYzc0NzM5YjgwNGQ0YWYxODliODA1MGExZGZiZjI4YV8wLTAtMS0xLTI3MjM0_e51ddb8f-0d6d-4dec-a033-136a975077d3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YmM3NDczOWI4MDRkNGFmMTg5YjgwNTBhMWRmYmYyOGEvdGFibGVyYW5nZTpiYzc0NzM5YjgwNGQ0YWYxODliODA1MGExZGZiZjI4YV8wLTItMS0xLTI3MjM0_99fcc043-1ef7-48b1-a95d-90deb1a90705">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDU3_c6d77d65-a488-4e8e-bc6c-d8fc6dd00828">2100 Wharton Street</ix:nonNumeric>, <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYz_e4d9be06-c7f8-4a9b-8bbf-e937455cf524">Suite 701</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY0_d7c024a0-0642-4782-bbcb-08891af2b26c">Pittsburgh</ix:nonNumeric>, <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYw_ca3a8f27-0090-4c35-b48b-2c9bbd186846">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV81OTk_e93859e0-dd0b-4aa1-8d12-b2e2397aa786">15203</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcx_c1ee6b70-fa68-49e4-910f-b31d4468355c">412</ix:nonNumeric>) <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYx_1e28941f-9c7a-4943-b751-07b78511dca4">586-5830</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTAtMS0xLTI3MjM0_179fce0e-92cd-463f-970e-cbcb74e5332a">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTEtMS0xLTI3MjM0_b7916cba-d7c4-4863-9a9e-84732f242fb8">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTItMS0xLTI3NTE2L3RleHRyZWdpb246ZDA2YWRkOTdmMjBiNGQ1NDgwMzAxNWE1NTEyMDE1OWFfMjc0ODc3OTA2OTQ3MQ_2bf43e16-cf37-4184-912b-f29ed47b1871">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcy_f3e37647-4c0f-493c-8f3f-900edd326ad3">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcz_7775e76a-f013-4970-833d-7909cb2bae91">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6NDQ3N2Y0Y2I0ZmU2NDY5NzgyMWM2NDc4OTRmNmFiZmYvdGFibGVyYW5nZTo0NDc3ZjRjYjRmZTY0Njk3ODIxYzY0Nzg5NGY2YWJmZl8wLTAtMS0xLTI3MjM0_4a880ad5-9028-4a81-8213-2f3daffd30e8">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6NDQ3N2Y0Y2I0ZmU2NDY5NzgyMWM2NDc4OTRmNmFiZmYvdGFibGVyYW5nZTo0NDc3ZjRjYjRmZTY0Njk3ODIxYzY0Nzg5NGY2YWJmZl8xLTYtMS0xLTI3MjM0_cf73fdba-f0bd-41f4-8e0a-4f74c835c3f7">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDc0_af0848ec-cf6b-4da5-aeff-349c8f260775">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY3_177f77d0-3e92-4a8e-90f0-49660579d68a">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of July&#160;29, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i68056f7be4b3479a8698326d9f76b95b_I20220729" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yMzkw_942df92f-97a6-4ab3-b25a-4bca1d225fd6">25,664,287</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_16">Ju</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_16">ne 30</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_16">, 2022 and December 31, 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19"> and </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19">Six</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19">June</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19">0</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_19">, 2022 and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">and Six </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">June</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">0</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_22">, 2022 and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25">Six</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25">June</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25">0</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_25">, 2022  and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_58">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_58">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_82">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_82">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_85">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_85">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_91">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_91">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_94">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_97">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_100">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_100">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_103">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_106">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_106">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_109">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_109">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7e672fe7391d467f924465926b4c2682_112">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7e672fe7391d467f924465926b4c2682_112">34</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i7e672fe7391d467f924465926b4c2682_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i7e672fe7391d467f924465926b4c2682_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNC0xLTEtMS0yNzIzNA_dfc32626-f092-4747-bc9f-7439e1ac38a6">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNC0zLTEtMS0yNzIzNA_62991d70-4ca9-4551-b53d-020ef9b14844">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNS0xLTEtMS0yNzIzNA_49739589-ab7f-4a3d-b2f3-7a4764db5002">206,845</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNS0zLTEtMS0yNzIzNA_75ba888b-b1fe-4377-949a-08a89a2ecbc9">96,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNi0xLTEtMS0yNzIzNA_317a46e4-8c65-4b85-8074-349a92198960">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNi0zLTEtMS0yNzIzNA_4cbed537-54f9-45f0-97f6-1142696198bd">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNy0xLTEtMS0yNzIzNA_78f99d7e-4409-4378-bd74-8941ff8d28de">428,770</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNy0zLTEtMS0yNzIzNA_9048a4d0-2904-4992-a2db-e784096ff5bc">442,267</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOC0xLTEtMS0yNzIzNA_a424c649-4308-4652-87cd-402b30fbec36">151,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOC0zLTEtMS0yNzIzNA_79e17724-daba-4405-ade0-d20d135d4699">112,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOS0xLTEtMS0yNzIzNA_2519ee6d-25a4-42bb-b685-11db3b6ed87b">12,902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOS0zLTEtMS0yNzIzNA_44c48bdb-f26f-47b0-9a7d-89d45bbf4a6b">64,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTAtMS0xLTEtMjcyMzQ_17d94e48-fd4c-44f4-91d3-64e6bc9ea6c3">8,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTAtMy0xLTEtMjcyMzQ_97461511-dcf7-45ad-85bd-e728c548edcc">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTEtMS0xLTEtMjcyMzQ_52fbd131-d9cf-42b1-a5f3-64f9c291943d">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTEtMy0xLTEtMjcyMzQ_01e09fe6-b8b4-45e1-a665-335e265af1fb">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTItMS0xLTEtMjcyMzQ_0f0a15c0-e601-4f9d-8e8d-5f77b7def00b">601,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTItMy0xLTEtMjcyMzQ_fdda5e44-ce45-4cab-b5fb-1bda832d4f20">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTUtMS0xLTEtMjcyMzQ_4477da43-8eab-418f-a050-1cdf57508116">9,229</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTUtMy0xLTEtMjcyMzQ_0caeb453-5c4c-4a07-a66e-9d20abc485fd">8,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTYtMS0xLTEtMjcyMzQ_8b29ced9-49a0-430b-81af-f1ac1a56bef7">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTYtMy0xLTEtMjcyMzQ_946d5a91-27c8-4bbf-8462-a2a90ea62427">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTctMS0xLTEtMjcyMzQ_23bd0690-3313-4252-9188-518709b9d394">23,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTctMy0xLTEtMjcyMzQ_1ff23735-203d-4263-a8b1-5f4446ee4210">16,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTktMS0xLTEtMjcyMzQ_2a6ca057-9996-4747-be80-9b2ab91a8db6">34,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTktMy0xLTEtMjcyMzQ_111795e6-f27a-4371-9e45-2f38a39ddde2">25,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjAtMS0xLTEtMjcyMzQ_77e1ab45-52c8-460c-af13-71244606d3a2">7,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjAtMy0xLTEtMjcyMzQ_376d2283-b99b-4043-8095-2b24bd965492">6,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjEtMS0xLTEtMjcyMzQ_16fc6bf6-a7bc-4870-88c2-10389dff4c8c">42,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjEtMy0xLTEtMjcyMzQ_be8ac43b-c9c0-4397-ab7c-02e2afba7826">32,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjItMS0xLTEtMjcyMzQ_abd022c3-280b-4eeb-8919-626e2eab0823"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjItMy0xLTEtMjcyMzQ_0479eb0a-d732-4416-9ffb-cec62f3ff5de"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8yMQ_615adb7a-7c93-4cc0-9adf-ed29367f4377"><ix:nonFraction unitRef="usdPerShare" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8yMQ_e6c29695-ae9d-4c66-9f5c-650d75196e26">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8zNQ_2e661dfb-f327-4fe7-8081-dde791e71f61"><ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8zNQ_a7188df8-97ad-4691-b59a-162fc99acc1c">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV84NQ_011f6469-a20a-49f8-bbd3-5c66a70fdc9d"><ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV84NQ_30813da5-5e14-492a-8391-273ffb5897bd">2,061,773</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued, and <ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8xMTA_47c7589e-05de-42b1-94b9-a8d75101dfa0"><ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8xMTA_81f20923-60d5-44d8-8b68-51cf92122c20">no</ix:nonFraction></ix:nonFraction> shares outstanding at June&#160;30, 2022</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited) and December&#160;31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMS0xLTEtMjcyMzQ_6ed31d88-b5db-40cc-9411-b1e5f6e6012f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMy0xLTEtMjcyMzQ_3dbbe955-10e7-4675-9115-74100dd70bd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xOA_3531db79-c46e-47cf-9f19-9b7ce240114f"><ix:nonFraction unitRef="usdPerShare" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xOA_3ed36b70-6e92-4a1c-ae3f-dea60d685d00">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8zMg_4b1a32cc-160e-4466-8db2-c0b8388fd666"><ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8zMg_d0eba9e0-fbea-4fe2-85cf-d8869ae54a75">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF84Mg_3d0ee1e4-878d-4c1c-96c3-fba848086b28"><ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF84Mg_77e14ac1-744b-4723-97f6-bc92b20ba574">25,664,287</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued and outstanding at June&#160;30, 2022</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited); and <ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xNDQ_036a5c68-1adb-4843-b7d8-545647026d61"><ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xNDQ_96e80d87-cdf7-46d0-a3dc-9e7c4501388f">25,207,985</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMS0xLTEtMjcyMzQ_4a495282-f5e7-4822-971a-3e4162c8b1da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMy0xLTEtMjcyMzQ_223389c1-d024-4282-8a2e-72917b1ad615">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjYtMS0xLTEtMjcyMzQ_2593544e-a5c8-4fad-8a16-3955a2c7c97e">779,583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjYtMy0xLTEtMjcyMzQ_5e967671-6f91-4c91-bb9e-a529d63d85f4">734,523</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjctMS0xLTEtMjcyMzQ_2e865d8d-2572-4da9-af16-acb6cbfefdaf">1,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjctMy0xLTEtMjcyMzQ_2eb8ab28-aec5-4dfe-a6be-aadb9fa1484d">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjgtMS0xLTEtMjcyMzQ_5f50a027-45d3-4df7-90b0-86d74b518e0b">218,857</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjgtMy0xLTEtMjcyMzQ_15713005-24c2-4d43-bf91-cffa19ca4874">140,784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjktMS0xLTEtMjcyMzQ_67e40293-1ba6-41d3-beaf-b2b554112b4f">559,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjktMy0xLTEtMjcyMzQ_3a12f2c2-9f37-49ad-9f10-462519c4918e">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMzAtMS0xLTEtMjcyMzQ_eae61aee-b593-440f-a628-55384d6c30dc">601,324</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMzAtMy0xLTEtMjcyMzQ_1aa7b8a6-ed08-4915-abdf-658f8480b39e">626,295</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy0xLTEtMS0yNzIzNA_5b6c246e-cece-45c6-956e-e6f0ea2670ff">10,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy0zLTEtMS0yNzIzNA_c36676cd-2c17-4c7d-b45d-97737227db34">6,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy01LTEtMS0yNzIzNA_9c8bab31-c8ed-4365-886d-139b408a32fa">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy03LTEtMS0yNzIzNA_e5a29b32-9cb6-4ca3-9614-21b3384453d1">12,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC0xLTEtMS0yNzIzNA_cccb80cc-c80e-4be0-988e-d93f3af92abb">17,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC0zLTEtMS0yNzIzNA_4f421ccc-8715-4100-9ef0-b8e5704bc900">9,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC01LTEtMS0yNzIzNA_4c2efd6e-7c2d-4a98-9bbd-f988fd9c6d74">33,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC03LTEtMS0yNzIzNA_10585a04-6119-4e7f-822c-6e3bb93a7338">17,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS0xLTEtMS0yNzIzNA_629b7e4f-e66f-4bb6-b9e4-b570a34ced9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS0zLTEtMS0yNzIzNA_30847c4d-825c-467e-bf82-ea803504b1c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS01LTEtMS0yNzQ3Mg_98e4caf0-d46d-4171-aa6b-84250dc579fd">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS03LTEtMS0yNzU1MA_0e2fff76-7918-4c86-bf91-cefb5b8a0961">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi0xLTEtMS0yNzIzNA_1fd6d396-7728-49b0-8085-65c4102f9e58">28,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi0zLTEtMS0yNzIzNA_496a81d1-9793-4a48-bbac-74a0930e9bdd">16,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi01LTEtMS0yNzIzNA_25ff0f71-3af0-43b4-a136-987e21207bd1">78,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi03LTEtMS0yNzIzNA_78dc4086-fe55-4711-9202-a5094c67de6e">30,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy0xLTEtMS0yNzIzNA_7472100a-61e5-4c8e-b805-2171958ad031">28,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy0zLTEtMS0yNzIzNA_011455f0-fc0f-4179-b942-f1fb940bdf22">16,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy01LTEtMS0yNzIzNA_8866ad4d-0c24-4236-8638-554e973b8f46">78,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy03LTEtMS0yNzIzNA_0df8ef26-335c-44ad-8220-a24f38f0ff63">30,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS0xLTEtMS0yNzIzNA_be568257-b4a7-4aae-b418-7e8bbf5240b6">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS0zLTEtMS0yNzIzNA_4c9a764f-ff4c-4353-abcd-089188af89e7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS01LTEtMS0yNzIzNA_415a438f-90d9-4be4-91e2-8a71c73e036e">902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS03LTEtMS0yNzIzNA_85f00e5b-f1ee-419c-9f5f-3add3bdb6bf3">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtMS0xLTEtMjcyMzQ_95b1ea3e-b69e-4702-8864-b7bc26b41b63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtMy0xLTEtMjcyMzQ_5c99137b-0969-4487-ab3c-8dd434a76988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtNS0xLTEtMjc1MTA_5c640e2f-3bf4-4dd2-a55b-c3e85242c56e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtNy0xLTEtMjc0OTg_39eeb8bd-4e35-4c57-a379-ac16205ae24a">1,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtMS0xLTEtMjcyMzQ_7ef4d382-1e39-4e95-b962-036a81ab8612">28,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtMy0xLTEtMjcyMzQ_603eac28-cff5-4f47-b1b4-295442d30acc">16,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtNS0xLTEtMjcyMzQ_6b95216f-fdb3-4cd8-8a4a-0e80717a6312">78,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtNy0xLTEtMjcyMzQ_2ef5f6ae-e679-419c-a59c-d7b81958fa5c">32,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities and currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItMS0xLTEtMjcyMzQ_8e88be3e-8edd-467b-8355-c759a16df35d">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItMy0xLTEtMjcyMzQ_361cc5ee-b4f8-4731-a8ab-8e4c48d43268">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItNS0xLTEtMjcyMzQ_ea8108a0-556e-4e75-9957-6fa01e023b3b">1,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItNy0xLTEtMjcyMzQ_470faf55-1964-43e2-95dc-93ef4f2ca427">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtMS0xLTEtMjcyMzQ_e1e0565b-9e91-45f0-8f21-2c30730adaab">28,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtMy0xLTEtMjcyMzQ_4d199bed-9bd7-408e-9ef0-a81b0aeb3eb7">16,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtNS0xLTEtMjcyMzQ_8635b489-3139-41ae-8d54-6c0744c7b50e">79,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtNy0xLTEtMjcyMzQ_2119bbe3-fd4c-4e5e-bb2e-cf5c03c07508">32,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMS0xLTEtMjcyMzQ_5de68f6a-3263-445e-b414-676586554d46"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMS0xLTEtMjcyMzQ_c674fd95-db47-467d-bc9c-1bf40ff70be2">1.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMy0xLTEtMjcyMzQ_4a6b08c0-4c17-4cc2-a8b6-ca86e2c7cb45"><ix:nonFraction unitRef="usdPerShare" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMy0xLTEtMjcyMzQ_c7b6f53c-b546-409e-86c4-5291cf42a407">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNS0xLTEtMjcyMzQ_38dbf8f1-1700-4611-a3f3-c5456db0f0d3"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNS0xLTEtMjcyMzQ_b9c25a00-f575-45ad-82c3-1546193cbd89">3.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNy0xLTEtMjcyMzQ_376d3ba4-0203-461a-8499-f4fa7531f95a"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNy0xLTEtMjcyMzQ_a25499e3-f91c-4657-8e78-69dad535f0af">1.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMS0xLTEtMjcyMzQ_4f7aae96-d6e0-4c1f-adc1-bf4dd6ede550"><ix:nonFraction unitRef="shares" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMS0xLTEtMjcyMzQ_9acc3572-5dbf-40ae-9598-e2b80133ce97">25,545,167</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMy0xLTEtMjcyMzQ_4b84cedc-44c1-4b67-a8d3-0a8bd6a6feab"><ix:nonFraction unitRef="shares" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMy0xLTEtMjcyMzQ_bc88cf0c-ca4c-47bd-9a3b-24fa48f3015b">22,204,659</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNS0xLTEtMjcyMzQ_4a79331f-b06e-4d64-96c5-2a5fcf45cbd3"><ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNS0xLTEtMjcyMzQ_eada6cbd-f90e-4800-8d7d-6ad57cef350a">25,331,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNy0xLTEtMjcyMzQ_1ba42434-8e88-4634-aee4-73149568e6f1"><ix:nonFraction unitRef="shares" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNy0xLTEtMjcyMzQ_f72a6827-9306-46d7-b473-39c25f63079c">21,731,711</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5e3e5b1d1904de1ab6caf2253008d57_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0xLTEtMS0yNzIzNA_86903754-de0c-4cfb-8b7a-318ba2e80eb0">25,207,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e3e5b1d1904de1ab6caf2253008d57_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0zLTEtMS0yNzIzNA_2b413e5d-95c4-4de6-bc8b-06a8e06a8a53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5ffa4369814ee099cdeb5c269a22a8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy01LTEtMS0yNzIzNA_6e8f6843-7224-431d-bef9-c077e5c0af58">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i167177dab94c4db6a7199e7c88c61883_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy03LTEtMS0yNzIzNA_0ef53696-33cb-4d5e-b27e-5c402891ef4f">163</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96d0e39fa84848fd83a65fbedcbd9193_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy05LTEtMS0yNzIzNA_249882b0-34dd-4c46-83dc-2d81d688f1c6">140,784</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0xMS0xLTEtMjcyMzQ_56067ebe-0d76-4306-84c0-f311fa7a7229">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC0xLTEtMS0yNzIzNA_db773e2c-0476-4ac3-bf06-b35c8244e57f">1,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC01LTEtMS0yNzIzNA_81ddb741-0fe9-4ee4-b965-1c21c7d803d0">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC0xMS0xLTEtMjcyMzQ_515e3eae-6ccd-4bf5-bdfc-c56f8b2db596">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS0xLTEtMS0yNzIzNA_7ed19712-486b-4aa1-8ef9-78292b6d2bf8">10,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS01LTEtMS0yNzIzNA_a068fbc8-6567-4e31-979d-d8567a0cf2db">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS0xMS0xLTEtMjcyMzQ_8cf5cdf9-0957-47ef-b1fd-00b679155f53">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNi01LTEtMS0yNzIzNA_a6bcf233-32da-4418-8408-6fc2759c4104">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNi0xMS0xLTEtMjcyMzQ_f5e35c25-acf6-44a2-af20-f5897076ac68">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id292fcdfa2ec483991762030cda62567_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNy03LTEtMS0yNzIzNA_97201810-5b54-4966-8b3c-65c3a8e85f05">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNy0xMS0xLTEtMjcyMzQ_ddc12498-3809-4925-9b2a-0413fd135114">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dd501c8dcab465e8865f8990e84b682_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOC05LTEtMS0yNzIzNA_1768c3de-dcf1-4893-a535-e56406a2d156">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOC0xMS0xLTEtMjcyMzQ_a12e9fe8-8277-46ad-b3be-8e2801c09923">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4799c83f8064ebaa62e85e4da5639e7_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0xLTEtMS0yNzIzNA_fac9a8d7-e3b2-457b-b545-c76c1b00fec7">25,199,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4799c83f8064ebaa62e85e4da5639e7_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0zLTEtMS0yNzIzNA_cb9844bc-1082-468e-9283-e8ebe40e4f1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab00efeb6ef4be2900da03084a5a9d4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS01LTEtMS0yNzIzNA_b2c98c20-8c7b-4d37-b6e4-7dd5cbab9f0a">740,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0ebd4532229468281c822de2a5e657c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS03LTEtMS0yNzIzNA_2fa56969-eeea-4c73-9eaa-8d33b3d911e6">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8f1e0e5c44a4cfe96d8a13d20f90db7_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS05LTEtMS0yNzIzNA_f4914cad-3ade-4c1b-8f8a-7bf891746bb0">190,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f8ca7c434f4946a365bbaa9a9d8bce_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0xMS0xLTEtMjcyMzQ_3102e1fb-e604-4384-ab64-578ed7b13a40">548,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if22db7b29d7e4ece89a75e653bd2115f_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtMS0xLTEtMjcyMzQ_2c95d472-22e7-4dfa-90e7-6a5add46d3b4">472,706</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtNS0xLTEtMjcyMzQ_65fab164-abc1-4fcd-9563-875381621607">30,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtMTEtMS0xLTI3MjM0_8ce94920-ca0f-4c5b-b347-170c1d1a3823">30,748</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares surrendered for taxes and forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtMS0xLTEtMzIxNjk_40a3ec3c-09e3-4ba2-a48a-9c144fd44050">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtNS0xLTEtMjcyMzQ_5c1c668a-988b-46c8-a1df-34a953a24f17">8,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtMTEtMS0xLTI3MjM0_a7055cfc-7ff0-460e-9d95-727020b4f5fa">8,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id814f4669c3d4394a7130b5293e3c8a6_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTItNy0xLTEtMjcyMzQ_a8e59370-47ff-4a69-a0b5-811820a1ec13">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTItMTEtMS0xLTI3MjM0_fcf2c86b-b8a8-444f-9732-9ec9a9e7a74b">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i775cfbfdc6864e3cb405ab41f9c0eb16_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTMtOS0xLTEtMjcyMzQ_ec9187c2-bfcc-4b6b-bcef-43d15ca1b4cd">28,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTMtMTEtMS0xLTI3MjM0_bf07f683-81a9-4f96-aece-c6a863f4216f">28,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibdb89f313eb14a259062ad4a9df63ca2_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMS0xLTEtMjcyMzQ_58edbe61-a877-4625-a1d4-0ba2e3f8793b">25,664,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdb89f313eb14a259062ad4a9df63ca2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMy0xLTEtMjcyMzQ_64c94db6-dd00-4610-a33c-df9d74efb53e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c29c2ed7724e3f9034ecf0a95d902e_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtNS0xLTEtMjcyMzQ_81c2387f-c732-48e1-bc95-2ee29780a0f7">779,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076da2ca9712409eb1f14f99f5da94d6_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtNy0xLTEtMjcyMzQ_b238aff7-828e-4eaf-bda9-90b731bc8e22">1,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dbf9c0f040d4dc69fe77d188302bf6b_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtOS0xLTEtMjcyMzQ_8a788800-ac49-41c2-b693-1e91bb00927f">218,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMTEtMS0xLTI3MjM0_c2e82515-79f9-406b-a1ab-a2cdb9b9b1d0">559,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0xLTEtMS0yNzIzNA_64a541f3-6fb6-42d4-8b5f-ac658edcab7d">19,714,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0zLTEtMS0yNzIzNA_c2acbab0-944d-4faf-bdcb-a230cc863bc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e05fc289824b83b4328d58ee1c1b1d_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy01LTEtMS0yNzIzNA_d850e3f6-875a-4937-9e14-5bc21a27918d">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bdfa279d35d4560b16eb6696604d967_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy03LTEtMS0yNzIzNA_82ff47d6-f448-4b77-9284-df2207786e2c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e70fa1b51374c78acd66828c63b4cee_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy05LTEtMS0yNzIzNA_0eaf988c-01a9-4cc5-b02b-b52c6c38b6d3">71,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d42d81e0d64f339007558ceec6d457_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0xMS0xLTEtMjcyMzQ_d8fb84c7-ea08-40a4-8965-2eec03a742a6">292,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i025425ccecb5443b909699e65613a02c_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC0xLTEtMS0yNzIzNA_0f0806b2-6849-485d-9a92-e68fc0f671b1">2,489,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC01LTEtMS0yNzIzNA_0f08365a-40b1-4675-987a-37fdccb89dbf">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC0xMS0xLTEtMjcyMzQ_fd6173f0-4cfa-4b49-81d3-e85b40a7a13c">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNS01LTEtMS0yNzIzNA_dd991763-88b2-437c-99e9-29506979f612">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNS0xMS0xLTEtMjcyMzQ_3ba92980-a28d-4363-95e6-a2b70c3edd29">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia784962b1a35445abaf692d9da0f8b7c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNi03LTEtMS0yNzIzNA_fca57710-6db4-4844-a562-20efef73b16c">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNi0xMS0xLTEtMjcyMzQ_4cb7c7fc-e4d4-4982-84ff-c82fd380fae0">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i472f7c3bc8534d648bd470f561540a57_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNy05LTEtMS0yNzIzNA_244fabfe-813d-4f21-ae42-4f53d243f7a6">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNy0xMS0xLTEtMjcyMzQ_c661f6d7-8332-4fc9-88aa-5a6064322116">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeb9d19bc36946b7a2b39686906270ce_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0xLTEtMS0yNzIzNA_614133ae-d702-4e91-b876-30907aaed1dc">22,204,057</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb9d19bc36946b7a2b39686906270ce_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0zLTEtMS0yNzIzNA_55ea58e5-3435-4be1-b3de-67ade619e126">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia88065ac15b8425ba0dc82f5b062b440_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC01LTEtMS0yNzIzNA_12e6c72c-d09e-465e-9b89-ca31e72f583f">517,675</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996e16354ef64539bf61d8bc11b8baf6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC03LTEtMS0yNzIzNA_02a7dc27-66fd-44ff-a91c-d0c0e5eb3dca">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60d5bf962dba470ab3a4481875ff9d28_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC05LTEtMS0yNzIzNA_88eba687-f4f8-4ee2-906b-f046eaa3e322">87,026</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da18ba1fb574a9c80c2ef998e02b45b_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0xMS0xLTEtMjcyMzQ_37883672-0751-480a-ab86-d54d92315573">430,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6eeb4e61f234a01a966fc80ccd9a356_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS0xLTEtMS0yNzIzNA_bef0822a-8f13-4077-aa0b-a9150f6c76d9">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7a3cc2b19144a7acff545065372722_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS01LTEtMS0yNzIzNA_2b1af034-ccfb-4c60-9b48-760311f4a58b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS0xMS0xLTEtMjcyMzQ_61d20357-6d5b-4b73-83f6-1baeb78239ed">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7a3cc2b19144a7acff545065372722_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTAtNS0xLTEtMjcyMzQ_171ef326-6c85-43f3-9db9-fe2d982b99e6">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTAtMTEtMS0xLTI3MjM0_35716570-8406-40db-ae85-a10fd4ac5730">4,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74ef1968bb10424d945aad572a1eebe8_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTEtNy0xLTEtMjcyMzQ_ad3ce583-4063-4abb-948b-3b77ca1ddf52">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTEtMTEtMS0xLTI3MjM0_1d12327a-c63d-4991-b60e-0df1a25d15d8">24</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic83b183ffa7240659fcc27d5a7aa5c0e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTItOS0xLTEtMjcyMzQ_e774e7b2-3a65-4e5a-a3a2-b50ae5db6392">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTItMTEtMS0xLTI3MjM0_8450980d-1859-4a8f-b67f-52b6c0018aec">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c755555716244b396f922347ef2dc75_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMS0xLTEtMjcyMzQ_ac6ec3de-7743-40dc-8e96-64e032a12c77">22,205,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c755555716244b396f922347ef2dc75_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMy0xLTEtMjcyMzQ_77279a72-543e-449b-a4b5-61435657a59a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab4702597e5e480a9bc82eb00ce29108_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtNS0xLTEtMjcyMzQ_4d8ac98b-e08f-4476-889d-adbe915070bf">521,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7198d64a2d734ca3839ec28f8cc1be55_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtNy0xLTEtMjcyMzQ_75df1a0e-327d-4fad-bf51-5e8ab5c8d9ee">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40e7fd3b4ff64b319e3403886234d050_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtOS0xLTEtMjcyMzQ_bf1c73ca-964b-4aa1-a3e3-7cfbc64ac757">103,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7496fd6b01444da889610d00b68a0e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMTEtMS0xLTI3MjM0_f922c37f-05d0-4086-92d9-9c9da8fa0ee7">418,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMy0xLTEtMS0yNzIzNA_36b613cd-1d15-4d9d-9633-90a84d68b98c">78,073</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMy0zLTEtMS0yNzIzNA_480bcca7-0ea2-462b-a13e-ec679035b5a6">32,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNS0xLTEtMS0yNzIzNA_8b42597d-0861-4525-b0d3-ecb4db77636f">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNS0zLTEtMS0yNzIzNA_1c467432-6b42-4d08-984a-d18b4203195b">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNi0xLTEtMS0yNzIzNA_a6cb7dfe-b199-4c68-a836-e5b2bae5a188">14,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNi0zLTEtMS0yNzIzNA_6f7247ba-f70a-48d6-bb90-ff6a939acbd8">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfOC0xLTEtMS0yNzIzNA_5c53806c-eaea-4f50-889a-0ca237313e1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfOC0zLTEtMS0yNzIzNA_aeee7faf-8d85-4896-8522-9b49d31b2102">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTAtMS0xLTEtMjcyMzQ_bbf200c3-8a4a-4d3a-8c03-0fc206851df0">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTAtMy0xLTEtMjcyMzQ_87de1e82-18f1-4336-b876-29473d2b333f">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTItMS0xLTEtMjcyMzQ_2482fbc3-bc1d-4f5c-8674-d6cef692eab5">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTItMy0xLTEtMjcyMzQ_5ea7075d-6f11-44ae-a7cb-8546ddec8419">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTQtMS0xLTEtMjcyMzQ_b08da3fa-e42c-47e8-bb77-9f3be31b2a9a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTQtMy0xLTEtMjcyMzQ_d2526622-8f77-4881-8b93-6510cf2eaf37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTUtMS0xLTEtMjcyMzQ_16666e69-d9bc-4858-9eaa-5ab305b45812">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTUtMy0xLTEtMjcyMzQ_a938db50-713d-456d-83a6-488c4c397156">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTYtMS0xLTEtMjcyMzQ_ff95fd99-700a-40a5-b344-411328d64c48">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTYtMy0xLTEtMjcyMzQ_432e336d-f7c9-4f3b-9fce-fc364830f2fc">680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTctMS0xLTEtMjcyMzQ_0bf143d2-2f9b-4384-9c01-3ecc90dcd467">2,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTctMy0xLTEtMjcyMzQ_e263578f-89c6-42ac-a431-770e94a5f310">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMS0xLTEtMjcyMzQ_52e8dae9-f8b9-4eb5-9b71-a59d8b51af72">58,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMy0xLTEtMjcyMzQ_799584f4-ba50-4bd1-8fe0-9194394b758d"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMy0xLTEtMjcyMzQ_8ac0bec3-9a74-4167-87c5-ea529f83eb26">19,783</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjItMS0xLTEtMjcyMzQ_76d152ed-e079-42e7-babe-a8b6368c5262">33,706</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjItMy0xLTEtMjcyMzQ_7b51a7d2-494d-4130-84f5-7eab6b08bae0">6,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjMtMS0xLTEtMjcyMzQ_cffdf4e1-f77d-414c-8a98-4632a36d6a8d">147,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjMtMy0xLTEtMjcyMzQ_df04bd6c-7b87-4c74-96c7-4558af4d578c">59,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjQtMS0xLTEtMjcyMzQ_525c605f-7a51-49e7-aa2f-387811536fc4">86,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjQtMy0xLTEtMjcyMzQ_f0879718-762e-4e28-8a08-fff05593780a">2,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjYtMS0xLTEtMjcyMzQ_0d0e076b-9936-4b94-86ce-2dc12e16fa9c">94,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjYtMy0xLTEtMjcyMzQ_f629a7c5-e4eb-4265-98f8-758df428cde6">63,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjktMS0xLTEtMjcyMzQ_06832c28-f88a-44f4-9eed-7945a2df4275">30,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjktMy0xLTEtMjcyMzQ_6e1f6c99-9ed8-4292-81b3-9c1b584e4df1">152,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to settlement of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzAtMS0xLTEtMjcyMzQ_2ca6020a-ca98-4a13-804c-a67e16eccbed">649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzAtMy0xLTEtMjcyMzQ_75dc827b-b644-47c8-9b51-f47b252094b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of ASTRA build to suit liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzEtMS0xLTEtMjcyMzQ_f58cf9a4-500c-4c5a-91da-5a192d5a14ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzEtMy0xLTEtMjcyMzQ_c4361ec9-08b9-454e-a653-975510eae2ba">7,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzItMS0xLTEtMjcyMzQ_e8f30e33-27c4-4d4e-999f-162849f87355">30,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzItMy0xLTEtMjcyMzQ_32b12551-12a9-4242-a441-aafe6a9a38fd">144,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzQtMS0xLTEtMjcyMzQ_23683422-4388-4d6a-a4cb-7b5119f8dfba">122,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzQtMy0xLTEtMjcyMzQ_3f204986-899a-4c23-a4d6-a0c6d67acaf2">61,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzYtMS0xLTEtMjcyMzQ_161034c1-9a1e-4bc0-b2e6-9f64143ea11f">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d42d81e0d64f339007558ceec6d457_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzYtMy0xLTEtMjcyMzQ_36c4fbbc-4b69-4dc8-b8d6-9ecfbc6f0e31">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzctMS0xLTEtMjcyMzQ_9418a574-3894-4118-9c82-bdfd9e50f426">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7496fd6b01444da889610d00b68a0e_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzctMy0xLTEtMjcyMzQ_77d0c43a-0d9b-40e2-808e-a00cdf5fc6ba">329,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDAtMS0xLTEtMjcyMzQ_7d26f6dd-3e05-41df-973a-6eec46599c00">22,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDAtMy0xLTEtMjcyMzQ_deb2b068-8595-492d-93e3-1a0e53a33e3d">10,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDEtMS0xLTEtMjcyMzQ_1fc74a03-6afb-4857-8619-6e98a708c7ff">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDEtMy0xLTEtMjcyMzQ_563b341c-59f1-46b3-8ad5-6c30642574e4">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i7e672fe7391d467f924465926b4c2682_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMzQ1Mg_308241ce-3b19-48a9-86cc-793286025af4" continuedAt="i462d152a86c349f792318ee337b19692" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i462d152a86c349f792318ee337b19692"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMTkxNQ_3ac1cd88-c7ac-432c-beb0-99711eb5fbab">218.9</ix:nonFraction> million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMjA5NA_b78e19c8-d315-4ba5-ae60-d30917673aab">425.6</ix:nonFraction> million as of June&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div></ix:continuation><div id="i7e672fe7391d467f924465926b4c2682_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODE_967eea93-6644-4dca-8a0f-2dc30fe45e16" continuedAt="ic7a92a374fb54804913dfab014c1d6b9" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic7a92a374fb54804913dfab014c1d6b9" continuedAt="i2504e54f6e8d4e7b94afc260aec995a6"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzY_328f485a-2599-4b3f-b3c3-497bb4438b64" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i2504e54f6e8d4e7b94afc260aec995a6" continuedAt="iff993fc748a14bc2a889e37f55eb3710"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="krys:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzc_7fbd237f-023e-418b-afdd-50689e2b4380" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzg_4ad42a0d-a366-48c9-8c57-eefa1e394b62" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzM_250ee1fc-bc78-4f42-8f6c-f3ed2bc8b28d" continuedAt="i6bd0c24943cb4a67bbb5a4ac332bc6c8" escape="true">Segment and Geographical Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bd0c24943cb4a67bbb5a4ac332bc6c8">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfNDE5MA_639c1add-2c4b-4bdc-b1de-ab2dff3405e1">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceutical products.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODI_20ce6810-a528-402d-b10b-f69aa5ab5e87" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzQ_3cee558e-c013-4f05-8e2b-3e8ed42a9eaa" continuedAt="i42e6b56b30f5447191b92e56ca51253d" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42e6b56b30f5447191b92e56ca51253d">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="iff993fc748a14bc2a889e37f55eb3710" continuedAt="i9589d268642a49ad802eed96c1f529d8"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzk_6871b56e-29fe-4c30-92fc-06461d699205" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODM_6f1f2817-8c04-4511-a115-0ae1bb626b47" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODA_0fbc186f-2099-4d11-85f4-f8078c16f87f" continuedAt="i97a5b36e2d7145d7a46663198c454d74" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i97a5b36e2d7145d7a46663198c454d74"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab27a23368df44c0b545b31a362ffad0_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMC0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjg1MzY2NTQ3MWFjMzRkNWY5YTJhYjQyNWQyNTg2Y2EzXzQ_5a738951-d691-43b3-8bff-5d6c12d07fe3">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i72afdcf0cb6547a990fc6bb8f48b7521_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMC0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjg1MzY2NTQ3MWFjMzRkNWY5YTJhYjQyNWQyNTg2Y2EzXzk_fc0d5b1b-0a7b-46bf-99a7-c446f9634804">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief5d94d6062c49e2b1db8c7414a71a7e_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMS0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjk1ZTgwODgxYmEzMDQwYzk5NmE4YTZiMTJkZDYyMTI5XzQ_188fcdd4-d5b0-4c93-bf62-6698d09821d1">3</ix:nonNumeric> - <ix:nonNumeric contextRef="ia69cd7bb89554aa38e45742bc5b22eb2_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMS0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjk1ZTgwODgxYmEzMDQwYzk5NmE4YTZiMTJkZDYyMTI5Xzk_aa86970f-4a45-4dde-a577-f49bffb2b8dc">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice52f49beadd49d5861085be75f4b8a0_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMi0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjRkMzZiMDBmNzQzYzRjODliZGE4ODlhZWNjOTViYzE4XzQ_ab25b0ab-a262-43b0-93de-fa8e158e19bc">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i87b630056ae3492b8a0991e9b5343757_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMi0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjRkMzZiMDBmNzQzYzRjODliZGE4ODlhZWNjOTViYzE4Xzk_9fa980a5-9369-4e86-8b95-5d4225057471">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODY_d85fcb68-d599-4671-8f4a-eb836428abc0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has <ix:nonFraction unitRef="usd" contextRef="i8721aeb105fc4c238df1588239e9c101_D20210101-20210630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_d5330314-6a2f-4e3a-bde1-7c782c8dece7"><ix:nonFraction unitRef="usd" contextRef="i2f2c361f936d4f35898fb47c6618dcf8_D20220101-20220630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_d863222a-0a95-4588-90a3-e39436218736"><ix:nonFraction unitRef="usd" contextRef="ic39c1f1d7ae6452eabc0f676318ed72a_D20220401-20220630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_fc7af7d2-9163-4c7b-a913-fb997818ba71"><ix:nonFraction unitRef="usd" contextRef="i5a0b896d15f540bd9cd89d793a7b3dd9_D20210401-20210630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_fe63e451-34d4-44c0-874e-4183de4a2f94">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognized any impairment losses for the three and six months ended June&#160;30, 2022 and 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i9589d268642a49ad802eed96c1f529d8" continuedAt="i2f3f3cf9b4704632ae32ca105cfece14"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzU_2ef58acd-81bd-45f2-8eae-13fbea35de1e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODQ_b0e75792-61ef-4ebc-9305-93717710e6d1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODU_a7cabf23-4feb-47d4-87c0-23c4e7b4e5b0" continuedAt="i963a5d744fe14c6594951faae3cc46c4" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i2f3f3cf9b4704632ae32ca105cfece14"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i963a5d744fe14c6594951faae3cc46c4">are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODc_5281330a-80e7-4212-a56c-995c7f1a90f2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODg_a581c14d-e647-45ad-84a4-4a4af253271a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i7e672fe7391d467f924465926b4c2682_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfOTU4_c6fec204-860a-497b-bd72-768a960ceb5b" continuedAt="i7cc5af89d1034bfdb6a1cbc8c5bf06fa" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i7cc5af89d1034bfdb6a1cbc8c5bf06fa"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfNjYz_90fb9ac4-07f2-4bdf-bd56-a29052ed064a">3,686,862</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfNjcw_9745e37e-a811-4c59-b45d-b5ba519e4a03">1,688,965</ix:nonFraction> common share equivalents outstanding as of June&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfOTU5_2ceadc21-3722-447a-91dc-29f72e6e05c9" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:47.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.272%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC0xLTEtMS0yNzIzNA_03a89603-0a60-4faa-a59f-c43980ad74f6">28,108</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC0zLTEtMS0yNzIzNA_5c8dcb72-6a86-4b7a-9e58-f46f38d01dda">16,363</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC01LTEtMS0yNzIzNA_6b95216f-fdb3-4cd8-8a4a-0e80717a6312">78,073</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC03LTEtMS0yNzIzNA_2ef5f6ae-e679-419c-a59c-d7b81958fa5c">32,174</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0xLTEtMS0yNzIzNA_740ad0de-ea71-4f88-8093-413756cfa6d7"><ix:nonFraction unitRef="shares" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0xLTEtMS0yNzIzNA_a356ffc5-d6ce-47ad-9ee7-a2af2e71d2a0">25,545,167</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0zLTEtMS0yNzIzNA_33399eb8-4243-45cc-809a-e6e821d74328"><ix:nonFraction unitRef="shares" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0zLTEtMS0yNzIzNA_79e1537d-d375-48ad-87be-08f6116a0c4e">22,204,659</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi01LTEtMS0yNzIzNA_4a79331f-b06e-4d64-96c5-2a5fcf45cbd3"><ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi01LTEtMS0yNzIzNA_eada6cbd-f90e-4800-8d7d-6ad57cef350a">25,331,000</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi03LTEtMS0yNzIzNA_1ba42434-8e88-4634-aee4-73149568e6f1"><ix:nonFraction unitRef="shares" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi03LTEtMS0yNzIzNA_f72a6827-9306-46d7-b473-39c25f63079c">21,731,711</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0xLTEtMS0yNzIzNA_33b29501-6c49-47c0-af3b-448ec135804c"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0xLTEtMS0yNzIzNA_7faabc14-99ae-417d-9a8a-e756117bb333">1.10</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0zLTEtMS0yNzIzNA_5cade551-50b1-4f96-bcbd-2c95c1352c0a"><ix:nonFraction unitRef="usdPerShare" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0zLTEtMS0yNzIzNA_74d70020-3a5b-4331-bbcb-0153fa20464b">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy01LTEtMS0yNzIzNA_38dbf8f1-1700-4611-a3f3-c5456db0f0d3"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy01LTEtMS0yNzIzNA_b9c25a00-f575-45ad-82c3-1546193cbd89">3.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy03LTEtMS0yNzIzNA_376d3ba4-0203-461a-8499-f4fa7531f95a"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy03LTEtMS0yNzIzNA_a25499e3-f91c-4657-8e78-69dad535f0af">1.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfNTAz_122d071f-cb83-4ab5-90a1-f4de03ad6f6f" continuedAt="id265348fb2f541219f2117eb7afbbe86" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><ix:continuation id="id265348fb2f541219f2117eb7afbbe86"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfNTA0_029534b7-c749-4519-9dc9-b080b90c6047" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of June&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC0xLTEtMS0yNzIzNA_1334620d-679e-4cc3-b522-4e5412df21cf">218,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC03LTEtMS0yNzIzNA_4f943517-5f84-4b9f-baef-18d65bcb8166">218,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e86db60e52a433cabc5c934bf137fd1_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC05LTEtMS0yNzIzNA_57b7853f-610d-4de5-b4ef-dcd1751f8f89">218,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d892ea64f341f094f64a0244811282_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS0xLTEtMS0yNzIzNA_4f5e87ea-9981-480f-ba6c-02e86e2396fa">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d892ea64f341f094f64a0244811282_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS03LTEtMS0yNzIzNA_6c401d73-d379-4776-8fa1-ecb628c45403">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4680df6fdb6448fe89234b2525155c51_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS05LTEtMS0yNzIzNA_a4609a1b-6c36-421f-8f59-62fff16a4d81">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xLTEtMS0yNzIzNA_07710e5c-d629-4131-9343-c63385f20f65">46,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0zLTEtMS0yNzIzNA_540cdd01-0748-4a60-b144-4a50269637eb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC01LTEtMS0yNzIzNA_835425d4-081b-49ba-89e4-36ddda7859e1">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC03LTEtMS0yNzIzNA_5f1ca193-c780-46f4-bba5-73923161f170">46,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic54be4b4a31245cfa953f2ed8fcbabb1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xMS0xLTEtMjcyMzQ_cdc9c630-8057-42db-b73c-d1f8af08cf99">46,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408fc3248f94e58a9239a4ddda6b92c_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xMy0xLTEtMjcyMzQ_0a33e655-ebcb-449b-b39e-cbf63c23c9f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xLTEtMS0yNzIzNA_2ff65a30-7715-4468-9ee1-895a2150cf50">97,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0zLTEtMS0yNzIzNA_b3666020-36f9-4654-8db8-2bf3f3186b5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS01LTEtMS0yNzIzNA_6b05fc55-1c8a-475a-8bc7-bed9c08b07a9">890</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS03LTEtMS0yNzIzNA_d6b4c18f-3032-4666-b074-42ffc8bd8af6">96,918</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc97aeb2c0514e00a399738e538f2fe7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xMS0xLTEtMjcyMzQ_57ed61ba-7e8b-42c8-bf60-528734762a2a">88,853</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f691466f4f4614820d160aeb87931d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xMy0xLTEtMjcyMzQ_e3199893-2211-4ace-b606-96ffda6b865f">8,065</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMS0xLTEtMjcyMzQ_304aed95-7b32-4371-aefa-d4d91fc64b79">77,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMy0xLTEtMjcyMzQ_d7f40174-4aa9-43c9-b6ce-405c20ed1ad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtNS0xLTEtMjcyMzQ_6c372141-095c-4b3e-a3bd-a884c0e1b39d">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtNy0xLTEtMjcyMzQ_40eb5f55-84a2-4187-963f-29692e651ec0">76,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14b5c1cb46b44daa8d2c7200a170896_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMTEtMS0xLTI3MjM0_0a79ec1e-32dc-4603-a754-cd9b468ffb92">71,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if10ba9e6940c4bcab91bee5cdf0f1577_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMTMtMS0xLTI3MjM0_99b23e73-9fe7-4ea4-a137-56b26562732b">4,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMS0xLTEtMjcyMzQ_364a49a1-2320-41fd-b025-e44eb366be9c">221,282</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMy0xLTEtMjcyMzQ_4410fe94-36a3-4f30-a665-a51711779632">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtNS0xLTEtMjcyMzQ_8b1ee511-b26d-486c-8669-0d9f070fba40">1,536</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtNy0xLTEtMjcyMzQ_3141040e-f6cc-40c4-9886-bf007acf18a7">219,747</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89e6376ee9b402191dd9c876f00ffd1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMTEtMS0xLTI3MjM0_d123887b-c0d8-44cc-81aa-21e7d33c7a4c">206,845</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685fdfb571504f15be2ba3d2c639db0d_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMTMtMS0xLTI3MjM0_02613695-e1a4-495e-b613-75dd343bc943">12,902</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMS0xLTEtMjcyMzQ_ac477eef-df35-4de2-932b-d2f7099fb895">440,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMy0xLTEtMjcyMzQ_dbf4edac-5674-4ec1-972d-140fd461eace">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItNS0xLTEtMjcyMzQ_7ec17e64-b18b-4f69-a1e3-62a0b2e6f746">1,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItNy0xLTEtMjcyMzQ_625a0482-8258-465c-9a6b-041f05ed9b7e">438,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f864a31b3d847e786f7d911b5e088ba_I20220630" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItOS0xLTEtMjcyMzQ_6781f396-c1c0-4df3-97d4-560485bea11b">218,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4792758104f47bfbfdd2f1ff6cc0f56_I20220630" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMTEtMS0xLTI3MjM0_22937882-4c88-4e0e-b63d-7a4a1c6ce84e">206,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id87854e9024645be88d96e81c1d80ce7_I20220630" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMTMtMS0xLTI3MjM0_6016ed13-1e3c-47fa-86c8-f86bed467f1d">12,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if698ad0c6a754e11892e9ad283a72091_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy0xLTEtMS0yNzIzNA_eb88c39a-a30e-48e2-a5f9-2e6aca2cd0b6">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if698ad0c6a754e11892e9ad283a72091_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy03LTEtMS0yNzIzNA_6418878f-563b-475e-95d3-1a8ea3c39c79">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ae7de2a25e4d8f9c91182ae7bd789a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy05LTEtMS0yNzIzNA_138acf61-7564-4bb1-b86e-a1ba3e92635f">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS0xLTEtMS0yNzIzNA_2f08aebd-b507-4b37-9526-0fb2e9c6ca4d">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS03LTEtMS0yNzIzNA_185f1ea6-fb9b-453c-943b-a000287ec7ce">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8f78f72c5f44daa3c018883cf88bc6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS05LTEtMS0yNzIzNA_f49def10-17ff-4830-937d-23a1ec4c0ceb">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xLTEtMS0yNzIzNA_9bcb8f91-d60f-4b6e-96b8-cadd0e8107de">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0zLTEtMS0yNzIzNA_321cdb5a-62e6-4efe-a9a8-5cba71ef36c9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy01LTEtMS0yNzIzNA_17193d64-5d54-4d30-ab41-95758b4faf77">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy03LTEtMS0yNzIzNA_74e9818e-db5d-46bf-9147-35330ea706d6">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7652f0186854d3eb2df5a9678980d1d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xMS0xLTEtMjcyMzQ_af001b7a-31d4-45a2-b756-8b98060e4ee3">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5248a77fa14049cf940a8cd1b7fef935_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xMy0xLTEtMjcyMzQ_53be8e73-f151-4076-b500-42e39cc31770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xLTEtMS0yNzIzNA_cb6e7a25-6239-4c75-b662-d6702203d7c8">83,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0zLTEtMS0yNzIzNA_47615fa8-5bfa-47de-9f56-641d073cc59d">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC01LTEtMS0yNzIzNA_a146498f-866a-4314-8ad0-bbb99457bb11">114</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC03LTEtMS0yNzIzNA_7aba612f-da2d-4559-8d55-f7e94e12b50f">83,196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4757de934847a3b5d4eb65e4f812c6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xMS0xLTEtMjcyMzQ_dbd9518e-7ade-4742-aee1-c0b673821636">35,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef97546d258466e8f022a081bfec632_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xMy0xLTEtMjcyMzQ_09dd8eae-9b19-4f54-a255-4057a1e03574">47,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xLTEtMS0yNzIzNA_0d6e4e88-9aa5-429f-bc48-962a31a40762">37,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0zLTEtMS0yNzIzNA_aa23e44e-6f1d-489f-81e1-55a383e75de0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS01LTEtMS0yNzIzNA_c86284bd-318c-4257-b758-210ca1b9c062">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS03LTEtMS0yNzIzNA_20714524-6c91-4b28-9ac8-249d8ccac48a">37,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ebc1166b3d48708f5ffd968b17c9cf_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xMS0xLTEtMjcyMzQ_8a4abffd-51db-4ea1-9e4d-f177d7a8b5fa">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ac529d98474127860b5706cc0a4e57_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xMy0xLTEtMjcyMzQ_8925b35a-9e7f-47be-828c-8b925f180fb3">16,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMS0xLTEtMjcyMzQ_339fa566-1dd1-4cf0-a217-4fe6a88d8787">161,390</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMy0xLTEtMjcyMzQ_9fbdf570-ab03-42e0-a5cb-ab966d606a5f">11</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtNS0xLTEtMjcyMzQ_1aed5e3a-95b5-40a9-a5b1-09b7656c969b">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtNy0xLTEtMjcyMzQ_bc453a0f-3782-4714-901a-d578c2ad9112">161,221</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7253ed7785a94823a46ec4162da143ce_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMTEtMS0xLTI3MjM0_80b9585f-aec0-40e8-a671-d2dbd861f800">96,850</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5f33620a0044aaaa5c0668e4413da8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMTMtMS0xLTI3MjM0_8225ea7c-1ce8-496c-944a-ca8c9396403f">64,371</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMS0xLTEtMjcyMzQ_f6ebffd5-be49-4a05-9d78-19771be95454">502,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMy0xLTEtMjcyMzQ_86d8099e-2bd7-4518-8f40-008a0bc930da">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtNS0xLTEtMjcyMzQ_81e7b3b2-6abb-4861-9d54-c4fc5426a509">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtNy0xLTEtMjcyMzQ_16b5f982-ec95-45e7-8420-fd354079b6fc">502,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075af6a44d40468781a120b2d5467942_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtOS0xLTEtMjcyMzQ_afef9856-8d9b-4dc2-ae85-ab0e554e67a0">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe24770e30b4ee5b669d117e9f452b4_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMTEtMS0xLTI3MjM0_f732e420-0069-416f-9fe2-71e67c7a64bd">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4223978e6e4043b43792467895392c_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMTMtMS0xLTI3MjM0_05c1e506-da84-42dc-9ce5-676b7ce4cea1">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="ie89e6376ee9b402191dd9c876f00ffd1_I20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMjcy_c6b4033e-9c73-46c1-bf2d-33934a080aa1">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between <ix:nonNumeric contextRef="ia02db18a6f9842168a740bb3825c2f42_I20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMzQ1_f23837ab-037a-4648-b4de-55fde884d233">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="ibe1d4e05d43f4749b3b95a6990387f23_I20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMzUy_bfcd1616-1909-4631-9656-513f835af25c">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU3_f541cc3c-6344-4fd3-8a33-a68cb6921f8f" continuedAt="i779fe9a182d4478eb7897b0ce06b40a6" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i779fe9a182d4478eb7897b0ce06b40a6"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU4_63b8a8a9-efd5-4491-9964-f0ee80a33792" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dbf144cc1344bc88a90e137beec2ff_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMi0xLTEtMS0yNzIzNA_4da87525-31d3-4637-a7f8-8a517036defc">142,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5474e41a39a4279ada916abbc519671_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMi0zLTEtMS0yNzIzNA_19ded535-4718-487f-b17a-59488a93d72f">104,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6353eacee0474f88b8a107b02b1652_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMy0xLTEtMS0yNzIzNA_ec4aead0-86ce-4622-9e0b-ac0c804795db">5,736</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aa852ef45a845dda2da256ef25ae970_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMy0zLTEtMS0yNzIzNA_bda38e2d-bef1-4dec-aa38-ff21819aad02">5,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9dbd4ee4e647aeaa50ea67ae6bab6a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNC0xLTEtMS0yNzIzNA_def333c1-cdf7-42da-a7eb-fe5570f49de0">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if59b699ffbf74fb6b067fb3fd3d26948_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNC0zLTEtMS0yNzIzNA_889383f8-2f7b-4acd-be14-0c24ce28675a">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f288e08976b441381de343a114c23bc_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNS0xLTEtMS0yNzIzNA_06b233eb-4227-41f6-8e76-22eccbd3bced">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id831f855902e4ca8a26e06da3c94f9ec_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNS0zLTEtMS0yNzIzNA_8f05d137-1074-4f30-9c11-4a0c3e1ece55">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0781359c8a514003ad12a9168fd9fc32_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNi0xLTEtMS0yNzIzNA_5e168a1a-c2f5-4b49-acfd-c4ca611e6e0a">6,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a061e6cc0574956ae21bc486e71b175_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNi0zLTEtMS0yNzIzNA_3c8ace6f-6a04-4d00-8346-55ecf45f7ab0">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNy0xLTEtMS0yNzIzNA_938c2d37-0351-49f3-83cf-1d61e6958090">156,365</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNy0zLTEtMS0yNzIzNA_d6c00be4-8c0d-4ad6-86a4-3c0d629e2e35">116,569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOC0xLTEtMS0yNzIzNA_d431b027-2287-41c9-ba36-4df22cdff04a">5,151</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOC0zLTEtMS0yNzIzNA_f81bb09c-a101-40d4-b71e-6f8c2b57ff30">4,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOS0xLTEtMS0yNzIzNA_c21bcf7b-d83f-49c8-be9d-f8cb3f431a52">151,214</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOS0zLTEtMS0yNzIzNA_9511c73a-8ab8-4356-a7bb-3de5d2e41d23">112,355</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTU3_42ab5476-4612-4339-8142-ce4d5440f106">494</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE5NA_0f847a20-d22b-42db-858e-68b91ca5eafa">956</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE4Nw_923923f3-4699-4c36-9efb-a04388e9d338">475</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE5OQ_12ef6d87-6290-422a-bcd8-8bf512d89a2e">914</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU2_a39c81cd-c167-44a9-8705-cd754aeebacd" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMi0xLTEtMS0yNzIzNA_d159d654-8838-470f-9de9-b82936c480a4">14,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMi0zLTEtMS0yNzIzNA_703a39fa-ecfb-491d-937c-57d030725b33">9,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMy0xLTEtMS0yNzIzNA_5db30f10-9aae-4cb3-8114-317e10f8e199">3,812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMy0zLTEtMS0yNzIzNA_84f8a15e-ca78-4ca8-8003-8e3ae4bb22f8">2,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNC0xLTEtMS0yNzIzNA_597fd132-6d85-48d3-acf7-1eb900152384">2,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNC0zLTEtMS0yNzIzNA_e577367c-a058-41cb-bc8e-d459aafeb304">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNS0xLTEtMS0yNzIzNA_421c770e-4d7a-4274-8d30-4e574de856a2">2,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNS0zLTEtMS0yNzIzNA_4b0bda67-9f56-472a-a58f-93032c4b35c1">1,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNi0xLTEtMS0yNzIzNA_1893c12e-63ae-4482-a689-740acd21a042">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNi0zLTEtMS0yNzIzNA_2ef5d58d-1bcc-414a-82d4-4b16b13ab2b7">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNy0xLTEtMS0yNzIzNA_061b859b-d735-454d-b115-1df56b29331c">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNy0zLTEtMS0yNzIzNA_b5774551-9726-4ebf-8ff5-821e4c8745de">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfOS0xLTEtMS0yNzIzNA_2efa4399-58ef-4f18-96a3-ac28625e5f40">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfOS0zLTEtMS0yNzIzNA_fed9b32f-32a7-4b95-a993-e8d12bd11879">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMTAtMS0xLTEtMjcyMzQ_4e541cc9-bc61-43af-ae0e-79d30763b06a">23,781</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMTAtMy0xLTEtMjcyMzQ_14685541-405b-4be4-a6ea-83807960d19e">16,297</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><span><br/></span></div><div id="i7e672fe7391d467f924465926b4c2682_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMDk_359c1dfa-e6c6-4196-8ef4-4b4967a5ee43" continuedAt="id0cb52eb775549d6b7072a08ecfbce51" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="id0cb52eb775549d6b7072a08ecfbce51" continuedAt="ifa3e84280e5a44488eb8b30f51ba2431"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately <ix:nonFraction unitRef="sqft" contextRef="ibb5217315fdc425a8f055a9896bfb0af_I20220630" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMzYy_9c3fe085-e6ba-4440-a4fb-c5403bd46b34">47,000</ix:nonFraction> square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ifa3e84280e5a44488eb8b30f51ba2431" continuedAt="i86b7f7d61432425b874f325e96af5574"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $<ix:nonFraction unitRef="usd" contextRef="ieb2b2a6f833a41e0b4880780fe93e686_I20200121" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTEwNw_df68dd73-ae15-4899-9a52-72041b95dc99">2.4</ix:nonFraction>&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $<ix:nonFraction unitRef="usd" contextRef="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTcxNg_95dd0a0f-4924-4d34-ad7d-7c88817f0139">9.4</ix:nonFraction>&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjAxMA_26da3317-c70f-415a-9779-0866fd6b804a"><ix:nonFraction unitRef="usd" contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjAxMA_6bd66670-305c-4c95-90ac-20ec75fd73da">10.0</ix:nonFraction></ix:nonFraction>&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $<ix:nonFraction unitRef="usd" contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjE2NA_0d24f284-dea1-4b50-849d-8ff7b6b1d600">2.4</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjM4MQ_fb93810c-f3e8-41da-a71c-f9d66243fbf3">9.4</ix:nonFraction>&#160;million. The Company held approximately $<ix:nonFraction unitRef="usd" contextRef="i119efa4588394a448de123d82168c14b_I20201015" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjQxNg_968a112c-c271-4ea6-9aa2-08093f3520f6">1.5</ix:nonFraction>&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="krys:LessorOperatingLeaseLiabilityAnnualLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDI3Mg_9d04c440-6ac8-4af9-beba-f471deff4aaf">82</ix:nonFraction>&#160;thousand, and are subject to a cumulative <ix:nonFraction unitRef="number" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="krys:CumulativeEscalationClausePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDMwOA_c38f2dfe-85ba-4479-8784-efe292073042">10</ix:nonFraction>% escalation clause every <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="krys:CumulativeEscalationClauseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDMzNQ_3b350587-d907-4865-842d-a3f9aa10d791">5</ix:nonNumeric> years through 2071. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a <ix:nonNumeric contextRef="i827059c44d894d608fa87db88be3f1d6_I20211215" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI5NjA1_8eb3b3af-86eb-4c1b-a069-b7007019c7a9">3</ix:nonNumeric> year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMTA_93562ba2-9335-4b67-9403-16ef80999bc7" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:83.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMS0xLTEtMS0yNzIzNA_34ee6ecd-e8bf-42ee-8a9a-0eff851b49a8">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMi0xLTEtMS0yNzIzNA_4165d688-5164-4321-91b6-e4c4ba783245">1,510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMy0xLTEtMS0yNzIzNA_a0b012f4-d087-4a87-ab06-238c2cd59df3">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNC0xLTEtMS0yNzIzNA_af1dad3a-93d3-4851-a71c-7a9b0d384e2c">1,277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNS0xLTEtMS0yNzIzNA_c02ce2a9-c5f7-440b-8baf-cb2530157dba">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNi0xLTEtMS0yNzIzNA_b1a1e6c3-ddb2-4947-9363-0ab28f4eaadf">12,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNy0xLTEtMS0yNzIzNA_a7a73a9f-040e-488f-88f5-b7e1924ceadb">18,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfOC0xLTEtMS0yNzIzNA_7f9a004f-af58-483c-a840-89e86fa3ef0e">9,276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfOS0xLTEtMS0yNzIzNA_f629727f-fb8b-47cb-939e-c8a0033f1953">9,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into a <ix:nonNumeric contextRef="i7d8365f8ec064a42b301d193885831a0_I20220516" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MjI3_d4fb6f48-8e86-4ccb-9f8c-2362e45da75f">16</ix:nonNumeric> month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $<ix:nonFraction unitRef="usd" contextRef="i26a85807415641c1bbd4c16458db46d6_I20220630" decimals="-3" name="krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MTkz_480d31e7-21da-4602-9957-5aa16640380e">22</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i26a85807415641c1bbd4c16458db46d6_I20220630" decimals="-3" name="krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MjA3_587ebb41-ad0c-4f0c-809c-9bd6a178e278">89</ix:nonFraction>&#160;thousand for the years ending 2022 and 2023, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i86b7f7d61432425b874f325e96af5574" continuedAt="i458005bd30ed47239c3647dec65b67a7"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMDg_f2b10869-2c67-4c19-b41b-c3667ea07a6f" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfMy0xLTEtMS0yNzIzNA_69f9a43d-aad7-450b-91fc-e91cd8451243">8,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfMy0zLTEtMS0yNzIzNA_e4d1ea32-38e2-4f0e-8924-6fef7c6d979d">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNC0xLTEtMS0yNzIzNA_4d05d6c2-9c39-443d-a96a-5d15ab21685a">1,417</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNC0zLTEtMS0yNzIzNA_be372e04-2e7c-4e84-952b-da9da594c807">1,041</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNS0xLTEtMS0yNzIzNA_23082fd8-a26e-4f3e-951b-da8021feb970">7,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNS0zLTEtMS0yNzIzNA_edce7cdf-3f6e-4d1c-b6b6-46016d2330c9">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNi0xLTEtMS0yNzIzNA_a90159be-20e3-46e7-b2d4-c70ccf612c7b">9,133</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNi0zLTEtMS0yNzIzNA_70dee08c-ea7c-4926-8fbe-82b68f3f6df9">8,024</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNy0xLTEtMS0yNzIzNA_ace31ad1-ccb2-47f0-b018-0e2e9ec914b7">12.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNy0zLTEtMS0yNzIzNA_c3430031-8e3b-4982-9228-57a5d3d53c8c">14.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfOC0xLTEtMS0yNzIzNA_c26778da-8f58-4c75-8a8e-622020b5e52d">9.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfOC0zLTEtMS0yNzIzNA_3cbe6376-ab45-4a38-9473-480a29deb1a1">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDgwNA_574f5fce-f9f9-444c-90d1-dacc002cc47b">391</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTQ4Mw_cd65fb30-6cdf-4181-81f6-c953b3764ac3">800</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTQ5NA_ad9afc09-a5c6-4b92-9faf-bd307f040d7d">278</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTUwNA_a945e34c-ca82-4c53-9d46-67eedb30a37c">497</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2021, respectively. The Company recorded variable lease costs of $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDg5MQ_8967f348-c82d-4635-a1ad-ae026204338e">71</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTU5NA_3abeefcc-90b1-4ab0-a00a-209d7ea39fbe">120</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTU5MA_c26184a2-c3a5-47af-b9f5-9bfb183f1a35">81</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTYwMg_3b25a233-c3e9-47a5-a5b6-84f594f6f340">118</ix:nonFraction> thousand for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June&#160;30, 2022 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="i2a4c19202a764797b2b092b8f85d150c_I20220630" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTg0Nw_9bbf357f-5142-4327-a8ca-b1a05b518ae5">2.1</ix:nonFraction> million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="ibef597c9a74640cfae1769e2be78cba6_D20220401-20220630" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjA1Ng_c0198b1c-4d65-40a1-937e-816deb0a21ca">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2eac4d8ff1bc4caf99aefef1cdf232b8_D20220101-20220630" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTY5OA_714d7ae3-313a-4071-9c86-23a3f61ee05f">3.0</ix:nonFraction> million for each of the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i4c3195ecfb794e2588cdb48c9b9e1fab_D20210401-20210630" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcwNw_34130380-ddbe-4a8b-bc1b-fae8c146a2be">718</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="if6f4b750dd5b41018b6987ded07fec01_D20210101-20210630" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcxNA_754734cc-f50f-4c5b-8b3c-fd627ad78c8f">2.5</ix:nonFraction> million for the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="ia7bff06aaa0b4172b5a7fc7c324cb8d1_I20220630" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjQ5NQ_d676ef84-7084-42b2-9c98-384a84b19163">5.1</ix:nonFraction> million. The Company has incurred expenses under these activities of $<ix:nonFraction unitRef="usd" contextRef="i4bbfc5ceb794438b99f03eab41975dd2_D20220401-20220630" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjU1OQ_9cd35bee-9229-4fd3-9b6e-15e2f78732e0">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icd330d2d7b434eadb065cd5a8d7e8433_D20220101-20220630" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcyMg_c368ee96-d38b-40bb-a7a4-085351a6fa6c">6.2</ix:nonFraction> million for the three and six months ended June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="if7a8f2da70c8489bbe7c8d73255d7a0e_D20210401-20210630" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTc4Nw_0f6bb598-811f-40e3-9dda-d624a98d59d4">974</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i88eeda34427444d59f2632f3fe3ce3c3_D20210101-20210630" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTc5NQ_d4fca84b-5b6f-4351-b8ac-271616d5076a">2.3</ix:nonFraction> million for the three and six months ended June&#160;30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i67fac24ea1814a04a46df8a1f2b0307d_I20220630" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNzA5MQ_eab09c9e-3db2-4922-ac3b-2617ed70cd1c">17.9</ix:nonFraction> million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to <ix:nonFraction unitRef="number" contextRef="i67fac24ea1814a04a46df8a1f2b0307d_I20220630" decimals="INF" name="krys:CostOfWorkPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNzcwNw_f9ee8a0c-1da4-4ac1-b20c-cacbd0f93a40">1.75</ix:nonFraction>% of the cost of work. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i458005bd30ed47239c3647dec65b67a7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid by the Company is $<ix:nonFraction unitRef="usd" contextRef="ifbc1d20961ac429694a43623cb59dc7f_I20210913" decimals="-5" name="krys:LossContingencyGuaranteedMaximumPriceToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MjA2Mw_ee4434a8-d08c-4780-b116-d0daf1435658">83.0</ix:nonFraction>&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8396aa2f370f4359935ac37bbca1ca43_D20220428-20220428" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTU2NDA_6e8f2f20-c5dd-4a88-a577-6e3cdec6ba54">25.0</ix:nonFraction>&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of Krystal&#8217;s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $<ix:nonFraction unitRef="usd" contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzMTI_82037f85-8ca9-473e-8bc9-eed5caf81bd3">12.5</ix:nonFraction>&#160;million, followed by <ix:nonFraction unitRef="milestone" contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630" decimals="INF" name="krys:NumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzMjg_68126afd-002c-4a80-88f4-55b387a8ceb5">three</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="ic0a6b6780e2744a78177e645108c3643_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_4986ee11-7a23-4e2d-bbad-d6395347a04e"><ix:nonFraction unitRef="usd" contextRef="iec561b9438fc47fa9736b2ab0dfa6e25_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_818a10be-a9a8-4cbf-80d0-05268dd7f28f"><ix:nonFraction unitRef="usd" contextRef="ic93ab2eb0c5b47bea0598419ed1fce33_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_ab8ad28d-6293-4ed6-9eab-84ac994ba698">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million contingent milestone payments upon reaching $<ix:nonFraction unitRef="usd" contextRef="i8283d8f8c4374e57ae8f04c23b4b7428_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzODk_09665f78-659e-45c8-aaf3-29438cd362d2">100.0</ix:nonFraction>&#160;million in total cumulative sales, $<ix:nonFraction unitRef="usd" contextRef="i3c54249f9c4e49ee9c88d0b3e52be617_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA0MTk_874332d9-3be0-453f-ae11-a8419fdf5594">200.0</ix:nonFraction>&#160;million in total cumulative sales and $<ix:nonFraction unitRef="usd" contextRef="iec04e4bd030243cd8732d95021dd1a4a_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA0NTI_4cd7e8cd-71ed-41c6-870e-515f7567604b">300.0</ix:nonFraction>&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $<ix:nonFraction unitRef="usd" contextRef="ibb2ca34f0ed04200a5c092337ff47225_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementTotalConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA4NTU_5b86a3a7-750a-4e7e-b5f0-77e778a2a9d9">75.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $<ix:nonFraction unitRef="usd" contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI2ODU5_3c5eb560-4a95-436e-8c70-2d266826499d">25.0</ix:nonFraction>&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE0OTE_6d8c50de-2ea8-4dd6-b458-80f7039c1b8d"><ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE0OTE_efd86485-84c2-4a7f-8ba4-b7f8ed3f67c3">768</ix:nonFraction></ix:nonFraction>&#160;thousand of insurance proceeds during the three and six months ended June&#160;30, 2022  and Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE1ODI_418e04c9-e603-43fa-a66c-7fe9efc8b293">369</ix:nonFraction>&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div></ix:continuation><div id="i7e672fe7391d467f924465926b4c2682_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTc5OQ_2956dcf1-f2f5-44e8-8dfe-38d6ad8e51f1" continuedAt="ia02b1c0b8a1045889f4a061e1c145e5b" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="ia02b1c0b8a1045889f4a061e1c145e5b" continuedAt="i6061090ff7224ac092f01d9b5f0933e0"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="ic988cc831aa04c98a4a7c73bda3df147_I20201231" decimals="-5" name="krys:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODIyMjQ5_c8e9bab3-22f7-4e75-b4d7-3f887c808aba">150.0</ix:nonFraction>&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="ie404abea35ec4537a1e5ce4db74c5ab6_D20210101-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjU2Mw_228f12c7-c7de-4098-9e93-07808b1e6365">262,500</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id2c43b6d200f4a04b123151eded83516_I20211231" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjYyMQ_fccd25e4-c90c-463f-86e3-f36f2b4467ff">66.50</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjY3OQ_1d3e2f80-2d82-4200-9cff-365300256401">16.9</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjc1NQ_7e531641-34e9-4e45-8c32-ae1a3807f160">524</ix:nonFraction>&#160;thousand. During the six months ended June 30, 2022, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="id0a266617fb74011b52795116bde11a2_D20220405-20220405" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDIw_226f0efd-f6c8-45a8-8307-7dd4b074b104">434,782</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i74bd7dcda88044e8bdc02d6eb3e42a31_I20220630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDI5_cf1b7756-853b-422a-8eba-56ac4187b7f7">69.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id0a266617fb74011b52795116bde11a2_D20220405-20220405" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDM3_b8fcf920-a3d3-4789-9e58-00fe4dcdd37a">29.1</ix:nonFraction>&#160;million after deducting selling commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjkyOA_4ee80ddd-0272-4c1d-ae76-99c270f9ab17">900</ix:nonFraction>&#160;thousand, resulting in a remaining $<ix:nonFraction unitRef="usd" contextRef="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630" decimals="-5" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE5MTA3_c1851f2a-9241-43c3-b235-3874a83a139c">102.5</ix:nonFraction>&#160;million available for issuance under the ATM Program.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i6061090ff7224ac092f01d9b5f0933e0"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1Njg5_3aa77b44-4f2d-4905-a519-aa9ec1faea99">2,866,667</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i4eb9b132e2e8429691c1fde0ba1c9948_D20211203-20211203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzAw_c11f2eea-cf1f-4f1c-9c09-4f259388cf92">200,000</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e198d54f3db4e3e9cc8a6aa406b6115_I20211203" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzA5_37f8336a-92b5-4896-9ed4-054d8d19095d">75.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzE3_5d4e48c6-2bec-4e19-9bca-c1f7d586fee5">201.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzMz_09e486cc-eba2-4566-ae0d-25b091e853fc">12.9</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzQ4_5a4f6361-0ee5-4ad9-97d7-13359941fe05">227</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTEw_ff929075-5dc1-4d77-8eef-6a036b156ee9">2,211,538</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i214b57f548b54a76aea79ee58885eda6_D20210201-20210201" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTUx_c5f8e928-e0a6-4d12-aab1-f11365417cb1">288,461</ix:nonFraction> shares purchased by the underwriters pursuant to their option to purchase additional shares, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fb77696fe7a4014a844960177bee7df_I20210201" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTk1_5fd0a587-5982-4971-a6fb-8e111dd37818">65.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNjYx_b0e4bda6-9489-4e53-9f8d-aae4b2fcdd2f">134.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNzM2_4dd5c104-1b59-4103-a2c2-7efad77455c7">8.6</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i9051ae2ee8f6429e8c5caaf5ba0b9a3b_D20210201-20210201" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNzk0_f74142f9-c3a3-411d-acc0-fca5b16c9688">198</ix:nonFraction>&#160;thousand.</span></div></ix:continuation><div id="i7e672fe7391d467f924465926b4c2682_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1NQ_28f4eba2-c7e9-46c9-a56e-c3fa5eddc541" continuedAt="i584079b5995a4f579e4a451d35624188" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i584079b5995a4f579e4a451d35624188" continuedAt="i424a7cf550bf4bb9b15f7f2ee50e33ae"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over <ix:nonNumeric contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1MA_4223a3a1-5b5e-49f5-b96f-74186c6d68ce">four-year</ix:nonNumeric> periods and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13">one</span>-year to <ix:nonNumeric contextRef="ifa739c94f7e4421b824446b65ca0970b_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Ng_264c2096-f5b0-4d40-9554-a9013d420afe">four-year</ix:nonNumeric> periods. Stock options have a life of <ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjM0_f05ccf92-dab9-4ad4-b11b-b3fe9875fba2">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i6d5e85dd3f394163a17aa2a7a2882596_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjU5_064e6f6a-bb75-4389-9626-94d3a8eb4eba">544,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idf15c469b0c14c2b8d582745c8548a55_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM1Ng_717f680b-5fb5-4d62-b2b9-07c6c71d4530">1,724,000</ix:nonFraction> stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="i9562a91cca5a4feeabc3e61cfce17db9_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM0Mw_4c926557-3ac2-4dfe-8680-d06e22147a78">297,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i63b754f6b02141f7aeffcecd25d8ee9f_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM1MQ_04470aae-6720-40d7-ba9b-a1f1b75a570d">799,950</ix:nonFraction> stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i13ecba4f425444fab5675e6879c78727_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEyOQ_65ada071-aaa5-4bb3-9283-99cc928b0257"><ix:nonFraction unitRef="shares" contextRef="iee3cd2503a6d4c0d87ab6c13960cd2bc_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEyOQ_d1215956-0dc7-4757-ade7-a6d113f30da5">45,000</ix:nonFraction></ix:nonFraction> stock options to non-employees during the three and six months ended June&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="i0801eb6aaac14234813d62b72db774ad_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEzOA_06671a2c-feb2-4d8a-9c5a-21171ea21ddc"><ix:nonFraction unitRef="shares" contextRef="id49480057f2645a7bdae78e27c951b23_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEzOA_06c80496-6c01-4a85-bb34-1ba114a7eb16">zero</ix:nonFraction></ix:nonFraction> stock options to non-employees during the three and six months ended June&#160;30, 2021, respectively.</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1MQ_f07d4890-33ac-406d-abb3-65208ad820dc" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:38.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS0xLTEtMS0yNzIzNA_b6b397c7-ceb6-4050-bc37-223b94bb252f">2,043,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS0zLTEtMS0yNzIzNA_dbb255a1-6026-4189-9338-09d4dd6197ed">57.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id67d27acccab4cc7b6215d625269df36_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS01LTEtMS0yNzIzNA_f070ddce-3d68-4e5c-8220-e81c0d76ead4">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS03LTEtMS0yNzIzNA_69b3db6c-dc7d-480a-9926-2b8416601c75">31,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMi0xLTEtMS0yNzIzNA_950560fc-706b-415c-bf72-570a43c85675">1,769,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMi0zLTEtMS0yNzIzNA_cb967d0a-c1dc-4445-8459-b7206b910d5b">62.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMy0xLTEtMS0yNzIzNA_b542aabe-7043-427d-83b2-5c1a7487226f">39,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMy0zLTEtMS0yNzIzNA_8c991236-6743-4864-9f1f-1fb28c78b0f1">44.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNC0xLTEtMS0yNzIzNA_7f2a16c9-6eab-4145-b67f-4b9088a6cb53">151,642</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNC0zLTEtMS0yNzIzNA_4b989eef-bb7b-4972-9293-0858a6f35ef8">55.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNS0xLTEtMS0yNzIzNA_b98de93f-bb72-42bb-ab41-b416e9a94b9c">876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNS0zLTEtMS0yNzIzNA_99cfe9c6-c7f5-4e85-bdce-ba9c8f7a9303">74.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi0xLTEtMS0yNzIzNA_4045c32f-be6a-4434-8e60-26b177297eb8">3,620,262</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi0zLTEtMS0yNzIzNA_fd4877cd-e251-4b23-a6ba-261e52daecd0">59.75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi01LTEtMS0yNzIzNA_70650852-a4f4-44da-9cf8-d5a8e4884a42">9.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi03LTEtMS0yNzIzNA_495b890e-3375-464e-a907-112c3fbedb91">28,341</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy0xLTEtMS0yNzIzNA_550abaa1-c9e1-4a65-9fd6-427c622ecf5b">536,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy0zLTEtMS0yNzIzNA_71c9ee4e-5d43-4418-b2d6-e1423413c7ce">47.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy01LTEtMS0yNzIzNA_315d5678-987e-4adb-b3d4-a45048d61a50">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy03LTEtMS0yNzIzNA_bc52e833-812a-4dc0-a912-8e2c574c8338">11,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfNzgz_0b1f4fa1-59af-45d8-b83a-3893247248b9">704</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM2MA_f44ccb3e-9457-4349-ae12-6a90a8ee12ed">739</ix:nonFraction>&#160;thousand, respectively, and during the three and six months ended June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjQyNg_be6a6a6f-8d75-4662-9d49-118f433c261a">64</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjQzNA_4c0f56bf-b9a5-47c9-b710-bb46e5d2435e">872</ix:nonFraction>&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June&#160;30, 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfOTQ4_3a63c458-3126-453b-b1ee-e7aea6f3ab0c">42.90</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUwOQ_7bbed4cb-6943-41f9-9ae0-b16324253d29">43.03</ix:nonFraction>, respectively, and during the three and six months ended June&#160;30, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUxMg_e91e5ae7-4b01-415a-b73f-8748b9f1fb2a">42.53</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUyMA_79e8d67d-992d-4940-9774-9cd4d6a413ef">47.25</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i43306d588f4a45bab466ead6783424bc_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfOTgz_4f017e88-dd5d-4590-829d-5de36fa77aa0">115.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i97b468c91f394f3982302387c06cb4bb_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTE1NA_c57fefab-45ec-43d3-aaa9-0cd177a39176">3.3</ix:nonNumeric> years as of June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Mw_ef09044f-8b7e-4e8c-9a20-94041a72a336" continuedAt="i9ce766a9a4394e14bf569fc0b3628ea8" escape="true">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i424a7cf550bf4bb9b15f7f2ee50e33ae" continuedAt="i2b056fa9139449d4a76f0802db4fd5fe"><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:continuation id="i9ce766a9a4394e14bf569fc0b3628ea8" continuedAt="i70435694c8f84ca493817cdbc2e2d413"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:36.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy0xLTEtMS0yNzIzNA_05ff9665-ad4a-489a-985d-43ea98f37e85">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58302432af964373a1478c96983fa353_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy0zLTEtMS0yNzIzNA_76bbdda6-1539-4c83-b175-d7515cdb6f1e">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idced79ac55904d99a6ebfa0dcd88778a_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy01LTEtMS0yODQ0OA_4551d39f-77f6-44e4-9087-c5c36c390301">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8924a2fba7e24e789eae274f8598c078_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy03LTEtMS0yODQ0OA_cd64df7d-40ad-41a7-9213-72447114916b">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f7d144aaf64425a30d562e60e9c259_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC0xLTEtMS0yNzIzNA_f522d3f8-ae09-4597-af18-32f5895dd49c">5,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i218c57c0818b4e67b3e40d185226720b_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC0zLTEtMS0yNzIzNA_050c29bc-e9ac-4676-b382-df086a5ee20e">2,625</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77dada28a724687b986b05a7dc8d862_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC01LTEtMS0yODQ0OA_47dd75ea-5861-4386-a333-e4e0e5062e12">10,357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0203af48a23c4ada819dd5d73122c9e4_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC03LTEtMS0yODQ0OA_56c4b667-4f2f-456b-b4dc-2d431ad67aa4">4,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS0xLTEtMS0yNzIzNA_4f092a22-4dfa-4b22-8da8-de33fbc21b9b">7,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS0zLTEtMS0yNzIzNA_d74a8914-d6dc-4bbe-8a46-21a1211b5857">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS01LTEtMS0yODQ0OA_84dc79fa-715b-4de1-bda1-b07f9ff456e2">13,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS03LTEtMS0yODQ0OA_dea073b5-4bde-4996-ba55-e0713b3f2380">5,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $<ix:nonFraction unitRef="usd" contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTUzMw_315a620a-1310-44c3-962d-ba6df568dfbc">146</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg0OQ_d3f7bf21-23f7-4261-9fb2-7bcc34d42209">287</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg1NQ_379e948b-593f-4d07-88e1-cc0740008460">66</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg1OQ_8be007b8-55bc-4f67-aca9-821b4f2928dd">103</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2021, respectively.</span></div><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Mg_bb5637db-0b58-4f53-94a5-068fab357bc1" escape="true"><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:37.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.713%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi0xLTEtMS0yNzIzNA_14151d91-6a7c-4f55-a599-1f674658726b">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi0zLTEtMS0yNzIzNA_6be6fc4e-233c-48e0-8ced-5df43f4054c7">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi01LTEtMS0yOTM1OQ_1fb491c0-5a65-48cb-ad03-f5af12bf2c24">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi03LTEtMS0yOTM1OQ_bb923309-5407-4892-a673-7eed96eff48f">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy0xLTEtMS0yNzIzNA_67f2adc0-ad6d-4d30-91e1-44e4770a10e8">6.17</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy0zLTEtMS0yNzIzNA_bf9cf579-a95c-4d80-b089-fb47c3a254cc">6.10</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy01LTEtMS0yOTM1OQ_db2b9498-90b4-4e15-9a73-18276f6ce274">6.21</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy03LTEtMS0yOTM1OQ_bb887f65-69da-444c-8f91-b8cb7bbc1d67">6.18</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC0xLTEtMS0yNzIzNA_d743e967-97e0-49a5-9c11-3cb497551bf8">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC0zLTEtMS0yNzIzNA_4d633a7c-6f4b-4e23-95d5-9162ea072ca4">1.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC01LTEtMS0yOTM1OQ_4a1c5006-8b4f-41b9-9c1c-7ad5d61343cd">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC03LTEtMS0yOTM1OQ_11f256ee-7fe1-474d-92f3-650fe93504ad">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS0xLTEtMS0yNzIzNA_14667385-8649-4d46-bb90-980257f87b9f">61.51</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS0zLTEtMS0yNzIzNA_a4af62f9-2328-4302-9d92-527e89e31b6d">66.58</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS01LTEtMS0yOTM1OQ_bc455d35-a434-40ab-b904-fb2244699e7c">62.19</ix:nonFraction></span></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS03LTEtMS0yOTM1OQ_ff9c54ac-a071-408d-8425-1996ab8c5a54">73.42</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi0xLTEtMS0yNzIzNA_94cbfc88-2bc5-41f2-97f6-f0f08e7162a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi0zLTEtMS0yNzIzNA_211a31e5-4644-498f-ab04-c4bc51bcb75c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi01LTEtMS0yOTM1OQ_36a92f13-7d2a-4cad-99b2-2b9fe2cc9275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi03LTEtMS0yOTM1OQ_35bfcd0a-1e28-4544-a187-23892e61ba1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <ix:nonNumeric contextRef="if75647732fba42e284fe467cf75d3e9e_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Nw_4bab7ea1-1146-4366-81eb-97299691fedf">four-year</ix:nonNumeric> period. The Company granted <ix:nonFraction unitRef="shares" contextRef="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjA3Nw_dc7e9792-58b9-4557-aa6d-e94e16f0d913"><ix:nonFraction unitRef="shares" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjA3Nw_e39aea73-69f4-4f73-93a4-4b11b557aced">zero</ix:nonFraction></ix:nonFraction> RSAs to employees of the Company during the three and six months ended June&#160;30, 2022, respectively, and <ix:nonFraction unitRef="shares" contextRef="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjY0NQ_477f78b5-e4cd-43fc-95d7-6bd3f7da76a1">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjY1Mw_29c60634-111c-4bb4-a968-da4fdc409b86">98,800</ix:nonFraction> RSAs to employees of the Company during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1OA_2e0bcd4a-6114-4011-9e61-32346ea50962" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:50.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c44a0f0edbf4e42a4210967f72907b4_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMS0xLTEtMS0yNzIzNA_45d0c171-a9d1-4798-8067-9b52b69f7751">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c44a0f0edbf4e42a4210967f72907b4_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMS0zLTEtMS0yNzIzNA_81e9eb7a-11d0-4ac8-a72c-44cc96301c39">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMi0xLTEtMS0yNzIzNA_6151d151-dd05-4001-ac27-65332875aedb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMi0zLTEtMS0yNzIzNA_c7f0d17c-0950-4a16-8062-0c2f67f84f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMy0xLTEtMS0yNzIzNA_b146ef70-276a-4d83-a2fb-fb95c3413816">14,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMy0zLTEtMS0yNzIzNA_4d68457f-9437-4065-9fdc-a70d0bb12a25">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNC0xLTEtMS0yNzIzNA_5e9449cd-fcbf-4885-933b-bcff292c64ab">17,879</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNC0zLTEtMS0yNzIzNA_cff3ae01-f9a6-49d4-9ff4-244012e37fe0">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNS0xLTEtMS0yNzIzNA_b6ce285e-40e3-4bbd-966e-dfe19dd64b02">66,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNS0zLTEtMS0yNzIzNA_506846ab-7471-40b4-aae5-ea4ddd9ca009">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjE4NA_b446af69-4c01-4f7e-a459-69b42c424208">4.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjMzMw_03104acd-6ffc-432b-b278-ad6aebd87413">2.7</ix:nonNumeric> years as of June&#160;30, 2022.</span></div><ix:continuation id="i70435694c8f84ca493817cdbc2e2d413"><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:36.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973bbe15b2c641d79452fafa91f79ca3_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy0xLTEtMS0yNzIzNA_35845c9a-88ef-4ebd-bccb-fe4026dd0c42">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232a7ab61f1e47368c74babe3c12332d_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy0zLTEtMS0yNzIzNA_661fd634-0570-463a-a0cc-a4a73b66fc2c">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503211a1f9354a229ff0440c90d6d24f_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy01LTEtMS0yOTQzMA_806dfac9-a5a8-4f25-94c7-cba782559efa">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f7b33d629c41b8a67324d2e7bb83ff_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy03LTEtMS0yOTQzMA_96120538-fef7-4c9b-950b-05164dfd42f1">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC0xLTEtMS0yNzIzNA_6f1ee4a3-8bcb-4f33-9ebd-02e665a9477b">418</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC0zLTEtMS0yNzIzNA_76b65f66-9ea8-476c-8f92-d74a83a7725a">486</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC01LTEtMS0yOTQ1Mw_fbb485e9-30b8-4448-821b-1bda4157fb61">899</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC03LTEtMS0yOTQ1Mw_093b5af9-d11c-4ce6-a15f-d76920939167">668</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b056fa9139449d4a76f0802db4fd5fe">Shares remaining available for grant under the Company&#8217;s stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="i34f6fa04b56749b38d5db99c77ee8cf9_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjY5MA_bf4a7c53-81e9-42f7-9d48-045e019d2dd1">530,991</ix:nonFraction>, with a sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="ic087ec71aa444b14b0f99f1a179b4d7b_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0MQ_23c45798-a2d0-4dfd-8204-6ac99f44bcfd">1,296</ix:nonFraction>, at June&#160;30, 2022.</ix:continuation></span></div><div id="i7e672fe7391d467f924465926b4c2682_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81NS9mcmFnOmU3NTZlN2YwYTcwOTQ5YWNiZDQzZGVkZTBkNDc1ZGMzL3RleHRyZWdpb246ZTc1NmU3ZjBhNzA5NDlhY2JkNDNkZWRlMGQ0NzVkYzNfNjE4_5914681d-1d55-4d1f-81e3-f83f55872520" continuedAt="i12352a5d806044759d2247daa18a3a8b" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i12352a5d806044759d2247daa18a3a8b">The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.</span></div><div id="i7e672fe7391d467f924465926b4c2682_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, cost, progress and results, of our research and development activities, preclinical studies and clinical trials for B-VEC (previously &#8220;KB103&#8221; and now known as Vyjuvek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), KB105, KB104, KB407, KB408, KB301, KB303, and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact that the COVID-19 pandemic and measures implemented to prevent its spread may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final US Food and Drug Administration (&#8220;FDA&#8221;), marketing and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates regarding the potential market opportunity for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to fund our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs associated with our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully develop and commercialize our product candidates, including B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business model and strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of building a medical affairs and commercial organization, including a sales force in anticipation of commercialization of B-VEC and any additional product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully avoid or resolve any litigation, intellectual property or other claims, that may be brought against us;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic conditions, including the recent rise in inflation; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in laws and regulations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Form 10-Q, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale cGMP manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:</span></div><div style="text-align:center;text-indent:31.5pt"><img src="krys-20220630_g1.jpg" alt="krys-20220630_g1.jpg" style="height:835px;margin-bottom:5pt;vertical-align:text-bottom;width:659px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-VEC is a topical gel containing our novel vector designed to deliver two copies of the COL7A1 transgene for the treatment of dystrophic epidermolysis bullosa ("dystrophic EB"), a serious rare skin disease caused by missing or mutated type VII collagen protein. Our randomized, double-blind, placebo-controlled GEM-3 pivotal study was designed to evaluate topical B-VEC as compared to placebo in dystrophic EB patients. Following public announcement of topline data from the GEM-3 study trial on November 29, 2021, we presented more detailed results at the 2022 American Academy of Dermatology Annual Meeting on March 26, 2022 and at the Society of Investigative Dermatology Annual Meeting on May 19, 2022. On March 28, 2022, we announced that results from the Phase 1 and 2 study of B-VEC were published in Nature Medicine. In 2Q 2021, we began enrolling patients into an open label extension ("OLE") study, including patients who participated in the Phase 3 study, as well as new participants who meet all enrollment criteria.  Based on the feedback from the FDA following their review of our human factors validation study report, we announced on April 11, 2022 our plan to offer dystrophic EB patients enrolled in the GEM-3 OLE, the opportunity to be dosed in their homes by a healthcare professional.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2022, we filed a Biologics License Application with the FDA seeking approval of B-VEC for the treatment of patients with dystrophic EB, and we expect to file a Marketing Authorization Application with the European Medicines Agency in 2H 2022. We can provide no assurances as to whether B-VEC will be approved or the ultimate timing of any approval from either agency.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length cystic fibrosis transmembrane conductance regulator ("CFTR") transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated CFTR gene. On August 1, 2022, we announced that the FDA had accepted our KB407 Investigational New Drug ("IND") application, and we plan to initiate a Phase 1 clinical study ("CORAL-1/US study") of inhaled KB407 in patients with cystic fibrosis ("CF") in the U.S. in 2H 2022. Previously, on September 29, 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study ("CORAL-1/AU study") of inhaled KB407 in patients with CF. We have begun screening patients for enrollment in the CORAL-1/AU study and plan to initiate dosing in 2H22.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB105 is a topical gel containing our novel vector designed to deliver two copies of the TGM1 transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. On July 1, 2021, we announced data from the fourth patient dosed in the trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. We plan to resume dosing in the KB105 Phase 1/2 study later this year.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the SPINK5 transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. We expect to initiate a Phase 1 clinical study in 2022.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several other product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary Jeune Aesthetics, Inc. ("Jeune").  A summary description of Jeune&#8217;s lead product candidate and its status is as follows: </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. On March 22, 2022, we announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301. In Q2 2022, subjects from the PEARL-1 Cohort 2 trial were enrolled in a durability trial to evaluate duration of treatment effect, reduction of the unevenness in placebo treated sites, and long term safety monitoring. We anticipate announcing data from the durability trial in 2H 2022 and initiating a Phase 2 trial in 4Q 2022 or early 2023. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune has several other aesthetic medicine product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date the impact of the COVID-19 pandemic on our business and clinical trials in the U.S. has been minimal. We will continue to assess the potential impact of the pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. Outside of the U.S., we have experienced pandemic-related delays in clinical trial initiation in Australia, and we will continue to closely monitor the impact that future pandemic developments have on this and our other clinical trials, going forward. For additional information regarding the impact of the coronavirus pandemic, please see "Risk Factor - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business." in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span></div><div id="i7e672fe7391d467f924465926b4c2682_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension study for B-VEC, resume dosing with KB105 Phase&#160;1/2 clinical trial, initiate a Phase 2 trial for KB301, initiate a Phase 1 trial for KB407, initiate a Phase 1 trial for KB104, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs.&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation for personnel in our executive, commercial, business development and other administrative functions. General and administrative expenses also include professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include travel expenses.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and to operate as a public company. These increases will likely include increased </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate that we will increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we closed on the purchase of the building that was constructed to house our second cGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who manages the construction of ASTRA.  Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct and validate this facility, which is expected to be completed in 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes during the three and six months ended June&#160;30, 2022 to our critical accounting policies, significant judgments and estimates as disclosed in our management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended June&#160;30, 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,753&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,393&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,360&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,108)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,363)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,745)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $4.3 million in the three months ended June&#160;30, 2022 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June&#160;30, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $1.3 million, payroll related expenses of $1.9 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $911 thousand increase in stock-based compensation, outsourced research and development activities of $803 thousand and other research and development expenses of $316 thousand, primarily due to software related costs and rent. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $8.1 million in the three months ended June&#160;30, 2022 as compared to the three months ended June&#160;30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $6.5 million, which was primarily driven by an increase in headcount in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $3.1 million increase in stock-based compensation, commercial preparedness expenses of approximately $1.7 million, medical affairs costs of $268 thousand, software related costs of $165 thousand, business development costs of $215 thousand, travel related activities of $136 thousand and other administrative expenses of $460 thousand, primarily due to charitable contributions and conference expenses. These increases were offset by a net decrease in legal and professional fees of approximately $1.3 million, which includes $68 thousand of insurance proceeds.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the three months ended June&#160;30, 2022 and 2021 was $645 thousand and $30 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six Months Ended June&#160;30, 2022 and 2021</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,975)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,746)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,073)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,174)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,899)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $7.4 million in the six months ended June&#160;30, 2022 compared to the six</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $2.5 million, payroll related expenses of $3.5 million, which were primarily driven by an increase in headcount to support overall growth, and includes a $1.8 million increase in stock-based compensation, outsourced research and development activities of $909 thousand and other research and development expenses of $586 thousand, primarily due to software related costs and rent. These increases were partially offset by a decrease in travel related activities of approximately $61&#160;thousand.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $15.8 million in the six months ended June&#160;30, 2022 as compared to the six months ended June&#160;30, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $12.2 million, which was primarily driven by an increase in headcount in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $6.4 million increase in stock-based compensation, commercial preparedness expenses of approximately $3.2 million, medical affairs costs of $336 thousand, software related costs of $295 thousand, business development costs of $378 thousand, travel related activities of $189 thousand, and other administrative expenses of $948 thousand, primarily due to rent, taxes, charitable contributions and conference expenses. These increases were offset by a net decrease in legal and professional fees of approximately $1.7 million, which includes $577 thousand of insurance proceeds.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation settlement </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement for the six months ended June&#160;30, 2022 and 2021 was $25.0 million and zero, respectively, and consisted of the settlement of litigation with PeriphaGen. See "Legal Proceedings" in Note 6 of the notes to condensed consolidated financial statements included in this Form 10-Q for more information.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the six months ended June&#160;30, 2022 and 2021 was $902 thousand and $64 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the six months ended June&#160;30, 2022 and 2021 was zero and $1.5 million, respectively, and related to accretion of the financial obligation for the build to suit lease liability during the six months ended June&#160;30, 2021 to a balance that equaled the purchase consideration for ASTRA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, our cash, cash equivalents and short-term investments balance was approximately $425.6 million. Since operations began, we have incurred operating losses. Our net losses were $28.1 million and $78.1 million for the three and six months ended June&#160;30, 2022, respectively, and $16.4 million and $32.2 million for the three and six months ended June&#160;30, 2021, respectively. At June&#160;30, 2022, we had an accumulated deficit of $218.9&#160;million. With the net proceeds raised from our previous public and private securities offerings and our ability to issue additional shares under our current ATM  program, the Company believes that our cash, cash equivalents and short-term investments as of June&#160;30, 2022 will be sufficient to allow the Company to fund operations for at least 12 months from the filing date of this Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. Furthermore, we expect to incur increasing costs associated with satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues until 4Q 2022, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out some of our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to continue to incur significant commercialization expenses as we prepare for product sales, marketing, manufacturing, and distribution. Furthermore, pursuant to our settlement agreement with PeriphaGen, we will be required to pay $12.5 million upon the approval of our first product by the FDA, followed by three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales.  Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, payments of settlement amounts to PeriphaGen and general overhead costs.  In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we may require substantial additional funding.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeline and cost of our OLE study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results and costs of our Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of manufacturing of B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing of an IND application for future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining our own commercial-scale cGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the six months ended June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,783)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,064)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,526)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,258&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June&#160;30, 2022 was $58.6&#160;million and consisted primarily of a net loss of $78.1&#160;million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of $16.4&#160;million, and including net changes in operating assets and liabilities of approximately $3.1&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June&#160;30, 2021 was $19.8&#160;million and consisted primarily of a net loss of $32.2&#160;million adjusted for non-cash items primarily comprised of depreciation and amortization and stock-based compensation expense of approximately $7.7&#160;million and build to suit interest expense of $1.5&#160;million, including net changes in operating assets and liabilities of approximately $3.2&#160;million. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June&#160;30, 2022 was $94.1&#160;million and consisted primarily of expenditures of $33.7&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $147.3 million on the purchase of short-term and long-term investments, partially offset by proceeds of $86.8&#160;million received from the maturities of short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June&#160;30, 2021 was $63.1&#160;million and consisted primarily of expenditures of $6.5&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $59.6 million on the purchase of short-term and long-term investments, partially offset by proceeds of $3.0&#160;million received from the maturities of short-term investments.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the six months ended June&#160;30, 2022 was $30.2&#160;million and consisted primarily of proceeds of $30.8&#160;million received from our ATM Program and exercises of stock options and offset by $649&#160;thousand used for the employee tax withholding payment for settlement of vested restricted stock awards. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting underwriting discounts and commissions of approximately $900&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2022, the Company received proceeds of $1.7&#160;million&#160;from the exercise of stock options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended June&#160;30, 2021 was $144.1&#160;million and consisted primarily of proceeds of $152.1&#160;million received from our ATM Program, a public offering, and exercises of stock options, partially offset by $8.0&#160;million used for the purchase of the ASTRA building. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock at $65.00 per share. Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million and other offering expenses of approximately $198&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, pursuant to the ATM Program the Company issued 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand. The Company also incurred $172 thousand of other offering expenses related to the ATM Program. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2021, the Company received proceeds of $360 thousand&#160;from the exercise of stock options.</span></div><div id="i7e672fe7391d467f924465926b4c2682_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements&#160;as defined in the rules and regulations of the SEC.</span></div><div id="i7e672fe7391d467f924465926b4c2682_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 other than as described in Note 6 &#8220;Commitments and Contingencies&#8221; of our condensed consolidated financial statements on this Form 10-Q.</span></div><div id="i7e672fe7391d467f924465926b4c2682_79"></div><div style="margin-top:18pt"><span><br/></span></div><div id="i7e672fe7391d467f924465926b4c2682_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $425.6 million at June&#160;30, 2022, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that the investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span><br/></span></div><div id="i7e672fe7391d467f924465926b4c2682_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we implemented a new enterprise resource planning software, Microsoft Dynamics D365 (&#8220;Dynamics&#8221;), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to strengthen our internal financial controls by automating a number of accounting and reporting processes and activities, thereby decreasing the number of manual processes previously required. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, no change in our internal control over financial reporting occurred during the quarter ended June&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i7e672fe7391d467f924465926b4c2682_91"></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.</span></div><div id="i7e672fe7391d467f924465926b4c2682_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in "Summary Risk Factors" and "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There have been no material changes from the risk factors previously disclosed in such filing.</span></div><div id="i7e672fe7391d467f924465926b4c2682_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7e672fe7391d467f924465926b4c2682_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7e672fe7391d467f924465926b4c2682_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i7e672fe7391d467f924465926b4c2682_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220630ex311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220630ex312.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220630ex321.htm">Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended June 30, 2022, are formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL. </span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i7e672fe7391d467f924465926b4c2682_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.240%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;8, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>krys-20220630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i851bb30c5af94fb98f93bac8c610a3c2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>krys-20220630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4899dd10710d43818a5d97595d603f50_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>krys-20220630ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iec45403b31004645a545718f72f09e3f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended June&#160;30, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended June&#160;30, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;8, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>krys-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>2112104 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>2313303 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>2115105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>2316304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2321305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail">
        <link:definition>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>2125107 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>2127108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>2328306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>2134109 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_PaymentToEscrowForReducingLeaseRentals" abstract="false" name="PaymentToEscrowForReducingLeaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_OtherContractualObligationsMember" abstract="true" name="OtherContractualObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LossContingencyGuaranteedMaximumPriceToBePaid" abstract="false" name="LossContingencyGuaranteedMaximumPriceToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SwitzerlandLeaseMember" abstract="true" name="SwitzerlandLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_TwoThousandSixteenLeaseAgreementMember" abstract="true" name="TwoThousandSixteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CostOfWorkPercentage" abstract="false" name="CostOfWorkPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_NumberOfMilestones" abstract="false" name="NumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CumulativeEscalationClauseTerm" abstract="false" name="CumulativeEscalationClauseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LitigationSettlementMilestonePaymentsSalesThreshold" abstract="false" name="LitigationSettlementMilestonePaymentsSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PurchasePriceOfPotentialBuildingPurchase" abstract="false" name="PurchasePriceOfPotentialBuildingPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" abstract="false" name="LessorOperatingLeaseLiabilityAnnualLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AdditionalAreaOfRealEstatePropertyLeased" abstract="false" name="AdditionalAreaOfRealEstatePropertyLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_BostonMassachusettsLeaseMember" abstract="true" name="BostonMassachusettsLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressCurrent" abstract="false" name="AccruedConstructionInProgressCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedFinancingFeesCurrent" abstract="false" name="AccruedFinancingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LitigationSettlementTotalConsideration" abstract="false" name="LitigationSettlementTotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClausePercent" abstract="false" name="CumulativeEscalationClausePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_PaymentsForSuitLiability" abstract="false" name="PaymentsForSuitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PeriphaGenMember" abstract="true" name="PeriphaGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>krys-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3f2b5c5d-f74a-481a-a0b9-c6ef44f3f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:to="loc_us-gaap_AssetsCurrent_3f2b5c5d-f74a-481a-a0b9-c6ef44f3f253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2da50cd-e9d5-461c-9dd6-c53d8dd9e7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2da50cd-e9d5-461c-9dd6-c53d8dd9e7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_14c6e22b-96de-4aff-9379-6c0f6648b55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:to="loc_us-gaap_LongTermInvestments_14c6e22b-96de-4aff-9379-6c0f6648b55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_51674a2b-fb75-4580-b5ef-ff1fd9fc290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_51674a2b-fb75-4580-b5ef-ff1fd9fc290c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_deffc227-9a79-4a3e-bace-2e0e61c90082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0131a61a-397b-4f7f-965b-c0c62e89f568" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_deffc227-9a79-4a3e-bace-2e0e61c90082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_94ac5ae3-b31e-4e14-adfa-d7056f5825cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_efa69f5a-3abe-465a-8054-cef5863d2c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94ac5ae3-b31e-4e14-adfa-d7056f5825cf" xlink:to="loc_us-gaap_LiabilitiesCurrent_efa69f5a-3abe-465a-8054-cef5863d2c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f5364d5-1593-4dc7-a88a-3479616a4986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_94ac5ae3-b31e-4e14-adfa-d7056f5825cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1f5364d5-1593-4dc7-a88a-3479616a4986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6db0992b-cb71-47c0-9e0e-779b84109d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fc6c8a86-fea1-4f34-ac4e-691f76732d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6db0992b-cb71-47c0-9e0e-779b84109d9b" xlink:to="loc_us-gaap_Liabilities_fc6c8a86-fea1-4f34-ac4e-691f76732d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b10fe28d-026e-4119-b764-4447c7bb5b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6db0992b-cb71-47c0-9e0e-779b84109d9b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b10fe28d-026e-4119-b764-4447c7bb5b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8de75dd3-f789-47f2-b130-0b8c2d1c53b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6db0992b-cb71-47c0-9e0e-779b84109d9b" xlink:to="loc_us-gaap_StockholdersEquity_8de75dd3-f789-47f2-b130-0b8c2d1c53b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_610c91d7-6970-4dca-8acb-8064097b078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f83de80-1df1-44d1-81c9-daed61bd9f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_610c91d7-6970-4dca-8acb-8064097b078e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f83de80-1df1-44d1-81c9-daed61bd9f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12a5428b-4825-4b03-8927-1815be5a7f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_610c91d7-6970-4dca-8acb-8064097b078e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12a5428b-4825-4b03-8927-1815be5a7f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2608fb4c-6c43-4587-bbba-2b859be5fd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_610c91d7-6970-4dca-8acb-8064097b078e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2608fb4c-6c43-4587-bbba-2b859be5fd69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_90f14d8d-8227-4314-89ae-8cf3d8563c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5e144d87-f6ce-4c12-a54a-26b8b38f6960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90f14d8d-8227-4314-89ae-8cf3d8563c6c" xlink:to="loc_us-gaap_AccountsPayableCurrent_5e144d87-f6ce-4c12-a54a-26b8b38f6960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_72f04653-4b5e-47f8-8b63-c514a319abba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90f14d8d-8227-4314-89ae-8cf3d8563c6c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_72f04653-4b5e-47f8-8b63-c514a319abba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c151896d-774c-47f8-8aee-d519d74a86db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_90f14d8d-8227-4314-89ae-8cf3d8563c6c" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c151896d-774c-47f8-8aee-d519d74a86db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a397dfb4-4b24-49a1-9553-3e0377aa236c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:to="loc_us-gaap_PreferredStockValue_a397dfb4-4b24-49a1-9553-3e0377aa236c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7a10223c-92be-4ba5-8575-1d3708112667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:to="loc_us-gaap_CommonStockValue_7a10223c-92be-4ba5-8575-1d3708112667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_72440ba8-8d29-41c8-8b75-2ecb6a6776af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:to="loc_us-gaap_AdditionalPaidInCapital_72440ba8-8d29-41c8-8b75-2ecb6a6776af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b67f95f5-0711-4753-89be-c881f5e9f291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b67f95f5-0711-4753-89be-c881f5e9f291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0e7314d3-e52b-4491-99df-eae551145a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_87f1d702-31f3-4d3d-81d7-508c88e04d78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0e7314d3-e52b-4491-99df-eae551145a09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2bd1254b-68b2-4b70-add0-8ba9b7a19c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b0181cc7-5428-4f96-9806-d6ddd2115804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2bd1254b-68b2-4b70-add0-8ba9b7a19c09" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b0181cc7-5428-4f96-9806-d6ddd2115804" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_83acdd33-3ee6-44c9-af5b-05a1480305e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2bd1254b-68b2-4b70-add0-8ba9b7a19c09" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_83acdd33-3ee6-44c9-af5b-05a1480305e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_70661846-f144-4145-9c2e-c5fe567332f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2bd1254b-68b2-4b70-add0-8ba9b7a19c09" xlink:to="loc_us-gaap_LitigationSettlementExpense_70661846-f144-4145-9c2e-c5fe567332f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e1fb61a-2025-4ac8-b530-e070d5876e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34e45c72-4bb0-47ad-81dd-d0affecf4056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e1fb61a-2025-4ac8-b530-e070d5876e5a" xlink:to="loc_us-gaap_NetIncomeLoss_34e45c72-4bb0-47ad-81dd-d0affecf4056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ba4045cf-2291-43a0-95f2-a2ddf423a689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e1fb61a-2025-4ac8-b530-e070d5876e5a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ba4045cf-2291-43a0-95f2-a2ddf423a689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fdc4794f-cec9-4dc5-ba8c-e9691efd63f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3e14f174-550a-478e-bd13-0256412c01b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fdc4794f-cec9-4dc5-ba8c-e9691efd63f0" xlink:to="loc_us-gaap_OperatingExpenses_3e14f174-550a-478e-bd13-0256412c01b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd3496c0-050f-4e75-8936-4e2adc6fe359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34c7a9d6-e584-4c2f-9690-b00a485f96eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd3496c0-050f-4e75-8936-4e2adc6fe359" xlink:to="loc_us-gaap_OperatingIncomeLoss_34c7a9d6-e584-4c2f-9690-b00a485f96eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_69ac5eb8-c95f-4ce0-84e3-65befc3eeb26" xlink:href="krys-20220630.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd3496c0-050f-4e75-8936-4e2adc6fe359" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_69ac5eb8-c95f-4ce0-84e3-65befc3eeb26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_da7d9471-6209-49a2-aa8e-9c1a8f7a835b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fd3496c0-050f-4e75-8936-4e2adc6fe359" xlink:to="loc_us-gaap_InterestExpense_da7d9471-6209-49a2-aa8e-9c1a8f7a835b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69bc9e72-74b9-4e97-8e1a-816dac9c65bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_563ca4b7-d196-49c2-9c91-3427b2ba768e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69bc9e72-74b9-4e97-8e1a-816dac9c65bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_563ca4b7-d196-49c2-9c91-3427b2ba768e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42e181db-e9a5-44b0-a970-eb8476e8b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69bc9e72-74b9-4e97-8e1a-816dac9c65bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_42e181db-e9a5-44b0-a970-eb8476e8b23b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e8a3a91-52b7-4f69-98a1-cc88511ee1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_69bc9e72-74b9-4e97-8e1a-816dac9c65bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e8a3a91-52b7-4f69-98a1-cc88511ee1b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fe10c67-bf05-425b-a237-a0da3c554f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22705164-d536-42d8-a278-5adb26cad841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fe10c67-bf05-425b-a237-a0da3c554f79" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22705164-d536-42d8-a278-5adb26cad841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_93b98fa3-822e-4f03-8e7f-b3631b2900de" xlink:href="krys-20220630.xsd#krys_PaymentsForSuitLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fe10c67-bf05-425b-a237-a0da3c554f79" xlink:to="loc_krys_PaymentsForSuitLiability_93b98fa3-822e-4f03-8e7f-b3631b2900de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_104b8ed3-c075-4936-8626-a2db671c8aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0fe10c67-bf05-425b-a237-a0da3c554f79" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_104b8ed3-c075-4936-8626-a2db671c8aa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f294917-fc28-459e-9658-010943acd2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_977c2206-6fc8-418f-a70f-56372f48a8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f294917-fc28-459e-9658-010943acd2d6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_977c2206-6fc8-418f-a70f-56372f48a8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e19fc645-7a53-4b58-bcea-736bf5585970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f294917-fc28-459e-9658-010943acd2d6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e19fc645-7a53-4b58-bcea-736bf5585970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_ca286956-6e6c-45d5-8e46-72262af7cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f294917-fc28-459e-9658-010943acd2d6" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_ca286956-6e6c-45d5-8e46-72262af7cb1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_846a585b-be0d-4f74-9b24-c40196eb34a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_NetIncomeLoss_846a585b-be0d-4f74-9b24-c40196eb34a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2df2c016-2f38-4942-a9d3-538302140a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_DepreciationAndAmortization_2df2c016-2f38-4942-a9d3-538302140a67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_662b7acb-520a-4f00-a967-98b652831f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_ShareBasedCompensation_662b7acb-520a-4f00-a967-98b652831f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_3ce8d4aa-e0f8-4ed1-8c52-d2328c822eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_OtherNoncashExpense_3ce8d4aa-e0f8-4ed1-8c52-d2328c822eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17cee886-f186-4315-b8d4-3807fd6c9e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_17cee886-f186-4315-b8d4-3807fd6c9e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_fc3e7261-3e65-4627-8ece-7dfcaa62801a" xlink:href="krys-20220630.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_fc3e7261-3e65-4627-8ece-7dfcaa62801a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3740d792-5342-4e52-98c5-f4a5fb33eea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3740d792-5342-4e52-98c5-f4a5fb33eea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2246d3b5-d192-42bc-80e7-04678b6406ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2246d3b5-d192-42bc-80e7-04678b6406ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cf19f51b-9804-4a07-8316-8ec6acf77262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_cf19f51b-9804-4a07-8316-8ec6acf77262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b336027a-a33d-4345-9459-cd4e8de13ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d452a090-028f-402c-9972-1138147d0457" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_b336027a-a33d-4345-9459-cd4e8de13ef1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_008790bc-198e-4b37-a1ca-85f5828c979d" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75259e8f-7f9c-4bb9-ab32-6e7326888026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_008790bc-198e-4b37-a1ca-85f5828c979d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75259e8f-7f9c-4bb9-ab32-6e7326888026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fa70799b-240c-48b9-ae98-62921665c5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_008790bc-198e-4b37-a1ca-85f5828c979d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fa70799b-240c-48b9-ae98-62921665c5c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41fa2e33-1e4a-46db-a57f-88cabdea2cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df926cba-0838-4bab-b030-a4fdc3b96400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41fa2e33-1e4a-46db-a57f-88cabdea2cb5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_df926cba-0838-4bab-b030-a4fdc3b96400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_69f2a251-5c13-4936-af26-c841bbfd0f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41fa2e33-1e4a-46db-a57f-88cabdea2cb5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_69f2a251-5c13-4936-af26-c841bbfd0f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6052c8f2-5190-4669-b2d7-3ba8e9d3b27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41fa2e33-1e4a-46db-a57f-88cabdea2cb5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6052c8f2-5190-4669-b2d7-3ba8e9d3b27b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_65065d9c-2979-4bc4-83cf-867529e5c777" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_747211dc-f61f-4a43-927d-a4d9b2e3ff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_65065d9c-2979-4bc4-83cf-867529e5c777" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_747211dc-f61f-4a43-927d-a4d9b2e3ff0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2aaf8de2-08d8-474a-ac64-c516bad59509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_65065d9c-2979-4bc4-83cf-867529e5c777" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2aaf8de2-08d8-474a-ac64-c516bad59509" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_629395ca-ac2a-4fc0-a4ee-718c0d064448" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_727d8337-bf8e-49ad-9cda-b743d41f16c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_629395ca-ac2a-4fc0-a4ee-718c0d064448" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_727d8337-bf8e-49ad-9cda-b743d41f16c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_262f5d09-000a-49c0-9e01-22c9d5bda814" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_629395ca-ac2a-4fc0-a4ee-718c0d064448" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_262f5d09-000a-49c0-9e01-22c9d5bda814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8342f43b-c2c6-484e-b293-1ea11673929c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_629395ca-ac2a-4fc0-a4ee-718c0d064448" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8342f43b-c2c6-484e-b293-1ea11673929c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ec54c15f-f7a4-4d3d-a238-0ee08daad4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cdb2e033-a878-438a-858b-912cb6e72e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ec54c15f-f7a4-4d3d-a238-0ee08daad4cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cdb2e033-a878-438a-858b-912cb6e72e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f176978-f2cb-4a47-913e-4b9c86ccbd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ec54c15f-f7a4-4d3d-a238-0ee08daad4cd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f176978-f2cb-4a47-913e-4b9c86ccbd69" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:href="krys-20220630.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_6fc68303-f315-44d6-b212-0bbb090b8e1f" xlink:href="krys-20220630.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_6fc68303-f315-44d6-b212-0bbb090b8e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d28acca7-5e15-4ff8-a287-bd609661458e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d28acca7-5e15-4ff8-a287-bd609661458e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_59529be7-b678-4c92-92f8-b6b0d20a3c95" xlink:href="krys-20220630.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_krys_AccruedPayrollAndBenefits_59529be7-b678-4c92-92f8-b6b0d20a3c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_509761e6-d852-4aa9-8619-4ce9cfed21a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_us-gaap_AccruedIncomeTaxes_509761e6-d852-4aa9-8619-4ce9cfed21a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_667ae65c-8596-460b-a2ce-069f1808dd7d" xlink:href="krys-20220630.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_667ae65c-8596-460b-a2ce-069f1808dd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_c74765da-69c9-4af8-a478-fa04d7829102" xlink:href="krys-20220630.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_krys_AccruedFinancingFeesCurrent_c74765da-69c9-4af8-a478-fa04d7829102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ad28ccdb-56c2-44f6-b7b0-917228782a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_6b4fecdb-07d2-44cc-86ba-4e1135f31aee" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ad28ccdb-56c2-44f6-b7b0-917228782a7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1738d3fe-6ed1-471b-af25-b7490414f4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_286890c1-d5be-4229-9488-0381008edf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1738d3fe-6ed1-471b-af25-b7490414f4fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_286890c1-d5be-4229-9488-0381008edf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1b6ce489-5dc0-45f1-907e-c4ed0750d4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1738d3fe-6ed1-471b-af25-b7490414f4fe" xlink:to="loc_us-gaap_OperatingLeaseLiability_1b6ce489-5dc0-45f1-907e-c4ed0750d4b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b491b3d6-736b-4dcf-b095-f0351a416a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b491b3d6-736b-4dcf-b095-f0351a416a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_21070bae-c5c2-4b0b-9fb6-bf5785549fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_21070bae-c5c2-4b0b-9fb6-bf5785549fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d783f0a6-da4c-4237-bf79-5f230d4c79ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d783f0a6-da4c-4237-bf79-5f230d4c79ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e6e93d7f-73c7-4b8c-b5b6-411044db6cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e6e93d7f-73c7-4b8c-b5b6-411044db6cf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8d5cec3-e957-4af0-937b-53a1749c5cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8d5cec3-e957-4af0-937b-53a1749c5cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_320ac448-6b6d-4de6-8212-5e3b4418a32c" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ecb06ff-a5d9-41ce-a828-c562fa34fb98" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_320ac448-6b6d-4de6-8212-5e3b4418a32c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cc27d0ea-fede-449a-a31c-2743d2ff37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2783ecb-7d17-45dc-ad3d-6a7a5a17f4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cc27d0ea-fede-449a-a31c-2743d2ff37e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c2783ecb-7d17-45dc-ad3d-6a7a5a17f4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3fb4690-7f04-40a7-a33b-9b09985011b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cc27d0ea-fede-449a-a31c-2743d2ff37e2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3fb4690-7f04-40a7-a33b-9b09985011b8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>krys-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended" id="i5f03f9d4033147f28f85ca48222cf8a1_CondensedConsolidatedStatementsofStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_08f2824e-3ecd-4538-b788-ff381fd7abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_SharesOutstanding_08f2824e-3ecd-4538-b788-ff381fd7abfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7e3b99e-4d37-4317-8707-d87ef1de4676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockholdersEquity_b7e3b99e-4d37-4317-8707-d87ef1de4676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ce4517a-6e4e-41ef-8d08-43c9bdf86bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ce4517a-6e4e-41ef-8d08-43c9bdf86bb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_142dee13-592e-4f15-bd4b-9405dace4b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_142dee13-592e-4f15-bd4b-9405dace4b6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_311f21fe-3280-4a8b-bdd9-3a1d8d819d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_311f21fe-3280-4a8b-bdd9-3a1d8d819d45" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_08d9df2b-805d-4d65-8b1d-386733cc8199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_08d9df2b-805d-4d65-8b1d-386733cc8199" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e75ad3ad-8d3f-448e-a6f0-857074b650e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e75ad3ad-8d3f-448e-a6f0-857074b650e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8ac1b8e-34c1-498f-8cc6-9b8f9783eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8ac1b8e-34c1-498f-8cc6-9b8f9783eb5a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db43e85c-cb39-4d84-b7b5-e9fef7afc547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_NetIncomeLoss_db43e85c-cb39-4d84-b7b5-e9fef7afc547" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e814b912-332e-4fa7-82ee-2c2d4de9549e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f52d5cfa-e2db-4986-a274-d070e0100d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:to="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d56c54ae-4a1b-4fda-b987-63498db7e916_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:to="loc_us-gaap_EquityComponentDomain_d56c54ae-4a1b-4fda-b987-63498db7e916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:to="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95bd2df4-c9d7-4385-9238-e4b409a6d549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_CommonStockMember_95bd2df4-c9d7-4385-9238-e4b409a6d549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8ca43bf3-4a82-4c46-b7f9-fa2353a0b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8ca43bf3-4a82-4c46-b7f9-fa2353a0b3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b52d71c-3628-4471-8d6c-102c8cca8003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b52d71c-3628-4471-8d6c-102c8cca8003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0cb5cf7a-b9b9-40de-8351-491c897191e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_RetainedEarningsMember_0cb5cf7a-b9b9-40de-8351-491c897191e9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="id07fc514cf2d4ba6b1c08b3ac904a562_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_68eb167e-20d5-4471-8301-78179e55fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_68eb167e-20d5-4471-8301-78179e55fc9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f9b66365-47a4-4d7d-92a8-91f7d0046297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f9b66365-47a4-4d7d-92a8-91f7d0046297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:to="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5b7a259-445a-4350-aed5-fad23388ca84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b5b7a259-445a-4350-aed5-fad23388ca84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ac00eff8-96fa-4fd2-9072-d787c5f03b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:to="loc_us-gaap_EquipmentMember_ac00eff8-96fa-4fd2-9072-d787c5f03b14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="i59c2efca605e4dddafcfc95cad52798d_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c931b346-378c-4ecd-ab19-f833086af730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c931b346-378c-4ecd-ab19-f833086af730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2a02268-351a-4d54-9ecf-c3d33adb008a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b2a02268-351a-4d54-9ecf-c3d33adb008a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f6fc9479-f253-41d4-9d39-e3214232af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_us-gaap_ComputerEquipmentMember_f6fc9479-f253-41d4-9d39-e3214232af06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_473b9976-78d3-4d58-aa41-b185d08949ca" xlink:href="krys-20220630.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_krys_LabEquipmentMember_473b9976-78d3-4d58-aa41-b185d08949ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f204d330-3b16-48fb-842f-e6dce1358f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f204d330-3b16-48fb-842f-e6dce1358f69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:to="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a6795b7-48c3-4665-8250-17e730bdafb2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:to="loc_srt_RangeMember_2a6795b7-48c3-4665-8250-17e730bdafb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:to="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7844320-ed93-4615-9034-15ee68dee452" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:to="loc_srt_MinimumMember_f7844320-ed93-4615-9034-15ee68dee452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e65e0b41-f3b0-4455-9864-f9c7382aa952" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:to="loc_srt_MaximumMember_e65e0b41-f3b0-4455-9864-f9c7382aa952" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i63e82df1510c40e69fe96fb37a91156e_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5a1a762-b553-4351-9ae4-5e4e274ebf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5a1a762-b553-4351-9ae4-5e4e274ebf62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5536808f-77f1-4992-8738-a99ebd81acd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5536808f-77f1-4992-8738-a99ebd81acd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_edb42e3f-4344-48df-9649-78740d28eae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_edb42e3f-4344-48df-9649-78740d28eae9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e01c13a-ebda-4f19-bcca-4e1252bf50b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e01c13a-ebda-4f19-bcca-4e1252bf50b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30db6b60-f3b1-4cf2-9eeb-9e7550f29c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30db6b60-f3b1-4cf2-9eeb-9e7550f29c84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff38b041-df02-4775-9bb9-2d568638ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff38b041-df02-4775-9bb9-2d568638ad51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_8d5159ed-f56f-4840-9cf1-882222aef150" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_8d5159ed-f56f-4840-9cf1-882222aef150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ae792166-3559-47fd-ab45-d23bd45d1d07" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ae792166-3559-47fd-ab45-d23bd45d1d07" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6197a381-7ccd-4a84-be9b-ebdd6d837432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6197a381-7ccd-4a84-be9b-ebdd6d837432" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4f2a1d60-20fb-487b-816e-f8b2ee61b609_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4f2a1d60-20fb-487b-816e-f8b2ee61b609_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_08af19a6-8359-4b58-a1c5-985f5ed3b2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:to="loc_us-gaap_CashMember_08af19a6-8359-4b58-a1c5-985f5ed3b2db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c8f23b23-47b2-4a34-83ea-e5ad25098bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c8f23b23-47b2-4a34-83ea-e5ad25098bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4fecb200-9031-48f6-bfe1-ec3228b6b484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4fecb200-9031-48f6-bfe1-ec3228b6b484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f55626d9-e3d7-423b-99c6-a445d93cf0b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f55626d9-e3d7-423b-99c6-a445d93cf0b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5128a9f9-ae13-491c-a28a-9c0518bbfd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5128a9f9-ae13-491c-a28a-9c0518bbfd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7bc651de-2ee1-4290-9d14-6d39af7e0744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7bc651de-2ee1-4290-9d14-6d39af7e0744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_6f65a5e7-7c39-47e5-8ab4-3c712eb674a6" xlink:href="krys-20220630.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_6f65a5e7-7c39-47e5-8ab4-3c712eb674a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17c63cf3-29c6-4624-b65b-316e81b51d24_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:to="loc_srt_RangeMember_17c63cf3-29c6-4624-b65b-316e81b51d24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:to="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_837b5721-b488-4e09-be04-8d2e7e6dd36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:to="loc_srt_MinimumMember_837b5721-b488-4e09-be04-8d2e7e6dd36d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65c4ca42-e2af-4c5b-8a17-035c05ec91d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:to="loc_srt_MaximumMember_65c4ca42-e2af-4c5b-8a17-035c05ec91d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a11b6c7b-5eed-4e6b-a68f-0c0da10377f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_CommercialPaperMember_a11b6c7b-5eed-4e6b-a68f-0c0da10377f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ee0cdc1b-737a-4b2e-a575-201836fd2f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ee0cdc1b-737a-4b2e-a575-201836fd2f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_71bd1bf7-6b9f-4a79-abb0-215efaf32e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_71bd1bf7-6b9f-4a79-abb0-215efaf32e06" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i094d80089d284ff0ad1f377b5548a939_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_da092727-dc50-41fd-a1cb-d430eba866ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_da092727-dc50-41fd-a1cb-d430eba866ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b8d818b-af9b-4975-93c1-972b5b9af717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b8d818b-af9b-4975-93c1-972b5b9af717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5fe4fe5a-e8a4-4d33-800c-3923a7c1cd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5fe4fe5a-e8a4-4d33-800c-3923a7c1cd1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4e3aafc-f883-46e9-98d7-429766f4426b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c4e3aafc-f883-46e9-98d7-429766f4426b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_08836434-0203-4927-abfb-b0a503c5963a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_ConstructionInProgressMember_08836434-0203-4927-abfb-b0a503c5963a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b0ae0da7-975f-49ff-b899-53621dcfa373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b0ae0da7-975f-49ff-b899-53621dcfa373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b440c16-693e-4c58-af72-70c72b5284d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b440c16-693e-4c58-af72-70c72b5284d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f26f6b1e-4c40-4b31-afb4-75325ed096c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_ComputerEquipmentMember_f26f6b1e-4c40-4b31-afb4-75325ed096c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_43441ed8-9517-443e-a481-c740b63988b2" xlink:href="krys-20220630.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_krys_LabEquipmentMember_43441ed8-9517-443e-a481-c740b63988b2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="iea261b8856184e9fae94115e0b698e42_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_6b2958b8-5cd4-4635-a2e0-d7de728ac698" xlink:href="krys-20220630.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_6b2958b8-5cd4-4635-a2e0-d7de728ac698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_52f577b4-450b-4755-8df3-61ce03fbd6d5" xlink:href="krys-20220630.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_52f577b4-450b-4755-8df3-61ce03fbd6d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_b77f08d9-731d-4dea-aea6-95395f5627e3" xlink:href="krys-20220630.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_b77f08d9-731d-4dea-aea6-95395f5627e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7051746c-218d-46d2-ab68-a69a55914d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ConstructionInProgressGross_7051746c-218d-46d2-ab68-a69a55914d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_90ad7261-1775-44c1-bf1a-e0caa244edaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_FinanceLeaseLiability_90ad7261-1775-44c1-bf1a-e0caa244edaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_59f47745-6b07-456b-abd9-940fc05b2c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_EscrowDeposit_59f47745-6b07-456b-abd9-940fc05b2c88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbd193fc-b665-4dbe-82ff-fb9fb793a796" xlink:href="krys-20220630.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbd193fc-b665-4dbe-82ff-fb9fb793a796" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_3b998a55-af64-4475-9554-b487c448a6ab" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CumulativeEscalationClausePercent_3b998a55-af64-4475-9554-b487c448a6ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_f6b05763-2b30-45a9-bf08-7c95162b126d" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CumulativeEscalationClauseTerm_f6b05763-2b30-45a9-bf08-7c95162b126d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c14adcd6-7eb5-428f-bea0-83a912f0d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c14adcd6-7eb5-428f-bea0-83a912f0d704" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_40f4ab6f-3861-404a-9cb4-094cf9525882" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_40f4ab6f-3861-404a-9cb4-094cf9525882" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_37922478-8f1c-42bc-85f5-a055a80fc314" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_37922478-8f1c-42bc-85f5-a055a80fc314" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0c47082f-16d5-41ec-80e6-b00a3bffd3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_OperatingLeaseCost_0c47082f-16d5-41ec-80e6-b00a3bffd3d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f548cd8d-da28-4330-9545-2a1aeb9575da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_VariableLeaseCost_f548cd8d-da28-4330-9545-2a1aeb9575da" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_4f61a36a-c54a-436f-ae37-09589b590706" xlink:href="krys-20220630.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_RemainingCommitmentAmount_4f61a36a-c54a-436f-ae37-09589b590706" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_eb084df8-700b-4e5f-9cbe-40d543d9c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ProfessionalFees_eb084df8-700b-4e5f-9cbe-40d543d9c73f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d26f819e-0e08-4dc8-902e-aa5d1cdfde1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ContractualObligation_d26f819e-0e08-4dc8-902e-aa5d1cdfde1f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_9b244d6b-6b62-41ad-acac-53294251fb38" xlink:href="krys-20220630.xsd#krys_CostOfWorkPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CostOfWorkPercentage_9b244d6b-6b62-41ad-acac-53294251fb38" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_293f8d01-6e5e-488d-b632-98489315cc2e" xlink:href="krys-20220630.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_293f8d01-6e5e-488d-b632-98489315cc2e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_1e04d636-758c-422b-9e63-63e0f4785ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LitigationSettlementExpense_1e04d636-758c-422b-9e63-63e0f4785ce4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_738833f8-082d-4ce5-8388-ac4eaac81399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_738833f8-082d-4ce5-8388-ac4eaac81399" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_4ecdc25d-ddf4-49d2-bcb1-917fd22930df" xlink:href="krys-20220630.xsd#krys_NumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_NumberOfMilestones_4ecdc25d-ddf4-49d2-bcb1-917fd22930df" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2778f358-6d98-4e29-9509-a02de9394036" xlink:href="krys-20220630.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2778f358-6d98-4e29-9509-a02de9394036" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_f0b59d8d-e270-40c8-8bfd-2b78f84e3bbd" xlink:href="krys-20220630.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LitigationSettlementTotalConsideration_f0b59d8d-e270-40c8-8bfd-2b78f84e3bbd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_123e273c-ef06-4d5d-a789-971fa68e58e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_123e273c-ef06-4d5d-a789-971fa68e58e5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6498d4fb-e865-49d7-a4c5-f4788c2611f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6498d4fb-e865-49d7-a4c5-f4788c2611f3" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5c946ba3-f00e-4140-a3b9-e1067c48b9de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5c946ba3-f00e-4140-a3b9-e1067c48b9de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_aa80c096-31ce-41ec-8d90-0257d9578db7" xlink:href="krys-20220630.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_aa80c096-31ce-41ec-8d90-0257d9578db7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_5275fa8e-9028-4151-a81e-59bbc3fe9179" xlink:href="krys-20220630.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_BostonMassachusettsLeaseMember_5275fa8e-9028-4151-a81e-59bbc3fe9179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_6aa6114a-4f67-4dbc-b112-b722842e678c" xlink:href="krys-20220630.xsd#krys_SwitzerlandLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_SwitzerlandLeaseMember_6aa6114a-4f67-4dbc-b112-b722842e678c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_4144edb7-4138-43b7-b17e-49bcc109389e" xlink:href="krys-20220630.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_ClinicalSupplyAgreementMember_4144edb7-4138-43b7-b17e-49bcc109389e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_6e52cd17-afb1-43bd-b566-cb77ab8133ff" xlink:href="krys-20220630.xsd#krys_OtherContractualObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_OtherContractualObligationsMember_6e52cd17-afb1-43bd-b566-cb77ab8133ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_d26dcbc9-9803-4a68-bf61-efabd2deebeb" xlink:href="krys-20220630.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_ASTRAFacilityMember_d26dcbc9-9803-4a68-bf61-efabd2deebeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cdb8297d-6e27-4b59-a833-9032779daed2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:to="loc_srt_LitigationCaseTypeDomain_cdb8297d-6e27-4b59-a833-9032779daed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:to="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_d32673f4-664d-409f-90be-096e9b68411f" xlink:href="krys-20220630.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:to="loc_krys_PeriphaGenMember_d32673f4-664d-409f-90be-096e9b68411f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:href="krys-20220630.xsd#krys_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_31e23c22-c077-44b1-b1fd-661a30e2a208_default" xlink:href="krys-20220630.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:to="loc_krys_MilestonesDomain_31e23c22-c077-44b1-b1fd-661a30e2a208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:href="krys-20220630.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:to="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_9e3a057d-2d62-4085-90f7-54dabfa865f3" xlink:href="krys-20220630.xsd#krys_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneTwoMember_9e3a057d-2d62-4085-90f7-54dabfa865f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_50add9cb-3f43-4248-914b-731b8fa59a5c" xlink:href="krys-20220630.xsd#krys_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneThreeMember_50add9cb-3f43-4248-914b-731b8fa59a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_f831e0c7-b2a2-49ff-84b2-3cc9e44bc799" xlink:href="krys-20220630.xsd#krys_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneOneMember_f831e0c7-b2a2-49ff-84b2-3cc9e44bc799" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="ia7158e9d725447229159bbe212ffdc43_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_be8c3c38-ad10-4fae-a611-56e2a2660e2f" xlink:href="krys-20220630.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_be8c3c38-ad10-4fae-a611-56e2a2660e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e52f0298-ff56-4ef3-85f2-94b74e75860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e52f0298-ff56-4ef3-85f2-94b74e75860f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f79377f2-6fda-46e1-b671-980b7ae9f749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f79377f2-6fda-46e1-b671-980b7ae9f749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a88021d-779c-4615-832d-780c0c7daec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a88021d-779c-4615-832d-780c0c7daec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e42c98aa-a5fa-4ad1-8129-46cb2bf875e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e42c98aa-a5fa-4ad1-8129-46cb2bf875e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03e5f0a4-09ee-4cc3-a44b-00a70b5efe47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03e5f0a4-09ee-4cc3-a44b-00a70b5efe47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_d2cb7fb9-deba-44d2-b8ef-726ac87873e9" xlink:href="krys-20220630.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_d2cb7fb9-deba-44d2-b8ef-726ac87873e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54ab9743-bf21-4457-8f01-5fef9dd17f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54ab9743-bf21-4457-8f01-5fef9dd17f58" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_24e73e53-d398-4026-8b2f-b7ec9fc94c28" xlink:href="krys-20220630.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_PlacementSharesMember_24e73e53-d398-4026-8b2f-b7ec9fc94c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_d191a846-606e-43fc-999a-c73028fafc1b" xlink:href="krys-20220630.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_PublicOfferingMember_d191a846-606e-43fc-999a-c73028fafc1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_b79be96d-ccfa-4f46-81a9-f3c59e4733bd" xlink:href="krys-20220630.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_ATMProgramMember_b79be96d-ccfa-4f46-81a9-f3c59e4733bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_441756a0-3f3d-422f-9d0c-889c96e29678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_441756a0-3f3d-422f-9d0c-889c96e29678" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="iaccdb8eb4591429fb14437ad8d9c59a2_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3bd43b07-e34d-40d4-916d-500fa6a54e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3bd43b07-e34d-40d4-916d-500fa6a54e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72e00e73-ae6d-4671-9c0c-384264747056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72e00e73-ae6d-4671-9c0c-384264747056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ad989530-3205-42ce-b77c-6cedc5ba60a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ad989530-3205-42ce-b77c-6cedc5ba60a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_96c6fcfc-3191-411e-a5e6-5943633a7d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_96c6fcfc-3191-411e-a5e6-5943633a7d01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f366c0f0-ab4f-4704-bcbb-9eb7d59d3ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f366c0f0-ab4f-4704-bcbb-9eb7d59d3ce8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9207d815-c439-4b90-a5df-44fd14461b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9207d815-c439-4b90-a5df-44fd14461b5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be99ee55-4387-43ac-a105-7333e7e4132a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be99ee55-4387-43ac-a105-7333e7e4132a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2283b8c4-329c-4eec-a487-45b859d87f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2283b8c4-329c-4eec-a487-45b859d87f82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97998bc0-2f46-4d2b-a4e5-e069843daf39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97998bc0-2f46-4d2b-a4e5-e069843daf39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c59d8fec-cb7f-41dd-9c80-3efcb8f124d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c59d8fec-cb7f-41dd-9c80-3efcb8f124d3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_88e5b43d-7975-48de-b4c5-e5d6f29f8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_88e5b43d-7975-48de-b4c5-e5d6f29f8e34" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ade8cc8-e1ec-44c0-b594-e934adc9012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43e06106-a3bc-4258-bfae-99d0d7f5dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43e06106-a3bc-4258-bfae-99d0d7f5dd6d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0accfdae-f195-48ae-acc3-6cff83a314be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0accfdae-f195-48ae-acc3-6cff83a314be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0cc352ca-3f94-4b35-ba25-ecfd68fa2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0cc352ca-3f94-4b35-ba25-ecfd68fa2006" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_1e420935-ca82-41b7-92ed-aea47a9b590b" xlink:href="krys-20220630.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_krys_NonEmployeeStockOptionMember_1e420935-ca82-41b7-92ed-aea47a9b590b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_97e1b58c-1738-4402-9f3b-9150360828af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_us-gaap_RestrictedStockMember_97e1b58c-1738-4402-9f3b-9150360828af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_c104864d-bbed-41af-8a57-5159861dcb31" xlink:href="krys-20220630.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_krys_IncentiveStockOptionsMember_c104864d-bbed-41af-8a57-5159861dcb31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28f799ee-5183-4610-8008-571405a20f6a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:to="loc_srt_RangeMember_28f799ee-5183-4610-8008-571405a20f6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:to="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ad38ecb5-4c5a-4ec5-9dec-6e6e188fc30d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:to="loc_srt_MinimumMember_ad38ecb5-4c5a-4ec5-9dec-6e6e188fc30d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f700493-1068-40bd-aba9-9f136afb04da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:to="loc_srt_MaximumMember_8f700493-1068-40bd-aba9-9f136afb04da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae7204f6-21cd-4180-93d5-e920745cd7b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:to="loc_us-gaap_PlanNameDomain_ae7204f6-21cd-4180-93d5-e920745cd7b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:to="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_3dbc8f7e-8613-4e71-b3a9-069c75283907" xlink:href="krys-20220630.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:to="loc_krys_StockIncentivePlanMember_3dbc8f7e-8613-4e71-b3a9-069c75283907" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce43fde8-84ce-48d5-9b5d-6302f4681eaa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce43fde8-84ce-48d5-9b5d-6302f4681eaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_e43aff18-2fb6-4cd3-b6e1-a4f7107539dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:to="loc_srt_DirectorMember_e43aff18-2fb6-4cd3-b6e1-a4f7107539dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_53636c2f-0b20-423c-a9d3-5b54c896731d" xlink:href="krys-20220630.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:to="loc_krys_NonEmployeeStockOptionMember_53636c2f-0b20-423c-a9d3-5b54c896731d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended" id="i570ad2ebfb6c44ef8413e3b8d03f1544_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3d93f14-2d01-46dd-b61e-3b47ea6d69e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3d93f14-2d01-46dd-b61e-3b47ea6d69e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d589f566-66eb-49a2-87c2-0e41be000da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d589f566-66eb-49a2-87c2-0e41be000da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a33a5fc-3dc1-4501-8824-a8420b97eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a33a5fc-3dc1-4501-8824-a8420b97eac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4ac0182f-e6fa-48ea-b6c1-e3aceeb38df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4ac0182f-e6fa-48ea-b6c1-e3aceeb38df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:to="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_155bdf61-f9d7-4039-ad61-37f39406ddd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_155bdf61-f9d7-4039-ad61-37f39406ddd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db6e648c-2971-49ae-af53-65465152a264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db6e648c-2971-49ae-af53-65465152a264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea0a4d75-682e-4224-b039-ad3b9429dc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:to="loc_us-gaap_RestrictedStockMember_ea0a4d75-682e-4224-b039-ad3b9429dc14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="i77afd0e2f72a45a195916c10f0413394_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e15f61b3-aaed-4058-b225-139e37983f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e15f61b3-aaed-4058-b225-139e37983f3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0cf257dc-a50a-42ba-805d-a2d6aaf0d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0cf257dc-a50a-42ba-805d-a2d6aaf0d5f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb9dfd9-6c3a-4a02-b406-2f65d3f605ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb9dfd9-6c3a-4a02-b406-2f65d3f605ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_e736c365-7771-4616-bae2-179436bd3c3e" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_e736c365-7771-4616-bae2-179436bd3c3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_3559bfc8-261f-4a09-8b79-a09467b556e6" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_3559bfc8-261f-4a09-8b79-a09467b556e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:to="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b50d70d4-3abc-4082-8be8-e1eaaa64eef3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b50d70d4-3abc-4082-8be8-e1eaaa64eef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa4cf666-79b5-4a3f-a404-9813e399097f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa4cf666-79b5-4a3f-a404-9813e399097f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended" id="i63f7ec0eac324469b50139502c843b2b_StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be382278-b388-4357-857e-cc815a116a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be382278-b388-4357-857e-cc815a116a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af4cf5ee-a7ee-4ef0-8065-539e421385a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af4cf5ee-a7ee-4ef0-8065-539e421385a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93b1ee52-33c3-4150-aef8-1797f0282409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93b1ee52-33c3-4150-aef8-1797f0282409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cfe01ec8-fc73-4f13-9e47-e4a782248daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cfe01ec8-fc73-4f13-9e47-e4a782248daf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd4db28d-ed98-4232-8912-164edf640795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8cd8121-b541-4b11-b1d8-cf5fdcda8c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8cd8121-b541-4b11-b1d8-cf5fdcda8c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c226db8b-c56b-49ab-9042-11c34579a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c226db8b-c56b-49ab-9042-11c34579a0b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9432d20a-8f42-451b-ac92-1bd71fd9d7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9432d20a-8f42-451b-ac92-1bd71fd9d7d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9767b73-ac3c-4536-832d-097f50730ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9767b73-ac3c-4536-832d-097f50730ee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72311ecb-e00a-43f2-bf77-2b1a16c92df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:to="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_423037c1-26d3-44f3-91f6-68c300315f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_423037c1-26d3-44f3-91f6-68c300315f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_75b4b737-bc14-4191-b015-93fd2487b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:to="loc_us-gaap_RestrictedStockMember_75b4b737-bc14-4191-b015-93fd2487b8a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>krys-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4efcfa6-39c2-406c-8a7c-df8b0105875a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dba3404-ad82-405a-bb91-addbf9db7686_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_c7e93d22-4b10-40ff-8238-4c989380c821_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20220630.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f71e67af-42ec-466a-b196-9ae3d2cea596_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e355c8a6-3b34-41a5-ba6d-e6e10eccb49a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40b247d6-e682-4959-8e61-c490d705c868_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f33d970-16fc-4937-9c6d-7d8bee94e4b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_377dff7b-6e26-4f64-9ad1-7b4419afd51c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_65dddd24-f450-4949-81f6-3efe8905cd0b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f152b391-3fa0-4735-a4bb-10fce62e0152_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4ef963de-3c2c-4943-bea6-6f9eb9d4d8bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d6021fdd-607c-42b2-b2a9-bfbb66063d4b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1199b8dc-cdf7-459d-af3b-551b022dfe04_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d05a8646-f1b2-4c53-8e79-80eac1ab904e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ca8f70e6-7b49-4a9b-b3e8-a13601a9eed9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_61b997a8-1eff-487e-bbb1-24273a7dbe8d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b616121f-a330-405b-b59d-e0f00d811d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61e2b51e-6331-4506-af05-9abeb4847382_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b0debe88-787e-4586-bfc2-35d775d170ea_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_05e17cae-0bf6-4b11-b28e-0c6580f4d6f8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_10d1fe4a-12a1-4fb3-98bd-8c2d3ae58ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_93493656-e251-4c77-942a-d70bdd7c146e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_5e2a8066-7a59-4c5c-9898-a698199f57d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4d914f8f-dfa9-4c2a-a710-1eb64583c98d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_2c87f04b-08e1-4000-aa34-a2118be93a2b_terseLabel_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, liability, annual lease payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_label_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_documentation_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:href="krys-20220630.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:to="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_67dea60b-377d-491d-9b51-5959cd360aa5_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20220630.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_dcfb58e8-8d87-45c3-a680-a09cca8dab2e_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_04558a47-8d09-4131-9714-4eec79fa79ae_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems" xlink:to="lab_krys_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_86e6d20f-b7ff-4ae1-b505-a6774a03794b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1a3696fe-7dd0-4885-ba7e-be12d6b5156c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; 25,664,287 &#160;&#160; shares issued and outstanding at June&#160;30, 2022 &#160;&#160; (unaudited); and 25,207,985 shares issued and outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_a5b44b2e-7aee-43e1-a853-518e8c18af5a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_1ade7b8d-9cec-4b24-b5e8-77e07afe44cb_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental condensed consolidated balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20220630.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SwitzerlandLeaseMember_25501473-362f-4a42-adf2-2ee3ce81fa6e_terseLabel_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_label_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease [Member]</link:label>
    <link:label id="lab_krys_SwitzerlandLeaseMember_documentation_en-US" xlink:label="lab_krys_SwitzerlandLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember" xlink:href="krys-20220630.xsd#krys_SwitzerlandLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SwitzerlandLeaseMember" xlink:to="lab_krys_SwitzerlandLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dec315fe-46c6-4a5a-a1bc-17b389171300_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ced4a5b4-b652-4b0a-aa79-fdb479862e20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_495d7d60-21f2-4499-b6cb-52c6d78fa10c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_99c9ec85-95c8-4cef-9a91-c1409fcef5af_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13843dd2-9132-420a-aea3-a4766c1d2b54_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesDomain_2cf3107b-38b8-484b-b2e0-5f0773c67e7a_terseLabel_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_label_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_documentation_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain" xlink:href="krys-20220630.xsd#krys_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesDomain" xlink:to="lab_krys_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e96c0bf6-c78f-46b9-9d6a-213f8f434e39_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3c22ae64-ff05-4d4c-ad3e-814339044201_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at June 30, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_9893eafb-d77f-4317-bc2c-90499bae85cd_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20220630.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20c77d9a-b38b-476a-b546-c05476d070db_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_04569a5b-b340-43fe-a626-202710331669_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4fa3976d-2f30-41d6-8aaa-cb958e832e51_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8df4946d-315e-423b-b890-7f1997a0b502_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c40a23d1-34f3-43bd-970f-742f6b527f6e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_a117a6c9-00d3-4b8e-8c84-03f6c8a69778_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20220630.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_594c7a36-8895-4f2c-9bde-ea0d80513e94_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_174dcdfd-51f9-4af0-b987-33bbd8c16199_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c0c2a334-e73d-4df0-8216-d603e1c46966_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9de6fa93-c208-4dc9-8fcf-66d096881201_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_125f9267-61e9-4a24-bc72-6b778d6886d7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aa8b1356-40dd-424e-a769-86fb72c16d27_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a86801b7-3b6d-4d52-968d-c0cf0c420f15_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_ce3857a9-ff8b-4f89-8d0f-64683ee1bf64_terseLabel_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_label_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease [Member]</link:label>
    <link:label id="lab_krys_BostonMassachusettsLeaseMember_documentation_en-US" xlink:label="lab_krys_BostonMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston, Massachusetts Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember" xlink:href="krys-20220630.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BostonMassachusettsLeaseMember" xlink:to="lab_krys_BostonMassachusettsLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a776299d-23db-4224-afaf-a78e127acaf9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_498802be-c3d0-4ac9-992e-7b48a115acca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ba43905d-05b7-4bde-919c-34edca204c3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_909f4379-3d4a-46c2-9655-f868d026fe08_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_01b6711d-4ba8-49a7-90a2-cc65f760bd51_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ea3b327-f336-48de-808e-849c434c3c7c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_3f059597-7760-415b-b964-e093e85326f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7f5f85ca-c2b2-40d9-8331-754965f48438_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8c7a6d14-999a-4cf5-9f6f-70a7b94d20aa_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ced65ef6-428e-4067-a426-01e9f7e9c152_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneThreeMember_1dd882ef-f75d-416a-bc03-b92a2793a381_terseLabel_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_label_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_documentation_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember" xlink:href="krys-20220630.xsd#krys_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneThreeMember" xlink:to="lab_krys_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_71bca0a9-38ea-42fd-8c3a-1e65580d4aa6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_b3edebd4-13c7-4744-b1d5-07e29bed4814_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5165df01-d481-45fa-bb21-338106acb665_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a48814c2-e98d-4917-b1d6-bd7fe6ff1bcc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_de7f8780-ab93-45b8-9346-d35e243a5d3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e934d9e-113d-4689-97d4-6013fdd76e0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a1dcf736-0086-4cc3-8488-806b66bfd497_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NumberOfMilestones_66632a95-4d08-4302-b5f3-6618c9fa19bd_terseLabel_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_label_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_documentation_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones" xlink:href="krys-20220630.xsd#krys_NumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NumberOfMilestones" xlink:to="lab_krys_NumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_4bd33820-59d0-4a6e-9f2d-8a8ad8e7e0c9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f70ad89-5313-4a76-92f8-251221de6bce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_03a9e6a2-50ff-4f04-80a9-25525b6e1fba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_92b2ca9a-1773-4dac-b8ba-a1fa59477702_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c134cac8-3acb-4d87-a0ba-9965954b7e17_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0c5dadee-c699-457f-8206-8f6a0f976301_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining six months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_af73d512-a538-475e-bc52-2f7cd9922ca6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_17474433-05f5-4ca8-ac69-c33e3e1374be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1f4ce8ea-cd64-43e6-bc8d-b94a71de8c4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_f0b19657-a2f1-4dbd-b3a4-bc2d84fa6f0d_terseLabel_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contribution</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_label_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Escrow For Reducing Lease Rentals</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_documentation_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to escrow for reducing lease rentals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:href="krys-20220630.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:to="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7fe6fae6-98a9-43bc-a116-93d5dbedb3fd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25e16208-453f-49f3-8642-0a170a2fa534_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad39e489-123e-4750-8dee-2175e21563a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_393fb455-f53d-4c9b-89cc-40df0b307609_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20220630.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_b2915a88-0feb-4c69-a3ee-17a07270d189_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4a7225c3-6032-42ba-86d5-5a8b4bbebd9d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fa6094-411f-4c1d-ad51-81690d4f39b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_91e23e21-930e-4a9a-b84d-5a2360dbf282_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_e52a6341-b9e0-44b9-ad33-273f08fe09d5_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20220630.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_544d4f58-67f7-4e85-b0af-bda99d4507f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e2c2b37b-e8fd-4fe9-8d3d-9e61077339f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4055304e-fbf4-44c5-a0fc-b9d29e20fe98_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e199c338-09df-4319-953d-c9f3e939fa56_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_48226317-1b50-4ca7-a1df-64b0aabbfacf_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b70f7ccf-12d5-4520-8219-1b14935bb5b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2bf7066c-3d55-4e39-bac9-86fea80e6d0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_04b215f2-9815-433f-8f71-0b496a7d4e92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_aadd3d36-105e-4726-b307-766bb4f91b73_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_53cf07bf-f801-4d94-bd8d-c2d0ae7833a8_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20220630.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d673be1a-7b5a-432e-be7c-9de1ea965cac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2a994e2f-87c1-4a3b-a850-44e75b53098d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c55b3337-558b-4afa-add0-9576bc6fc750_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_562edf03-3678-4dc2-8a13-3bd732f43d21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_92f21c4a-3ee2-4428-a346-65541aa403a8_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20220630.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_163da8d7-a84e-46cb-b205-3b6518c594fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ee8d5f11-ba2d-4a15-8ba0-b95e9d942a68_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d6d748d0-698c-419c-a1f0-4bf5a8873ebe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c73a36d0-1c17-4d54-8e89-1016c08dfa86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ae4808d3-4df2-40ca-a575-076906ca6a23_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_42d45095-ebea-4939-90e8-9e59e559dc69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c32b5131-36de-442e-9d8e-af2b68aca021_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_58972f4c-1a38-4ca1-9272-cc511ebe39cd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d104f8d5-6275-4920-aed7-a63cd42ca380_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3541efcf-99c6-4c2c-ab2a-45a5329f2b38_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8f24a08-b626-45f0-91f6-f97e64be9b33_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4dd96e0c-4c41-4492-a63e-3133f2f74e60_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_17225f06-2582-467e-9d9f-4ab54f09b8bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_e2e5748c-c407-469a-8303-5f84cb198053_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7a1212fe-e72c-40cc-8c7b-4cff98d8a3e0_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b947829c-ab64-4198-aa4b-1470c76049e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c7acaec8-bb08-4205-a4a9-a24e2b74f134_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6faf668f-7256-44ca-a6a2-be1cc243b278_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_64c5ed9a-45dd-4610-9929-bf05b0ec53c0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_06c140f1-ef4b-4553-bdcd-80b6891cb75e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e1ba783b-f437-4f25-94ec-8537ac0983c9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a05a64b3-1cd5-46ee-a21b-ecc4e7907408_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6a9801cd-2096-4144-9f61-265fa44d6166_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_4007ee07-0ccf-458e-bd83-e6b4f70fb4df_terseLabel_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued financing costs</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_label_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_documentation_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent" xlink:href="krys-20220630.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedFinancingFeesCurrent" xlink:to="lab_krys_AccruedFinancingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7d6d18dd-a862-4c03-9112-5a37b6262e5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_70638929-6223-4c15-be4c-806845300056_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_804cbe9a-cd48-42f6-9532-856d1656b0cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b0621734-5914-4854-836c-190b996ba9d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_861e8a00-94e7-4784-9358-239c546eb802_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_610572d3-d84e-4df2-8da9-d0cbb96a1c9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fdc47cd-05ec-47fc-8c6f-205e37eca15b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_90f3afd3-0b27-413f-9223-593203977bc3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_77bf76c4-a20d-4370-9723-4fc343a2758d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4174f007-5667-430c-9451-1a3d7a559b3d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66cbc513-2eb2-4b0f-9cde-1bbe9c2a4b30_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_73ba267d-7474-4648-813a-f9331c071fab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e6ae55e8-70cb-4f97-8278-a51633eacae7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PeriphaGenMember_16a7d977-8425-4f15-8e6e-e847d2d02c55_terseLabel_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:label id="lab_krys_PeriphaGenMember_label_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen [Member]</link:label>
    <link:label id="lab_krys_PeriphaGenMember_documentation_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember" xlink:href="krys-20220630.xsd#krys_PeriphaGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PeriphaGenMember" xlink:to="lab_krys_PeriphaGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_55ba25b3-cb39-4400-b527-350b83bd0f9b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_d18d4140-ce73-4797-9afe-79d0a4f29180_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8a983f75-0018-4e2d-bfb5-5d79c6aaf3ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_92789111-2b09-4ffc-8b18-ce3e0e89b2cc_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_4e61423b-60f7-4785-af6b-fb7930ca938e_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, total consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_label_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_documentation_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration" xlink:href="krys-20220630.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementTotalConsideration" xlink:to="lab_krys_LitigationSettlementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_8ff83227-cad7-40c2-834d-732ee9af6f20_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20220630.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_223a7331-5472-47b5-8208-12794589e0bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6d58615d-f768-4947-882a-0e65e3f58ac2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7c5067e1-674d-4ca1-a650-3313c50e85eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0a95e058-7e20-45ce-a6f0-a8329a225c5f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_eed9d1f5-4070-4227-ba80-49b11e5228ef_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_2ae04667-3ad7-4d17-a2cf-0c13f745b1f6_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_label_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClausePercent" xlink:to="lab_krys_CumulativeEscalationClausePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_34a0632f-2d11-46a9-aee7-2f47ca9b495b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5b3723aa-2e0c-40cc-b1d3-fe8b3578d465_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_4422b6e1-7a73-4a89-a881-d273efc59b96_terseLabel_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of potential purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_label_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_documentation_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:href="krys-20220630.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:to="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_251fbc24-ff73-4f8d-8e26-18f1815e289a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_94bc0994-a7ff-430b-90c1-5db6cb39f3a6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_34aedc96-b627-42fd-8b2e-85d950bdd88a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_4f36eb18-e591-400b-8173-5a9ca120efda_terseLabel_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, guaranteed maximum price to be paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_label_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_documentation_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:href="krys-20220630.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:to="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentsForSuitLiability_78cf8b3c-94af-4084-a199-6c5fe500283f_negatedTerseLabel_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of ASTRA build to suit liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_label_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_documentation_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability" xlink:href="krys-20220630.xsd#krys_PaymentsForSuitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentsForSuitLiability" xlink:to="lab_krys_PaymentsForSuitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_9b5ad44b-333b-4d8f-a450-ef49a304a74a_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6744fff4-20e0-4248-9c2e-932ee1e7e774_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_bd0eabbb-cea5-4eaf-8f20-60cf7772a9cc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c4b5af52-2c8c-4cf9-9cbd-6c297f211ecf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_52aeaa70-5cb2-4d2a-99cc-859b0a12c905_terseLabel_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Lease Agreement</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_label_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Lease Agreement [Member]</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_documentation_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:href="krys-20220630.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:to="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_45b9dd99-685f-4c58-a400-1ffefa3ab157_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_81d44d6d-8008-4656-9eef-c208febe356f_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_label_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClauseTerm" xlink:to="lab_krys_CumulativeEscalationClauseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e70a8413-b9cc-42df-859f-4329decbb5c7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_821d105b-a36c-4a24-9c4f-c3e0c608644a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_97744fd6-08a5-4ee1-8143-21a6943a0d22_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6a0d77f9-3416-4c6f-9358-40a0621c5634_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d6340a92-09bc-48c6-9270-e13042c5795b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_677fd958-022e-4cee-b0aa-9c67c97f88c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c56e34ab-bbe9-4bbb-be1a-066ff5a6dfb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eb139c73-45ac-4024-b4c2-ba4a6fa17707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a7db21db-16c8-45e5-8545-eb1d116807b5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1a71091e-5aea-405f-8128-f748e9135482_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_09610d07-f2b9-4cd9-b93e-cf7326d0486e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_a207e369-5b10-498c-9339-16415576d79a_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20220630.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_795c84e5-5e00-48aa-b259-4b807a8b917c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_bca5d91a-9e40-4aa3-883a-dac091c0950c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d99f818d-73e3-4134-8e6c-c1bb5418c23b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7790990b-3c95-4447-a932-e50c4dea683a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5909e127-7a92-4e13-a029-0706c2decad2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e6756ea-50f1-47d2-a05a-ca575373c194_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fabd66ba-d4c2-45dd-9594-560d9fe9f207_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_9585567d-f051-4de7-8bdb-13a7ef9a1967_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from insurance settlement, operating activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_184866ad-9ccc-40e8-b248-d3c21bae08d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1d85a850-c817-4505-8795-eb3870bfd4b4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3f72239c-92a4-471c-b05e-4beafb35f7eb_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_4c9a8811-e0bd-4fbd-9e7d-33777cc3501b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_438df2fc-8fc5-49cc-971b-9e5fd8ff835f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_325c09e8-adb1-4b8d-94f9-3e6106b31e3e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f2adaac-e740-4c37-af8d-59d46515a8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00e1e0fe-d066-4715-9486-c65ce5ed433a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d23a3789-5334-4525-86c9-323747216935_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_cd4b7ab8-3e81-4fe0-82aa-0722e5a5eae4_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_45fb8d18-d583-4ae9-8283-1d419946d5a6_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e85628b2-88ad-40a1-ab81-e92d26a496e5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b3560e01-7ad4-4aad-a018-3a430979e565_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ca2e822a-8843-4f86-961a-d677b1825fff_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_90e861ae-d494-4ab7-ba09-ca3ed79bbed0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5ba65e00-ba65-4840-af34-98f22e71923e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_52ca25dc-f46d-4afa-a7d2-e2b3cacc70e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_035b5257-0a45-4602-9179-4a5277b1f181_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c6b31028-e0f0-4254-b3a0-f6c2c7fbe9e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net, (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_07950e6c-6048-4705-9fa5-81d710db1b7f_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, liability, to be paid, year one</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:to="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_368f4602-09e8-4f0f-bcff-3e20204790b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_23a178ce-f8b4-4b24-bb61-1bd90a623a60_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at June&#160;30, 2022 &#160;&#160; (unaudited) and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_47d8c3e8-0015-4e9f-9396-be2a48e2682b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_bd1caa1e-e120-4eca-914c-9f78a8845552_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20220630.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_41b2db20-a0cb-41dd-a297-c5cb2b6a0958_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_fe486bb5-cfb5-4d76-82d5-3ecd8300eaa7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_4f379458-1c06-45a2-8cd9-22ddc60bd8ea_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_0920d155-875d-42cf-a7c4-562373a6a918_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3875bbd9-9e71-4115-88dc-b415ac39d67c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_95c0c956-709f-4d4c-ac65-705b4fbd5ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_885091bf-260c-4d70-ab34-269ab5b54206_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesTable" xlink:to="lab_krys_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_fd8782d4-b0a9-4302-a10f-05b33e8eec7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a64597a9-96ad-4b0d-a8c0-f280bd3dc8a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_66c01a9c-5bc1-4206-a3ed-6d199ba82a6a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_849ee84e-4361-480a-ac33-6e407177592d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7ecbeb0d-ca97-4a9e-80d4-93abbf359d62_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d63c0df5-ffd0-4427-840b-54af0980b56a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_47f83436-e17b-4597-ab3e-82a4a33a93cd_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_339840e8-3168-46e7-8623-cf004786b473_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7e3bc4fb-63c2-4638-ab75-13c10f5923e1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e2cfca44-e157-4121-abeb-2edb96e03325_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_ae8c5b7b-bded-4e11-813d-eb81e7dc207d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_5656b740-d420-47eb-ab88-3dd271f0c265_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d7ec5507-5def-470f-9e23-a00d6a20dc2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a6429480-dfe3-4ffb-9688-3f0387e0405b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ecef6641-40d3-402b-a738-5017f8f74b56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4af02016-2b66-4dab-8396-266345d9d1ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to settlement of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3e336ae3-815e-45d2-8e79-d71694b2b691_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4df34b2c-f926-4219-8006-78cd713c85c0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c40670e1-6e46-445f-b128-30f6b5dedc6a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_ec025ab4-87f2-4902-a79f-2cadd8cfae89_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20220630.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_724b486f-d625-4ef2-b94c-88ce109dd154_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesAxis_3c84f327-6fd5-4ec2-ab03-b38daed8af75_terseLabel_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_label_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_documentation_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis" xlink:href="krys-20220630.xsd#krys_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesAxis" xlink:to="lab_krys_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_d178c447-ce55-4e92-81ea-1f181631adb2_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_e7b79d3b-85d6-4731-a549-3fb66dbd5057_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2c123850-9a62-4f55-b66f-290595960ba4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f4918773-d50d-4de1-973e-d3e3b8a81c71_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_410011e2-be8c-4d46-9c1b-9179edded271_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_197e0d8d-1479-4dcc-be12-e0f8314babb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d024f926-d56e-4470-9ec3-f84d869f0712_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b3840a82-6550-4a83-ba35-972e0518a1a0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_285c3301-5de2-4ea8-8f54-2c8556227aac_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20220630.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_303b6357-e41b-4688-b5dc-111b1cdaf5b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CostOfWorkPercentage_574334a3-a4d7-4207-a5b3-692cc3635c02_terseLabel_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of work, percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_label_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_documentation_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage" xlink:href="krys-20220630.xsd#krys_CostOfWorkPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CostOfWorkPercentage" xlink:to="lab_krys_CostOfWorkPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e8547ae1-d2fc-4ec5-b172-821f111ffebe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3d091275-983c-4064-aa4d-5dc83b9391dd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_91ddd53a-7fa8-4435-bcf2-e916ed2f829e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff659d79-5aef-4662-9f8d-c2baa568de25_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5c24a345-5cd7-44a9-b752-4fed6cdfe5ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8f33a594-080f-43de-b94f-70484cacbc49_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ced3e129-4df8-40cb-9230-be13ca2e687e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_071f4bb5-9dbe-4e6e-bee8-78e6fb4c4821_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c0699409-bf2a-4f43-91d6-aac617365dbd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_1f5d3ec2-b344-49ce-906d-4a20ff6b681e_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, milestone payments, sales threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_label_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_documentation_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:href="krys-20220630.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:to="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneOneMember_0d637f9e-e1f3-4a31-9e36-e0447f10d3a1_terseLabel_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_krys_MilestoneOneMember_label_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_krys_MilestoneOneMember_documentation_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember" xlink:href="krys-20220630.xsd#krys_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneOneMember" xlink:to="lab_krys_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cc3e1ab8-daf5-42ce-8627-98dc513d5f9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_c2ab4941-f2b5-43ef-9a34-7642377d2837_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20220630.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d1c29907-faf0-4ef2-a9ed-e2f128d9d10f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_a6ded89c-2841-48b1-94bb-bbdaa3fc27d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4d92b358-f0f3-4305-ad2d-ac0d1aff44a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_97ff44dd-6e1b-46c8-a275-f44e04e23bb9_terseLabel_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:href="krys-20220630.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_2381e1b6-459b-409b-ba4d-7357052d0fc4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress, gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2c09edfe-af86-46a6-9853-dddb8f0f5813_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2471a65a-bf72-41cf-8316-0b2125f94619_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ab303372-1e53-4c62-8a64-bcbd9c260181_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_79c145b2-c619-4dbc-8b08-a33510bad3d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4d3813be-95f3-4f6a-b59b-ffe31757d111_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ecf9f8a0-1ae1-452a-af08-1ab75036bee4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6e3509cb-f4f4-476a-afd4-9babbea41c81_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_70b89441-9c66-4569-aa10-f61c5f6bd011_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b7d8565d-10b6-47a7-85e1-ab90357bafba_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_d7513464-37fb-4a4d-bb1e-590ba7e99b36_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_a0855022-5f6e-468a-bdfe-290819c5b9b9_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cf28dc27-4229-4341-a1e9-c68e77b459fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_784b273a-6c32-4b50-86d2-f12937d26af7_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20220630.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_efb9539e-5612-4729-8f24-5bf770cde753_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a8ee4425-e33b-44d2-8a19-a28b8bb885b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b223b401-9738-4b0e-bb85-c54000d16e5a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2f736484-a8f9-48fe-9dee-23c1c9d3b319_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eb44648c-a9eb-4f43-9a9e-79bbc3317ab3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities and currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4767a680-e18a-4267-a6d4-5a67397141e2_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d857a83-82a2-4317-9832-5eeb23609852_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a45e503c-b60e-44f8-963e-f542fceb6893_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ec0d8b61-5390-416d-af5e-424eeb68fa39_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_9185a2f6-2e16-451d-a439-e69b85fab58d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_7e2c7d7a-d5b5-467d-9461-33630a69b2d2_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20220630.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_57967916-82f0-4e0a-992c-270444e928e4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f285251-31ff-47ca-8599-eecdd498f924_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_64363513-2dbe-4c18-a817-4e67a3961dc8_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_007f2808-491a-4947-bcf3-61b94310b8e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_5cdfba6f-ceb5-48bf-ad6c-a274528dca6d_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f39245b4-ae46-4ba3-9f5f-1dc185f03f7f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_47196279-ffe8-4dfb-83d2-e2b38e29d283_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1c8f8012-0095-40e7-8eb7-4f847ba78b94_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_66b8a4f2-c1c9-4b28-ad6c-f7c3ecce6ffd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_ca0e15c0-54a6-492f-ad4c-b92efe2bfba4_terseLabel_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_label_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area Of Real Estate Property Leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_documentation_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:href="krys-20220630.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:to="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9938b129-94cf-45d9-85ca-b0fdcd65fb79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e3b01019-2e71-4b10-ba6b-24a4b168901b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_d85ab379-02d5-4478-ac8c-2d81b5a3791a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9b605a2d-7696-4c61-9477-e0951d17fd9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_0b39b3b4-9df8-4abd-a0a5-c675a4da25ae_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20220630.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_602249d3-fc67-40d0-9425-fa438f094c08_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_004fa6d7-3e97-4763-b397-ea2975fc79e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_c936877a-fc5d-447f-8977-2b2a71f50eaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bc1a4a1e-cf47-4320-bce8-aae7d6875704_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_01738702-1a41-49ee-9eed-267277cc6d51_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2f9226cc-f11a-43b4-9530-514e68a054f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5783fb01-eeab-4f49-8c0f-75896d8d676a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_058e6080-f397-49bc-81f8-4755c8408cad_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c799621-3b5c-42c8-911e-b26b7792d89b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0cf19622-239b-4b82-a20f-4e5e3b4a322a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a6db1e75-3003-4ef4-bbce-1898a86d137d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b16cd0fa-3630-432a-9272-a9ca3d9ef5e5_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_695e2f43-ccc1-4e67-9907-ef5675850bad_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress Current</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent" xlink:href="krys-20220630.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressCurrent" xlink:to="lab_krys_AccruedConstructionInProgressCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_514b9785-9371-4869-83c9-70716628b33e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ea826137-d7e3-4846-a652-47dbd3f45e27_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2b8f5977-05c8-471e-a59f-80b30be4e8b3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29c4586f-e3a8-47a2-aaa2-34fb3c3d829c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ce010ef2-25fe-48f2-ab98-e2f40455e21f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0b59f70c-081f-4109-808f-db94f18f0f2a_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2ecbd515-1dea-4d33-8a0d-801581837d1c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a23f7daa-b3cc-4587-a618-3f9124191c6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered for taxes and forfeitures</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f695699f-53b2-457a-9d05-a6991d0324e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_bdf837a8-39af-44c3-ba32-267865a13112_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OtherContractualObligationsMember_cff4eabc-9c88-4718-8ca7-610a0ea33804_terseLabel_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_label_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations [Member]</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_documentation_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contractual obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember" xlink:href="krys-20220630.xsd#krys_OtherContractualObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OtherContractualObligationsMember" xlink:to="lab_krys_OtherContractualObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_06354806-6ee8-4b19-ab67-ee4118de8c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9f729ecc-8f4a-4882-980f-57b4a7a8d7d2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_fe5d93dc-633b-49ae-b29a-e6a040f4c966_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bd79fc38-c3c4-4560-b091-c610826a9ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2b40c88f-1dcb-49f7-9799-dfdbfef3c47a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneTwoMember_671184be-0fd6-4fb4-80b7-3647fbb408ea_terseLabel_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_label_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_documentation_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember" xlink:href="krys-20220630.xsd#krys_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneTwoMember" xlink:to="lab_krys_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_daf94bfb-8aa9-40fa-883d-8124eb18c9f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c64134a9-e76b-4008-af35-c2fe4378bc33_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_a159ecdf-73af-4942-89fd-3f671b27a56e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_53c75b9c-5a29-4b31-9e66-5b3c7301c473_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ba3b4bf8-c23e-46e1-bf58-d52f8a1a6a79_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_68dfa421-1554-413a-904d-e9399050eeff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f21ae317-ed59-439a-b4f9-e6503458dbff_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dbd4377d-662c-4d04-ba94-40f6f5220424_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_047f85a3-0106-4d89-9e5e-85e42aee82d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_423b271a-7998-40f4-8b3a-3e07b48e8bea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_97ca0ad0-5e47-4107-a316-96cdfb12e8c2_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20220630.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1ffd9a16-3536-440e-9102-20ecb5cff06e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_720c5609-f05b-404c-90ae-12f057a6e946_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0de3fdc1-2e9d-4342-853b-6a2dee95b7ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_97f6031d-3f84-418a-8080-93c620fd2bc1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d238586-9fa7-449a-9383-3852ec5fc55a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b90b9a2e-0931-4626-898b-7463e193c3c3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6d6ab53e-4194-4c22-b9ad-e8e7fb032c58_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d66d0dd8-b274-4515-9782-b5c35b5ca0f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_cbbeecf9-c385-4901-8865-ac3b4f489e3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9862898a-889b-44cf-88ec-e1fae770b545_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_74c51a26-3976-49f3-8c19-aa6e5a08de00_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20220630.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40ec57e8-100e-47b7-896f-e888c257cf41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_63272555-4cfc-43c5-b921-3929aa65b8e5_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:to="lab_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8323056d-ec71-4ab9-89f2-b140968db164_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8ce85d02-93d9-467f-9b2c-2ba2786fa22c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_af62a16a-8855-4c0b-b03c-1ce57bfe64c7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b1d14b92-6630-47eb-bf00-6c75ec3d807a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_71662f85-cb03-4327-89e7-69b0d2f6e2f9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fe74b1da-4fc0-4850-9deb-1c500258ab01_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_1d7c01de-97cd-49ba-9549-0c3368598bf3_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bf4fdb92-5fb5-4a6d-8ff9-9a2749c0f646_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_f3f4a9a4-3f53-40f5-9c2e-e36d4b1782d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7868e2c7-d233-4089-802e-ce57356833fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d40194aa-c964-4414-82f8-20e606765fd5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2531e0b8-ce18-438a-b940-1175bcd2ed78_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9fcbde86-7024-449c-969e-5c4a6717b8cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_72141b2d-5519-4ecd-b5b4-b1cfa0ad9960_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a2fd6913-0381-456e-91c2-95322bc72779_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>krys-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a19ade0d-c5f0-4a0b-856c-556fe9740668,g:032f89f1-bd11-43ca-9358-ad6d1828aa77-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_36c7c560-5063-450a-80d6-527bea3f6a85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentType_36c7c560-5063-450a-80d6-527bea3f6a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1a2db82d-7a65-4df8-abee-80cf0c063026" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentQuarterlyReport_1a2db82d-7a65-4df8-abee-80cf0c063026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3d852f64-d9bf-4442-9e5f-305bb4a6c6b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentPeriodEndDate_3d852f64-d9bf-4442-9e5f-305bb4a6c6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a11ee9c5-108a-474f-bac4-cc0793fbcfb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentTransitionReport_a11ee9c5-108a-474f-bac4-cc0793fbcfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ca53ee8f-9b3f-461e-880e-57803ebec813" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityFileNumber_ca53ee8f-9b3f-461e-880e-57803ebec813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_68bfae5e-460f-4fea-8996-314a8507c573" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityRegistrantName_68bfae5e-460f-4fea-8996-314a8507c573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_59a40173-7fe4-42de-8a8e-2fe8b4ca0393" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_59a40173-7fe4-42de-8a8e-2fe8b4ca0393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_312675b8-a8fe-4b68-9b10-3ffdd2a67511" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityTaxIdentificationNumber_312675b8-a8fe-4b68-9b10-3ffdd2a67511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4803ceba-0999-4973-a568-506cc8938412" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityAddressAddressLine1_4803ceba-0999-4973-a568-506cc8938412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_5e762211-c645-4aad-b5bc-132d40e34839" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityAddressAddressLine2_5e762211-c645-4aad-b5bc-132d40e34839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_56cb9999-ac0d-48ce-9863-ef0f7cab2308" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityAddressCityOrTown_56cb9999-ac0d-48ce-9863-ef0f7cab2308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_01b764e4-122e-4c61-a9cb-ea2793d80093" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityAddressStateOrProvince_01b764e4-122e-4c61-a9cb-ea2793d80093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28ee7bff-eeab-4954-bf94-7a808eeb2fd4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityAddressPostalZipCode_28ee7bff-eeab-4954-bf94-7a808eeb2fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_54794dc8-6364-4404-b093-1d5d42bddb0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_CityAreaCode_54794dc8-6364-4404-b093-1d5d42bddb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5f0c247c-8b1b-440b-9397-2fcf1c4eb5c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_LocalPhoneNumber_5f0c247c-8b1b-440b-9397-2fcf1c4eb5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_583ab0fc-2a72-448d-bd6a-1b2cfce8a409" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_Security12bTitle_583ab0fc-2a72-448d-bd6a-1b2cfce8a409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_52bc2ea2-e3c1-4611-9a9e-b3e3fd248dd6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_TradingSymbol_52bc2ea2-e3c1-4611-9a9e-b3e3fd248dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_68714bf5-570c-48f7-946e-7ead4c9a0500" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityCurrentReportingStatus_68714bf5-570c-48f7-946e-7ead4c9a0500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_da290a30-517b-40de-959c-0374b7d37d08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityInteractiveDataCurrent_da290a30-517b-40de-959c-0374b7d37d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a515435f-bcab-4f9e-b3f1-0cd0d7269ec6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityFilerCategory_a515435f-bcab-4f9e-b3f1-0cd0d7269ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_56c223e6-d874-47b5-9596-72ac9e4505e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntitySmallBusiness_56c223e6-d874-47b5-9596-72ac9e4505e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ad73659c-37fb-4c8e-b0cc-c68ab14cb212" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityEmergingGrowthCompany_ad73659c-37fb-4c8e-b0cc-c68ab14cb212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f9a92320-84cd-4076-91a8-7b153a7deb6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityShellCompany_f9a92320-84cd-4076-91a8-7b153a7deb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_38988011-c8fe-43c0-81c9-9de1760d9b83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_38988011-c8fe-43c0-81c9-9de1760d9b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_68ec270f-873b-44c9-b41c-99e547d96513" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_AmendmentFlag_68ec270f-873b-44c9-b41c-99e547d96513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e8995ffc-aedb-4095-9685-b360ab527053" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentFiscalYearFocus_e8995ffc-aedb-4095-9685-b360ab527053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0f719a9d-cc53-40fc-834d-a6200d656149" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0f719a9d-cc53-40fc-834d-a6200d656149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9288be48-fc2b-4a4d-865e-be5198fc2dba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_EntityCentralIndexKey_9288be48-fc2b-4a4d-865e-be5198fc2dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_413b2cfa-40b1-40ad-ab92-0e112e75438f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_CurrentFiscalYearEndDate_413b2cfa-40b1-40ad-ab92-0e112e75438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8f753d7e-9ec7-4b12-b654-1263f2499a2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d77b86b-b1dd-45af-b7d8-944f6b1f77e4" xlink:to="loc_dei_SecurityExchangeName_8f753d7e-9ec7-4b12-b654-1263f2499a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_52b102f2-c6c3-488b-85f5-c18859d69a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52b102f2-c6c3-488b-85f5-c18859d69a25" xlink:to="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeba7915-7b20-421e-b758-611d619b066c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeba7915-7b20-421e-b758-611d619b066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4477a6a5-3f12-47b6-b4ae-bdceccba6b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4477a6a5-3f12-47b6-b4ae-bdceccba6b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3366db8-acc7-437e-bda5-7060f1c613e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3366db8-acc7-437e-bda5-7060f1c613e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_23a82a6c-960d-49da-87e6-e3c50130c48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a5647800-1c4a-4d7c-ba44-84290717ab5b" xlink:to="loc_us-gaap_AssetsCurrent_23a82a6c-960d-49da-87e6-e3c50130c48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17bd6f11-055c-4f7f-b237-dbf8927d7617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17bd6f11-055c-4f7f-b237-dbf8927d7617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_a1be3094-3515-4ec5-a582-5bb932b0c512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_LongTermInvestments_a1be3094-3515-4ec5-a582-5bb932b0c512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_23b27d92-767d-462f-9644-fdb57344e6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_23b27d92-767d-462f-9644-fdb57344e6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0cab1ffa-769d-4e71-8be1-f4f2059a4a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0cab1ffa-769d-4e71-8be1-f4f2059a4a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_14b70bc9-d3a5-4aa2-984e-1349bfa4f488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d4a3f5f0-1eec-4b09-8566-a333aa81117a" xlink:to="loc_us-gaap_Assets_14b70bc9-d3a5-4aa2-984e-1349bfa4f488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_52b102f2-c6c3-488b-85f5-c18859d69a25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_defdff05-8b8d-4163-ac75-64cea230f7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:to="loc_us-gaap_AccountsPayableCurrent_defdff05-8b8d-4163-ac75-64cea230f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2998cb08-18e3-4f51-8131-c226a5afe8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2998cb08-18e3-4f51-8131-c226a5afe8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e9c2964e-194e-4c58-aca8-9a362e4f33b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_e9c2964e-194e-4c58-aca8-9a362e4f33b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ac49067f-f0bf-41e8-b1f8-39865cd8d4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_dbaf7ee9-342e-4417-a488-4c947b2c765a" xlink:to="loc_us-gaap_LiabilitiesCurrent_ac49067f-f0bf-41e8-b1f8-39865cd8d4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e997b7f8-ab7b-4a72-8d64-b9825780c840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e997b7f8-ab7b-4a72-8d64-b9825780c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7079d64-9571-491a-bf17-60d24cd78d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_Liabilities_b7079d64-9571-491a-bf17-60d24cd78d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_808ba676-0325-49c1-a612-413314161aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_808ba676-0325-49c1-a612-413314161aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e8ace92c-b335-4dfd-9bab-d0030a255e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_PreferredStockValue_e8ace92c-b335-4dfd-9bab-d0030a255e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_407ea1e9-f15d-4155-8e6e-5662bf0f1d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_CommonStockValue_407ea1e9-f15d-4155-8e6e-5662bf0f1d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_58c93d6b-9f42-437a-ba03-428634efad7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_58c93d6b-9f42-437a-ba03-428634efad7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f647cbe7-3b40-446a-85b6-aa0ec8d3ecd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f647cbe7-3b40-446a-85b6-aa0ec8d3ecd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57891a10-1f72-439d-8af1-a271f5e41780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_57891a10-1f72-439d-8af1-a271f5e41780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c47d9afb-63b0-4116-b971-0d788ee34e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1ecef851-4429-43e0-8d65-6a4e8bf61fd4" xlink:to="loc_us-gaap_StockholdersEquity_c47d9afb-63b0-4116-b971-0d788ee34e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30f84e90-2f18-4879-aa29-1df1c76e482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7e46c630-8ddb-40f1-9275-c69d50871ffb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_30f84e90-2f18-4879-aa29-1df1c76e482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_36e48f38-3248-4edb-95e2-0ad215e35f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_36e48f38-3248-4edb-95e2-0ad215e35f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af76fa8e-59a4-4efa-af2d-75a71b97aaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af76fa8e-59a4-4efa-af2d-75a71b97aaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_76af794d-e235-4095-a839-3ecedbf2082a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_PreferredStockSharesIssued_76af794d-e235-4095-a839-3ecedbf2082a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_10b45457-7f0b-480e-94a0-ee327e811083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_10b45457-7f0b-480e-94a0-ee327e811083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5cb77888-4506-4fa3-ae2b-9a4180e88c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5cb77888-4506-4fa3-ae2b-9a4180e88c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_eaae8092-fd2b-4546-9066-20e838fa2360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_eaae8092-fd2b-4546-9066-20e838fa2360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7b9aa33f-05cb-4835-bbd3-3338e380470d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_CommonStockSharesIssued_7b9aa33f-05cb-4835-bbd3-3338e380470d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33bc855b-2495-40ac-9a0d-6617ca9365de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72f9101b-6e0f-4e08-9ffd-d305beb75d71" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33bc855b-2495-40ac-9a0d-6617ca9365de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a798bd3a-33ac-4aed-a97f-430eef4ea851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a798bd3a-33ac-4aed-a97f-430eef4ea851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ffd0f724-6cce-45c1-8e50-dbc33ff3a0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ffd0f724-6cce-45c1-8e50-dbc33ff3a0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7d751b98-495c-4d6f-9de9-1c386f0deb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:to="loc_us-gaap_LitigationSettlementExpense_7d751b98-495c-4d6f-9de9-1c386f0deb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0a0c7e6a-9ca3-49b9-9140-3708b39c347f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44e6f810-56b8-4d07-8b28-c5c179d16806" xlink:to="loc_us-gaap_OperatingExpenses_0a0c7e6a-9ca3-49b9-9140-3708b39c347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b528548e-b766-4597-92c7-cd2cd1b55189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_OperatingIncomeLoss_b528548e-b766-4597-92c7-cd2cd1b55189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_27ec3a68-9f74-40a5-8c4e-e9cb6df4955a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_27ec3a68-9f74-40a5-8c4e-e9cb6df4955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_af976088-535c-46ef-8e42-5d318f347af0" xlink:href="krys-20220630.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_27ec3a68-9f74-40a5-8c4e-e9cb6df4955a" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_af976088-535c-46ef-8e42-5d318f347af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_077805e9-86c4-42a6-b250-235c1c2b1baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_27ec3a68-9f74-40a5-8c4e-e9cb6df4955a" xlink:to="loc_us-gaap_InterestExpense_077805e9-86c4-42a6-b250-235c1c2b1baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8552edf7-2be6-4055-92c6-521334fd6821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_NetIncomeLoss_8552edf7-2be6-4055-92c6-521334fd6821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5b59ae99-b8b0-4550-b148-326a7c712af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5b59ae99-b8b0-4550-b148-326a7c712af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e33e5b4e-6c45-4eac-83c9-7a3dfb5173eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e33e5b4e-6c45-4eac-83c9-7a3dfb5173eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3feb4fbf-83b7-4f24-bfc4-570049be0366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_EarningsPerShareBasic_3feb4fbf-83b7-4f24-bfc4-570049be0366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b6a45489-7492-4285-a484-96accfd0ce92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b6a45489-7492-4285-a484-96accfd0ce92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_36644107-31e8-4365-a864-c30afdbf2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_36644107-31e8-4365-a864-c30afdbf2abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb995a35-cedb-4529-8bbd-8649c1c94300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90913ff9-69cf-420e-beeb-9566fbe39dc1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cb995a35-cedb-4529-8bbd-8649c1c94300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_76b6b9b7-da46-4eea-9a7e-52c0fe648ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_76b6b9b7-da46-4eea-9a7e-52c0fe648ead" xlink:to="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d56c54ae-4a1b-4fda-b987-63498db7e916" xlink:to="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_95bd2df4-c9d7-4385-9238-e4b409a6d549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_CommonStockMember_95bd2df4-c9d7-4385-9238-e4b409a6d549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8ca43bf3-4a82-4c46-b7f9-fa2353a0b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8ca43bf3-4a82-4c46-b7f9-fa2353a0b3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b52d71c-3628-4471-8d6c-102c8cca8003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b52d71c-3628-4471-8d6c-102c8cca8003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0cb5cf7a-b9b9-40de-8351-491c897191e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7c0e98e1-643b-4957-aed1-98d13e76bcda" xlink:to="loc_us-gaap_RetainedEarningsMember_0cb5cf7a-b9b9-40de-8351-491c897191e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d80ef3c4-80af-44eb-911c-91fdcd2ef788" xlink:to="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_81bfe1c0-573b-484c-91e0-dd8ba28b688c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_08f2824e-3ecd-4538-b788-ff381fd7abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_SharesOutstanding_08f2824e-3ecd-4538-b788-ff381fd7abfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7e3b99e-4d37-4317-8707-d87ef1de4676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockholdersEquity_b7e3b99e-4d37-4317-8707-d87ef1de4676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ce4517a-6e4e-41ef-8d08-43c9bdf86bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ce4517a-6e4e-41ef-8d08-43c9bdf86bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_142dee13-592e-4f15-bd4b-9405dace4b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_142dee13-592e-4f15-bd4b-9405dace4b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_311f21fe-3280-4a8b-bdd9-3a1d8d819d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_311f21fe-3280-4a8b-bdd9-3a1d8d819d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_08d9df2b-805d-4d65-8b1d-386733cc8199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_08d9df2b-805d-4d65-8b1d-386733cc8199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e75ad3ad-8d3f-448e-a6f0-857074b650e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e75ad3ad-8d3f-448e-a6f0-857074b650e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8ac1b8e-34c1-498f-8cc6-9b8f9783eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e8ac1b8e-34c1-498f-8cc6-9b8f9783eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db43e85c-cb39-4d84-b7b5-e9fef7afc547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_NetIncomeLoss_db43e85c-cb39-4d84-b7b5-e9fef7afc547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e814b912-332e-4fa7-82ee-2c2d4de9549e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_SharesOutstanding_e814b912-332e-4fa7-82ee-2c2d4de9549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f52d5cfa-e2db-4986-a274-d070e0100d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93d2b4da-a1bb-49b7-8099-11bd604d7fea" xlink:to="loc_us-gaap_StockholdersEquity_f52d5cfa-e2db-4986-a274-d070e0100d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="krys-20220630.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_822fcf46-3313-4124-b4e8-a0298d1da22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:to="loc_us-gaap_NetIncomeLoss_822fcf46-3313-4124-b4e8-a0298d1da22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2f9b4557-3b6a-40e0-995f-2046b3d2f734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:to="loc_us-gaap_DepreciationAndAmortization_2f9b4557-3b6a-40e0-995f-2046b3d2f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_21e6cd0f-3f80-4042-9945-da3a85d0ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:to="loc_us-gaap_ShareBasedCompensation_21e6cd0f-3f80-4042-9945-da3a85d0ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_9cc377db-05a3-45f2-af35-4552992348fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:to="loc_us-gaap_OtherNoncashExpense_9cc377db-05a3-45f2-af35-4552992348fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_10459584-8c69-4157-a743-4f9c0ac4b814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80000b6b-683c-4ba3-a3f4-f17c14b82f4c" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_10459584-8c69-4157-a743-4f9c0ac4b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a7cd502-dcce-44fd-a0a4-e68411c4d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3a7cd502-dcce-44fd-a0a4-e68411c4d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_56df1da0-35b4-4b98-8f6a-f4a2965b3388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_56df1da0-35b4-4b98-8f6a-f4a2965b3388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_0ba40052-1f2c-4ff8-bef2-13552e0fdafb" xlink:href="krys-20220630.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_0ba40052-1f2c-4ff8-bef2-13552e0fdafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b830b816-7667-454f-9fed-8a7baec93034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b830b816-7667-454f-9fed-8a7baec93034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_62af9781-4aff-40da-bc3c-ab56263f8b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa99742f-30f3-4c67-8538-b44d82bd67c8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_62af9781-4aff-40da-bc3c-ab56263f8b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ac8c700-a454-4464-9237-54354c812949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf24de25-25a9-43bf-8665-47c08e613da5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ac8c700-a454-4464-9237-54354c812949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf270c17-86a1-45e3-9fbf-1ee1a312d489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf270c17-86a1-45e3-9fbf-1ee1a312d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0a30c019-19a9-4f50-af5a-fe95da01e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_0a30c019-19a9-4f50-af5a-fe95da01e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_1733553b-ae79-4097-8e33-45cdb67781a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_1733553b-ae79-4097-8e33-45cdb67781a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5294d74a-208c-4517-9553-0f8dcfcdcd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d1248344-c5cc-4eeb-a274-da707e7e29de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5294d74a-208c-4517-9553-0f8dcfcdcd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0b63f280-acda-4bb2-8665-7ed410b3b94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0b63f280-acda-4bb2-8665-7ed410b3b94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_282daab7-ccf2-4620-b917-7b902327e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_282daab7-ccf2-4620-b917-7b902327e12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_55e371c3-d414-4ba1-82dc-0f0892908b61" xlink:href="krys-20220630.xsd#krys_PaymentsForSuitLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:to="loc_krys_PaymentsForSuitLiability_55e371c3-d414-4ba1-82dc-0f0892908b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b637cd7f-31de-4efc-a735-228141880d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a04f5073-05fb-4cf2-b827-d47565aaa364" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b637cd7f-31de-4efc-a735-228141880d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e43df010-3cb3-4bca-97e5-8c431e9f3f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e43df010-3cb3-4bca-97e5-8c431e9f3f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57a4f053-5c90-43ba-ba88-88e382d535de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_57a4f053-5c90-43ba-ba88-88e382d535de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f559c831-e0db-46d8-ad7c-085a06967aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f559c831-e0db-46d8-ad7c-085a06967aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_350b0f49-87b0-4b33-8463-87cf370d739b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_6f8cf647-8545-4d4f-abee-f2c408dfe6bb" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_350b0f49-87b0-4b33-8463-87cf370d739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a0f52eee-7c5f-4b4a-bdf7-a0762d739af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_350b0f49-87b0-4b33-8463-87cf370d739b" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a0f52eee-7c5f-4b4a-bdf7-a0762d739af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_63ccd7bd-5d76-4e92-a4e1-51c8a13478d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_350b0f49-87b0-4b33-8463-87cf370d739b" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_63ccd7bd-5d76-4e92-a4e1-51c8a13478d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20220630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90dbe3c0-adee-4eda-ad85-1602bcac2e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_93b05952-5bc7-4e26-9091-591f586a379c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90dbe3c0-adee-4eda-ad85-1602bcac2e3c" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_93b05952-5bc7-4e26-9091-591f586a379c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e2a404c1-6e76-440d-a7e3-5e016d264c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa8c935a-263f-4690-9896-751070f25bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e2a404c1-6e76-440d-a7e3-5e016d264c63" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa8c935a-263f-4690-9896-751070f25bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_03150c68-6f82-4907-8543-085d9bd8deeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e2a404c1-6e76-440d-a7e3-5e016d264c63" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_03150c68-6f82-4907-8543-085d9bd8deeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d6d5c34-b993-4fd5-901a-96c074045cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ab30eb46-7a06-4145-ac6d-390efad47dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d6d5c34-b993-4fd5-901a-96c074045cc1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ab30eb46-7a06-4145-ac6d-390efad47dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d855d120-e344-47db-9dea-5425aa5fbbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d855d120-e344-47db-9dea-5425aa5fbbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock_a8c90b24-b990-4cc3-8e8c-b004cd59d09a" xlink:href="krys-20220630.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_krys_RisksAndUncertaintiesPolicyTextBlock_a8c90b24-b990-4cc3-8e8c-b004cd59d09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_907ab7a6-68aa-4501-af24-c0854bbf639f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_UseOfEstimates_907ab7a6-68aa-4501-af24-c0854bbf639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_acf5668e-0144-44d7-a5f7-220af9281e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_acf5668e-0144-44d7-a5f7-220af9281e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2c8a4e91-c857-452d-a1db-90d5538a788f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2c8a4e91-c857-452d-a1db-90d5538a788f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_11ffe1f9-1074-4bfc-909e-3fa542c8b3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_11ffe1f9-1074-4bfc-909e-3fa542c8b3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7f830508-0f42-458a-8cdf-0b3d75140a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7f830508-0f42-458a-8cdf-0b3d75140a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8dbbe97-60f6-42bd-a804-c1b9cdb44efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8dbbe97-60f6-42bd-a804-c1b9cdb44efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c2f59427-54c5-4a26-b5a3-2e690e9ab1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_c2f59427-54c5-4a26-b5a3-2e690e9ab1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0a9350d4-557e-4b29-94f9-6e69b8ee5603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0a9350d4-557e-4b29-94f9-6e69b8ee5603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_b6f1e40d-a5c8-411c-993e-97a93aff70e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_b6f1e40d-a5c8-411c-993e-97a93aff70e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fadf63e5-6799-400c-90b0-737f3d3c881d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fadf63e5-6799-400c-90b0-737f3d3c881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fb0fdfe7-8223-46ff-a1ea-16ed7db98a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fb0fdfe7-8223-46ff-a1ea-16ed7db98a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6057debb-4289-4739-a05b-f320f1503bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_432750be-f679-43be-8c04-3c1effb22887" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6057debb-4289-4739-a05b-f320f1503bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39ae1850-a192-40e7-ae58-d56e22fff083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_fd223ff9-967c-42c3-a277-98da1b4a5b2b" xlink:href="krys-20220630.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39ae1850-a192-40e7-ae58-d56e22fff083" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_fd223ff9-967c-42c3-a277-98da1b4a5b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_48aefab5-cd20-4e53-8ae0-4a6ce8c6d211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_48aefab5-cd20-4e53-8ae0-4a6ce8c6d211" xlink:to="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b5b7a259-445a-4350-aed5-fad23388ca84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ac00eff8-96fa-4fd2-9072-d787c5f03b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8ceb1b1c-61a9-492c-9dc2-fa1e58e58c1a" xlink:to="loc_us-gaap_EquipmentMember_ac00eff8-96fa-4fd2-9072-d787c5f03b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:href="krys-20220630.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_a43016c7-c268-4742-9359-6cbf3209e1a4" xlink:to="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_68eb167e-20d5-4471-8301-78179e55fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_68eb167e-20d5-4471-8301-78179e55fc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f9b66365-47a4-4d7d-92a8-91f7d0046297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_db34b672-f805-4a5d-93b0-f34ce8d14fe1" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_f9b66365-47a4-4d7d-92a8-91f7d0046297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d24a96d6-58fc-4699-897a-9e9f97eb9427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d24a96d6-58fc-4699-897a-9e9f97eb9427" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b2a02268-351a-4d54-9ecf-c3d33adb008a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f6fc9479-f253-41d4-9d39-e3214232af06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_us-gaap_ComputerEquipmentMember_f6fc9479-f253-41d4-9d39-e3214232af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_473b9976-78d3-4d58-aa41-b185d08949ca" xlink:href="krys-20220630.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_krys_LabEquipmentMember_473b9976-78d3-4d58-aa41-b185d08949ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f204d330-3b16-48fb-842f-e6dce1358f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fbd4a33-efd5-4657-87ef-b3d881beb328" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f204d330-3b16-48fb-842f-e6dce1358f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:to="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a6795b7-48c3-4665-8250-17e730bdafb2" xlink:to="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7844320-ed93-4615-9034-15ee68dee452" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:to="loc_srt_MinimumMember_f7844320-ed93-4615-9034-15ee68dee452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e65e0b41-f3b0-4455-9864-f9c7382aa952" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_620546e9-b8a8-4740-9146-eeb3cbb831d2" xlink:to="loc_srt_MaximumMember_e65e0b41-f3b0-4455-9864-f9c7382aa952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fb5481a-02c3-4b61-b000-f8e0c7a85801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c931b346-378c-4ecd-ab19-f833086af730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_22fe0274-98af-4695-a1cf-ace991a3c24e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c931b346-378c-4ecd-ab19-f833086af730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20220630.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f649443d-ea23-494e-93d9-0b12ad2817d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0328a834-46f5-4244-8080-541b563da721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f649443d-ea23-494e-93d9-0b12ad2817d3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0328a834-46f5-4244-8080-541b563da721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20220630.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6ab22751-2125-41de-9f36-6e96e95e3821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_45592417-5e2d-49c6-9f47-a00de22c3f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6ab22751-2125-41de-9f36-6e96e95e3821" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_45592417-5e2d-49c6-9f47-a00de22c3f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2e8f3fec-6a84-4eec-8238-015f779cce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_711664b9-2d7e-4850-a151-594127ee504f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2e8f3fec-6a84-4eec-8238-015f779cce3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_711664b9-2d7e-4850-a151-594127ee504f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3d1efe11-d5aa-488c-a53a-6b8bbfd3c171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0711cc7f-555a-4207-9f39-a518929f7451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d1efe11-d5aa-488c-a53a-6b8bbfd3c171" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0711cc7f-555a-4207-9f39-a518929f7451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f983c51-b1ba-45de-a18e-7dcfa87d41c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_0711cc7f-555a-4207-9f39-a518929f7451" xlink:to="loc_us-gaap_NetIncomeLoss_6f983c51-b1ba-45de-a18e-7dcfa87d41c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2406726f-dc2c-4573-9aa1-18f97f78d5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d1efe11-d5aa-488c-a53a-6b8bbfd3c171" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_2406726f-dc2c-4573-9aa1-18f97f78d5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_961f5d58-e05d-447f-a116-3e510119ae09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2406726f-dc2c-4573-9aa1-18f97f78d5b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_961f5d58-e05d-447f-a116-3e510119ae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aefacf23-7438-4a11-b594-bb4b04c9f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2406726f-dc2c-4573-9aa1-18f97f78d5b2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aefacf23-7438-4a11-b594-bb4b04c9f24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_88815307-a9c8-4eb3-9ef5-7d6db7d97d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d1efe11-d5aa-488c-a53a-6b8bbfd3c171" xlink:to="loc_us-gaap_EarningsPerShareBasic_88815307-a9c8-4eb3-9ef5-7d6db7d97d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_44f1bd4c-f764-49e1-ae66-9016be8d01f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d1efe11-d5aa-488c-a53a-6b8bbfd3c171" xlink:to="loc_us-gaap_EarningsPerShareDiluted_44f1bd4c-f764-49e1-ae66-9016be8d01f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4fa63a80-1849-43b1-8540-71ca2cdb9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5759df22-c437-48f1-a7c3-5f25f1b30821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4fa63a80-1849-43b1-8540-71ca2cdb9ea3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5759df22-c437-48f1-a7c3-5f25f1b30821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_de5fa3e3-8c6f-4fdb-8b7b-84885967bb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6ba38482-20d1-4dd3-8b8a-ae7a58e53620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_de5fa3e3-8c6f-4fdb-8b7b-84885967bb9e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6ba38482-20d1-4dd3-8b8a-ae7a58e53620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f8f0591-4b2a-493d-902e-fdd5ca38ed67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f8f0591-4b2a-493d-902e-fdd5ca38ed67" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4f2a1d60-20fb-487b-816e-f8b2ee61b609" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_08af19a6-8359-4b58-a1c5-985f5ed3b2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a3a3028-6f47-4d5e-85db-e6d7fe29dca8" xlink:to="loc_us-gaap_CashMember_08af19a6-8359-4b58-a1c5-985f5ed3b2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_39ec0e34-acaa-4cd7-9d17-2d86c30f0b06" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c8f23b23-47b2-4a34-83ea-e5ad25098bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c8f23b23-47b2-4a34-83ea-e5ad25098bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4fecb200-9031-48f6-bfe1-ec3228b6b484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_561148e9-7b94-4495-81cc-0eb46d58f8c2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4fecb200-9031-48f6-bfe1-ec3228b6b484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f55626d9-e3d7-423b-99c6-a445d93cf0b9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_5128a9f9-ae13-491c-a28a-9c0518bbfd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_5128a9f9-ae13-491c-a28a-9c0518bbfd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7bc651de-2ee1-4290-9d14-6d39af7e0744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7bc651de-2ee1-4290-9d14-6d39af7e0744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_6f65a5e7-7c39-47e5-8ab4-3c712eb674a6" xlink:href="krys-20220630.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_49d7dc09-6edf-4f61-9878-01a72381235f" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_6f65a5e7-7c39-47e5-8ab4-3c712eb674a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17c63cf3-29c6-4624-b65b-316e81b51d24" xlink:to="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_837b5721-b488-4e09-be04-8d2e7e6dd36d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:to="loc_srt_MinimumMember_837b5721-b488-4e09-be04-8d2e7e6dd36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_65c4ca42-e2af-4c5b-8a17-035c05ec91d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1e3cb9c1-aa3d-4739-a2d6-529a69f382f2" xlink:to="loc_srt_MaximumMember_65c4ca42-e2af-4c5b-8a17-035c05ec91d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eec98b7b-bd82-4ce8-ad00-9c3c73cb358b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a11b6c7b-5eed-4e6b-a68f-0c0da10377f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_CommercialPaperMember_a11b6c7b-5eed-4e6b-a68f-0c0da10377f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ee0cdc1b-737a-4b2e-a575-201836fd2f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ee0cdc1b-737a-4b2e-a575-201836fd2f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_71bd1bf7-6b9f-4a79-abb0-215efaf32e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e707b69-0adc-445d-8e3f-9e014040a83f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_71bd1bf7-6b9f-4a79-abb0-215efaf32e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d930366c-2220-4826-8c87-83a5a259b81b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5a1a762-b553-4351-9ae4-5e4e274ebf62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5a1a762-b553-4351-9ae4-5e4e274ebf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5536808f-77f1-4992-8738-a99ebd81acd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5536808f-77f1-4992-8738-a99ebd81acd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_edb42e3f-4344-48df-9649-78740d28eae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_edb42e3f-4344-48df-9649-78740d28eae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e01c13a-ebda-4f19-bcca-4e1252bf50b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8e01c13a-ebda-4f19-bcca-4e1252bf50b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30db6b60-f3b1-4cf2-9eeb-9e7550f29c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_30db6b60-f3b1-4cf2-9eeb-9e7550f29c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff38b041-df02-4775-9bb9-2d568638ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff38b041-df02-4775-9bb9-2d568638ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_8d5159ed-f56f-4840-9cf1-882222aef150" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_8d5159ed-f56f-4840-9cf1-882222aef150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ae792166-3559-47fd-ab45-d23bd45d1d07" xlink:href="krys-20220630.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_ae792166-3559-47fd-ab45-d23bd45d1d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6197a381-7ccd-4a84-be9b-ebdd6d837432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08ab83ac-bbf0-4304-9b41-bb0f49f91ae1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_6197a381-7ccd-4a84-be9b-ebdd6d837432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220630.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fa611f1c-6900-4715-a2a8-037d13c3ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0b4dc929-7a16-4049-8312-f77265a2e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_fa611f1c-6900-4715-a2a8-037d13c3ae72" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0b4dc929-7a16-4049-8312-f77265a2e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7e612837-2728-46d4-ba47-8c9040cef684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_08dd73de-5281-43ed-8e1c-04c6b593e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7e612837-2728-46d4-ba47-8c9040cef684" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_08dd73de-5281-43ed-8e1c-04c6b593e8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5815b5b7-e122-4519-bb4f-3c2d0b9df21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7e612837-2728-46d4-ba47-8c9040cef684" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5815b5b7-e122-4519-bb4f-3c2d0b9df21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f4eb26ea-b8fc-4172-bd2e-fc2b026790a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f4eb26ea-b8fc-4172-bd2e-fc2b026790a2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c4e3aafc-f883-46e9-98d7-429766f4426b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_08836434-0203-4927-abfb-b0a503c5963a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_ConstructionInProgressMember_08836434-0203-4927-abfb-b0a503c5963a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b0ae0da7-975f-49ff-b899-53621dcfa373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b0ae0da7-975f-49ff-b899-53621dcfa373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3b440c16-693e-4c58-af72-70c72b5284d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3b440c16-693e-4c58-af72-70c72b5284d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_f26f6b1e-4c40-4b31-afb4-75325ed096c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_us-gaap_ComputerEquipmentMember_f26f6b1e-4c40-4b31-afb4-75325ed096c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_43441ed8-9517-443e-a481-c740b63988b2" xlink:href="krys-20220630.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_79db3431-86af-4009-8d6d-2996205a21ce" xlink:to="loc_krys_LabEquipmentMember_43441ed8-9517-443e-a481-c740b63988b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_22c44cd5-c354-4c6d-8f2e-b5fa6fb17e14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_da092727-dc50-41fd-a1cb-d430eba866ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_da092727-dc50-41fd-a1cb-d430eba866ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b8d818b-af9b-4975-93c1-972b5b9af717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3b8d818b-af9b-4975-93c1-972b5b9af717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5fe4fe5a-e8a4-4d33-800c-3923a7c1cd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bb9338ee-1392-4377-9e66-b5e0f8b940ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5fe4fe5a-e8a4-4d33-800c-3923a7c1cd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6d673ed2-9f6d-4b98-b226-1d6448ee9f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4d667b73-a397-4fc0-9b10-0f9a49d8fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6d673ed2-9f6d-4b98-b226-1d6448ee9f69" xlink:to="loc_us-gaap_Depreciation_4d667b73-a397-4fc0-9b10-0f9a49d8fbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_285aa541-c3a5-4a8d-b522-8f2f0554595b" xlink:href="krys-20220630.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_285aa541-c3a5-4a8d-b522-8f2f0554595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8ada06b7-933f-4121-a446-218932a4d4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8ada06b7-933f-4121-a446-218932a4d4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_b02fd69f-5388-4d3b-adb5-3fe4724ab659" xlink:href="krys-20220630.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_krys_AccruedPayrollAndBenefits_b02fd69f-5388-4d3b-adb5-3fe4724ab659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_01994510-dce8-481a-9489-01c448ed9d8f" xlink:href="krys-20220630.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_01994510-dce8-481a-9489-01c448ed9d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_c6e04fab-7482-4e67-8bef-15f0e31e7e4c" xlink:href="krys-20220630.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_krys_AccruedFinancingFeesCurrent_c6e04fab-7482-4e67-8bef-15f0e31e7e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_21095416-e92e-4fc9-9664-4d513a1683f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_us-gaap_AccruedIncomeTaxes_21095416-e92e-4fc9-9664-4d513a1683f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2c48ad9a-3d6f-46b3-ab18-b9419bc499b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2c48ad9a-3d6f-46b3-ab18-b9419bc499b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_1923cc83-5e5a-4c80-aa39-cf8a2bef87fe" xlink:href="krys-20220630.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_aa9baa19-b696-4134-99e0-5d6ff56bc87f" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_1923cc83-5e5a-4c80-aa39-cf8a2bef87fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03e7fe6b-4838-4e6d-b870-481471ccabd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bdc2d08a-3069-4485-8086-5123e6bcb99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03e7fe6b-4838-4e6d-b870-481471ccabd0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bdc2d08a-3069-4485-8086-5123e6bcb99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dcb90a8a-1e0f-4831-b070-cec4b91fd491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da92044d-f73a-48e5-8442-2616d253058b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dcb90a8a-1e0f-4831-b070-cec4b91fd491" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_da92044d-f73a-48e5-8442-2616d253058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_3620aca5-0c8c-4975-b208-4f06ff744145" xlink:href="krys-20220630.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dcb90a8a-1e0f-4831-b070-cec4b91fd491" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_3620aca5-0c8c-4975-b208-4f06ff744145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_097920dc-4848-4373-9410-4ef326496c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_097920dc-4848-4373-9410-4ef326496c2f" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5c946ba3-f00e-4140-a3b9-e1067c48b9de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_aa80c096-31ce-41ec-8d90-0257d9578db7" xlink:href="krys-20220630.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_aa80c096-31ce-41ec-8d90-0257d9578db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonMassachusettsLeaseMember_5275fa8e-9028-4151-a81e-59bbc3fe9179" xlink:href="krys-20220630.xsd#krys_BostonMassachusettsLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_BostonMassachusettsLeaseMember_5275fa8e-9028-4151-a81e-59bbc3fe9179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SwitzerlandLeaseMember_6aa6114a-4f67-4dbc-b112-b722842e678c" xlink:href="krys-20220630.xsd#krys_SwitzerlandLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_89564033-1508-47cf-8561-21d1ff007d79" xlink:to="loc_krys_SwitzerlandLeaseMember_6aa6114a-4f67-4dbc-b112-b722842e678c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_c8e5b53f-a328-4f3b-94c5-d2bea3fce5b4" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_4144edb7-4138-43b7-b17e-49bcc109389e" xlink:href="krys-20220630.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_ClinicalSupplyAgreementMember_4144edb7-4138-43b7-b17e-49bcc109389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_6e52cd17-afb1-43bd-b566-cb77ab8133ff" xlink:href="krys-20220630.xsd#krys_OtherContractualObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_OtherContractualObligationsMember_6e52cd17-afb1-43bd-b566-cb77ab8133ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_d26dcbc9-9803-4a68-bf61-efabd2deebeb" xlink:href="krys-20220630.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_629c7a51-6593-40a0-9e09-6c0be4f645d0" xlink:to="loc_krys_ASTRAFacilityMember_d26dcbc9-9803-4a68-bf61-efabd2deebeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cdb8297d-6e27-4b59-a833-9032779daed2" xlink:to="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_d32673f4-664d-409f-90be-096e9b68411f" xlink:href="krys-20220630.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d62f06de-119b-46fd-ae81-20588294d2ca" xlink:to="loc_krys_PeriphaGenMember_d32673f4-664d-409f-90be-096e9b68411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:href="krys-20220630.xsd#krys_MilestonesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:href="krys-20220630.xsd#krys_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesAxis_31e23c22-c077-44b1-b1fd-661a30e2a208" xlink:to="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_9e3a057d-2d62-4085-90f7-54dabfa865f3" xlink:href="krys-20220630.xsd#krys_MilestoneTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneTwoMember_9e3a057d-2d62-4085-90f7-54dabfa865f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_50add9cb-3f43-4248-914b-731b8fa59a5c" xlink:href="krys-20220630.xsd#krys_MilestoneThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneThreeMember_50add9cb-3f43-4248-914b-731b8fa59a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_f831e0c7-b2a2-49ff-84b2-3cc9e44bc799" xlink:href="krys-20220630.xsd#krys_MilestoneOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_69b90555-0bf3-4a8c-8958-d8b804e3a712" xlink:to="loc_krys_MilestoneOneMember_f831e0c7-b2a2-49ff-84b2-3cc9e44bc799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_22618f1c-1003-48b4-9b1a-cf9263f32031" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_6b2958b8-5cd4-4635-a2e0-d7de728ac698" xlink:href="krys-20220630.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_6b2958b8-5cd4-4635-a2e0-d7de728ac698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_52f577b4-450b-4755-8df3-61ce03fbd6d5" xlink:href="krys-20220630.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_52f577b4-450b-4755-8df3-61ce03fbd6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_b77f08d9-731d-4dea-aea6-95395f5627e3" xlink:href="krys-20220630.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_b77f08d9-731d-4dea-aea6-95395f5627e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_7051746c-218d-46d2-ab68-a69a55914d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ConstructionInProgressGross_7051746c-218d-46d2-ab68-a69a55914d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_90ad7261-1775-44c1-bf1a-e0caa244edaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_FinanceLeaseLiability_90ad7261-1775-44c1-bf1a-e0caa244edaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_59f47745-6b07-456b-abd9-940fc05b2c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_EscrowDeposit_59f47745-6b07-456b-abd9-940fc05b2c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbd193fc-b665-4dbe-82ff-fb9fb793a796" xlink:href="krys-20220630.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_fbd193fc-b665-4dbe-82ff-fb9fb793a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_3b998a55-af64-4475-9554-b487c448a6ab" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CumulativeEscalationClausePercent_3b998a55-af64-4475-9554-b487c448a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_f6b05763-2b30-45a9-bf08-7c95162b126d" xlink:href="krys-20220630.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CumulativeEscalationClauseTerm_f6b05763-2b30-45a9-bf08-7c95162b126d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c14adcd6-7eb5-428f-bea0-83a912f0d704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_c14adcd6-7eb5-428f-bea0-83a912f0d704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_40f4ab6f-3861-404a-9cb4-094cf9525882" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear_40f4ab6f-3861-404a-9cb4-094cf9525882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_37922478-8f1c-42bc-85f5-a055a80fc314" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne_37922478-8f1c-42bc-85f5-a055a80fc314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0c47082f-16d5-41ec-80e6-b00a3bffd3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_OperatingLeaseCost_0c47082f-16d5-41ec-80e6-b00a3bffd3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f548cd8d-da28-4330-9545-2a1aeb9575da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_VariableLeaseCost_f548cd8d-da28-4330-9545-2a1aeb9575da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_4f61a36a-c54a-436f-ae37-09589b590706" xlink:href="krys-20220630.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_RemainingCommitmentAmount_4f61a36a-c54a-436f-ae37-09589b590706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_eb084df8-700b-4e5f-9cbe-40d543d9c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ProfessionalFees_eb084df8-700b-4e5f-9cbe-40d543d9c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d26f819e-0e08-4dc8-902e-aa5d1cdfde1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ContractualObligation_d26f819e-0e08-4dc8-902e-aa5d1cdfde1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_9b244d6b-6b62-41ad-acac-53294251fb38" xlink:href="krys-20220630.xsd#krys_CostOfWorkPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_CostOfWorkPercentage_9b244d6b-6b62-41ad-acac-53294251fb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_293f8d01-6e5e-488d-b632-98489315cc2e" xlink:href="krys-20220630.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_293f8d01-6e5e-488d-b632-98489315cc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_1e04d636-758c-422b-9e63-63e0f4785ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LitigationSettlementExpense_1e04d636-758c-422b-9e63-63e0f4785ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_738833f8-082d-4ce5-8388-ac4eaac81399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_738833f8-082d-4ce5-8388-ac4eaac81399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_4ecdc25d-ddf4-49d2-bcb1-917fd22930df" xlink:href="krys-20220630.xsd#krys_NumberOfMilestones"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_NumberOfMilestones_4ecdc25d-ddf4-49d2-bcb1-917fd22930df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2778f358-6d98-4e29-9509-a02de9394036" xlink:href="krys-20220630.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_2778f358-6d98-4e29-9509-a02de9394036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_f0b59d8d-e270-40c8-8bfd-2b78f84e3bbd" xlink:href="krys-20220630.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_krys_LitigationSettlementTotalConsideration_f0b59d8d-e270-40c8-8bfd-2b78f84e3bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_123e273c-ef06-4d5d-a789-971fa68e58e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_123e273c-ef06-4d5d-a789-971fa68e58e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6498d4fb-e865-49d7-a4c5-f4788c2611f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_b3ee5814-9e5c-4a82-bba8-6575c55977c1" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6498d4fb-e865-49d7-a4c5-f4788c2611f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a8b647a8-283d-40cd-874f-8ad6470f9746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a8b647a8-283d-40cd-874f-8ad6470f9746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_957b1587-5d4b-4212-894c-824568c5b6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_957b1587-5d4b-4212-894c-824568c5b6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8dd5f1c4-2a4c-45b7-82fd-117b35b1acc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8dd5f1c4-2a4c-45b7-82fd-117b35b1acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e9bcb8b-1e1b-4b21-a47a-e7826d8ce204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9e9bcb8b-1e1b-4b21-a47a-e7826d8ce204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f1aa3e28-4e51-4e9f-ac2b-354aa15c23fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f1aa3e28-4e51-4e9f-ac2b-354aa15c23fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6dcc40ce-2c54-448c-89a3-4aa9ebfedc4d" xlink:href="krys-20220630.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6dcc40ce-2c54-448c-89a3-4aa9ebfedc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7fa0f23c-0fb5-4d3d-9d46-69c5ede70be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7fa0f23c-0fb5-4d3d-9d46-69c5ede70be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a1162da0-ec22-443a-b1f7-61a17369b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a1162da0-ec22-443a-b1f7-61a17369b7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e4348abf-a0c0-46c8-83f2-df4e02db66d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3880cc0-3494-460f-82cf-efdfa1a141bc" xlink:to="loc_us-gaap_OperatingLeaseLiability_e4348abf-a0c0-46c8-83f2-df4e02db66d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a02fb482-4dc5-4ae4-a6dc-1bd0aa4523d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a02fb482-4dc5-4ae4-a6dc-1bd0aa4523d0" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_99b18a40-a944-4a36-bbec-4b215d208bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_99b18a40-a944-4a36-bbec-4b215d208bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffce6ddf-9442-4ce7-a7c9-ed2ef9709fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ffce6ddf-9442-4ce7-a7c9-ed2ef9709fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97a3eb8e-25ee-45c0-b106-b3d2d08932d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97a3eb8e-25ee-45c0-b106-b3d2d08932d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b60a78a7-3c83-4469-8fcb-0d3672d5fb24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseLiability_b60a78a7-3c83-4469-8fcb-0d3672d5fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab832d58-b7b9-4ef7-a31c-7811049a9638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ab832d58-b7b9-4ef7-a31c-7811049a9638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_44dab09f-3f10-433c-b417-af04e4cadd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_38d39b2e-341a-4e06-bffb-9aff632b77aa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_44dab09f-3f10-433c-b417-af04e4cadd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20220630.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_847152c1-3758-4f9e-83d5-a08a17947aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38a4cc20-5bed-462e-a058-23b0fda768d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_847152c1-3758-4f9e-83d5-a08a17947aa0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38a4cc20-5bed-462e-a058-23b0fda768d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0c59942a-ff42-47a3-82ab-008656c5e6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c59942a-ff42-47a3-82ab-008656c5e6de" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d5ee802c-8a7d-4711-9f7c-c08b55dcbea7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_24e73e53-d398-4026-8b2f-b7ec9fc94c28" xlink:href="krys-20220630.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_PlacementSharesMember_24e73e53-d398-4026-8b2f-b7ec9fc94c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_d191a846-606e-43fc-999a-c73028fafc1b" xlink:href="krys-20220630.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_PublicOfferingMember_d191a846-606e-43fc-999a-c73028fafc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_b79be96d-ccfa-4f46-81a9-f3c59e4733bd" xlink:href="krys-20220630.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_krys_ATMProgramMember_b79be96d-ccfa-4f46-81a9-f3c59e4733bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_441756a0-3f3d-422f-9d0c-889c96e29678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_85f80643-ce04-4a7c-8d7a-10ed979ed40d" xlink:to="loc_us-gaap_OverAllotmentOptionMember_441756a0-3f3d-422f-9d0c-889c96e29678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_2e4f72f7-8600-40de-ba41-ba1f2b37cd0f" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_be8c3c38-ad10-4fae-a611-56e2a2660e2f" xlink:href="krys-20220630.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_be8c3c38-ad10-4fae-a611-56e2a2660e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e52f0298-ff56-4ef3-85f2-94b74e75860f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e52f0298-ff56-4ef3-85f2-94b74e75860f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f79377f2-6fda-46e1-b671-980b7ae9f749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f79377f2-6fda-46e1-b671-980b7ae9f749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a88021d-779c-4615-832d-780c0c7daec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_2a88021d-779c-4615-832d-780c0c7daec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e42c98aa-a5fa-4ad1-8129-46cb2bf875e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_e42c98aa-a5fa-4ad1-8129-46cb2bf875e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03e5f0a4-09ee-4cc3-a44b-00a70b5efe47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03e5f0a4-09ee-4cc3-a44b-00a70b5efe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_d2cb7fb9-deba-44d2-b8ef-726ac87873e9" xlink:href="krys-20220630.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_d2cb7fb9-deba-44d2-b8ef-726ac87873e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54ab9743-bf21-4457-8f01-5fef9dd17f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_90e4d386-2a7e-42fa-abae-dfd8f7eebae4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_54ab9743-bf21-4457-8f01-5fef9dd17f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab0f011-d008-4856-8d90-04c5cbff9589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3c6faf5-74de-4dba-99a1-30772feefcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab0f011-d008-4856-8d90-04c5cbff9589" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a3c6faf5-74de-4dba-99a1-30772feefcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e4a7e7-1b28-4362-9551-1908246314a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0fcd508b-571c-4a64-ac7a-cd78de832c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e4a7e7-1b28-4362-9551-1908246314a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0fcd508b-571c-4a64-ac7a-cd78de832c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_de56aa52-d6f6-4704-bcc1-784854d3a1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e4a7e7-1b28-4362-9551-1908246314a0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_de56aa52-d6f6-4704-bcc1-784854d3a1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_491aaef3-a79b-4142-aa1c-f9a5f75e7c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e4a7e7-1b28-4362-9551-1908246314a0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_491aaef3-a79b-4142-aa1c-f9a5f75e7c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_aec72b4d-830f-4491-bda8-1e00aa59a999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9e4a7e7-1b28-4362-9551-1908246314a0" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_aec72b4d-830f-4491-bda8-1e00aa59a999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e2e279c-b485-4855-b802-9551c8184c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e2e279c-b485-4855-b802-9551c8184c69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0accfdae-f195-48ae-acc3-6cff83a314be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0cc352ca-3f94-4b35-ba25-ecfd68fa2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0cc352ca-3f94-4b35-ba25-ecfd68fa2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_1e420935-ca82-41b7-92ed-aea47a9b590b" xlink:href="krys-20220630.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_krys_NonEmployeeStockOptionMember_1e420935-ca82-41b7-92ed-aea47a9b590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_97e1b58c-1738-4402-9f3b-9150360828af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_us-gaap_RestrictedStockMember_97e1b58c-1738-4402-9f3b-9150360828af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_c104864d-bbed-41af-8a57-5159861dcb31" xlink:href="krys-20220630.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0958d3f-9d69-4541-a49e-8fd3670cd6dc" xlink:to="loc_krys_IncentiveStockOptionsMember_c104864d-bbed-41af-8a57-5159861dcb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28f799ee-5183-4610-8008-571405a20f6a" xlink:to="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ad38ecb5-4c5a-4ec5-9dec-6e6e188fc30d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:to="loc_srt_MinimumMember_ad38ecb5-4c5a-4ec5-9dec-6e6e188fc30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f700493-1068-40bd-aba9-9f136afb04da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_871fd111-7477-45a8-a2de-d26297fb6b38" xlink:to="loc_srt_MaximumMember_8f700493-1068-40bd-aba9-9f136afb04da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ae7204f6-21cd-4180-93d5-e920745cd7b6" xlink:to="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_3dbc8f7e-8613-4e71-b3a9-069c75283907" xlink:href="krys-20220630.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2b5d9d98-8117-45eb-8290-3564b1ba6dee" xlink:to="loc_krys_StockIncentivePlanMember_3dbc8f7e-8613-4e71-b3a9-069c75283907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_ce43fde8-84ce-48d5-9b5d-6302f4681eaa" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_e43aff18-2fb6-4cd3-b6e1-a4f7107539dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:to="loc_srt_DirectorMember_e43aff18-2fb6-4cd3-b6e1-a4f7107539dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_53636c2f-0b20-423c-a9d3-5b54c896731d" xlink:href="krys-20220630.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1df0b949-34a8-4d05-9ad6-c9f930a27fb9" xlink:to="loc_krys_NonEmployeeStockOptionMember_53636c2f-0b20-423c-a9d3-5b54c896731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7437c399-3e15-47f5-92e3-587735c3461a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3bd43b07-e34d-40d4-916d-500fa6a54e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3bd43b07-e34d-40d4-916d-500fa6a54e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72e00e73-ae6d-4671-9c0c-384264747056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_72e00e73-ae6d-4671-9c0c-384264747056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ad989530-3205-42ce-b77c-6cedc5ba60a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ad989530-3205-42ce-b77c-6cedc5ba60a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_96c6fcfc-3191-411e-a5e6-5943633a7d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_96c6fcfc-3191-411e-a5e6-5943633a7d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f366c0f0-ab4f-4704-bcbb-9eb7d59d3ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f366c0f0-ab4f-4704-bcbb-9eb7d59d3ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9207d815-c439-4b90-a5df-44fd14461b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9207d815-c439-4b90-a5df-44fd14461b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be99ee55-4387-43ac-a105-7333e7e4132a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_be99ee55-4387-43ac-a105-7333e7e4132a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2283b8c4-329c-4eec-a487-45b859d87f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2283b8c4-329c-4eec-a487-45b859d87f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97998bc0-2f46-4d2b-a4e5-e069843daf39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97998bc0-2f46-4d2b-a4e5-e069843daf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c59d8fec-cb7f-41dd-9c80-3efcb8f124d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c59d8fec-cb7f-41dd-9c80-3efcb8f124d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_88e5b43d-7975-48de-b4c5-e5d6f29f8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_88e5b43d-7975-48de-b4c5-e5d6f29f8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ade8cc8-e1ec-44c0-b594-e934adc9012c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43e06106-a3bc-4258-bfae-99d0d7f5dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5718b9f-f94b-44b7-9e1a-338dcfa9a0ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43e06106-a3bc-4258-bfae-99d0d7f5dd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd1362f9-ddd5-4ea0-9bf5-1a97f17dadb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd1362f9-ddd5-4ea0-9bf5-1a97f17dadb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0844afac-6397-4b8c-a56c-ea117e8d7b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0844afac-6397-4b8c-a56c-ea117e8d7b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_811f85a8-8a1b-487d-a452-1d88a407b278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_811f85a8-8a1b-487d-a452-1d88a407b278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bd99e842-223c-4e8c-a893-cfa37ef5442d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bd99e842-223c-4e8c-a893-cfa37ef5442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b07fb50-19af-41aa-b2dd-9c4cbf5adf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b07fb50-19af-41aa-b2dd-9c4cbf5adf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4cdb9b97-9bbb-474a-bc57-96bb281eefa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bbbb244b-b786-465f-96d0-2b1202203536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4cdb9b97-9bbb-474a-bc57-96bb281eefa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0238888b-b3c5-4354-be46-9b581314806b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0238888b-b3c5-4354-be46-9b581314806b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5c4f43f-685b-46e6-84bc-ace6907d04bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5c4f43f-685b-46e6-84bc-ace6907d04bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2914c908-4a6c-4499-a3a4-730d31271677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2914c908-4a6c-4499-a3a4-730d31271677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a051c921-18d6-4e5b-96c3-6ea61a09d179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a051c921-18d6-4e5b-96c3-6ea61a09d179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88be2a5d-9552-4d0b-83af-e8e998b0b5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_88be2a5d-9552-4d0b-83af-e8e998b0b5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_865dd059-7a0f-4a6b-bdbf-6c7e797d514a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_865dd059-7a0f-4a6b-bdbf-6c7e797d514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c0514f7-b476-4b5a-ba2f-0ab996c4e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4d15fba-34bc-4818-b2ff-38a81b134613" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6c0514f7-b476-4b5a-ba2f-0ab996c4e0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d1441011-a26c-42ca-94fc-36c5e8130941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d1441011-a26c-42ca-94fc-36c5e8130941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a78adf8c-dc82-4f20-9b43-17a1489d84f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a78adf8c-dc82-4f20-9b43-17a1489d84f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9563983e-e766-4f43-b30f-d7d0dee0d5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a78adf8c-dc82-4f20-9b43-17a1489d84f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9563983e-e766-4f43-b30f-d7d0dee0d5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31bc0f06-d21a-49e9-94b7-a1b92c96cd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31bc0f06-d21a-49e9-94b7-a1b92c96cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_cda48b5d-88f2-4064-8c32-4a9f589de9a0" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_cda48b5d-88f2-4064-8c32-4a9f589de9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5c457967-5814-4f89-9df1-5b3bcd4678a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_cda48b5d-88f2-4064-8c32-4a9f589de9a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5c457967-5814-4f89-9df1-5b3bcd4678a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd7e8bd6-fd1a-4525-b294-cd50f4dc6858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3bd24393-922c-4af3-bf76-597c6997dd05" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd7e8bd6-fd1a-4525-b294-cd50f4dc6858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d248e740-c986-43d8-b73f-c6e21ead4940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d248e740-c986-43d8-b73f-c6e21ead4940" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d589f566-66eb-49a2-87c2-0e41be000da3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a33a5fc-3dc1-4501-8824-a8420b97eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8a33a5fc-3dc1-4501-8824-a8420b97eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4ac0182f-e6fa-48ea-b6c1-e3aceeb38df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5704d8a9-27b1-4c28-8940-42050740d74c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4ac0182f-e6fa-48ea-b6c1-e3aceeb38df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:to="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_155bdf61-f9d7-4039-ad61-37f39406ddd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db6e648c-2971-49ae-af53-65465152a264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db6e648c-2971-49ae-af53-65465152a264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea0a4d75-682e-4224-b039-ad3b9429dc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e95591e-fee5-4d19-8863-3fcbd805afad" xlink:to="loc_us-gaap_RestrictedStockMember_ea0a4d75-682e-4224-b039-ad3b9429dc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9f74f1e1-4ee6-4eb3-a9a0-8111f8fcbfc4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3d93f14-2d01-46dd-b61e-3b47ea6d69e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cfeaabd2-9307-4ccf-a504-1c914690d4cc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c3d93f14-2d01-46dd-b61e-3b47ea6d69e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90ae01a0-bb36-4fce-9eef-c74fe9a70012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90ae01a0-bb36-4fce-9eef-c74fe9a70012" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:to="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b50d70d4-3abc-4082-8be8-e1eaaa64eef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa4cf666-79b5-4a3f-a404-9813e399097f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f56b7646-3895-4761-b485-40cf6bfb9d65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa4cf666-79b5-4a3f-a404-9813e399097f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1fecfb12-6877-4d1c-9bbd-e3977c4f6731" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e15f61b3-aaed-4058-b225-139e37983f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e15f61b3-aaed-4058-b225-139e37983f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0cf257dc-a50a-42ba-805d-a2d6aaf0d5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0cf257dc-a50a-42ba-805d-a2d6aaf0d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb9dfd9-6c3a-4a02-b406-2f65d3f605ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_acb9dfd9-6c3a-4a02-b406-2f65d3f605ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_e736c365-7771-4616-bae2-179436bd3c3e" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_e736c365-7771-4616-bae2-179436bd3c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_3559bfc8-261f-4a09-8b79-a09467b556e6" xlink:href="krys-20220630.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68f3f23e-b628-42d6-a338-9c23026f2d13" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_3559bfc8-261f-4a09-8b79-a09467b556e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220630.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73c37d0a-7d04-4585-92fc-2729692f0611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73c37d0a-7d04-4585-92fc-2729692f0611" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:to="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_423037c1-26d3-44f3-91f6-68c300315f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_75b4b737-bc14-4191-b015-93fd2487b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56ee3e7d-66a8-4923-82b2-bc659e953def" xlink:to="loc_us-gaap_RestrictedStockMember_75b4b737-bc14-4191-b015-93fd2487b8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d14f8a2-2841-4300-bdc1-ee52af19eafa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be382278-b388-4357-857e-cc815a116a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_be382278-b388-4357-857e-cc815a116a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af4cf5ee-a7ee-4ef0-8065-539e421385a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af4cf5ee-a7ee-4ef0-8065-539e421385a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93b1ee52-33c3-4150-aef8-1797f0282409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_93b1ee52-33c3-4150-aef8-1797f0282409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cfe01ec8-fc73-4f13-9e47-e4a782248daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cfe01ec8-fc73-4f13-9e47-e4a782248daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd4db28d-ed98-4232-8912-164edf640795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c656e7a-3fb6-4506-9e7e-4ec38cbcc03c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cd4db28d-ed98-4232-8912-164edf640795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c458048a-8b68-4c76-96a7-2eefb4c975c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8cd8121-b541-4b11-b1d8-cf5fdcda8c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8cd8121-b541-4b11-b1d8-cf5fdcda8c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c226db8b-c56b-49ab-9042-11c34579a0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c226db8b-c56b-49ab-9042-11c34579a0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9432d20a-8f42-451b-ac92-1bd71fd9d7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9432d20a-8f42-451b-ac92-1bd71fd9d7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9767b73-ac3c-4536-832d-097f50730ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f9767b73-ac3c-4536-832d-097f50730ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72311ecb-e00a-43f2-bf77-2b1a16c92df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_12a8c7d9-df4a-4948-937d-7f609d7e6f4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72311ecb-e00a-43f2-bf77-2b1a16c92df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1ea2eb2b-845a-4026-9dca-a77c1e90fa07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_10b7472d-1d0e-4f4e-a14d-456d34214e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1ea2eb2b-845a-4026-9dca-a77c1e90fa07" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_10b7472d-1d0e-4f4e-a14d-456d34214e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>krys-20220630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 krys-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :&!2T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!KCP3\>+SQ)I=G:ZWX0\2^'%675O#OC"Q_L^_M(F&1*\99ALQ@DAOEW+N
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MB'E7![=P002"">ZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
M2U36+;1XT>Z,H5SM'E0/+S_P!3C\:SO^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&
MD_W[O_P N/\ XBC_ (3C2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*
M/^$XTG^_=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_
M !% &]16#_PG&D_W[O\ \ +C_P"(H_X3C2?[]W_X 7'_ ,10!O45@_\ "<:3
M_?N__ "X_P#B*/\ A.-)_OW?_@!<?_$4 ;U%8/\ PG&D_P!^[_\  "X_^(H_
MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
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MTG^_=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !%
M&]16#_PG&D_W[O\ \ +C_P"(H_X3C2?[]W_X 7'_ ,10!O45@_\ "<:3_?N_
M_ "X_P#B*/\ A.-)_OW?_@!<?_$4 ;U%8/\ PG&D_P!^[_\  "X_^(H_X3C2
M?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\ $4 ;
MU%8/_"<:3_?N_P#P N/_ (BC_A.-)_OW?_@!<?\ Q% &]16#_P )QI/]^[_\
M +C_ .(H_P"$XTG^_=_^ %Q_\10!O45@_P#"<:3_ '[O_P  +C_XBC_A.-)_
MOW?_ ( 7'_Q% &]16#_PG&D_W[O_ , +C_XBC_A.-)_OW?\ X 7'_P 10!O4
M5@_\)QI/]^[_ / "X_\ B*/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P
MN/\ XBC_ (3C2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_
M=_\ @!<?_$4 ;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16
M#_PG&D_W[O\ \ +C_P"(H_X3C2?[]W_X 7'_ ,10!O45@_\ "<:3_?N__ "X
M_P#B*KWWQ&T'3+5[F[N;BWMTQNDDL9P!D@#^#U(H Z:BL'_A.-)_OW?_ ( 7
M'_Q%'_"<:3_?N_\ P N/_B* -ZBL'_A.-)_OW?\ X 7'_P 11_PG&D_W[O\
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MX3C2?[]W_P" %Q_\10!O45@_\)QI/]^[_P# "X_^(H_X3C2?[]W_ . %Q_\
M$4 ;U%8/_"<:3_?N_P#P N/_ (BC_A.-)_OW?_@!<?\ Q% &]16#_P )QI/]
M^[_\ +C_ .(H_P"$XTG^_=_^ %Q_\10!O45S,OQ&T&"[@M9+FX2XG#&*,V,^
MY]HR<?)V%6/^$XTG^_=_^ %Q_P#$4 ;U%8/_  G&D_W[O_P N/\ XBC_ (3C
M2?[]W_X 7'_Q% &]16#_ ,)QI/\ ?N__   N/_B*/^$XTG^_=_\ @!<?_$4
M;U%8/_"<:3_?N_\ P N/_B*/^$XTG^_=_P#@!<?_ !% &]16#_PG&D_W[O\
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MI/\ ?N__   N/_B* -ZBL'_A.-)_OW?_ ( 7'_Q%'_"<:3_?N_\ P N/_B*
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M4?\ "<:3_?N__ "X_P#B* -ZBL'_ (3C2?[]W_X 7'_Q%'_"<:3_ '[O_P
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M>HV%XP%X)R<GT!KK:P=5\4_V9XLT+1?LOF?VHL[>?YF/+\M0WW<<YSZC%;U
M!1110 4444 %%%% !1110 4444 %87CG3;G6/!VLV-G'YUU<6LD<4>X+N8C
M&20!^-;M9GB;6O\ A'?#^HZIY/VC[) TWE;MN_:,XS@X_*@!WARUEL/#VEVT
MZ;)X;6*.1<@X8( 1D>XK1JII&H?VKI-E>^7Y7VF!)O+SG;N4'&>_6K= !111
M0 4444 %%%% !1110 4444 %%%% ')2:%?-\58=8$'_$N71VM3-O7_6>=NV[
M<YZ<YQBNMK!?Q3M\<1^'?LN=^GF^^T^9TQ)LV;<?CG/X4>/=>N/"W@7Q'K5H
MD<EUIVFW-Y$DP)1GCB9U# $$C(&<$?6@#>HKX'\+_M_^/OB!\%?A%!X4\/\
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MF1#AALF1&XSUQB@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$;;0#]&*S/$VB_\ "1>']1TOSOL_VN!H?-V[MFX8SC(S^=4?AWX?O?"?P_\
M#.B:E=_;]1TW3+:SN;K<6\Z6.)4=\D G)!//K4GCG4KG1_!VLWUG)Y-U;VLD
MD4FT-M8#(.""#^- &EI%A_96DV5EYGF_9H$A\S&-VU0,X[=*YOQQ\8? 7PQN
M+6#QCXW\.>$Y[M6>WBUS5K>R:95(#%!*ZE@"1DCUK>\.7<M_X>TNYG;?/-:Q
M22-@#+% 2<#W-? ?[?6I:)I'[9W[/]WXC\":A\2]&CTW5O/\+Z7HZ:M<7N8R
M%V6KG;)L8ASGH$+=J /M76/C=X#T7X9ZC\0I/%6G7O@K3XC-<:UI<OV^!4!
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M0><DT =/1110 4444 8+^%]WCB/Q%]JQLT\V/V;R^N9-^_=G\,8_&L[XQ?\
M)(_&_P#V [[_ -)WITFNWR_%6'1Q/_Q+FT=KHP[%_P!9YVW=NQGIQC.*ZV@#
M\:_V85U']DKX9_!O]I*PBN-2\&ZW'=^&/&UH%:9[2$ZA/Y-U%G.Q1L3*C +(
M!UE)KN_V@O$&M?"_]M[Q5\0KKXJW/PE\)>+=!LFT'QPO@R/Q)9W=OY$0:U3(
M8Q99&;Y!\PP6P&4G]6:* /S$T/\ 9CB\:?\ !//XE6WAO7]9\7WJ^(+CQ?H&
MJZEX=.AM)-$D3N]I;M(Q$<JK,%8; 2Y 08R>]_X)RZAJ_P"T=\3_ (A?M%^)
M+?RI[NTL_"VF1L/]7Y,$3W93_9:3801W9^E?;WQ \/ZAXL\"^(=#TK5O[ U+
M4K">SM]5\CSS:/)&4$HCW+N*DY W#D=:XS]F/X"V/[,_P5\/_#ZPU!M7731*
M\VHM!Y)N99)&D=_+W-M&6P!N. !R: /"O^"EWA/Q!=>"_AEXVT/0K[Q';>!O
M%]IKFIV&FQ&2X^RIDLZJ.2 0H/H&W' !(\C_ &EOV@_"7[=&K?"/P!\&3JOB
MS4[7Q99:WJUTNE7%O;Z3;1!@YN'E1<$;R?ER#L(!R5!_22B@#\U_%WQC\#?
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M!SOP]T/7_#?@O2=,\4>)6\8^(+>+;>:XUC'9?;'W$[_(C^2/@@8'IZUT5%%
M!1110 4444 %%%% !1110 5XC^T7^S3_ ,+^\4?"K6?^$C_L+_A!?$46O^3]
MA^T?;=CHWE;O,3R\[/O8;KTKVZB@# \?^%O^$Y\"^(_#GVK[%_;&G7&G_:?+
M\SRO-B9-^W(W8W9QD9QU%>0>'?V0-!A_9%M/@'XEU6;7M'CL&LI=5MH!:S%O
M.:9)40M($9&*D9+#*\\'%>_44 ?(/@S]@WQ WBKP'>_$_P",^J_$[P]X#E2X
M\.Z!+H\-A'#*@ B>XD1W:Y*!4P7P<J><,RGKX?V3=<\._M3:S\7?"/Q,NO#F
MF>)#:'Q)X6;1X;M-2$"; JW#OF$$ <JA8$MAL$ ?1]% 'R!H/["_C7X97NL:
M5\+?C[KG@'X>:I?27TOAE=#M;Z6W,A_>+;7<IW0C'"D*2, DL>3Z%J7[*IOO
MVBOAK\4CXONYSX,T"30_L-_;?:+C4-T<B>?+<^8,/^\W']V=Q!Y&>/?:* /E
M'P?^PG_PB?[+?Q%^#G_";_:O^$OU"YOO[:_LG9]D\XQ'9Y/GG?CRNN]<[N@Q
M7T5\-?!__"O/AWX7\+?:_P"T/[$TRVTW[7Y7E^=Y,2Q[]F3MSMSC)QGJ:Z2B
M@ HHHH **** "BBB@ HHHH **** /$?BU^S5_P +1^/WPF^)G_"1_P!F?\(&
M]V_]E_8?-^W>>JK_ *WS%\O;M_NMG/:LGX=_LE_\(#XB^/&J?\)5]O\ ^%HS
MO/Y7]G>7_9FY)EQGS3YV/.ST3[OOQ]"44 ?'%Y_P3O4?!7X3^%M)^(]YH7CC
MX:W4UUHOC*STQ2,RS&5U>T:4AE/RC!D_AYR&*G8\"_L-ZIX9\;?$GQ9KOQ5U
M+QEKOCKPM)X?O[O4]+B1HIG !GC6-U58@ H6 *,8^_7U?10!\?7/_!/&U;X%
M_"[P?9>/KS2/&WPXNY;W0O&EEIJ I(\YE8/:M(P9,[?E\SDH#G!*F[X__8<\
M1?%KX6PZ-XV^-&L^(_&]GKT'B'3O%$VD6\=M930Q^6D::>I$?ED$L5W#+8)/
M4'ZTHH ^8O@G^QWKWP[^-GB+XF^,_BE=?$C7O$&@C1-0^T:-%8 XD0AXQ%)M
MC0)&J^6%Z[FW<XKBO#/_  3U\0^&?@7X[^#Z?&6YO? &N0M'H^FW/AV$MH[-
M=+.TC2K*'G)"[<91<L6 '2OM*B@#Y6\;_L/7FI2?#/Q#X)^)5]X!^(_@?0H?
M#T7B6VTJ*[AOK5(]A6:TD?:<G<0"Y W'(8A2*%O_ ,$_;8_!CXJ>&=2\?7VM
M^._B3)%-KOC;4-/0LS1R*Z+':K(JI&,-A _&[KA54?7%% 'SKXR_9$_X2W3/
M@%:?\)9]D_X55=V=UO\ [-W_ -J>1%''MQYH\G=Y><_/C/?%?15%% !1110
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M!XC_ .>6E_G)1_PD'B/_ )Y:7^<E '9T5QG_  D'B/\ YY:7^<E'_"0>(_\
MGEI?YR4 =G17&?\ "0>(_P#GEI?YR4?\)!XC_P">6E_G)0!V=%<9_P )!XC_
M .>6E_G)1_PD'B/_ )Y:7^<E '9T5QG_  D'B/\ YY:7^<E'_"0>(_\ GEI?
MYR4 =G17&?\ "0>(_P#GEI?YR4?\)!XC_P">6E_G)0!V=%<9_P )!XC_ .>6
ME_G)1_PD'B/_ )Y:7^<E '9T5QG_  D'B/\ YY:7^<E'_"0>(_\ GEI?YR4
M=G17&?\ "0>(_P#GEI?YR4?\)!XC_P">6E_G)0!V=%<9_P )!XC_ .>6E_G)
M1_PD'B/_ )Y:7^<E '9T5QG_  D'B/\ YY:7^<E'_"0>(_\ GEI?YR4 =G17
M&?\ "0>(_P#GEI?YR4?\)!XC_P">6E_G)0!V=%<9_P )!XC_ .>6E_G)1_PD
M'B/_ )Y:7^<E '9T5QG_  D'B/\ YY:7^<E'_"0>(_\ GEI?YR4 =G17&?\
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M (2#Q'_SRTO\Y*/^$@\1_P#/+2_SDH [.BN,_P"$@\1_\\M+_.2C_A(/$?\
MSRTO\Y* .SHKC/\ A(/$?_/+2_SDH_X2#Q'_ ,\M+_.2@#LZ*XS_ (2#Q'_S
MRTO\Y*/^$@\1_P#/+2_SDH [.BN,_P"$@\1_\\M+_.2C_A(/$?\ SRTO\Y*
M.SHKC/\ A(/$?_/+2_SDJYH^L:W=:C#%=1Z>MNV=YA+[^A/&>* .GHHHH **
M** "BBB@ HHHH ***YOQ5(R:[X-"L5#:M(& /4?8;LX/X@?E5PCSNWK^"N1.
M7*K^GXNQI:]_QYI_UT'\C6#6]KW_ !YI_P!=!_(U@U!84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8_B[Q!_P (KX=N]4^S_:O(V?NM^S=N=5ZX./O9Z=JV*Q_%
MWA__ (2KP[=Z7]H^R^?L_>[-^W:ZMTR,_=QU[T ;%%%% !1110 4444 %%%%
M !1110 4444 %8_AOQ!_PD,>H-]G^S_9+V6TQOW;MF/FZ#&<]*V*Q_#?A_\
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MR/[T9[FM;Q%9W.K?%30X+C3+"^T^WLIKB/[5.24;S(090AB(WKT7YOXCRO<
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M1CC- '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%7-(_P"0A%^/\C5.KFD?\A"+\?Y&@#I**** "BBB@ HHHH **** "N9\6?\
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MJ!44K*B[2"</)RP]5K%\,^#]+\(Q7*:='<;KAP\TUY>37<TA"A5!DF=G( &
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M994##J,J2,\C\Z +M%<'??$:_L9=5N#H]L^DZ;?I82S"_87#EC&-R1>5M/\
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M&^"/^@)_Y-S_ /Q='_"C?!'_ $!/_)N?_P"+H^O4^S_KYA]5GW1\FT5]9?\
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M-%>VM98F1=2C(C$H(QPC<_\  AD>PIG@WX6>$_"&K164@_M37?)^TA[J,D!
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MZ3(SV%I-*GE6ZLCH4 " L,/P7+,-HP>3G4U;PC9ZQ?75W-).LEQI\FFN(V4
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M'&1Z5J4 %%%% !1110 4444 %7-(_P"0A%^/\C5.KFD?\A"+\?Y&@#I****
M"BBB@ HHHH **** "N9\6?\ (>\%_P#87D_](+NNFKF?%G_(>\%_]A>3_P!(
M+NMZ/Q/T?Y,QK?"O5?FC4U[_ (\T_P"N@_D:P:WM>_X\T_ZZ#^1K!K V"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4&^S_9_LE[+:8W[MVS'S=!C.>E &Q1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %8_B[P__P )5X=N]+^T?9?/
MV?O=F_;M=6Z9&?NXZ]ZV*YOXBZO=Z#X-U"^L9?(NHO+V2;0V,R*IX((Z$T =
M)1110 4444 %%%% !1110 4444 %%%% !6/X;\/_ /"/1Z@GVC[1]KO9;O.S
M;MWX^7J<XQUK8KF_!&KW>L0ZPUW+YQM]3GMX_E"[8U(VC@<]>IYH Z2BBB@
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MN<XST[9Q724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S2/\
MD(1?C_(U3JYI'_(0B_'^1H Z2BBB@ HHHH **** "BBB@ KF?%G_ "'O!?\
MV%Y/_2"[KIJYGQ9_R'O!?_87D_\ 2"[K>C\3]'^3,:WPKU7YHW[RT2\C".6
M!W?+53^P;?\ OR?F/\*TJ*P-C-_L&W_OR?F/\*/[!M_[\GYC_"M*B@#-_L&W
M_OR?F/\ "C^P;?\ OR?F/\*TJ* ,W^P;?^_)^8_PH_L&W_OR?F/\*TJ* ,W^
MP;?^_)^8_P */[!M_P"_)^8_PK2HH S?[!M_[\GYC_"C^P;?^_)^8_PK2HH
MS?[!M_[\GYC_  H_L&W_ +\GYC_"M*B@#-_L&W_OR?F/\*/[!M_[\GYC_"M*
MB@#-_L&W_OR?F/\ "C^P;?\ OR?F/\*TJ* ,W^P;?^_)^8_PH_L&W_OR?F/\
M*TJ* ,W^P;?^_)^8_P */[!M_P"_)^8_PK2HH S?[!M_[\GYC_"C^P;?^_)^
M8_PK2HH S?[!M_[\GYC_  H_L&W_ +\GYC_"M*B@#-_L&W_OR?F/\*/[!M_[
M\GYC_"M*B@#-_L&W_OR?F/\ "C^P;?\ OR?F/\*TJ* ,W^P;?^_)^8_PH_L&
MW_OR?F/\*TJ* ,W^P;?^_)^8_P */[!M_P"_)^8_PK2HH S?[!M_[\GYC_"C
M^P;?^_)^8_PK2HH S?[!M_[\GYC_  H_L&W_ +\GYC_"M*B@#-_L&W_OR?F/
M\*/[!M_[\GYC_"M*B@#-_L&W_OR?F/\ "C^P;?\ OR?F/\*TJ* ,W^P;?^_)
M^8_PH_L&W_OR?F/\*TJ* ,W^P;?^_)^8_P */[!M_P"_)^8_PK2HH S?[!M_
M[\GYC_"C^P;?^_)^8_PK2HH S?[!M_[\GYC_  H_L&W_ +\GYC_"M*B@#-_L
M&W_OR?F/\*/[!M_[\GYC_"M*B@#-_L&W_OR?F/\ "C^P;?\ OR?F/\*TJ* ,
MW^P;?^_)^8_PH_L&W_OR?F/\*TJ* ,W^P;?^_)^8_P */[!M_P"_)^8_PK2H
MH S?[!M_[\GYC_"J>K^"M,U[3Y;&^62>UEQOCW[<X(8<C!Z@5O5P?QT_Y)9K
M?_;#_P!'QT =5_8-O_?D_,?X4?V#;_WY/S'^%:5% &;_ &#;_P!^3\Q_A1_8
M-O\ WY/S'^%:5% &;_8-O_?D_,?X4?V#;_WY/S'^%:5% &;_ &#;_P!^3\Q_
MA1_8-O\ WY/S'^%:5% &;_8-O_?D_,?X4?V#;_WY/S'^%:5% &;_ &#;_P!^
M3\Q_A1_8-O\ WY/S'^%:5% &;_8-O_?D_,?X53TWP5IFCK<+:+)$+B9KB3Y]
MVZ1OO'GITZ#BMZN#^$?_ !Z^*/\ L8+S^:T =5_8-O\ WY/S'^%']@V_]^3\
MQ_A6E10!F_V#;_WY/S'^%']@V_\ ?D_,?X5I44 9O]@V_P#?D_,?X4?V#;_W
MY/S'^%:5% &;_8-O_?D_,?X4?V#;_P!^3\Q_A6E10!F_V#;_ -^3\Q_A1_8-
MO_?D_,?X5I44 9O]@V_]^3\Q_A1_8-O_ 'Y/S'^%:5% &#<>"M,NM2M+^59&
MN[0.(9-^-NX8;CH<CUJY_8-O_?D_,?X5ROBK_DK'@;_KG??^BA7>4 9O]@V_
M]^3\Q_A1_8-O_?D_,?X5I44 9O\ 8-O_ 'Y/S'^%']@V_P#?D_,?X5I44 9O
M]@V_]^3\Q_A1_8-O_?D_,?X5I44 9O\ 8-O_ 'Y/S'^%']@V_P#?D_,?X5I4
M4 9O]@V_]^3\Q_A1_8-O_?D_,?X5I44 9O\ 8-O_ 'Y/S'^%5[_PG8:I93VE
MSYDMO,A21-^,J>HR.:VJYGXF?\D^\0_]>4O_ *": +]KX9L[.VBMX3(D42!$
M7=G"@8 Y'I4O]@V_]^3\Q_A47A'_ )%/1?\ KR@_]%K6O0!F_P!@V_\ ?D_,
M?X4?V#;_ -^3\Q_A6E10!F_V#;_WY/S'^%']@V_]^3\Q_A6E10!F_P!@V_\
M?D_,?X4?V#;_ -^3\Q_A6E10!F_V#;_WY/S'^%']@V_]^3\Q_A6E10!F_P!@
MV_\ ?D_,?X4?V#;_ -^3\Q_A6E10!F_V#;_WY/S'^%']@V_]^3\Q_A6E10!@
MGP5IC:LNIE9/MRP_9Q+O_P"6>[=C'3KWQFKG]@V_]^3\Q_A7*S?\ERM_^Q?;
M_P!**[R@#-_L&W_OR?F/\*/[!M_[\GYC_"M*B@#-_L&W_OR?F/\ "C^P;?\
MOR?F/\*TJ* ,W^P;?^_)^8_PH_L&W_OR?F/\*TJ* ,W^P;?^_)^8_P */[!M
M_P"_)^8_PK2HH S?[!M_[\GYC_"C^P;?^_)^8_PK2HH S?[!M_[\GYC_  H_
ML&W_ +\GYC_"M*B@#-_L&W_OR?F/\*/[!M_[\GYC_"M*B@#-_L&W_OR?F/\
M"C^P;?\ OR?F/\*TJ* ,W^P;?^_)^8_PH_L&W_OR?F/\*TJ* ,W^P;?^_)^8
M_P */[!M_P"_)^8_PK2HH S?[!M_[\GYC_"C^P;?^_)^8_PK2HH S?[!M_[\
MGYC_  H_L&W_ +\GYC_"M*B@#-_L&W_OR?F/\*/[!M_[\GYC_"M*B@#-_L&W
M_OR?F/\ "C^P;?\ OR?F/\*TJ* ,W^P;?^_)^8_PH_L&W_OR?F/\*TJ* ,W^
MP;?^_)^8_P */[!M_P"_)^8_PK2HH S?[!M_[\GYC_"C^P;?^_)^8_PK2HH
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M^)M(\(Z7)J>NZK8Z+IL9 >\U"X2"%23@ NY &3QUK\WO$VJ>$]4^(OP'?2?
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M_P M -@DW?O,X]Z/9I[,7/W1]*:EKEEI-YIEK=S&*?4K@VMJNQF\R01O*5R
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M:;X5\#ZQ;:E=G5'^SZ1-9-:R:=_;MYJGGLQ'[S?.JF+:H9<)][><D;16_?\
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MR>&K/Q#I6GQ:QI5S:WBRF:]748MEML4%0W)'S'@9(_&M;_A97A#_ *&K1/\
MP8P__%5\"T4?48_S!]:EV/OK_A97A#_H:M$_\&,/_P 51_PLKPA_T-6B?^#&
M'_XJO@6BCZC'^8/K4NQ]]?\ "RO"'_0U:)_X,8?_ (JOGK]J;Q'I/B'4/#K:
M5JEGJ:Q13"0V=PDH3)3&=I.,X/Y5X516M+"QI24DS.IB'4CRM'7>"/BIXD^'
M\H_LJ_;[+G+64_SP-_P'M]5P?>OHOP%^TUX?\2>7;:TO]@W[<;Y&W6[GV?\
MA_X%P/4U\C45K4P\*NZU,X5IT]C]&X9H[B))8G66)QN5T((8'N#WI]?''P3F
M^(XO%7PF)7TW?^]%[G[$/7.>A]=GS5]@6/VG['#]L$0NM@\WR"2F[OMSSCZU
MXM:C[%VO<]2G4]HKVL3T445SFP5F>)M:_P"$=\/ZCJGD_:/LD#3>5NV[]HSC
M.#C\JTZS/$VB_P#"1>']1TOSOL_VN!H?-V[MFX8SC(S^= %C2-0_M72;*]\O
MROM,"3>7G.W<H.,]^M6ZJ:18?V5I-E9>9YOV:!(?,QC=M4#..W2K= !1110
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MB;XBP^./AWXQM1_9KSZ>MN6ETC41?6SK(ZE<2;$^8%6!4KQQR<\>ST %%%%
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M*,NXY!^\=BY]&.,'%=-7%>,[<6?C;P7K#C$$-Q/82.3PGGQ_(3]7C1?JX]:
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M?:;*;;YD6]ESA@PY4@]0.] &5_PK7PA_T*NB?^"Z'_XFC_A6OA#_ *%71/\
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M!OO;$2"WEWL-@<8;@'!R/4&K]'/+N'+'L<W_ ,*U\(?]"KHG_@NA_P#B:/\
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M=RLEL0[,LD9$0,O#ME"(^@^8=: +>J?%#P_:Z9;7$=_*_P!NL3?V[0V<TNV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17*_;+C_ )[R?]]FC[9<?\]Y/^^S0!U5%<K]LN/^>\G_ 'V:/MEQ_P ]Y/\
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M8]0;$EO]DO9;3'G%MVS'S=!C.>E 'H5%<K]LN/\ GO)_WV:/MEQ_SWD_[[-
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M_P#L+R?^D%W6%X*MM-M?&%TVB:-J,5O<6F^]U35[>[6=Y RK%&LER=S *&)
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M*P?^$^\,?]#'I/\ X'1?_%4?\)]X8_Z&/2?_  .B_P#BJ.278.:/<WJ*P?\
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M *": -FUMX[.VBMX5V11($1<DX4# '/M4M9OAG_D6]*_Z](O_0!6E0 4444
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MCQ%JVD1:QIEQ/;"'4HV_TO2R-J!0#@^46.3L;/SME6%>@:5I%IH=H;:RB\F
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M5RN;^(ND7>O>#=0L;&+S[J7R]D>X+G$BL>20.@- 'RGX^_Y'KQ'_ -A*Y_\
M1K5@U]J7'@GP[=7$D\^@:7--(Q=Y)+.-F9B<DDE>23WJ/_A ?#'_ $+FD_\
M@#%_\37KQQL4DK'G/"R;O<^+Z*^T/^$!\,?]"YI/_@#%_P#$T?\ " ^&/^A<
MTG_P!B_^)I_7H_RB^JR[GQ?17VA_P@/AC_H7-)_\ 8O_ (FC_A ?#'_0N:3_
M . ,7_Q-'UZ/\H?59=SXOHK[0_X0'PQ_T+FD_P#@#%_\31_P@/AC_H7-)_\
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ME(SP1@YYZT 9'@OQ-J6L7U_:7\,DB0HDD5]_9-SIZ/NR#'LGR2R[0<AB"&'
MQ7!>(-)BU[1]2TZ9GCCN?&0B+QL59<A<,".A!Y_"O5]'\/6NA>;]FEOI?-QN
M^V7\]UC&>GFNVWKVQGOTJ/\ X1/2CG_1>M\-2/[Q_P#CX&,/U]AQT]J /,K/
M7I];UK5XK\*FKZ?X<NK.^1>GFK(/G _NNI5Q[-5H^']+\,>"_"NN:/86VF:U
MFPB$EG$L378E:-9(Y-H'F @EN<X*YZBO09?"&CS:O>ZHUDOV^]M?L=Q,K,#)
M%_=(!QGWZ].:K:3X!T31KFUG@@N)9+5=EM]LO9[I8!C'[M978(<<94 XXZ4
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M2HSN YRP7(QDCLJXKXKK)_8-C+:W+6NIQ7T;V1ALOM<S2X8;8XRZ+DJ6R6.
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M^/7Q1_V,%Y_-:[RJ&D:[8Z\MTUC/YZVMP]K-\C+ME3&Y>0,XR.1Q0!?HHHH
M**** "BBB@ HHHH **** "BBB@#@_%7_ "5CP-_USOO_ $4*[RJ%UKMC8ZM8
MZ9-/LO;X2&WBV,=X09;D# P/4BK] !1110 4444 %%%% !1110 4444 %<S\
M3/\ DGWB'_KRE_\ 037355U/4K;1]/N+Z\D\FUMT,DLFTMM4#). "3^% %+P
MC_R*>B_]>4'_ *+6M>H;.[BO[2"Y@;?!,BR1M@C*D9!P?8U-0 4444 %%%%
M!1110 4444 %%%% !1110!P<W_)<K?\ [%]O_2BN\J@VNV*ZXNCF?_B8M;_:
MA#L;_5;MN[=C'7C&<U?H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *YGQ9_R'O!?_87D_P#2"[KIJYGQ9_R'
MO!?_ &%Y/_2"[K>C\3]'^3,:WPKU7YHZ:BBBL#8**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/)YJ2CK:*** "BBB@ HHHH **** "BBB@ HHHH P=5\+_P!I^+-"UK[5Y?\
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MP4<*">I':K]<E\5M"OO$O@'5--TV#[3>S>5Y<6]5SB5&/+$#H#WH ZVBBB@
MHHHH **** "BBB@ HHHH **** "J&D:[8Z\MTUC/YZVMP]K-\C+ME3&Y>0,X
MR.1Q5^N2^'>A7V@V^O+?0>0UUK%S=0_.K;HW*[6X)QG!X/- '6T444 %%%%
M!1110 4444 %%%% !1110!0NM=L;'5K'3)I]E[?"0V\6QCO"#+<@8&!ZD5?K
MDO$&A7U]\0O"FIPP;[*Q2[%Q+O4;"\8"\$Y.3Z UUM !1110 4444 %%%% !
M1110 4444 %5=3U*VT?3[B^O)/)M;=#)+)M+;5 R3@ D_A5JL+QSIMSK'@[6
M;&SC\ZZN+62.*/<%W,1@#)( _&@#7L[N*_M(+F!M\$R+)&V",J1D'!]C4U9W
MARUEL/#VEVTZ;)X;6*.1<@X8( 1D>XK1H **** "BBB@ HHHH **** "BBB@
M HHHH H-KMBNN+HYG_XF+6_VH0[&_P!5NV[MV,=>,9S5^N2DT*^;XJPZP(/^
M)<NCM:F;>O\ K/.W;=N<].<XQ76T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<SXL_Y#W@O_L+R?^D%W735
MS/BS_D/>"_\ L+R?^D%W6]'XGZ/\F8UOA7JOS1T<DJ1+EW5!TRQQ3/MEO_SW
MC_[[%4]>_P"/-/\ KH/Y&L&L#8ZK[9;_ //>/_OL4?;+?_GO'_WV*Y6B@#JO
MMEO_ ,]X_P#OL4?;+?\ Y[Q_]]BN5HH ZK[9;_\ />/_ +[%'VRW_P">\?\
MWV*Y6B@#JOMEO_SWC_[[%'VRW_Y[Q_\ ?8KE:* .J^V6_P#SWC_[[%'VRW_Y
M[Q_]]BN5HH ZK[9;_P#/>/\ [[%'VRW_ .>\?_?8KE:* .J^V6__ #WC_P"^
MQ1]LM_\ GO'_ -]BN5HH ZK[9;_\]X_^^Q1]LM_^>\?_ 'V*Y6B@#JOMEO\
M\]X_^^Q1]LM_^>\?_?8KE:* .J^V6_\ SWC_ .^Q1]LM_P#GO'_WV*Y6B@#J
MOMEO_P ]X_\ OL4?;+?_ )[Q_P#?8KE:* .J^V6__/>/_OL4?;+?_GO'_P!]
MBN5HH ZK[9;_ //>/_OL4?;+?_GO'_WV*Y6B@#JOMEO_ ,]X_P#OL4?;+?\
MY[Q_]]BN5HH ZK[9;_\ />/_ +[%'VRW_P">\?\ WV*Y6B@#JOMEO_SWC_[[
M%'VRW_Y[Q_\ ?8KE:* .J^V6_P#SWC_[[%'VRW_Y[Q_]]BN5HH ZK[9;_P#/
M>/\ [[%'VRW_ .>\?_?8KE:* .J^V6__ #WC_P"^Q1]LM_\ GO'_ -]BN5HH
M ZK[9;_\]X_^^Q1]LM_^>\?_ 'V*Y6B@#JOMEO\ \]X_^^Q1]LM_^>\?_?8K
ME:* .J^V6_\ SWC_ .^Q1]LM_P#GO'_WV*Y6B@#JOMEO_P ]X_\ OL4?;+?_
M )[Q_P#?8KE:* .J^V6__/>/_OL4?;+?_GO'_P!]BN5HH ZK[9;_ //>/_OL
M4?;+?_GO'_WV*Y6B@#JOMEO_ ,]X_P#OL4?;+?\ Y[Q_]]BN5HH ZK[9;_\
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MRM% '5?;+?\ Y[Q_]]BC[9;_ //>/_OL5RM% '5?;+?_ )[Q_P#?8H^V6_\
MSWC_ .^Q7*T4 =5]LM_^>\?_ 'V*/MEO_P ]X_\ OL5RM% '5?;+?_GO'_WV
M*/MEO_SWC_[[%<K10!U7VRW_ .>\?_?8H^V6_P#SWC_[[%<K10!=U3QE#IOB
MK1-'$:2KJ2SL;CS@!%Y:ANF.<YQU'XUN_;+?_GO'_P!]BO/=0\/_ &_Q'I&J
M_:/+_L]9E\G9GS-Z@=<\8QZ&MB@#JOMEO_SWC_[[%'VRW_Y[Q_\ ?8KE:* .
MJ^V6_P#SWC_[[%'VRW_Y[Q_]]BN5HH ZK[9;_P#/>/\ [[%'VRW_ .>\?_?8
MKE:* .J^V6__ #WC_P"^Q1]LM_\ GO'_ -]BN5HH ZK[9;_\]X_^^Q1]LM_^
M>\?_ 'V*Y6B@#JOMEO\ \]X_^^Q6;XD\20>'] U#4E\NZ-K"TPA$H7?@9QGG
M'Y5CU0U[2_[<T6]T_P WR?M,31>9MW;<C&<9&: .NTG6H-4TJSO"\<)N(4F\
MOS =NY0<9[XS5O[9;_\ />/_ +[%<9IMG_9VFVEIO\SR(DBWXQNVJ!G';I5F
M@#JOMEO_ ,]X_P#OL4?;+?\ Y[Q_]]BN5HH ZK[9;_\ />/_ +[%'VRW_P">
M\?\ WV*Y6B@#JOMEO_SWC_[[%'VRW_Y[Q_\ ?8KE:* .J^V6_P#SWC_[[%'V
MRW_Y[Q_]]BN5HH ZK[9;_P#/>/\ [[%'VRW_ .>\?_?8KE:* .J^V6__ #WC
M_P"^Q1]LM_\ GO'_ -]BN5HH NOXRA7QM'X?\M"K6!O?M?G# (DV;-N/QSG\
M*W?MEO\ \]X_^^Q7GK>']WBY-;^T8VV1M/(V>K[MV[/X8Q6Q0!U7VRW_ .>\
M?_?8H^V6_P#SWC_[[%<K10!U7VRW_P">\?\ WV*/MEO_ ,]X_P#OL5RM% '5
M?;+?_GO'_P!]BC[9;_\ />/_ +[%<K10!U7VRW_Y[Q_]]BC[9;_\]X_^^Q7*
MT4 =5]LM_P#GO'_WV*/MEO\ \]X_^^Q7*T4 =5]LM_\ GO'_ -]BC[9;_P#/
M>/\ [[%<K10!U7VRW_Y[Q_\ ?8H^V6__ #WC_P"^Q7*T4 =5]LM_^>\?_?8H
M^V6__/>/_OL5RM% '5?;+?\ Y[Q_]]BC[9;_ //>/_OL5RM% '5?;+?_ )[Q
M_P#?8H^V6_\ SWC_ .^Q7*T4 =5]LM_^>\?_ 'V*/MEO_P ]X_\ OL5RM% '
M5?;+?_GO'_WV*/MEO_SWC_[[%<K10!U7VRW_ .>\?_?8H^V6_P#SWC_[[%<K
M10!U7VRW_P">\?\ WV*/MEO_ ,]X_P#OL5RM% '5?;+?_GO'_P!]BC[9;_\
M/>/_ +[%<K10!U7VRW_Y[Q_]]BC[9;_\]X_^^Q7*T4 =5]LM_P#GO'_WV*/M
MEO\ \]X_^^Q7*T4 =5]LM_\ GO'_ -]BC[9;_P#/>/\ [[%<K10!U7VRW_Y[
MQ_\ ?8H^V6__ #WC_P"^Q7*T4 =5]LM_^>\?_?8I4NH9&"I*C,>@5@37*5<T
MC_D(1?C_ "- '24444 %%%% !1110 4444 %<SXL_P"0]X+_ .PO)_Z07==-
M7,^+/^0]X+_["\G_ *07=;T?B?H_R9C6^%>J_-&IKW_'FG_70?R-8-;VO?\
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M)5.XTBTNM2M+^6+==V@<0R;B-NX8;C.#D>M7* "BBB@ HHHH **** "BBB@
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M >)H-"_M*V^VW%NMQ%^_CVN&("J/FR68$, !R.:T;7Q)I%]J4^G6VJV5QJ$
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M X..E0_\(KK,FGR^'WTDY;6O[1&N>=$8MGV@3!\;O-\P+^[QMQQ][% '??\
M"4:,=2CTX:M8G4)"P2T^TIYK%20P"9R<%3GCL?2J]GXFA^QZI=:DUKI=M8W3
MV[327D;)M7&'=@<(3G[K<CCUKE+GP9?_ -CSI#8(MY)XECU$LK(&:$7*L9"<
M]?+!XZXXQVJ.;PKJ]O))?+IYO/L_B234UL5EC#7$+1[ REF"AE)W ,5^[]*
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M_:!%M/\ J]VW.<8Z]LYJY0 4444 %%%% !1110 4444 %%%% !1110 4444
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M)D)M ()&4YSR#6UV;4]4CBL+K7+O?IGBFWLX[Q8K=9)%9(Y%9AY>W<ID(&%
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M_BO_ *!7_DQ%_P#%T?\ "I_%?_0*_P#)B+_XNOHJBC^V<1_*OQ_S#ZA2[O\
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M(\76,^J>&-4M+9/-N)K=TC3(&6(X&3Q6O5#7M4_L/1;W4/*\[[-$TOE[MN[
MSC.#B@!=#MY+/1=/MYEV2Q6\:.N0<,% (X]ZO56TV\_M'3;2[V>7Y\22[,YV
M[E!QGOUJS0 4444 %%%% !1110 4444 %%%% !1110!S<FD7;?$2+4Q%_H*Z
M8;<R[A_K/-W8QG/3OC%=)6.WB#;XN31/L_WK(W?G[_1]NW;C\<YK8H ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*N:1_P A"+\?Y&J=7-(_Y"$7X_R- '24444 %%%% !1110 4444 %<]XFM)[
MC6O"4D43R1V^IO)*RJ2(U-E=+N;T&YE'U8>M=#15QERN_K^*L1*/,K>GX.YF
MZ]_QYI_UT'\C6#71:M;R75LJ1+N8/G&0.QK)_LB[_P">7_CP_P :@LIT5<_L
MB[_YY?\ CP_QH_LB[_YY?^/#_&@"G15S^R+O_GE_X\/\:/[(N_\ GE_X\/\
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MB[_YY?\ CP_QH_LB[_YY?^/#_&@"G15S^R+O_GE_X\/\:/[(N_\ GE_X\/\
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MB[_YY?\ CP_QH_LB[_YY?^/#_&@"G15S^R+O_GE_X\/\:/[(N_\ GE_X\/\
M&@"G15S^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QH IT5<_LB[_ .>7_CP_QH_L
MB[_YY?\ CP_QH IU3U?2+37M/EL;Z+S[67&^/<5S@AAR"#U K8_LB[_YY?\
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M?^/#_&C^R+O_ )Y?^/#_ !H IT5<_LB[_P">7_CP_P :/[(N_P#GE_X\/\:
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MG:MZL'QUX7_X33PK?:-]J^Q_:=G[_P O?MVNK_=R,YVXZ]Z -ZBBB@ HHHH
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M9SM*%3(HXSNB;KFN@E\8:1#9M=/=X@6^&FEO*?\ X^#((@F,9^^0,].^<<T
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MJHVNKB>VAXG_ ,-A?]2E_P"5+_[31_PV%_U*7_E2_P#M-><?\,[?$+_H7_\
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M_N/1_P#AL+_J4O\ RI?_ &FC_AL+_J4O_*E_]IKSC_AG;XA?]"__ .3MO_\
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M+2RTAHK&YCLI+."PT*;3(97#$2-';.S,&^50QX)V@XQ@GZ"H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQ9_R'O!?_87D_P#2"[KI
MJYGQ9_R'O!?_ &%Y/_2"[K>C\3]'^3,:WPKU7YHZ:BBBL#8Q]!\&Z!X6GU";
M1=#TW2)M0E\^\DL+2.!KF3).^0J!O;+'ELGD^M9,?PA\"0Z5J&EQ^"?#L>FZ
MA(LUY9KI4 AN74Y5I$V8=@>06!(-==13NQ'*^&?A3X)\%WS7OA[P=H&@WC+L
M-QIFF06\A7T+(H.*ZEE#*58 J1@@]#2T47ON,R/#?A'0O!M@]CX?T73M"LI)
M#,]MIMI';QLY !<J@ +$ <]>!6?HGPN\&>&=8DU;1_".A:5JLFXO?6.FPPSM
MGKEU4,<]^:Z>BB[$8FK>"/#FO:U8:QJ>@:7J.KZ?S9W]W91RSVW.?W<C*63G
MG@BMNBBD,**** "BBB@ HHHH **** "BBB@ K@_'-Q#H?C7PMKNI'R]%M8[J
MWENG!\NUEE$?ER.>B*0KIO. -XR1FN\HH \R\;>/-,U:UTAK#7,>&FU%8-7U
M?3IV6**,QN47[2G" R"-696!7< 2NX5@V]U=:E''8Z?KNIS>&YO$D=M8:C%>
MN\LUN;9FEC6X)+2()-ZAR21CY6^4$>UT4 >(7FJW&EK?:5>:SJ%KX;L_%(L[
MG4);^4306IM4F5'N2V]4,S*NXN" P7/-5O#6LVVB+JVHVNKW/]@Q^+XC-J-U
M.^TVS6<2JTDC??CW% '8D,-K%FSN/O%% 'A\_C"34'U>XDUJZA\*R>*$@N=1
MCN7B6&T-G$R;)<@QQ/*4^=2 0^0<-FI?$$/AIM=\":B?$%]+H0N;RW34YM8N
M$CSL8HHGWKO!8%0Q8E@-NY@,5[710!X+JOCB5_'=JUE>217::_'8RVUQKDIN
M!"9/+;=IRIY2Q$'Y9&.3E&SN(%:5T]]:PR:\NLZH]Y'XL6P2%KV3[.MN]X(F
MB\G.QAM=L%@2#C!   ]HHH \J\+:Q:7GB2\&J:_>1>+TU.YB31EO9-OD MY(
M^RYV>68MC^;LSDYWUSOPUU[5M1U[0S=:YIL6M2/(-5T^Z\232W4ORN6C&GO$
M$A96"D;",*IY8$D^[T4 %%%% !1110 4444 %%%% !5'5-%L]:%J+V'SUMIT
MNHE+, )$Y5B ><'G!R,X/:KU% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<'\=/^26:W_P!L/_1\==Y5#7==L?#6E3ZEJ4_V:RAV^9+L9L98
M*.%!/4CM0!?HHHH **** "BBB@ HHHH **** "BBB@ K@_A'_P >OBC_ +&"
M\_FM=Y5#2-=L=>6Z:QG\];6X>UF^1EVRIC<O(&<9'(XH OT444 %%%% !111
M0 4444 %%%% !1110!X)^U%;37G]B06\3SS20W"I'&I9F.Z+@ =37#^ OV8-
M<U_R[K7Y?[#LCSY. URP_P!WHGX\^U?4EUKMC8ZM8Z9-/LO;X2&WBV,=X09;
MD# P/4BK]=-/$2IPY8F$Z,9RYI'+^"_AIX=\ VX32-/2*8C#W4GSS/\ 5SV]
MA@>U=1116$I.3NS9)15D%%%%2,**** "BBB@ HHHH *YGXF?\D^\0_\ 7E+_
M .@FNFJKJ>I6VCZ?<7UY)Y-K;H9)9-I;:H&2< $G\* *7A'_ )%/1?\ KR@_
M]%K6O4-G=Q7]I!<P-O@F19(VP1E2,@X/L:FH **** "BBB@ HHHH **** "B
MBB@ HHHH X.;_DN5O_V+[?\ I173^*YI+?POK$L3M%+'9S,DB$AE8(2"".AJ
M9M=L5UQ=',__ !,6M_M0AV-_JMVW=NQCKQC.:OT >/V=K=>*)K&*[UG5XH4\
M*6MWLL]0E@+SMO'FLR$,6X]<'^(' QVO@OQ-YOPPT37]9NE3=I4-Y=W+C '[
MH,[''XGBNKHH \9TGQ7I'CZ/Q/XBBUC3WNIM&FMK'28;N*2XBM0&8RRHK$AG
M8J=I^X H/S$BH6T&^LO"OPWNIO$>IW\#7^EXL;B.U$*Y48P4A5^.V6/OFO;*
M* /*-4\>>'_&7CZTT9M>TVQL]#OU>5;B[CCFO+U<A(8D+;MJ,V6;'S-A1G#4
M:IX\\/\ C+Q]::,VO:;8V>AWZO*MQ=QQS7EZN0D,2%MVU&;+-CYFPHSAJ]7H
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HW>BV=]J-
MC?SP^9=6)<V[EFQ&77:QQG!..,D<9..M7J* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQ9_P A[P7_ -A>3_T@NZZ:
MN9\6?\A[P7_V%Y/_ $@NZWH_$_1_DS&M\*]5^:.FHHHK V"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N ^*'B230M0\,0/XC_P"$7T^]
MNIH[J^S;KA5A9E&Z=&498#M7?UB:UX;_ +8UW0=2^T>5_94TLOE;-WF[XFCQ
MG/&-V>AZ4 <OX;\>7%CX9%QJ9N=;EGU*2QTJ2V@1)M3CZQR*,I'RH8[_ )4(
M3<, BM*3XG6<=B&;2]2&JF^&G?V-MB^U>>4\P+GS/*QY?S[O,VX[YXK*U'X-
MVM]HKZ9]HM7M(-5;5-/MKRQ$]O;[@=T,D1;$D9+R$ %"-PQ]VN<\9> 9=%T/
M1K6.QL((UU7[5+=>&=%N;=("('5'>WM93-(V21N21,9&<@8(!W6C_$FVU6VM
MI9=)U+33/J;:4L5V(=XF4-N)V2, H*,,YR>H!!S67XL\8?;KBSM]/DNK22Q\
M3VFG71#;!+N59"HVGYD*R*"#CD'BJ/A7PYJ.N>#X8$1-$N-,U3[3IU[-83H+
MH#EI9;>:7S@6+RJ=\FYB-^>16E:_"^X7S9;O6A=74VNPZY+(MH(UW)&B&)5W
MG"_)P220" =Q!8@&O?>/(]-U>"UN='U2&RFNELDU22.-;<S-D*NTN)<%OE#>
M7M)(.<<UA:'\59Y+;Q%<ZUHMWI]OIVH/90.@B<S-E%CA"K*S-*S..@"\CGK5
M&X^"/VGQ(NJ2:A82-'JJZHEU)I0?4#B0-Y+7)DR8P/E "J0 HR0"#J7GPPN;
MJ/7K9=:2*TO[]=6M=MGF:TNU:-U8L7VR)NC'R; <$C=WH L77Q8L-+L]3DU3
M2M5TN[T\VYEL)HHY)VCFD$<<B>4[JZ[B00K%@5(QG&9?&GBN]TWX<ZGJJ65Q
MH^H&+R8(;QHC)'*[".-CY;NOWF!^]]<51U#X8W>O+J%SJVLPSZK=FS03VMD8
M88H;><3*BQF1B2S;LL7/48 Q@[7Q*T*?Q)X&U>QM4$EX8A+;H?XI8V$B#\64
M4 9EU/J=]XF@\*:;JEQIEMI^G1W5WJ*A)[N4LS)&BM*KK_RS=F9E8GC&.363
MXTUB_P#"=YX7T[4O&[:597<]TL^KR1VD$C*L>Z-7,D;1[L\955SZ"NBO_#]W
MK%_8>)-%OO[&U1[002I?61ECEA/SA)8MR.&5B2"&!&6!!S3X_"-_<ZOH6IZE
MJZWEWILEQ(PBM!%&_FQ[ J#<2BKU^8N22>>F #F?%#:K:V'AV\TCQYJ=U:ZC
MJ%M9^?''I\L<D<A(,BL+;&?0CCVJ+Q9KTWASQ7I.C:EX_N-"L6TV:X:_N?L,
M<EQ,)4"@F2'9PK'Y449Q7=>*/#?_  DBZ6/M'V?[#J$-]]S=O\LD[.HQG/7G
M'I4=]X1BU+Q4FKW$BRP?V=+ITEF\6Y9%D=&))STPN,8YSUH Y.#7]:71_ >M
M:J9;6[FO/L-];E7@25)@Z([1'[K;EB8!N5W,.,XKTNO-[CP?>:?9^"?#*SS7
MUI8ZC]K>[\A@L=M ':*-V)(W;C"@R06"D@<''I% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<E\5M"OO$O@'5--TV#[3
M>S>5Y<6]5SB5&/+$#H#WKK:P?'7BG_A"_"M]K/V7[9]FV?N?,\O=N=4^]@XQ
MNST[4 ;U%%% !1110 4444 %%%% !1110 4444 %<E\.]"OM!M]>6^@\AKK6
M+FZA^=6W1N5VMP3C.#P>:ZVL'PCXI_X2J+5'^R_9?L.H36./,W[_ "\?/T&,
MYZ<_6@#>HHHH **** "BBB@ HHHH **** "BBB@#DO$&A7U]\0O"FIPP;[*Q
M2[%Q+O4;"\8"\$Y.3Z UUM8.J^*?[,\6:%HOV7S/[46=O/\ ,QY?EJ&^[CG.
M?48K>H **** "BBB@ HHHH **** "BBB@ K"\<Z;<ZQX.UFQLX_.NKBUDCBC
MW!=S$8 R2 /QK=K,\3:U_P ([X?U'5/)^T?9(&F\K=MW[1G&<''Y4 .\.6LM
MAX>TNVG39/#:Q1R+D'#! ",CW%:-5-(U#^U=)LKWR_*^TP)-Y><[=R@XSWZU
M;H **** "BBB@ HHHH **** "BBB@ HHHH Y*30KYOBK#K @_P")<NCM:F;>
MO^L\[=MVYSTYSC%=;6"_BG;XXC\._9<[]/-]]I\SIB39LVX_'.?PK>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M(\0^+-+\*1P2ZK<-9V\S[!<-#(T*$D >9(%*Q@EARY K7KEO%UQJ]QJ6GZ1I
M&LVNBS7D4SF>6R:YF^0Q_P"K&1&O#')?/;"GG&M**E-*6W]>3_(QJR<(-QW_
M *\U^9T.GZC::M9Q7=C<PWEI*,QSV\@D1QG&0P.#S6#XL_Y#W@O_ +"\G_I!
M=UCZ'\%]"\/ZA+J=I<ZFFKSW(N;B_CNS$TYW[RCQQA8BAY!&SH3WYK8\6?\
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M\A_C1_;UO_<D_(?XU@T4 ;W]O6_]R3\A_C1_;UO_ ')/R'^-8-% &]_;UO\
MW)/R'^-']O6_]R3\A_C6#10!O?V];_W)/R'^-']O6_\ <D_(?XU@T4 ;W]O6
M_P#<D_(?XT?V];_W)/R'^-8-% &]_;UO_<D_(?XT?V];_P!R3\A_C6#10!O?
MV];_ -R3\A_C1_;UO_<D_(?XU@T4 ;W]O6_]R3\A_C1_;UO_ ')/R'^-8-%
M&]_;UO\ W)/R'^-']O6_]R3\A_C6#10!O?V];_W)/R'^-']O6_\ <D_(?XU@
MT4 ;W]O6_P#<D_(?XT?V];_W)/R'^-8-% &]_;UO_<D_(?XT?V];_P!R3\A_
MC6#10!O?V];_ -R3\A_C1_;UO_<D_(?XU@T4 ;W]O6_]R3\A_C1_;UO_ ')/
MR'^-8-% &]_;UO\ W)/R'^-']O6_]R3\A_C6#10!O?V];_W)/R'^-']O6_\
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MY#_&C^WK?^Y)^0_QK!HH WO[>M_[DGY#_&C^WK?^Y)^0_P :P:* -[^WK?\
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M:/[>M_[DGY#_ !K!HH <]K:MXUC\1>;,'2P-C]G\L8P9-^[.?PQBMS^WK?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *IZOIUGJVGRVFH1K+:28WH[$ X((Y!]0*N5R'Q:1I/A_
MJJHI9CY6 HR?]:E '7T444 %%%% !1110 4444 %%%% !1110 53TW3K/35N
M!9QK&)IFFEVL3F1OO$\]:N5R'PX1DM]?W*5SK%R1D8R,KS0!U]%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7CC%0ZCX$DTS09WAN&O)K;PX^D)#' =TK!<AA@GDXQMYZ]: )-6\?1WVBZI
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M8GG##(QKQ^!KF7QA%KMS=:=')$[-OT_3C;W,RE2JQS3&5O,0#!QM'*J>,8H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9'BS7_\
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MB#6M2U:P\5:5JIF>$7*G0YX'$*@E%B+7'W#EV5\,"68Y(&!T_BS_ )#W@O\
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M%:PQ6UM%#"H6&- B*#D!0,#]*EH **** "BBB@ HHHH **** "BBB@ HHHH
MYF35+I?B/%IPF/V)M+,YAP,;_-QNSUZ5TU4SIUF=66^,:_;Q#Y(DW'=Y>[.,
M9Z9JY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7-(_P"0A%^/
M\C5.KFD?\A"+\?Y&@#I**** "BBB@ HHHH *\_U;X>:W>PZE:6VNZ?!I]YJ"
MZCY<^E/+(K"1) N\7"@C*#^$<$UZ!16M.K*D[Q_K[S&I2A55I_FU^1EZ+;ZS
M!YW]K7]C?9QY?V*Q>VV]<[MTTF[MTQC!Z]LWQ9_R'O!?_87D_P#2"[KIJYGQ
M9_R'O!?_ &%Y/_2"[JZ;<IMOL_R9-2*C!)=U^:-37O\ CS3_ *Z#^1K!KI[^
MS^W0B/?LPV[.,]C5#_A'_P#IX_\ '/\ Z]<YT&/16Q_PC_\ T\?^.?\ UZ/^
M$?\ ^GC_ ,<_^O0!CT5L?\(__P!/'_CG_P!>C_A'_P#IX_\ '/\ Z] &/16Q
M_P (_P#]/'_CG_UZ/^$?_P"GC_QS_P"O0!CT5L?\(_\ ]/'_ (Y_]>C_ (1_
M_IX_\<_^O0!CT5L?\(__ -/'_CG_ ->C_A'_ /IX_P#'/_KT 8]%;'_"/_\
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M'_CG_P!>@#'HK8_X1_\ Z>/_ !S_ .O1_P (_P#]/'_CG_UZ ,>BMC_A'_\
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M3PFP4E52[R<<#]V*Z^I[Q;*QUC3]+FO&6\OQ(T""(D,$&6YS@<'O6C_PC_\
MT\?^.?\ UZ ,>BMC_A'_ /IX_P#'/_KT?\(__P!/'_CG_P!>@#'HK8_X1_\
MZ>/_ !S_ .O1_P (_P#]/'_CG_UZ ,>BMC_A'_\ IX_\<_\ KT?\(_\ ]/'_
M (Y_]>@#'HK8_P"$?_Z>/_'/_KT?\(__ -/'_CG_ ->@#'HK8_X1_P#Z>/\
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MX_\ '/\ Z] &/16Q_P (_P#]/'_CG_UZ/^$?_P"GC_QS_P"O0!CT5L?\(_\
M]/'_ (Y_]>C_ (1__IX_\<_^O0!CT5L?\(__ -/'_CG_ ->C_A'_ /IX_P#'
M/_KT 8]%;'_"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O0!CT5L?\ "/\ _3Q_
MXY_]>C_A'_\ IX_\<_\ KT 8]%;'_"/_ /3Q_P".?_7H_P"$?_Z>/_'/_KT
M8]%;'_"/_P#3Q_XY_P#7H_X1_P#Z>/\ QS_Z] &/16Q_PC__ $\?^.?_ %Z/
M^$?_ .GC_P <_P#KT 8]%;'_  C_ /T\?^.?_7H_X1__ *>/_'/_ *] &/16
MQ_PC_P#T\?\ CG_UZ/\ A'_^GC_QS_Z] &/16Q_PC_\ T\?^.?\ UZ/^$?\
M^GC_ ,<_^O0!CT5L?\(__P!/'_CG_P!>C_A'_P#IX_\ '/\ Z] &/16Q_P (
M_P#]/'_CG_UZ/^$?_P"GC_QS_P"O0!CT5L?\(_\ ]/'_ (Y_]>C_ (1__IX_
M\<_^O0!CT5L?\(__ -/'_CG_ ->C_A'_ /IX_P#'/_KT 8]%;'_"/_\ 3Q_X
MY_\ 7H_X1_\ Z>/_ !S_ .O0!CT5L?\ "/\ _3Q_XY_]>C_A'_\ IX_\<_\
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M"K,,<YJOJ'PQO;RR\36$>N1PZ=K%U]M6,V9+QR$QETD82 2Q-L(*;5)#$;J
M*?C;QU+?^!_%"06VH^']9TU8"\-P\:S(LCKM=7AD=<$!APV>#D#OZ97EUC\$
MEM=+\2VJWNGV9UN.W1H]*TE;2W@,3$Y6(2'.X$9RV<Y.<8 ]1H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=:T>34]2T&Y21473KUK
MIU;.6!MIHL#WS*#] :UJ*J,G%W1,HJ2LPHHHJ2@HHHH **** "BBB@ HHHH
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M_#^F6LZ[9H+6*)U!SAE0 C/U%:% !1110 4444 %%%% !1110 4444 %%%%
M&<VOV2^(%T4R-_:#6QNQ'M./+#;<YZ=>U:-<I)H%ZWQ2AUH1K_9ZZ0;0R;AG
MS#-NQCKT[UU= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!QG\:N54TFP&EZ79V0?S!;0I"'(QNVJ!G'X5;H **** "BBB@ HHHH ****
M"BBB@ HHHH Y]_%#KX\C\._9U*/IQOOM&[G(DV;<8_'.:Z"L-_"ZMXUC\1?:
M&#I8&Q^S[.,&3?NSG\,8K<H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *6J65U>QHMKJ$NGLIR6BC1]
MWM\ZFL[^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[
M_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?
M[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\
MXBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P#
M:W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;
M_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^
MP=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^
M(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;
MO_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_
MZ&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>H
MH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&
MM_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[
M_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?
M[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\
MXBC^P=6_Z&6[_P# :W_^(K>HH P?[!U;_H9;O_P&M_\ XBC^P=6_Z&6[_P#
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M4?V#JW_0RW?_ (#6_P#\16]10!@_V#JW_0RW?_@-;_\ Q%']@ZM_T,MW_P"
MUO\ _$5O44 8/]@ZM_T,MW_X#6__ ,11_8.K?]#+=_\ @-;_ /Q%;U% &#_8
M.K?]#+=_^ UO_P#$4?V#JW_0RW?_ (#6_P#\16]10!@_V#JW_0RW?_@-;_\
MQ%']@ZM_T,MW_P" UO\ _$5O44 8/]@ZM_T,MW_X#6__ ,11_8.K?]#+=_\
M@-;_ /Q%;U% '-2>&]:>ZAD7Q5>)&F[=']E@^;(X_@[5/_8.K?\ 0RW?_@-;
M_P#Q%;U% &#_ &#JW_0RW?\ X#6__P 11_8.K?\ 0RW?_@-;_P#Q%;U% &#_
M &#JW_0RW?\ X#6__P 11_8.K?\ 0RW?_@-;_P#Q%;U% &#_ &#JW_0RW?\
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M@_V#JW_0RW?_ (#6_P#\11_8.K?]#+=_^ UO_P#$5O44 8/]@ZM_T,MW_P"
MUO\ _$4?V#JW_0RW?_@-;_\ Q%;U% &#_8.K?]#+=_\ @-;_ /Q%']@ZM_T,
MMW_X#6__ ,16]10!@_V#JW_0RW?_ (#6_P#\11_8.K?]#+=_^ UO_P#$5O44
M 8/]@ZM_T,MW_P" UO\ _$4?V#JW_0RW?_@-;_\ Q%;U% &#_8.K?]#+=_\
M@-;_ /Q%']@ZM_T,MW_X#6__ ,16]10!@_V#JW_0RW?_ (#6_P#\11_8.K?]
M#+=_^ UO_P#$5O44 8/]@ZM_T,MW_P" UO\ _$4?V#JW_0RW?_@-;_\ Q%;U
M% &#_8.K?]#+=_\ @-;_ /Q%']@ZM_T,MW_X#6__ ,16]10!@_V#JW_0RW?_
M (#6_P#\11_8.K?]#+=_^ UO_P#$5O44 8/]@ZM_T,MW_P" UO\ _$4?V#JW
M_0RW?_@-;_\ Q%;U% &#_8.K?]#+=_\ @-;_ /Q%']@ZM_T,MW_X#6__ ,16
M]10!@_V#JW_0RW?_ (#6_P#\11_8.K?]#+=_^ UO_P#$5O44 8/]@ZM_T,MW
M_P" UO\ _$4?V#JW_0RW?_@-;_\ Q%;U% &#_8.K?]#+=_\ @-;_ /Q%']@Z
MM_T,MW_X#6__ ,16]10!@_V#JW_0RW?_ (#6_P#\11_8.K?]#+=_^ UO_P#$
M5O44 8/]@ZM_T,MW_P" UO\ _$4?V#JW_0RW?_@-;_\ Q%;U% &#_8.K?]#+
M=_\ @-;_ /Q%3V.DZC;7223ZY<7<2_>A>"%0W'JJ _K6O10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-RJJJN, G@#GJ-'^**>(M4T6ULK>UAAU*P2_5[R]\J9@V[*P((V68IM^;Y@
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MCN;.TAU"*VTZ7[7)/#*751C:N) 8VRHR.F&:@#M**0'(!Z4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5X]^U%JM[I'P_T^:PO+BRF;4X
MT,EO*T;%?*E.,@],@?E7L->*?M9_\DYT[_L*Q_\ HF:NC#_Q8F-;^&SYG_X3
MCQ'_ -!_5/\ P-D_^*H_X3CQ'_T']4_\#9/_ (JL2BOH>6/8\?F?<V_^$X\1
M_P#0?U3_ ,#9/_BJ/^$X\1_]!_5/_ V3_P"*K$HHY8]@YGW-O_A./$?_ $']
M4_\  V3_ .*H_P"$X\1_]!_5/_ V3_XJL2BCECV#F?<V_P#A./$?_0?U3_P-
MD_\ BJ/^$X\1_P#0?U3_ ,#9/_BJQ**.6/8.9]S;_P"$X\1_]!_5/_ V3_XJ
MC_A./$?_ $']4_\  V3_ .*K$KN/@[X'L/B%XTCTC49;B&V:"24M:LJOE1D<
MLI'Z5,N6*<FAQYI.R9A?\)QXC_Z#^J?^!LG_ ,51_P )QXC_ .@_JG_@;)_\
M57H<WPU\'>)/"OB34?"U_K,-[H*^9<0:P(BLBC=]TH.,[6QD]NG.:Y;1?@SX
MS\0:0FIV&@S364B[TD:2.,NOJJLP8@]L#FLU.GUT]2W&?34Q?^$X\1_]!_5/
M_ V3_P"*H_X3CQ'_ -!_5/\ P-D_^*J_X=^%WBGQ9;RS:5H\MU'#<?99/G1#
M'(!DJP9@1CU/ ]:FT7X1>+_$-[J%KI^BR3RZ?,UO<GS8T1)%."@=F"L1[$]1
MZU7-36[1-I^9E?\ "<>(_P#H/ZI_X&R?_%4?\)QXC_Z#^J?^!LG_ ,55/7-!
MU#PSJDVG:I:265["</#(.1Z$'H0?4<&MKPO\+_%'C+3Y[_1](EO;.%BKRAT0
M$@9(7<P+'V7/6J?(E=VL)<S=D4?^$X\1_P#0?U3_ ,#9/_BJ/^$X\1_]!_5/
M_ V3_P"*KV;4/ACX;T_XM)H\?ABZU+3_ .Q5NFL;6[*.)=Q!D+22KP.F-W?I
M7EGA_P"%/BOQ9I<NIZ1HLUU8(S#S-Z+NQUVAF!?'3Y0>>*RC4IR5]ON-)0FG
M;<S/^$X\1_\ 0?U3_P #9/\ XJC_ (3CQ'_T']4_\#9/_BJN>$_AGXF\<QSR
M:)I,MY%"VR24ND:!O[NYR 3TX'(R*BA^'GB2?Q,_AY-'N&UB/E[7 RJ_WBV=
MNWD?-G'(YK2].[6A'O[ZD'_"<>(_^@_JG_@;)_\ %4?\)QXC_P"@_JG_ (&R
M?_%5=\3?#'Q1X/FM(M6T>:W>[?RX/+99A(_904)&[VZFE\5?##Q1X)L8+S6M
M)DLK6=@B2>8CC<1D [6.#@'@XZ&B]-VM;4+3\RC_ ,)QXC_Z#^J?^!LG_P 5
M1_PG'B/_ *#^J?\ @;)_\56U=?!?QK9Z&VKS>'[B.R6/S6)9/,5?4Q[MXQWR
MO%<53CR2^&S$^:.YM_\ "<>(_P#H/ZI_X&R?_%4?\)QXC_Z#^J?^!LG_ ,56
M)15<L>PN9]S;_P"$X\1_]!_5/_ V3_XJC_A./$?_ $']4_\  V3_ .*K$HHY
M8]@YGW-O_A./$?\ T']4_P# V3_XJC_A./$?_0?U3_P-D_\ BJQ**.6/8.9]
MS;_X3CQ'_P!!_5/_  -D_P#BJ/\ A./$?_0?U3_P-D_^*K$HHY8]@YGW.[^'
M?C#7[KX@>&89M;U*6&34[5'CDNY&5E,J@@@GD$5]QU\"_#7_ )*-X5_["MK_
M .CDK[ZKR,:DI*QZ.%;:84445YIVA1110 4444 %%%% !1110 445F>)M8;P
M_P"'=2U1(5N#96\EP8GD\L,$4L1NP<< ]J &W7ARWFT6\TVUEN-+CN6D=IK&
M7RY4=W+NZMS@EB3^-.U;0;?6+C2IIWE5]-NOM<6P@!G\MX\-D'(Q(>F.0*YW
M3_B//>/JXF\,ZM9MI]I#=&TD$<EU.)"X7RXXW92/D/5P<@C Q3_B5XNN/"5G
MHTD&H:;I*7U^MK+?:O&7@@0Q2/D@21\Y0#EAUH NZ[X+;5];35;77=3T6[6V
M^R,;$6[!X]V[D2Q/@Y[C%4C\(_"\S:>+K3(M2MK&&6*"UU!5N8@TCAY)2'!+
M2,PY8DGKZFLZW\2>(M:U:RT_1]>\/74;Z<;UM2CT^2:"<^:4 C"W0V@ <_,W
M(/3I1=?$/5+KP?#)86=K!XIGO9=,CL[AF>'[1$S^:005+)LC=@>.",T =%I'
M@32-%T&_T."#=HUX\S&P8 11++DO&@4#:F2Q [;CCC %;2? ,>GWUC<W>LZI
MK(T\$64-^\12W)4H6'EQH7;82NZ0L<$]R35F'Q4NH^ O^$CL0K"33C>Q*_(!
M\O<%./0\&N8\ _$2^U^X<SW^E^(++^SA>27.@6TG^BRY&;=P)9=SD-D $-\A
M^7D4 6M>^'\RZ5X/TG29[N*WTO4!*UY')&)H4$$RA_F&UCN=1C:0<\@C-;&C
M_#^PT:\L+N.XNY[JU6Z#33.I,[W#H\LCX4#<608V[5&2,8QBG)\3K2SL]4EU
M#2=4TVYT[R&FLIDBDF9)GV1NGE2.K L&&-V?E/'3)J7Q*BTO<)M!U8RV]J+V
M_BC$#-80DL TI$N&)".=L9=L*>.F0"A<?!?3)-+_ +.AU?5[.TDTV/2KF."6
M+-S#'OV;BT9*D>8WW"H.>01Q6Y=> =/O%U17FN0-0O+:^EVLORO!Y6P+\O0^
M2N<Y/)P1QAGC/7M0L+;1%T6:SCFU*^CMEN+N!IXU1HW?<%61"3\H_B[UD:1\
M39Y;&&&;2Y]9UDW%W!Y.C+&$E2WD\MYU\V155-Q4;2Y.XD#=@F@#IO%'AE/%
M%G;0M?76G2VUREU#<V?E^8CKG'$B.I')ZK66OPWL)+*^CN[V^O[V^>![G4;A
MT\^00N'C3"H$50<_*J <L>I)K$\8?%F&'PKJ-SH-M?WEP-';45O+>%&2R#(_
ME-*KL#G<I^558C:2P K9L/&D[KJB+97>KW-G/#;K;6-NB.2]O'*<N\H0C#$[
MF,8_A )QN '^+/AS9^+KB[DFU'4;!;RR^P7<5E(BK<198J&W(Q!4NY!4KG<0
MVX<5Q9\$ZW:?$B[UBRTJ2&[DU"-DU+RK![5K39&KAW8?:PY17&U,+NQ_#DUT
MK?$J>\OO#8TW0[Z[M-2DGBN,^2LEN\1*NC!IA\R,K;L;@0/E).*EO?B0C6]_
M);6-[!!97\=A)>SV\;Q/(;A(61%\Y6/WL[L;0#_$04H U_$OA/\ X2*\TZ[B
MU6^TB\L3(8I[$0DD.H5@1+&ZD8'I5 _#6P73XXX+V_M]12[-_P#VNDB-=-<%
M-C2-N0H<I\NW9M P HP,7-'\9QZYJDUM;:9J!LDDEA35&1/LTDD9VNJX<N,$
M,-S(%)4X)XSDWFL>*K_Q+KUIHT^D1V^EK"4M[RTE=[AG3>5\U9@(^F,^6V,Y
MP>E %[5/ LFN:?:6.H>(M5N[6)PT\;):K]KQ('42%8 1C '[O8<>_-</XY^&
M#OJUB]KI5[J]DAO+D26J:?--%<S3K*05O!Y83K@H-_&"<=>AL_BU:W%JM\]O
M.8I=.LKN.Q2)5E\RXE>)8_,>0*3O7;R% QG<<X&CJWQ(AT<E9=$U626WM%O;
M^.$0,;"(EL&4^;AC\CG;$7.%/'3( 0^!WUC2KI]>N&.K:IHT>E:@UF0(Q@2;
MFCRO!S*_)XX'%1W7PLL;G4))QJNJ0VTEY;W\EC')%Y+SP^7L<DQE^D2 KNV\
M9P#S5_4O'$&EZA:Q2:;J#Z?/-%;C542/[,LDI C4Y<.02RC<J%<M@G@XK?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\4_:S_ .2<Z=_V%8__ $3-7M=>*?M9_P#)
M.=._["L?_HF:NC#_ ,6)C6_AL^3****^C/%"BBB@ HHHH **** "O6?V8O\
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MC[#U-GTGQA?>)['PG97=K/!\WB.?Q(4MY(BHX,9# #C& I'H:^/Y6$DCLJA
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M#T4U<%*4DH;DR:2O+8YG_A0O@+_H7(/^_LO_ ,51_P *%\!?]"Y!_P!_9?\
MXJF?\+X\&_\ 00F_\!I/\*/^%\>#?^@A-_X#2?X5V^QQG\LOQ.?GP_=?@/\
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M\!I/\*/^%\>#?^@A-_X#2?X4>QQG\LOQ#GP_=?@/_P"%"^ O^A<@_P"_LO\
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M<FY=K@@%3N R!DCK6U10!P?@S1/$>EZ7<W4H4ZK?ZDLL[:N4,YM%VH _V?\
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M'LI?+GB89PR'(YY/<=OI1XX\8:;K.EP6.G77B"]"R^:\^MWIDZ C:L8)7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;M*3)(^5.Y3OQL 8$L!S0!]:T5X_)\;/%*_M+0?#5?A?K3^$I-+^WGQ^&?[
MLNTGR,>3LW9 7_6[LG[N.:]@H **** "BOGCP+^UM+XZ^/'Q@^&EKX-E$_@"
MS6YCO(K_ ,R35'* B-8?*'EDDX!WMGCBNU_9O^+GB3XU_#6/Q+XJ^'>K?##5
M6NY;<Z#K)D,X1,;9?GBB;:V3C*#H>O6@#U*BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^"/^"I7_(Q?LW_ /8\0_\
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M[<\)WT?_  C^I:GYVDZ?LNI1NM;?:/*9MN6.XY)/K7*W7AOXC_!G_@G[\/\
MXW^'?C3XPMM5TE+,VGAR":.'18[62X\M87ME7$S MDO*6W#(VCBOK;X?_L*>
M*O!?P#\:_!^]^,MQKO@S5],FT[1K6;PY#$='\V5I'D+K+ON"=WW2R@<X S@=
M!XQ_8G_X2S]BW2_@!_PF?V7[#!:P_P#"1?V7OW^3.)L_9_.&,XQ_K#CKSTH
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M5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\
MZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_
M .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@
M#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J,ZM_X%?_
M %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\ ZC.K?^!7
M_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,'_A$_P#J
M,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\ 6H_X1/\
MZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_ %JWJ* ,
M'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HSJW_@5_\
M6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:C_A$_P#J,ZM_X%?_
M %JWJ* ,'_A$_P#J,ZM_X%?_ %J/^$3_ .HSJW_@5_\ 6K>HH P?^$3_ .HS
MJW_@5_\ 6H_X1/\ ZC.K?^!7_P!:MZB@#!_X1/\ ZC.K?^!7_P!:N<T/P[JL
MOC#Q-#=ZGK2:9%]E^PR-<$*^8R9,$C!PV.E>@UR_A_Q)=ZGXV\5Z3,(Q:Z9]
MD\@JI#?O(BS;CGGD<5M33<9V73]49R>L?7]&6O\ A$_^HSJW_@5_]:C_ (1/
M_J,ZM_X%?_6K>HK$T,'_ (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_
M (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_ (1/_J,ZM_X%?_6H_P"$
M3_ZC.K?^!7_UJWJ* ,'_ (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* ,'_
M (1/_J,ZM_X%?_6H_P"$3_ZC.K?^!7_UJWJ* /.O''AW5[5_#O\ 9.I:U,)=
M7@CO/+N&.RV(?>QP. "%Y/'-=/\ \(G_ -1G5O\ P*_^M5'Q_P")[SPS)X8%
MF(R-1UJWT^;S%)_=NKEL<\'Y1S765O-/V<&UW,XM<TC!_P"$3_ZC.K?^!7_U
MJ/\ A$_^HSJW_@5_]:MZBL#0P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K
M>HH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K>HH P?\ A$_^HSJW_@5_
M]:C_ (1/_J,ZM_X%?_6K>HH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K
M>HH P?\ A$_^HSJW_@5_]:C_ (1/_J,ZM_X%?_6K>HH \Z^&?AW6+[P'HT^O
MZEK5MK$D.;F*6X965MQX(()Z8ZUT_P#PB?\ U&=6_P# K_ZU4?A3XHO/&GP[
MT/6]0$2WE[!YDHA4JF=Q' )/IZUUE;UTXU9IJSN]O4SIM.$6NQ@_\(G_ -1G
M5O\ P*_^M1_PB?\ U&=6_P# K_ZU;U%8&A@_\(G_ -1G5O\ P*_^M1_PB?\
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M44 8/_")_P#49U;_ ,"O_K4?\(G_ -1G5O\ P*_^M6]10!@_\(G_ -1G5O\
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MXFT=K"+5K3G]_:[F+,A + NJY .,X. #Z#HK\^/VMO\ @H7X8U[X+_%'1/
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MM=S;F4JK,"ZID*<9P:^AZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?%E_X6O&\/-X*MK:RURYT]S:&??$'CCG*[-^W<"JG.,YXS7S7X;\"_&OX?\
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M_P""G_C6RTC1OB'K2?"C_A -1OTAE\'Z9XB>?Q=8VSR%!-)&&V,5 WE0@."
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M_$=IH&J77A[3O#NIP7NK0V<CVEM(\<H1))0NQ&)(P&()R*^'_'G@KQ/\/?\
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M!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+
M\-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?
M_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?
M\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"
MBN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?
MT4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH
M Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_
M]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^
M_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\
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MXV\5/>:W#_93_9?L'F3@IQ&?-V#/'S8S6]-OEG9]/U6QG*UX^OZ,]'HKG_\
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M*E94XV71'045S_\ PL#PW_T&K/\ [^BC_A8'AO\ Z#5G_P!_16!J=!17/_\
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M)#="[N?LGV;;C9N^S[_,]MF/]JON_P#X6!X;_P"@U9_]_11_PL#PW_T&K/\
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MZ'^S;H7A36M-N;'X:Z\^LZU=ZFTD,M\TDL<DK0(B.,EE8!688&T;CR:^NO\
MA8'AO_H-6?\ W]%'_"P/#?\ T&K/_OZ* / =:_9-U/Q9^T[\3_&NM7NGGP3X
MR\$_\(H;:WE?[?&S!%=RICV ;0V#O)SCBO#? /\ P3Y^)?@O3[+P=+IOP%U3
MPQ:2E5\9:EX)%WXD>'?N&Z.1/(9\?+EV8XY))%?>'_"P/#?_ $&K/_OZ*/\
MA8'AO_H-6?\ W]% &^JA5"J  !@ =J6N?_X6!X;_ .@U9_\ ?T4?\+ \-_\
M0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@
M>&_^@U9_]_11_P + \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-
M_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\
M^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P +
M \-_]!JS_P"_HH Z"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN
M?_X6!X;_ .@U9_\ ?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4
M?\+ \-_]!JS_ ._HH Z"BN?_ .%@>&_^@U9_]_11_P + \-_]!JS_P"_HH Z
M"BN?_P"%@>&_^@U9_P#?T4?\+ \-_P#0:L_^_HH Z"BN?_X6!X;_ .@U9_\
M?T4?\+ \-_\ 0:L_^_HH Z"BN?\ ^%@>&_\ H-6?_?T4?\+ \-_]!JS_ ._H
MH Z"BN?_ .%@>&_^@U9_]_16OI^HVVJVJ7-G/'<V[YVR1G*G!P?U% %FBBB@
M HHHH **** "BBB@ HHKE--\=?VA\5/$/@W[%L_LG1M,U?[9YF?-^USW\7E[
M,<;/L.<Y.?,Q@;>0!;S_ (_)_P#KHW\ZAJ:\_P"/R?\ ZZ-_.H: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:A'X4%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=P=V%YQR0*R%^*^CW4NA7L&IZ>FA7UO-+<7<]P@$#*(MJ,X?:K9DP0<\X%
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M],OH[.\UG3[2\DD$26\]U&DC.0"%"DY)(9>/]H>M:U @HHHH **** "BBB@
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MWC_X$_\ ,OVF-\_N_P" =+_PT)<?] 6+_P "#_\ $T?\-"7'_0%B_P# @_\
MQ-<U_P *9\5?\^,?_@0G^-'_  IGQ5_SXQ_^!"?XT?5<A[Q_\"?^8>TQOG]W
M_ .E_P"&A+C_ * L7_@0?_B:/^&A+C_H"Q?^!!_^)KFO^%,^*O\ GQC_ / A
M/\:/^%,^*O\ GQC_ / A/\:/JN0]X_\ @3_S#VF-\_N_X!TO_#0EQ_T!8O\
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M2X_Z L7_ ($'_P")H_X:$N/^@+%_X$'_ .)KFO\ A3/BK_GQC_\  A/\:/\
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M/3X_"_\ 88EN3;M/]I>8LOFO)YWG%B=N.7Z\=*Z2BB@ HHHH **** "BBB@
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M-N7.8W5R0/0_*.:ZBNB=_9PNM-3.-N:04445SF@4444 %%%% !1110 4444
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M_2[7J]5KRKPY_P G3?$/_L3/#/\ Z7:]0!U=Y_Q^3_\ 71OYU#4UY_Q^3_\
M71OYU#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[(N_^>7_ (\/\:Z2B@#F_P"R+O\ YY?^/#_&C^R+O_GE_P"/#_&NDHH YO\
MLB[_ .>7_CP_QK#CT&T'C>YF4YUTZ=$DD/F#BW$LA1L>[EQGVKT"L"+PMY?C
MRY\2?:L^=IL6G?9?+Z;)9)-^[/?S,8QVZ\UK3:2E=VT^_P B)7TLB+^R+O\
MYY?^/#_&C^R+O_GE_P"/#_&NDHK(LYO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_
MQKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\
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M .>7_CP_QKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\
MGE_X\/\ &C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_
MQKI** .;_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\
M&C^R+O\ YY?^/#_&NDHH YO^R+O_ )Y?^/#_ !H_LB[_ .>7_CP_QKI** .;
M_LB[_P">7_CP_P :/[(N_P#GE_X\/\:Z2B@#F_[(N_\ GE_X\/\ &C^R+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS.N^62/9MQV\O.<]^G%;4]I:7T^[;4SETUMJ;]%%%8F@4444 %%%% !1110
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M0]?0TFA^+M"\3R7,>CZUI^K/;$"=;&ZCF,1.<!@I.W.#U]#0!K4444 %%%%
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MCD# RQ4D\ ?E7O4\\IJ<JTE*-2<.64HNSNFO>79M*S.*6#E905G%.Z3[=O\
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ME"6S/$_^&:M<_P"@II__ )$_^)H_X9JUS_H*:?\ ^1/_ (FOHJBO6_UBQ_\
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M>&?_ $NUZO5:\J\.?\G3?$/_ +$SPS_Z7:]0!ZK1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8.C^%_[)\5>(=9^U>;_:WV?]QY>/*\I"GWL_-G.>@Q[UO5
MR_A_PW=Z9XV\5ZM,8S:ZG]D\@*Q+?NXBK;ACCD\5M3?NSUMI]^JT_7Y$2WCI
M_5F=11116)84444 %%%% !1110 4444 %%%% '/>,/"7_"6-H3?:_LO]EZI#
MJ7^KW^;Y88;.HQG=UYZ=*Z&N3\?^&+SQ-)X8-F8P-.UJWU";S&(_=HKAL<<G
MYAQ765O-_NXKFOOIV,X_$] HHHK T"BBB@ HHHH **** "BBB@ HHHH YWX>
M^$O^$#\%Z3H'VO[=]@B\K[1Y?E[^2<[<G'7U-=%7)_"GPO>>"_AWH>B:@8FO
M+*#RY3"Q9,[B>"0/7TKK*VKN]63O?5Z]_/YF=/2$5:VFP4445B:!1110 444
M4 %%%% !1110 5@1>%O+\>7/B3[5GSM-BT[[+Y?39+))OW9[^9C&.W7FM^N7
MA\-W<?Q.O-?)C^PS:/!8J-QW^8D\SGC'3$B\Y]:VINREK;3[]M#.732^IU%%
M%%8F@4444 %%%% !1110 4444 %%%% !5#7]+_MS0=2TWS?(^V6TEOYNW=LW
MJ5SC(SC/3-7ZR_%.FRZQX9U>PM]HGNK.:"/><+N9"HR?3)JX?$M;$RV8[PSH
M_P#PCOAO2M)\[[1]AM(K7SMNW?L0+NQDXSC.,FM*L?P;I,^@^$-#TRY*FYL[
M&"VE\LY7<D:J<'TR*V**GQO6X1^%:!1114%!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>5>'/^3IOB'_V)GAG_P!+
MM>KU6O*O#G_)TWQ#_P"Q,\,_^EVO4 >JT5GR:U!%(Z%),J2#@#M^--_MZW_N
M2?D/\: -*BLW^WK?^Y)^0_QH_MZW_N2?D/\ &@#2HK-_MZW_ +DGY#_&C^WK
M?^Y)^0_QH TJ*S?[>M_[DGY#_&C^WK?^Y)^0_P : -*BLW^WK?\ N2?D/\:/
M[>M_[DGY#_&@#2HK-_MZW_N2?D/\:/[>M_[DGY#_ !H TJ*S?[>M_P"Y)^0_
MQH_MZW_N2?D/\: -*BLW^WK?^Y)^0_QH_MZW_N2?D/\ &@#2HK-_MZW_ +DG
MY#_&C^WK?^Y)^0_QH TJ*S?[>M_[DGY#_&C^WK?^Y)^0_P : -*BLW^WK?\
MN2?D/\:/[>M_[DGY#_&@#2HK-_MZW_N2?D/\:/[>M_[DGY#_ !H TJ*S?[>M
M_P"Y)^0_QH_MZW_N2?D/\: -*BLW^WK?^Y)^0_QH_MZW_N2?D/\ &@#2HK-_
MMZW_ +DGY#_&C^WK?^Y)^0_QH TJ*S?[>M_[DGY#_&C^WK?^Y)^0_P : -*B
MLW^WK?\ N2?D/\:/[>M_[DGY#_&@#2HK-_MZW_N2?D/\:/[>M_[DGY#_ !H
MTJ*S?[>M_P"Y)^0_QH_MZW_N2?D/\: -*BLW^WK?^Y)^0_QH_MZW_N2?D/\
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M ')/R'^-']O6_P#<D_(?XT :5%9O]O6_]R3\A_C1_;UO_<D_(?XT :5%9O\
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M\:RNGQ327&P<P&20*F[KPP<X]ZUII-2NKZ?=YD2OIJ;=%%%9%A1110 4444
M%%%% !1110 4444 %4M<U+^QM%O]0\OSOLMO)/Y>[;NVJ6QG!QG%7:HZY<6U
MKHNH37L?G6<=O(\\>W=NC"DL,=\C-7#62NKBELQOAW5O[>\/Z9J?E>1]MM8K
MGRMV[9O0-MS@9QGKBM"L_P .W-G>>'],N-/B\BPEM8GMXMH79&4!5<#I@8XK
M0HGI)I*PH[(****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z32/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%(S!5))P!R30 M%>=^"_&&IWWB#?J=R&TO6[>2]TF+RU7R8
MXY"I7< "V^-HI/FY&6["M?2?B19ZM=6(&G:A;:?J!=;#4ITC$%V5!;"!7,B[
ME5F7>BY"\=1D&=;17$I\1YM2\+ZAK6F>']1EM([22YM+J5K;R[G'0A1/O _B
M(<*< CAN*Q(_'FJ7=UX*U"71]46:_L[AWTRU:(_:&V0L''[TH$&YB#(X(Z=2
M 0+'J-%<?%\3+&\L-+EL-/U#4+W4#,(]-A2-9T\IMLV\NZHNQOE/S\DC&:S;
MSXH7,FL>&8=,T.\O;74GN([E/W*30R1 AHOFF4!D93NZ@@?*30!Z%17#6/CE
M--@U0W4UYK%S_;4NG6EI%;1QRLVT,(D^<*55=QWN5X!SC%=5I.IOJNGBX:QN
MM/FRRM:WJJLB,#C!*EE(]U)!!ZT"+]%>0:/XMU&\\,>(5U+Q!=0^)H-+N9KK
M0[FV2V>S<!MKVY55=HQT#[I <J=P.<[.H^/UF\%ZA-I]U>P'3X(!+K$-M'/'
MYI90\:!V'F..0W92<9W B@=CT:BN-USXH66@WVJ0R:5JES!I?EF_O((H_)MT
M=58.2S@L &R0@9A@DC&">Q5@R@CD'D4"%HHHH **** "BBB@ K$TJUTJ+Q)K
MLUI+OU.7R/MT>XG9A"(^.V5S6W6)I7AO^S/$FNZM]H\S^U/(_<[,>7Y:%>N>
M<YST&*U@THRN[:??JO\ A_D1*]UI_5F;=%%%9%A1110 4444 %%%% !1110
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MS#^SZW='SN;R<\&>0C_?-0U]'?\ "F?"O_/C(?\ MX?_ !J;_A4'A'_H$_\
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M/\Q_V=5[H^9:*^FO^%5^%?\ H#Q_]_'_ /BJ/^%5^%?^@/'_ -_'_P#BJ/\
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M^Q_;8O,\CS-^SDC&[ ST]*W:WKZ59KEMJ].VNWR,Z?P1UOIN%%%%8&@4444
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MSUQ6A3J?&]+:A'X4%%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(L);6)[>+:%V1E 57 Z8&.*T*S_#L-E;^'],BTU_-TZ.UB6V?.=T00!#GO\
M+BM"B=N9V%'9!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !72:1_
MR#XOQ_F:YNNDTC_D'Q?C_,T 7**** "BBB@ HHHH **** "O*O#G_)TWQ#_[
M$SPS_P"EVO5ZK7E7AS_DZ;XA_P#8F>&?_2[7J /0)M#\Z:23S\;F+8V>I^M,
M_P"$?_Z>/_'/_KUL44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C
M_P#"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!C_\ "/\ _3Q_XY_]>C_A
M'_\ IX_\<_\ KUL44 8__"/_ /3Q_P".?_7H_P"$?_Z>/_'/_KUL44 8_P#P
MC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\ 3Q_XY_\ 7H_X1_\
MZ>/_ !S_ .O6Q10!C_\ "/\ _3Q_XY_]>C_A'_\ IX_\<_\ KUL44 8__"/_
M /3Q_P".?_7H_P"$?_Z>/_'/_KUL44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_
M ,<_^O6Q10!C_P#"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!C_\ "/\
M_3Q_XY_]>C_A'_\ IX_\<_\ KUL44 8__"/_ /3Q_P".?_7H_P"$?_Z>/_'/
M_KUL44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\ 3Q_X
MY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!C_\ "/\ _3Q_XY_]>C_A'_\ IX_\<_\
MKUL44 8__"/_ /3Q_P".?_7H_P"$?_Z>/_'/_KUL44 8_P#PC_\ T\?^.?\
MUZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6
MQ10!C_\ "/\ _3Q_XY_]>C_A'_\ IX_\<_\ KUL44 8__"/_ /3Q_P".?_7H
M_P"$?_Z>/_'/_KUL44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C
M_P#"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!C_\ "/\ _3Q_XY_]>C_A
M'_\ IX_\<_\ KUL44 8__"/_ /3Q_P".?_7H_P"$?_Z>/_'/_KUL44 8_P#P
MC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\ 3Q_XY_\ 7H_X1_\
MZ>/_ !S_ .O6Q10!C_\ "/\ _3Q_XY_]>C_A'_\ IX_\<_\ KUL44 8__"/_
M /3Q_P".?_7H_P"$?_Z>/_'/_KUL44 8_P#PC_\ T\?^.?\ UZQ-*^'?]F>)
M-=U;^T/,_M3R/W/DX\ORT*]=W.<YZ#%=G7+^'_#=WIGC;Q7JTQC-KJ?V3R K
M$M^[B*MN&..3Q6U-^[/6VGWZK3]?D1+>.G]69H?\(_\ ]/'_ (Y_]>C_ (1_
M_IX_\<_^O6Q16)9C_P#"/_\ 3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!C_\
M"/\ _3Q_XY_]>C_A'_\ IX_\<_\ KUL44 8__"/_ /3Q_P".?_7H_P"$?_Z>
M/_'/_KUL44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\
M3Q_XY_\ 7H_X1_\ Z>/_ !S_ .O6Q10!Q7BKX;_\),VBG^T?LW]FZE%J'^HW
M^9L##9]X8SNZ\].E;O\ PC__ $\?^.?_ %ZR_'_AB\\32>&#9F,#3M:M]0F\
MQB/W:*X;'')^8<5UE;S?[N*YK[Z=C./Q/0Q_^$?_ .GC_P <_P#KT?\ "/\
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M44 8_P#PC_\ T\?^.?\ UZ/^$?\ ^GC_ ,<_^O6Q10!C_P#"/_\ 3Q_XY_\
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M>MPC\*T,?_A'_P#IX_\ '/\ Z]'_  C_ /T\?^.?_7K8HJ"C'_X1_P#Z>/\
MQS_Z]'_"/_\ 3Q_XY_\ 7K8HH Q_^$?_ .GC_P <_P#KT?\ "/\ _3Q_XY_]
M>MBB@#'_ .$?_P"GC_QS_P"O1_PC_P#T\?\ CG_UZV** ,?_ (1__IX_\<_^
MO1_PC_\ T\?^.?\ UZV** ,?_A'_ /IX_P#'/_KT?\(__P!/'_CG_P!>MBB@
M#'_X1_\ Z>/_ !S_ .O1_P (_P#]/'_CG_UZV** ,?\ X1__ *>/_'/_ *]'
M_"/_ /3Q_P".?_7K8HH Q_\ A'_^GC_QS_Z]'_"/_P#3Q_XY_P#7K8HH Q_^
M$?\ ^GC_ ,<_^O1_PC__ $\?^.?_ %ZV** ,?_A'_P#IX_\ '/\ Z]'_  C_
M /T\?^.?_7K8HH Q_P#A'_\ IX_\<_\ KT?\(_\ ]/'_ (Y_]>MBB@#'_P"$
M?_Z>/_'/_KT?\(__ -/'_CG_ ->MBB@#'_X1_P#Z>/\ QS_Z]'_"/_\ 3Q_X
MY_\ 7K8HH Q_^$?_ .GC_P <_P#KT?\ "/\ _3Q_XY_]>MBB@#'_ .$?_P"G
MC_QS_P"O1_PC_P#T\?\ CG_UZV** ,?_ (1__IX_\<_^O1_PC_\ T\?^.?\
MUZV** ,?_A'_ /IX_P#'/_KT?\(__P!/'_CG_P!>MBB@#'_X1_\ Z>/_ !S_
M .O1_P (_P#]/'_CG_UZV** ,?\ X1__ *>/_'/_ *]:5G;_ &6W2+=NVYYQ
MCOFIJ* "BBB@ HHHH **** "BBB@ KRKPY_R=-\0_P#L3/#/_I=KU>JUY5X<
M_P"3IOB'_P!B9X9_]+M>H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ']O:9S_P 3&TXN?L9_
M?K_K_P#GEU^_R/EZ^U %^BBB@ HHHH **IZOK6G^']/DOM4OK;3;*/&^YO)E
MBC7)P,LQ &20/QIVEZI9:W80WVG7EO?V4PW17-K*LD;C.,JRD@\@]* +5%%%
M !1110 4444 %%%027MO#=0VTD\27,P9HH6<!W"XW%1U(&1G'3(H GHHHH *
M*** "BHKFYBL[>6XN)4@@B4O)+(P544#)))X  [T^.1)HUDC971@&5E.00>A
M!H =1110 4444 %%%% !1110 5R_A^/5U\;^*VO#/_93?9/L'F-F/_5'S-@[
M?-C/O745ROA[Q#>:EXZ\6Z7,R&TTW[)]G"K@CS(BS9/?D5O3ORSLNGZK;^MC
M.5KQOW_1G54445@:!1110 4444 %%%% !1110 4444 <GX_CUF23PQ_8YN %
MUJW-[]G;'^C;7W[_ %7.W(^E=97(_$+Q+>^&Y/"XLF11J&MV]A/O7=F)U<L!
MZ'Y1S775T3O[.%UIJ9QMS2"BBDSTKG-!:*** "BBB@ HHHH **** "BBB@#D
M_A3'K,7P[T-/$)N#K0@_TK[4VZ7=N/WCZXQ765R/PE\2WOC#X<Z#K.HLC7UY
M!YDIC7:N=Q' [=*ZZM\1=5IJ2L[O;;<RI6]G&VUD%%%%8&H4444 %%%% !11
M10 4444 %<O"FK_\+.O'?S_[!_L> 1Y/[K[3Y\V_ _O;-F?;%=17*P>(KR3X
MI7NA%D_L^+1H+U5V_-YCSS(QSZ81>*WI7M*RZ?JC.=KJ_<ZJBBBL#0**** "
MBBB@ HHHH **** "BBB@ K+\4K=MX8U<:?YGV\V<PM_*.'\S8=NWWSBM2LKQ
M7J$VD>%]8OK<@7%K9S3QEAD;E0L,CZBM*=^=6[DR^%C/!JWR>$-#74_,_M(6
M, NO..7\WRUW[CZ[LYK8K&\%ZI/KG@[0M2NBIN;RP@N)2HP-[QJS8'89)K9H
MJ7YY7[A'X58****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/2W+\1/%%O,VI2II']AQ^(AH9M4AE-S(C7'DK+YGF;5(++E=C9"DY7.!V/\
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M $')O^_<?_Q->[_JOB_YX_C_ )''_:-+LSZVHKY)_P"%Q>,O^@Y-_P!^X_\
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M+M>H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7\/\ AN[TSQMXKU:8
MQFUU/[)Y 5B6_=Q%6W#'')XKJ*Y?P_'JZ^-_%;7AG_LIOLGV#S&S'_JCYFP=
MOFQGWK>FWRSL^GZK8SE:\?7]&=11116!H%%%% !1110 4444 %%%% !1110!
MR?C_ ,,7GB:3PP;,Q@:=K5OJ$WF,1^[17#8XY/S#BNLKD_'\>LR2>&/['-P
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M_MZX_N1_D?\ &MYK]W%\MM]>YG'XGJ;U%8/]O7']R/\ (_XT?V]<?W(_R/\
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M-']O7']R/\C_ (T ;U%8/]O7']R/\C_C1_;UQ_<C_(_XT ;U%8/]O7']R/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ;<N3SGOSFMVMJUO:2M>UWOO\_,BG?D5PHHHK$L**** "BBB@ HHHH ****
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MIC L-7@OIO,8C]VBN#CCD_,.*Z>JF_W<5>^^G8F/Q/0****P- HHHH ****
M"BBB@ HHHH **** ,+P+X<B\(^$M,T>&Z^VQ6D7EK<;0-_).< GU]:W:YCX:
M>';OPEX$T;1[XQF[M(?+D,3%ESN)X.!ZUT];5W>K)WOJ]>_F9T_@CI;38***
M*Q- HHHH **** "BBB@ HHHH *Q(_#\<?C2XUS[3F:73XK(VV!PJ22.'SGN7
M(Z=JVZYR'P_=1_$2[ULF/['+I4-DHW?/YBS2N>,=,.._K6U-Z2UMI]^VAG+I
MI?4Z.BBBL30**** "BBB@ HHHH **** "BBB@ JCKFGKJVBZA8O+Y*7-O)"9
M,9V!E(S^&:O5F^)-/EU;P[JEC!M$US:RPIN.!N9"!GVR:N'Q+6Q,MF.\.Z8F
MB^'],TZ.7[0EI:Q6ZS8QO"(%#?CC-:%97A/3)M%\+:-I]QM-Q:64-O)L.5W(
M@4X/ID5JT5/C>MPC\*T"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "NDTC_D'Q?C_,US==)I'_(/B_'^9H N4444 %%%% !1110 4444 %>5>'/^
M3IOB'_V)GAG_ -+M>KU6O*O#G_)TWQ#_ .Q,\,_^EVO4 =7>?\?D_P#UT;^=
M>(?M0$CP[X<(&3_:T?'K\C5[?>?\?D__ %T;^=><?&/X?:C\0M+TBVTZ:UA>
MSOEN9#=.R@J%(P-JGGFO;R6M3P^84JM5VBGJ_DSDQ<93H2C%:G'?!MHO'/Q"
M\2>(]>8CQ)8S&U@TR4<6473*YZG.Y<C&#N/\59&EZMKFE?&OQ\=#\.CQ%+(J
MK)$UXEN(UPO)W#YO3 KO/%7PSU7_ (61IOC#PO<6=I= >5J-O=,Z)<Q\#^%6
MY*\<_P!U3VK-;X?^.-!^(GB+Q%X>G\/O#JI4>7J;3[E4 =D7@Y![FOJ(XS"U
M9U*JE&TZ22A)M*+4H^[I9VT;3OKUZGG.E4BHQL[J3=UUNGKK]S,[]G.WL#X.
M\0Z;)!]IU2.\9[[2[B((D;XPB $D$90\GH1TX!//?$+5=2U;Q[X-N/&>@/X/
MTNTGS%<0RI=EVW*P1I$P%'RCL2,DX/;T;PC\+=6\*Z;X@O(M;A'BK69UN);T
M6P:",ARQ0(3R#N<$\'D8'%96O?#'QC\2+[38?&&HZ+!HUE-YQ@T=)=\[=/F\
MSIQD<'N>**>.PG]I5L6ZD>5WU][F5X6?(K6=WHKINRUMNR5&I["-/E=UZ6WZ
M]?N*_A9EU;]I7Q3+<[9'L+!(K8-SL!$>=OI]YO\ OH^M<[X>T>XN_$'QE\/Z
M5!D7$3>1;J0J^8=^ ,D 9W'VKO?$WPYUZS\>_P#"6^$+O3H+VXM_LUW::HK^
M3(   V4&<\+_ -\]>U2^#?AGK'A?2M?N_P"V+<^+-8F^T2WJV^Z&-@V0@4X)
M7EAGCKP.*Q^OT(TO:0J*[A2BHN^DH23;:MLK-W6]]"O8S<N5QV<G?R:>QRGA
MOXCZO\)='\.:!XL\*3Z;98%JFI1WD<X+9ZE$!QUSC=G . :]SKR+6OAIXP^(
MNH::GC'4='@T>QF\\6^C)+OG8<?,9/N\9&03U/'>O7.G%>'F\L-4<*E.WM)<
MSGRN3C=O2W-?7O9V.S"JI&\97Y5:U[7_  %HHHKYX[@HHHH **** "BBB@ H
MHHH CN(5N8)(7+A)%*DQNR-@C'#*00?<'(KR9=/.@^(O&=S;/K>K#0X;6ZM-
M/EU^\VL3&SNIW2,&SMZ,".,=Z]=K+L?#]OI^MZIJD;RM<:B(5E5B"@\M2J[1
MC/0G.2:!G,:Q\4XK/SI+#3VU6WAL;6\:2*8(3]HE"1(N1C)7<W) X [Y$&I_
M%67PS;ZPOB#2H;"^L8(+B..WOA+#*DTAB3,K(FS#J0V1@#D$UC:5\+[O3?AC
MJ>EI;3+?ZCJ*W+6YN1O@A%PFR-9 W 2)!C:>#G%=5_PK&PN(-3&HZAJ.K7=^
MD*-?74D:S1+$Q:+R_+1%4JY+ [223R3TH'H)X%^(UOXRU#4+#S-+DN[-(YB^
MCZD+ZW:-]P'[P(A# JV5*\ J<G/'.>*+C69M2\=-IM]=+<:2-/OK:W29@K;%
M9Y(MH.,2*I4CH21GI7H&AZ/=Z3YWVK7=0UKS,;?MR6Z^7C.=ODQ1]<]\]!C'
M-+9^';:QUK5=31I'GU)8EF1R"@$:E5VC&>0QSDF@1SUCK4GBKQY9/87,O]CV
M.F"[D\MB(YI;C'E!L<-MC1FP>GF*?2KFL>+-0C\02Z-HFDPZI=VMJMW=&XO/
MLRHKLRHJD(^YVV/P=H&.6YJQX)\#Z?X#TZ>STY[B6.:8S,URX9A\JJJ @#Y5
M554#L!3=<\%1ZMJW]IVVJZAHUZUO]EGDT]HQY\6[<JMYB/@J2V&7:PW'F@#'
MUGXD7ME_;=S8Z&M[IFA8_M*66\$,RD1K+(L4>QED*1L#\SH"3@$]:Y#QI<)=
M6_Q,FC.8Y+;2W4XQP1D5W6I?#.QU"[U!TU+4[.RU()_:&GV\R>3>;5"$N61G
M4L@56*.NX 9YYJ?4OAWIFJ1ZY&\EQ$FKQV\<RPLH$:P_<V?+Q[YS^%(9D^.O
MBK'X'U!HKB/2Q#$J.\=UJR0WDJ,<%H+?:QDQS]YDR5('K3/$GQ.U#2[_ %6+
M3-%M;ZWTRYM;.>2[U$VSF6?9MV((GRH$B\D@GYL XYN:]\*[+7KC6&.K:I96
MNL;6OK.U>(1S.JA5;<T9<'"KP&"G;R""0>-U_P #ZZOC35]8T[1Y#J\ERCZ?
MJ,<.GO;!1&B SO/NN5QA@PBP-H^49)) T-SQ3\;++PSK&IV;C2PNE!#>)>:L
MEO<N2@=A;PE#YI"D=2F3P*MZ]\4+W2WURXM=#CO-)T58IKJ\>^\MFB>-9"8H
M]AW,%8G#%0<##9) VKOP2TFJW6HZ?KFI:'/>;&NX[$6[QS.J[0Y$T4F#M 'R
MXR ,]*?JO@2PUBQ\1VL\UR$UY!'<LC*"H$8CRGR\' [YYIBT.C5@ZAAT(R*6
MFHH154= ,4Z@04444 %07EE;ZC;/;7=O%=6\G#PS('1N<\@\'FIZS/$VN)X9
M\.ZGJTL9ECL;:2Y,:G!;8I;&??% %N\L+74(XTNK:&Y2.19469 X5U.589Z$
M$ @]C6;'X)\.QZLVJIH.F)J;%F:]6SC$Q+ AB7V[LD$@\\Y-9FA:7X@\FQU3
M4O$LC2NHFNM/6UA%FJE<E(SM$HQD89I&Z9(YP&Z7\2['4[S3D_L[4;6PU-F7
M3]3N(XQ;W; %@%PY==RJS+O50P'';(,V-%\'Z#X;:9M)T33M+:8!9396D<)<
M#H&V@9')ZU)I?A?1M$6)=.TFQL%B+M&+6V2,(6QN(V@8SM&?7 ]*Y_0_BE8Z
MY=:8G]F:G8VNI^8+.]O(HTBF=%+,@ <N#A6()4*=IP3QG"N/B!+XC\4>"/L%
MIJMAIEY?S[+J;:L%]$MM/@@(Y.W(5@) I/! .#@#4[N\\*Z)J.G?V?=Z/I]U
M8>:9OLLUJCQ>826+[2,;B68YZY)]:C;P9X?DTNWTUM"TUM.MI/-@LS9QF&)\
MD[E3&%.2>0.YKAM+^)&K0CPA;Q65YXB35&NUGO/)M[>1O+9\!4\X*I7;SURH
MX^8XK9L?'2:?#J8N9KS6;LZU+I]G9PVT<<K,%#")/G"LJKN8R.5X!SC% '47
M7AW2KZRNK.XTRSN+2[D\VXMY;=&CF?(.YU(PQR!R?058T[3;31[**SL+6&RM
M(AB.WMXQ'&@SG 4# Y-<J_Q1L8[(N^EZHM^M\--DTOR4:YCG9"Z X<H59<$.
M&*X8$D -@_X6A9?8/,.F:B-1_M#^R_[*80BX^T;-^S<9/*Y3Y@?,P1P.>* -
MRP\'Z#I?VP66B:=9B]!6Z^SVD:>>#G(? ^;J>OJ:FN?#NE7C%[C3+.=C"+<M
M);HQ\H$,(^1]W(!QTR*GTV[EOK&*>>RGTZ5\YMKEHS(G..3&S+[\,>M6J!%.
M?1["ZCO(YK&VFCO!BY62%6$XQMPX(^;CCGM5L *  ,"EHH **** "BBB@ HH
MHH *\D\8>/M<\!^,-49[5KK3;SROLGVAR$79&N_8!_M-S]*];KQCX@Z'X@\?
M^,-0T^T2%K32/+\OS"$/[V-6//?E3]*]K*(T98FV)MR6=[Z>GXV./%.:@O9[
MWT*W_#0.H_\ 0*M?^_C4?\- ZC_T"K7_ +^-6/\ \*2\3_\ /*V_[_BC_A27
MB?\ YY6W_?\ %?:^PR'O'_P+_@GE<^-\_N-C_AH'4?\ H%6O_?QJ/^&@=1_Z
M!5K_ -_&K'_X4EXG_P">5M_W_%'_  I+Q/\ \\K;_O\ BCV&0]X_^!?\$.?&
M^?W&Q_PT#J/_ $"K7_OXU'_#0.H_] JU_P"_C5C_ /"DO$__ #RMO^_XH_X4
MEXG_ .>5M_W_ !1[#(>\?_ O^"'/C?/[C8_X:!U'_H%6O_?QJ/\ AH'4?^@5
M:_\ ?QJQ_P#A27B?_GE;?]_Q1_PI+Q/_ ,\K;_O^*/89#WC_ .!?\$.?&^?W
M&Q_PT#J/_0*M?^_C5Y]XGUZ3Q/KEUJ<L2PR7!4F-"2!A0O\ 2NI_X4EXG_YY
M6W_?\5R&N:+<^'M4GT^\"K<PD!PC9'(!'/T(KT<!3RV%1O!VYK='?3[_ $.>
MM+$./[V]BDCM&RLC%64Y#*<$&O0/"OQHUC0]D-__ ,36T''[QL2J/9^_XY^M
M>>UTOA?X>ZUXL96M+4QVI/-U/\L?X'O^&:[<=2PE2D_K:7+Y_H_\C*C*K&7[
MK<]8U#QW'XP_X1P>';N9)QJT#7MKGRY!;[7W[AGYESMSC(Z5Z37C5U\.;;P#
M-X9N$_XF=[=:Q;VLSS1YC2-@Y)5>QRHY.?PKV6ORG,(X:+C]5;<-=_7^NB/H
MZ#F[^TW"BBBO(.L**** "BBB@ HHHH **** "BBB@#F/AHFK1^!-&77?/.KB
M'_2?M+9DW;C]X^N,5T]<Q\--<OO$W@31M3U( 7US#OEVIL&=Q'3MTKIZWQ%U
M6GS+6[VVWZ&5*WLXV[(****P-0HHHH **** "BBB@ HHHH *YR%=4_X6)=LW
MG?V+_94(CR?W7VCSI=^!_>V[/PQ71USD.M7K_$2[TD@?V='I4-TOR<^:TTJM
M\W^ZB\5O3O:5ET_5&<[75^YT=%%%8&@4444 %%%% !1110 4444 %%%% !6;
MXD6Z;P[J@L=_VTVLH@\LX;S-AVX]\XK2K-\27LVF^'=4N[;'VBWM998\C/S*
MA(X[\BM*=^=6[DR^%C/":WB^%M&74?,_M 64(N?-.7\S8-^[WSG-:M97A/4+
MC5O"VC7UWC[5<V4,TN%VC>R MQVY)K5HJ7YY7[A'X58****S*"BBB@ HHHH
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M@WPV?"?A^WTPW)NO+9VW!"D:;F+;(TR=D:YVJN3@ #)K;HHH$%%%% !1110
M4444 %%%% !6'I/B-M2\3Z]I)@$:Z9]GQ*&R9/,0MTQQC%;E8FE7VF7'B37;
M:UM_+U&W\C[9-L \S<A,?/?"Y'/2M8)<LKJ^GW:K7]/F1*]UK_5F;=%%%9%A
M1110 4444 %%%% !7AGC#X?:UXN^(FJM9VWEVN^,&ZF^6/\ U:=#W_#->YT5
MZ6!Q]3+YRJ4DKM6U]5_D<]:C&NE&6QP'A7X-Z-H.R:]']JW8YS,N(E/LG?\
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MII+C8.8#)(%3=UX8.<>]:TTFI75]/N\R)7TU-NBBBLBPHHHH **** "BBB@
MHHHH **** "J.NZD='T/4+]8_--K;R3B,G&[:I;&?PJ]5'7+BVM=%U":]C\Z
MSCMY'GCV[MT84EACOD9JX?$KJY,MF,\-ZL=>\.Z7J;1B%KRUBN3&#D+O0-C/
M?&:T:S_#MS9WGA_3+C3XO(L);6)[>+:%V1E 57 Z8&.*T*)Z2=E8([(****@
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVC_A7NC^N
MI?\ @VN__CM=)10!S?\ PKW1_74O_!M=_P#QVC_A7NC^NI?^#:[_ /CM=)10
M!S?_  KW1_74O_!M=_\ QVC_ (5[H_KJ7_@VN_\ X[7244 <W_PKW1_74O\
MP;7?_P =H_X5[H_KJ7_@VN__ ([7244 <W_PKW1_74O_  ;7?_QVJT'PM\/V
M]Y<W4<=\D]SM\V1=3N0S[1@9(DR<#U)QVKK:*=V@.;_X5[H_KJ7_ (-KO_X[
M1_PKW1_74O\ P;7?_P =KI**0'-_\*]T?UU+_P &UW_\=H_X5[H_KJ7_ (-K
MO_X[7244 <W_ ,*]T?UU+_P;7?\ \=H_X5[H_KJ7_@VN_P#X[7244 <W_P *
M]T?UU+_P;7?_ ,=H_P"%>Z/ZZE_X-KO_ ..UTE% '-_\*]T?UU+_ ,&UW_\
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M*5"CJVJ73 @C!!!DP1[&NIHH Y:U^&FA6-K#;PKJ$<,*+&B)JETJJH&  !(
M!CL!BI?^%>Z/ZZE_X-KO_P".UTE%&X'-_P#"O=']=2_\&UW_ /':/^%>Z/ZZ
ME_X-KO\ ^.UTE% '-_\ "O=']=2_\&UW_P#':/\ A7NC^NI?^#:[_P#CM=)1
M0!S?_"O=']=2_P#!M=__ !VC_A7NC^NI?^#:[_\ CM=)10!S?_"O=']=2_\
M!M=__':/^%>Z/ZZE_P"#:[_^.UTE% '-_P#"O=']=2_\&UW_ /':/^%>Z/ZZ
ME_X-KO\ ^.UTE% '-_\ "O=']=2_\&UW_P#':/\ A7NC^NI?^#:[_P#CM=)1
M0!S?_"O=']=2_P#!M=__ !VC_A7NC^NI?^#:[_\ CM=)10!S?_"O=']=2_\
M!M=__':/^%>Z/ZZE_P"#:[_^.UTE% '-_P#"O=']=2_\&UW_ /':/^%>Z/ZZ
ME_X-KO\ ^.UTE% '-_\ "O=']=2_\&UW_P#':/\ A7NC^NI?^#:[_P#CM=)1
M0!S?_"O=']=2_P#!M=__ !VC_A7NC^NI?^#:[_\ CM=)10!S?_"O=']=2_\
M!M=__':/^%>Z/ZZE_P"#:[_^.UTE% '-_P#"O=']=2_\&UW_ /':/^%>Z/ZZ
ME_X-KO\ ^.UTE% '-_\ "O=']=2_\&UW_P#':/\ A7NC^NI?^#:[_P#CM=)1
M0!S?_"O=']=2_P#!M=__ !VC_A7NC^NI?^#:[_\ CM=)10!S?_"O=']=2_\
M!M=__':/^%>Z/ZZE_P"#:[_^.UTE% '-_P#"O=']=2_\&UW_ /':/^%>Z/ZZ
ME_X-KO\ ^.UTE% '-_\ "O=']=2_\&UW_P#':/\ A7NC^NI?^#:[_P#CM=)1
M0!S?_"O=']=2_P#!M=__ !VC_A7NC^NI?^#:[_\ CM=)10!S?_"O=']=2_\
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M"J, 9/7I5VBB@ HHHH *JV6F6NGR74EO"L<EU*9YVY)D? 7))]E4>P %6J*
M"BBB@ KD-)^&MII-_9S?VGJ%Y9V-Q+=66GW!A,-M))ORRLL8D; D<#>[?>[D
M CKZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$&@V_B331
M97+R1Q>?#/NA(#;HI5D4<@\909]L]*TJ** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005891933200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,664,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893838256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 218,720<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">206,845<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">428,770<span></span>
</td>
<td class="nump">442,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">151,214<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">12,902<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,279<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">601,324<span></span>
</td>
<td class="nump">626,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,229<span></span>
</td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">23,781<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">34,427<span></span>
</td>
<td class="nump">25,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,143<span></span>
</td>
<td class="nump">32,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at June&#160;30, 2022 &#160;&#160; (unaudited) and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; June&#160;30, 2022 (unaudited) and December&#160;31, 2021; 25,664,287 &#160;&#160; shares issued and outstanding at June&#160;30, 2022 &#160;&#160; (unaudited); and 25,207,985 shares issued and outstanding at December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">779,583<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,545)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(218,857)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">559,181<span></span>
</td>
<td class="nump">593,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 601,324<span></span>
</td>
<td class="nump">$ 626,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005891817408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">2,061,773<span></span>
</td>
<td class="nump">2,061,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,664,287<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,664,287<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893879856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,890<span></span>
</td>
<td class="nump">$ 6,594<span></span>
</td>
<td class="nump">$ 20,204<span></span>
</td>
<td class="nump">$ 12,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,863<span></span>
</td>
<td class="nump">9,799<span></span>
</td>
<td class="nump">33,771<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,753<span></span>
</td>
<td class="nump">16,393<span></span>
</td>
<td class="nump">78,975<span></span>
</td>
<td class="nump">30,746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,753)<span></span>
</td>
<td class="num">(16,393)<span></span>
</td>
<td class="num">(78,975)<span></span>
</td>
<td class="num">(30,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,108)<span></span>
</td>
<td class="num">(16,363)<span></span>
</td>
<td class="num">(78,073)<span></span>
</td>
<td class="num">(32,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities and currency translation adjustment</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(1,382)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (28,456)<span></span>
</td>
<td class="num">$ (16,387)<span></span>
</td>
<td class="num">$ (79,455)<span></span>
</td>
<td class="num">$ (32,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,545,167<span></span>
</td>
<td class="nump">22,204,659<span></span>
</td>
<td class="nump">25,331,000<span></span>
</td>
<td class="nump">21,731,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,545,167<span></span>
</td>
<td class="nump">22,204,659<span></span>
</td>
<td class="nump">25,331,000<span></span>
</td>
<td class="nump">21,731,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005888933536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 363,292<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,812)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">363,292<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,205,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">418,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">521,950<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(103,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,205,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">418,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">521,950<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(103,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures</a></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740,500<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(190,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(1,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(78,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,664,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">559,181<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">779,583<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
<td class="num">(218,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">740,500<span></span>
</td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(190,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">$ 30,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares surrendered for taxes and forfeitures (in shares)</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,664,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 559,181<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 779,583<span></span>
</td>
<td class="num">$ (1,545)<span></span>
</td>
<td class="num">$ (218,857)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893886896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,073)<span></span>
</td>
<td class="num">$ (32,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,619<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(58,552)<span></span>
</td>
<td class="num">(19,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(33,706)<span></span>
</td>
<td class="num">(6,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(147,255)<span></span>
</td>
<td class="num">(59,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">86,829<span></span>
</td>
<td class="nump">2,959<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94,132)<span></span>
</td>
<td class="num">(63,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">30,807<span></span>
</td>
<td class="nump">152,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to settlement of restricted stock awards</a></td>
<td class="num">(649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentsForSuitLiability', window );">Repayment of ASTRA build to suit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,960)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">30,158<span></span>
</td>
<td class="nump">144,105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(122,526)<span></span>
</td>
<td class="nump">61,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">341,246<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">329,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">22,234<span></span>
</td>
<td class="nump">10,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets</a></td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">$ 4,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentsForSuitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Suit Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentsForSuitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894234224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had an accumulated deficit of $218.9 million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $425.6 million as of June&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005897757616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894621408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,686,862 and 1,688,965 common share equivalents outstanding as of June&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,545,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204,659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,731,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.08)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.48)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005897105344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value Instruments<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of June&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,282&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,747&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894240800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,365&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,214&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $494 thousand and $956 thousand for the three and six months ended June&#160;30, 2022 and $475 thousand and $914 thousand for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,631&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894400560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $22&#160;thousand and $89&#160;thousand for the years ending 2022 and 2023, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $391 thousand and $800 thousand for the three and six months ended June&#160;30, 2022 and $278 thousand and $497 thousand for the three and six months ended June&#160;30, 2021, respectively. The Company recorded variable lease costs of $71 thousand and $120 thousand for the three and six months ended June&#160;30, 2022 and $81 thousand and $118 thousand for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June&#160;30, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.2 million and $3.0 million for each of the three and six months ended June&#160;30, 2022 and $718 thousand and $2.5 million for the three and six months ended June&#160;30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $5.1 million. The Company has incurred expenses under these activities of $3.1 million and $6.2 million for the three and six months ended June&#160;30, 2022 and $974 thousand and $2.3 million for the three and six months ended June&#160;30, 2021.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $17.9 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid by the Company is $83.0&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of Krystal&#8217;s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $768&#160;thousand of insurance proceeds during the three and six months ended June&#160;30, 2022  and Company recorded an additional $369&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005897186368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894624160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13">one</span>-year to four-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 544,500 and 1,724,000 stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 45,000 stock options to non-employees during the three and six months ended June&#160;30, 2022, respectively, and zero stock options to non-employees during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,620,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,341&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June&#160;30, 2022 was $704&#160;thousand and $739&#160;thousand, respectively, and during the three and six months ended June&#160;30, 2021 was $64&#160;thousand and $872&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June&#160;30, 2022 was $42.90 and $43.03, respectively, and during the three and six months ended June&#160;30, 2021 was $42.53 and $47.25, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $115.7 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#8217; option awards that is expected to be recognized over a weighted-average period of 3.3 years as of June&#160;30, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:36.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $146&#160;thousand and $287&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2022, respectively, and $66&#160;thousand and $103&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:37.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.713%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19</span></td><td colspan="3" style="padding:0 7pt 0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and six months ended June&#160;30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $4.7 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.7 years as of June&#160;30, 2022.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:36.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Shares remaining available for grant under the Company&#8217;s stock incentive plan were 530,991, with a sublimit for incentive stock options of 1,296, at June&#160;30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005999515712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893700592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div>As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the condensed consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June&#160;30, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates </span></div>are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894273216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894391328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:47.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.272%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,108)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,363)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,073)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,545,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,204,659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,731,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.10)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.08)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.48)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894352048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of June&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,853&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,065&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,837&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,282&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,747&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">440,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,536)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,720&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,845&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893876736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,365&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,151)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,214&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,631&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893876736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,279&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,716&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,133&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental condensed consolidated balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894630784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,620,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.75&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,341&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June&#160;30, 2022 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</a></td>
<td class="text">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:36.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.448%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.977%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,357&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,720&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands): </span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"/><td style="width:36.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.927%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"/><td style="width:37.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.631%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.465%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.713%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.51</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.19</span></td><td colspan="3" style="padding:0 7pt 0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.42</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surrendered or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005896149856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 218,857<span></span>
</td>
<td class="nump">$ 140,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 425,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893856736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005891987648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894219440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</a></td>
<td class="nump">3,686,862<span></span>
</td>
<td class="nump">1,688,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893791632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss per common share</a></td>
<td class="num">$ (28,108)<span></span>
</td>
<td class="num">$ (49,965)<span></span>
</td>
<td class="num">$ (16,363)<span></span>
</td>
<td class="num">$ (15,812)<span></span>
</td>
<td class="num">$ (78,073)<span></span>
</td>
<td class="num">$ (32,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,545,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,331,000<span></span>
</td>
<td class="nump">21,731,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,545,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,331,000<span></span>
</td>
<td class="nump">21,731,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005892697328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 218,720<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,536)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">440,002<span></span>
</td>
<td class="nump">502,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">438,467<span></span>
</td>
<td class="nump">502,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">46,157<span></span>
</td>
<td class="nump">40,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">46,105<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">97,808<span></span>
</td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(890)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">96,918<span></span>
</td>
<td class="nump">83,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">77,317<span></span>
</td>
<td class="nump">37,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">76,724<span></span>
</td>
<td class="nump">37,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">206,845<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">46,105<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">88,853<span></span>
</td>
<td class="nump">35,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">71,887<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">12,902<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">8,065<span></span>
</td>
<td class="nump">47,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities | U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">4,837<span></span>
</td>
<td class="nump">16,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">221,282<span></span>
</td>
<td class="nump">161,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,536)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">219,747<span></span>
</td>
<td class="nump">161,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 206,845<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 12,902<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">218,720<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 218,720<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893792736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 156,365<span></span>
</td>
<td class="nump">$ 116,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(5,151)<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">151,214<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">142,893<span></span>
</td>
<td class="nump">104,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,736<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,740<span></span>
</td>
<td class="nump">$ 5,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005894598208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893860352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">$ 14,631<span></span>
</td>
<td class="nump">$ 9,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedFinancingFeesCurrent', window );">Accrued financing costs</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 23,781<span></span>
</td>
<td class="nump">$ 16,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedFinancingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedFinancingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005886791136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
<th class="th">
<div>Sep. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentToEscrowForReducingLeaseRentals', window );">Cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments', window );">Lessor, operating lease, liability, annual lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClausePercent', window );">Cumulative escalation clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClauseTerm', window );">Cumulative escalation clause, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid', window );">Loss contingency, guaranteed maximum price to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from insurance settlement, operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_NumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementTotalConsideration', window );">Litigation settlement, total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">718<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember', window );">Other Contractual Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">ASTRA Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CostOfWorkPercentage', window );">Cost of work, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember', window );">2016 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember', window );">Boston, Massachusetts Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember', window );">Switzerland Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear', window );">Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne', window );">Lessee, operating lease, lease not yet commenced, liability, to be paid, year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdditionalAreaOfRealEstatePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional area of real estate property leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdditionalAreaOfRealEstatePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CostOfWorkPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Work, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CostOfWorkPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClausePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClausePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClauseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClauseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Liability, Annual Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LessorOperatingLeaseLiabilityAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payments, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementMilestonePaymentsSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Guaranteed Maximum Price to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyGuaranteedMaximumPriceToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentToEscrowForReducingLeaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to escrow for reducing lease rentals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentToEscrowForReducingLeaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonMassachusettsLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_SwitzerlandLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893677216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining six months)</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">18,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">9,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 9,133<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005891890272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,279<span></span>
</td>
<td class="nump">$ 7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,417<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 9,133<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">12 years 10 months 24 days<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005886777744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember', window );">Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">434,782<span></span>
</td>
<td class="nump">2,866,667<span></span>
</td>
<td class="nump">2,211,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.00<span></span>
</td>
<td class="nump">$ 65.00<span></span>
</td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="nump">$ 66.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="nump">$ 201,900<span></span>
</td>
<td class="nump">$ 134,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Sale of stock, remaining available issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">288,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005892350144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">544,500<span></span>
</td>
<td class="nump">297,500<span></span>
</td>
<td class="nump">1,724,000<span></span>
</td>
<td class="nump">799,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">530,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 42.90<span></span>
</td>
<td class="nump">$ 42.53<span></span>
</td>
<td class="nump">$ 43.03<span></span>
</td>
<td class="nump">$ 47.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,771<span></span>
</td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 13,720<span></span>
</td>
<td class="nump">$ 5,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock award outstanding (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 899<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005893018800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,043,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(39,399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares) | shares</a></td>
<td class="num">(151,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">3,620,262<span></span>
</td>
<td class="nump">2,043,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable end of period (in shares) | shares</a></td>
<td class="nump">536,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">62.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">44.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">55.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">74.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">59.75<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 47.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (Years)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (Years), exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding | $</a></td>
<td class="nump">$ 28,341<span></span>
</td>
<td class="nump">$ 31,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at June 30, 2022 | $</a></td>
<td class="nump">$ 11,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005886760176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 7,771<span></span>
</td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 13,720<span></span>
</td>
<td class="nump">$ 5,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">5,776<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">10,357<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 899<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005891862560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - Share-based Payment Arrangement, Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.92%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">2.17%<span></span>
</td>
<td class="nump">1.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 61.51<span></span>
</td>
<td class="nump">$ 66.58<span></span>
</td>
<td class="nump">$ 62.19<span></span>
</td>
<td class="nump">$ 73.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140005892003488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Surrendered or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Surrendered or forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>krys-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20220630"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20220630.xsd" xlink:type="simple"/>
    <context id="icbee1991dd3644fc8d747892be43b680_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68056f7be4b3479a8698326d9f76b95b_I20220729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="ia226ea26d38a4e37a6f721a29cd03d76_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9e4439435f24487b699ba4fbdccaff9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5e3e5b1d1904de1ab6caf2253008d57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f5ffa4369814ee099cdeb5c269a22a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i167177dab94c4db6a7199e7c88c61883_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96d0e39fa84848fd83a65fbedcbd9193_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4776963ce5424903852057d81548f3d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id292fcdfa2ec483991762030cda62567_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6dd501c8dcab465e8865f8990e84b682_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4799c83f8064ebaa62e85e4da5639e7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icab00efeb6ef4be2900da03084a5a9d4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if0ebd4532229468281c822de2a5e657c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8f1e0e5c44a4cfe96d8a13d20f90db7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i41f8ca7c434f4946a365bbaa9a9d8bce_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if22db7b29d7e4ece89a75e653bd2115f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id814f4669c3d4394a7130b5293e3c8a6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i775cfbfdc6864e3cb405ab41f9c0eb16_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibdb89f313eb14a259062ad4a9df63ca2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie1c29c2ed7724e3f9034ecf0a95d902e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i076da2ca9712409eb1f14f99f5da94d6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9dbf9c0f040d4dc69fe77d188302bf6b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6e05fc289824b83b4328d58ee1c1b1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bdfa279d35d4560b16eb6696604d967_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e70fa1b51374c78acd66828c63b4cee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib5d42d81e0d64f339007558ceec6d457_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i025425ccecb5443b909699e65613a02c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia784962b1a35445abaf692d9da0f8b7c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i472f7c3bc8534d648bd470f561540a57_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaeb9d19bc36946b7a2b39686906270ce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia88065ac15b8425ba0dc82f5b062b440_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i996e16354ef64539bf61d8bc11b8baf6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i60d5bf962dba470ab3a4481875ff9d28_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5da18ba1fb574a9c80c2ef998e02b45b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6eeb4e61f234a01a966fc80ccd9a356_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idf7a3cc2b19144a7acff545065372722_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74ef1968bb10424d945aad572a1eebe8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic83b183ffa7240659fcc27d5a7aa5c0e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c755555716244b396f922347ef2dc75_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab4702597e5e480a9bc82eb00ce29108_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7198d64a2d734ca3839ec28f8cc1be55_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i40e7fd3b4ff64b319e3403886234d050_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2a7496fd6b01444da889610d00b68a0e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab27a23368df44c0b545b31a362ffad0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i72afdcf0cb6547a990fc6bb8f48b7521_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ief5d94d6062c49e2b1db8c7414a71a7e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia69cd7bb89554aa38e45742bc5b22eb2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ice52f49beadd49d5861085be75f4b8a0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i87b630056ae3492b8a0991e9b5343757_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8721aeb105fc4c238df1588239e9c101_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f2c361f936d4f35898fb47c6618dcf8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic39c1f1d7ae6452eabc0f676318ed72a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5a0b896d15f540bd9cd89d793a7b3dd9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2e86db60e52a433cabc5c934bf137fd1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if4d892ea64f341f094f64a0244811282_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4680df6fdb6448fe89234b2525155c51_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5b201c5d548540d7bff79745cf60be1d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic54be4b4a31245cfa953f2ed8fcbabb1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0408fc3248f94e58a9239a4ddda6b92c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ffb971f777745b180e887cf34cc8df6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifc97aeb2c0514e00a399738e538f2fe7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i85f691466f4f4614820d160aeb87931d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia14b5c1cb46b44daa8d2c7200a170896_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if10ba9e6940c4bcab91bee5cdf0f1577_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i15568dc832834ddaaefabea39a936bcb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie89e6376ee9b402191dd9c876f00ffd1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i685fdfb571504f15be2ba3d2c639db0d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f864a31b3d847e786f7d911b5e088ba_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id4792758104f47bfbfdd2f1ff6cc0f56_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id87854e9024645be88d96e81c1d80ce7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if698ad0c6a754e11892e9ad283a72091_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21ae7de2a25e4d8f9c91182ae7bd789a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice8f78f72c5f44daa3c018883cf88bc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ea1041fd3974f6cbd157670806fb0b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7652f0186854d3eb2df5a9678980d1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5248a77fa14049cf940a8cd1b7fef935_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia56331706bfb4519876ce6149c9d3899_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife4757de934847a3b5d4eb65e4f812c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifef97546d258466e8f022a081bfec632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20ebc1166b3d48708f5ffd968b17c9cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4ac529d98474127860b5706cc0a4e57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19f873a9b5ad47d6bb38039da03ea567_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7253ed7785a94823a46ec4162da143ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb5f33620a0044aaaa5c0668e4413da8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i075af6a44d40468781a120b2d5467942_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fe24770e30b4ee5b669d117e9f452b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b4223978e6e4043b43792467895392c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia02db18a6f9842168a740bb3825c2f42_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibe1d4e05d43f4749b3b95a6990387f23_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i19dbf144cc1344bc88a90e137beec2ff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if5474e41a39a4279ada916abbc519671_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e6353eacee0474f88b8a107b02b1652_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7aa852ef45a845dda2da256ef25ae970_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e9dbd4ee4e647aeaa50ea67ae6bab6a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if59b699ffbf74fb6b067fb3fd3d26948_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f288e08976b441381de343a114c23bc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id831f855902e4ca8a26e06da3c94f9ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0781359c8a514003ad12a9168fd9fc32_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8a061e6cc0574956ae21bc486e71b175_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb5217315fdc425a8f055a9896bfb0af_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieb2b2a6f833a41e0b4880780fe93e686_I20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-01-21</instant>
        </period>
    </context>
    <context id="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="i119efa4588394a448de123d82168c14b_I20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="i827059c44d894d608fa87db88be3f1d6_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="i7d8365f8ec064a42b301d193885831a0_I20220516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="i26a85807415641c1bbd4c16458db46d6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:SwitzerlandLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a4c19202a764797b2b092b8f85d150c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibef597c9a74640cfae1769e2be78cba6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2eac4d8ff1bc4caf99aefef1cdf232b8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4c3195ecfb794e2588cdb48c9b9e1fab_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6f4b750dd5b41018b6987ded07fec01_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia7bff06aaa0b4172b5a7fc7c324cb8d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4bbfc5ceb794438b99f03eab41975dd2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd330d2d7b434eadb065cd5a8d7e8433_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7a8f2da70c8489bbe7c8d73255d7a0e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i88eeda34427444d59f2632f3fe3ce3c3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i67fac24ea1814a04a46df8a1f2b0307d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifbc1d20961ac429694a43623cb59dc7f_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="i8396aa2f370f4359935ac37bbca1ca43_D20220428-20220428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-28</startDate>
            <endDate>2022-04-28</endDate>
        </period>
    </context>
    <context id="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic0a6b6780e2744a78177e645108c3643_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec561b9438fc47fa9736b2ab0dfa6e25_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic93ab2eb0c5b47bea0598419ed1fce33_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8283d8f8c4374e57ae8f04c23b4b7428_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i3c54249f9c4e49ee9c88d0b3e52be617_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="iec04e4bd030243cd8732d95021dd1a4a_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="ibb2ca34f0ed04200a5c092337ff47225_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="ic988cc831aa04c98a4a7c73bda3df147_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie404abea35ec4537a1e5ce4db74c5ab6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id2c43b6d200f4a04b123151eded83516_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0a266617fb74011b52795116bde11a2_D20220405-20220405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="i74bd7dcda88044e8bdc02d6eb3e42a31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if777d493610b46fea5b70595880f2427_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i4eb9b132e2e8429691c1fde0ba1c9948_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i5e198d54f3db4e3e9cc8a6aa406b6115_I20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i214b57f548b54a76aea79ee58885eda6_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i2fb77696fe7a4014a844960177bee7df_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i9051ae2ee8f6429e8c5caaf5ba0b9a3b_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83a3fd81529e4a88b0a3828660a59f92_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifa739c94f7e4421b824446b65ca0970b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d5e85dd3f394163a17aa2a7a2882596_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf15c469b0c14c2b8d582745c8548a55_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9562a91cca5a4feeabc3e61cfce17db9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i63b754f6b02141f7aeffcecd25d8ee9f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13ecba4f425444fab5675e6879c78727_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iee3cd2503a6d4c0d87ab6c13960cd2bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0801eb6aaac14234813d62b72db774ad_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id49480057f2645a7bdae78e27c951b23_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id67d27acccab4cc7b6215d625269df36_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i43306d588f4a45bab466ead6783424bc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i97b468c91f394f3982302387c06cb4bb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58302432af964373a1478c96983fa353_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idced79ac55904d99a6ebfa0dcd88778a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8924a2fba7e24e789eae274f8598c078_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i65f7d144aaf64425a30d562e60e9c259_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i218c57c0818b4e67b3e40d185226720b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia77dada28a724687b986b05a7dc8d862_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0203af48a23c4ada819dd5d73122c9e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if75647732fba42e284fe467cf75d3e9e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i953b502a78c24cafa839047b77dd0496_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c44a0f0edbf4e42a4210967f72907b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12dcce19b02242d3a86e91bf7df20519_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i973bbe15b2c641d79452fafa91f79ca3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i232a7ab61f1e47368c74babe3c12332d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i503211a1f9354a229ff0440c90d6d24f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2f7b33d629c41b8a67324d2e7bb83ff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34f6fa04b56749b38d5db99c77ee8cf9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic087ec71aa444b14b0f99f1a179b4d7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>krys:milestone</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV8zLTEtMS0xLTI3MjM0_6fdd4a15-d3c7-449f-80f0-9a5cf15182c1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV81LTEtMS0xLTI3MjM0_559ce2e8-bcfc-47be-818b-23bfca94262d">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV82LTEtMS0xLTI3MjM0_8eafcea0-782a-4e32-b64e-f220cb90eee5">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV85LTEtMS0xLTI3MjM0_7bb98eaf-b1ab-4aac-9873-4be85914cea1">0001711279</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80L2ZyYWc6Zjg4ZDZkMjg4NDJkNDA3Yzk0Y2E4YTg3NTE4ODU1MTgvdGFibGU6OTFkZGQ5MjMzNDYxNDhmYTk5ZTU5YTU3YmQxMjhiNWUvdGFibGVyYW5nZTo5MWRkZDkyMzM0NjE0OGZhOTllNTlhNTdiZDEyOGI1ZV8xMC0xLTEtMS0yNzIzNA_b4bd065c-4b11-4559-aece-cc5ef63cc560">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i83a3fd81529e4a88b0a3828660a59f92_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY4_5c167b63-6ddc-41b1-8049-053543e3d104">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YTBjNTY2MzM2MjFmNGI4M2ExZmM0YWUyZWZhNmY4N2QvdGFibGVyYW5nZTphMGM1NjYzMzYyMWY0YjgzYTFmYzRhZTJlZmE2Zjg3ZF8wLTAtMS0xLTI3MjM0_f611a45f-6fa1-4004-b573-aa438fc390b4">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDI_74116ef6-6b07-4445-9fa7-6c2310b98f34">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MzIxNWEyZDMyMGVjNDViN2IwOGNhMzhkODhhMDg5NWIvdGFibGVyYW5nZTozMjE1YTJkMzIwZWM0NWI3YjA4Y2EzOGQ4OGEwODk1Yl8wLTAtMS0xLTI3MjM0_7b25fbe2-f830-4b8b-b584-8b6dc3e3201d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY5_8d75484b-6cd3-4c59-bfdb-e0beca2bca8a">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcw_20018c02-8098-4ad0-8273-19496b0812c7">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YmM3NDczOWI4MDRkNGFmMTg5YjgwNTBhMWRmYmYyOGEvdGFibGVyYW5nZTpiYzc0NzM5YjgwNGQ0YWYxODliODA1MGExZGZiZjI4YV8wLTAtMS0xLTI3MjM0_e51ddb8f-0d6d-4dec-a033-136a975077d3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6YmM3NDczOWI4MDRkNGFmMTg5YjgwNTBhMWRmYmYyOGEvdGFibGVyYW5nZTpiYzc0NzM5YjgwNGQ0YWYxODliODA1MGExZGZiZjI4YV8wLTItMS0xLTI3MjM0_99fcc043-1ef7-48b1-a95d-90deb1a90705">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDU3_c6d77d65-a488-4e8e-bc6c-d8fc6dd00828">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYz_e4d9be06-c7f8-4a9b-8bbf-e937455cf524">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY0_d7c024a0-0642-4782-bbcb-08891af2b26c">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYw_ca3a8f27-0090-4c35-b48b-2c9bbd186846">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV81OTk_e93859e0-dd0b-4aa1-8d12-b2e2397aa786">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcx_c1ee6b70-fa68-49e4-910f-b31d4468355c">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDYx_1e28941f-9c7a-4943-b751-07b78511dca4">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTAtMS0xLTI3MjM0_179fce0e-92cd-463f-970e-cbcb74e5332a">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTEtMS0xLTI3MjM0_b7916cba-d7c4-4863-9a9e-84732f242fb8">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6MjQ1MWI3YWU5NzJlNDM3NTlkMjhkMTIwMDUwMGM0OTkvdGFibGVyYW5nZToyNDUxYjdhZTk3MmU0Mzc1OWQyOGQxMjAwNTAwYzQ5OV8xLTItMS0xLTI3NTE2L3RleHRyZWdpb246ZDA2YWRkOTdmMjBiNGQ1NDgwMzAxNWE1NTEyMDE1OWFfMjc0ODc3OTA2OTQ3MQ_2bf43e16-cf37-4184-912b-f29ed47b1871">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcy_f3e37647-4c0f-493c-8f3f-900edd326ad3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDcz_7775e76a-f013-4970-833d-7909cb2bae91">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6NDQ3N2Y0Y2I0ZmU2NDY5NzgyMWM2NDc4OTRmNmFiZmYvdGFibGVyYW5nZTo0NDc3ZjRjYjRmZTY0Njk3ODIxYzY0Nzg5NGY2YWJmZl8wLTAtMS0xLTI3MjM0_4a880ad5-9028-4a81-8213-2f3daffd30e8">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGFibGU6NDQ3N2Y0Y2I0ZmU2NDY5NzgyMWM2NDc4OTRmNmFiZmYvdGFibGVyYW5nZTo0NDc3ZjRjYjRmZTY0Njk3ODIxYzY0Nzg5NGY2YWJmZl8xLTYtMS0xLTI3MjM0_cf73fdba-f0bd-41f4-8e0a-4f74c835c3f7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDc0_af0848ec-cf6b-4da5-aeff-349c8f260775">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yNDY3_177f77d0-3e92-4a8e-90f0-49660579d68a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i68056f7be4b3479a8698326d9f76b95b_I20220729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xL2ZyYWc6M2ZmOTExNjIzYjE3NGRiNmE5NDkxNjAzOTE1YTQzNWEvdGV4dHJlZ2lvbjozZmY5MTE2MjNiMTc0ZGI2YTk0OTE2MDM5MTVhNDM1YV8yMzkw_942df92f-97a6-4ab3-b25a-4bca1d225fd6"
      unitRef="shares">25664287</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNC0xLTEtMS0yNzIzNA_dfc32626-f092-4747-bc9f-7439e1ac38a6"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNC0zLTEtMS0yNzIzNA_62991d70-4ca9-4551-b53d-020ef9b14844"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNS0xLTEtMS0yNzIzNA_49739589-ab7f-4a3d-b2f3-7a4764db5002"
      unitRef="usd">206845000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNS0zLTEtMS0yNzIzNA_75ba888b-b1fe-4377-949a-08a89a2ecbc9"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNi0xLTEtMS0yNzIzNA_317a46e4-8c65-4b85-8074-349a92198960"
      unitRef="usd">3205000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNi0zLTEtMS0yNzIzNA_4cbed537-54f9-45f0-97f6-1142696198bd"
      unitRef="usd">4171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNy0xLTEtMS0yNzIzNA_78f99d7e-4409-4378-bd74-8941ff8d28de"
      unitRef="usd">428770000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfNy0zLTEtMS0yNzIzNA_9048a4d0-2904-4992-a2db-e784096ff5bc"
      unitRef="usd">442267000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOC0xLTEtMS0yNzIzNA_a424c649-4308-4652-87cd-402b30fbec36"
      unitRef="usd">151214000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOC0zLTEtMS0yNzIzNA_79e17724-daba-4405-ade0-d20d135d4699"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOS0xLTEtMS0yNzIzNA_2519ee6d-25a4-42bb-b685-11db3b6ed87b"
      unitRef="usd">12902000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfOS0zLTEtMS0yNzIzNA_44c48bdb-f26f-47b0-9a7d-89d45bbf4a6b"
      unitRef="usd">64371000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTAtMS0xLTEtMjcyMzQ_17d94e48-fd4c-44f4-91d3-64e6bc9ea6c3"
      unitRef="usd">8279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTAtMy0xLTEtMjcyMzQ_97461511-dcf7-45ad-85bd-e728c548edcc"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTEtMS0xLTEtMjcyMzQ_52fbd131-d9cf-42b1-a5f3-64f9c291943d"
      unitRef="usd">159000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTEtMy0xLTEtMjcyMzQ_01e09fe6-b8b4-45e1-a665-335e265af1fb"
      unitRef="usd">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTItMS0xLTEtMjcyMzQ_0f0a15c0-e601-4f9d-8e8d-5f77b7def00b"
      unitRef="usd">601324000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTItMy0xLTEtMjcyMzQ_fdda5e44-ce45-4cab-b5fb-1bda832d4f20"
      unitRef="usd">626295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTUtMS0xLTEtMjcyMzQ_4477da43-8eab-418f-a050-1cdf57508116"
      unitRef="usd">9229000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTUtMy0xLTEtMjcyMzQ_0caeb453-5c4c-4a07-a66e-9d20abc485fd"
      unitRef="usd">8398000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTYtMS0xLTEtMjcyMzQ_8b29ced9-49a0-430b-81af-f1ac1a56bef7"
      unitRef="usd">1417000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTYtMy0xLTEtMjcyMzQ_946d5a91-27c8-4bbf-8462-a2a90ea62427"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTctMS0xLTEtMjcyMzQ_23bd0690-3313-4252-9188-518709b9d394"
      unitRef="usd">23781000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTctMy0xLTEtMjcyMzQ_1ff23735-203d-4263-a8b1-5f4446ee4210"
      unitRef="usd">16297000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTktMS0xLTEtMjcyMzQ_2a6ca057-9996-4747-be80-9b2ab91a8db6"
      unitRef="usd">34427000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMTktMy0xLTEtMjcyMzQ_111795e6-f27a-4371-9e45-2f38a39ddde2"
      unitRef="usd">25736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjAtMS0xLTEtMjcyMzQ_77e1ab45-52c8-460c-af13-71244606d3a2"
      unitRef="usd">7716000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjAtMy0xLTEtMjcyMzQ_376d2283-b99b-4043-8095-2b24bd965492"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjEtMS0xLTEtMjcyMzQ_16fc6bf6-a7bc-4870-88c2-10389dff4c8c"
      unitRef="usd">42143000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjEtMy0xLTEtMjcyMzQ_be8ac43b-c9c0-4397-ab7c-02e2afba7826"
      unitRef="usd">32719000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjItMS0xLTEtMjcyMzQ_abd022c3-280b-4eeb-8919-626e2eab0823"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjItMy0xLTEtMjcyMzQ_0479eb0a-d732-4416-9ffb-cec62f3ff5de"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8yMQ_615adb7a-7c93-4cc0-9adf-ed29367f4377"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8yMQ_e6c29695-ae9d-4c66-9f5c-650d75196e26"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8zNQ_2e661dfb-f327-4fe7-8081-dde791e71f61"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8zNQ_a7188df8-97ad-4691-b59a-162fc99acc1c"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV84NQ_011f6469-a20a-49f8-bbd3-5c66a70fdc9d"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV84NQ_30813da5-5e14-492a-8391-273ffb5897bd"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8xMTA_47c7589e-05de-42b1-94b9-a8d75101dfa0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo3N2JhYTBmMmM1MmI0MmU0YTkwNTI1YWZhNzFhNzdjYV8xMTA_81f20923-60d5-44d8-8b68-51cf92122c20"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMS0xLTEtMjcyMzQ_6ed31d88-b5db-40cc-9411-b1e5f6e6012f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjQtMy0xLTEtMjcyMzQ_3dbbe955-10e7-4675-9115-74100dd70bd7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xOA_3531db79-c46e-47cf-9f19-9b7ce240114f"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xOA_3ed36b70-6e92-4a1c-ae3f-dea60d685d00"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8zMg_4b1a32cc-160e-4466-8db2-c0b8388fd666"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8zMg_d0eba9e0-fbea-4fe2-85cf-d8869ae54a75"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF84Mg_3d0ee1e4-878d-4c1c-96c3-fba848086b28"
      unitRef="shares">25664287</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF84Mg_77e14ac1-744b-4723-97f6-bc92b20ba574"
      unitRef="shares">25664287</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xNDQ_036a5c68-1adb-4843-b7d8-545647026d61"
      unitRef="shares">25207985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMC0xLTEtMjcyMzQvdGV4dHJlZ2lvbjo5OGUxMzJmMGI0Y2I0MGNlODM0MzM5MWZmZWRkZTM0NF8xNDQ_96e80d87-cdf7-46d0-a3dc-9e7c4501388f"
      unitRef="shares">25207985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMS0xLTEtMjcyMzQ_4a495282-f5e7-4822-971a-3e4162c8b1da"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjUtMy0xLTEtMjcyMzQ_223389c1-d024-4282-8a2e-72917b1ad615"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjYtMS0xLTEtMjcyMzQ_2593544e-a5c8-4fad-8a16-3955a2c7c97e"
      unitRef="usd">779583000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjYtMy0xLTEtMjcyMzQ_5e967671-6f91-4c91-bb9e-a529d63d85f4"
      unitRef="usd">734523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjctMS0xLTEtMjcyMzQ_2e865d8d-2572-4da9-af16-acb6cbfefdaf"
      unitRef="usd">-1545000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjctMy0xLTEtMjcyMzQ_2eb8ab28-aec5-4dfe-a6be-aadb9fa1484d"
      unitRef="usd">-163000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjgtMS0xLTEtMjcyMzQ_5f50a027-45d3-4df7-90b0-86d74b518e0b"
      unitRef="usd">-218857000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjgtMy0xLTEtMjcyMzQ_15713005-24c2-4d43-bf91-cffa19ca4874"
      unitRef="usd">-140784000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjktMS0xLTEtMjcyMzQ_67e40293-1ba6-41d3-beaf-b2b554112b4f"
      unitRef="usd">559181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMjktMy0xLTEtMjcyMzQ_3a12f2c2-9f37-49ad-9f10-462519c4918e"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMzAtMS0xLTEtMjcyMzQ_eae61aee-b593-440f-a628-55384d6c30dc"
      unitRef="usd">601324000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xNi9mcmFnOjNkN2VjNjMwZjJjMjQ0NmZhZTU0Yjc4ZTZkZDNjZmFjL3RhYmxlOmJkZWE2YjQ2M2IzMTQ4MjE4ODNjODE0N2YxMTA1ZDMzL3RhYmxlcmFuZ2U6YmRlYTZiNDYzYjMxNDgyMTg4M2M4MTQ3ZjExMDVkMzNfMzAtMy0xLTEtMjcyMzQ_1aa7b8a6-ed08-4915-abdf-658f8480b39e"
      unitRef="usd">626295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy0xLTEtMS0yNzIzNA_5b6c246e-cece-45c6-956e-e6f0ea2670ff"
      unitRef="usd">10890000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy0zLTEtMS0yNzIzNA_c36676cd-2c17-4c7d-b45d-97737227db34"
      unitRef="usd">6594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy01LTEtMS0yNzIzNA_9c8bab31-c8ed-4365-886d-139b408a32fa"
      unitRef="usd">20204000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMy03LTEtMS0yNzIzNA_e5a29b32-9cb6-4ca3-9614-21b3384453d1"
      unitRef="usd">12795000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC0xLTEtMS0yNzIzNA_cccb80cc-c80e-4be0-988e-d93f3af92abb"
      unitRef="usd">17863000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC0zLTEtMS0yNzIzNA_4f421ccc-8715-4100-9ef0-b8e5704bc900"
      unitRef="usd">9799000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC01LTEtMS0yNzIzNA_4c2efd6e-7c2d-4a98-9bbd-f988fd9c6d74"
      unitRef="usd">33771000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNC03LTEtMS0yNzIzNA_10585a04-6119-4e7f-822c-6e3bb93a7338"
      unitRef="usd">17951000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS0xLTEtMS0yNzIzNA_629b7e4f-e66f-4bb6-b9e4-b570a34ced9f"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS0zLTEtMS0yNzIzNA_30847c4d-825c-467e-bf82-ea803504b1c4"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS01LTEtMS0yNzQ3Mg_98e4caf0-d46d-4171-aa6b-84250dc579fd"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNS03LTEtMS0yNzU1MA_0e2fff76-7918-4c86-bf91-cefb5b8a0961"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi0xLTEtMS0yNzIzNA_1fd6d396-7728-49b0-8085-65c4102f9e58"
      unitRef="usd">28753000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi0zLTEtMS0yNzIzNA_496a81d1-9793-4a48-bbac-74a0930e9bdd"
      unitRef="usd">16393000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi01LTEtMS0yNzIzNA_25ff0f71-3af0-43b4-a136-987e21207bd1"
      unitRef="usd">78975000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNi03LTEtMS0yNzIzNA_78dc4086-fe55-4711-9202-a5094c67de6e"
      unitRef="usd">30746000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy0xLTEtMS0yNzIzNA_7472100a-61e5-4c8e-b805-2171958ad031"
      unitRef="usd">-28753000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy0zLTEtMS0yNzIzNA_011455f0-fc0f-4179-b942-f1fb940bdf22"
      unitRef="usd">-16393000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy01LTEtMS0yNzIzNA_8866ad4d-0c24-4236-8638-554e973b8f46"
      unitRef="usd">-78975000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfNy03LTEtMS0yNzIzNA_0df8ef26-335c-44ad-8220-a24f38f0ff63"
      unitRef="usd">-30746000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS0xLTEtMS0yNzIzNA_be568257-b4a7-4aae-b418-7e8bbf5240b6"
      unitRef="usd">645000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS0zLTEtMS0yNzIzNA_4c9a764f-ff4c-4353-abcd-089188af89e7"
      unitRef="usd">30000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS01LTEtMS0yNzIzNA_415a438f-90d9-4be4-91e2-8a71c73e036e"
      unitRef="usd">902000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfOS03LTEtMS0yNzIzNA_85f00e5b-f1ee-419c-9f5f-3add3bdb6bf3"
      unitRef="usd">64000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtMS0xLTEtMjcyMzQ_95b1ea3e-b69e-4702-8864-b7bc26b41b63"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtMy0xLTEtMjcyMzQ_5c99137b-0969-4487-ab3c-8dd434a76988"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtNS0xLTEtMjc1MTA_5c640e2f-3bf4-4dd2-a55b-c3e85242c56e"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTAtNy0xLTEtMjc0OTg_39eeb8bd-4e35-4c57-a379-ac16205ae24a"
      unitRef="usd">1492000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtMS0xLTEtMjcyMzQ_7ef4d382-1e39-4e95-b962-036a81ab8612"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtMy0xLTEtMjcyMzQ_603eac28-cff5-4f47-b1b4-295442d30acc"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtNS0xLTEtMjcyMzQ_6b95216f-fdb3-4cd8-8a4a-0e80717a6312"
      unitRef="usd">-78073000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTEtNy0xLTEtMjcyMzQ_2ef5f6ae-e679-419c-a59c-d7b81958fa5c"
      unitRef="usd">-32174000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItMS0xLTEtMjcyMzQ_8e88be3e-8edd-467b-8355-c759a16df35d"
      unitRef="usd">-348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItMy0xLTEtMjcyMzQ_361cc5ee-b4f8-4731-a8ab-8e4c48d43268"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItNS0xLTEtMjcyMzQ_ea8108a0-556e-4e75-9957-6fa01e023b3b"
      unitRef="usd">-1382000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTItNy0xLTEtMjcyMzQ_470faf55-1964-43e2-95dc-93ef4f2ca427"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtMS0xLTEtMjcyMzQ_e1e0565b-9e91-45f0-8f21-2c30730adaab"
      unitRef="usd">-28456000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtMy0xLTEtMjcyMzQ_4d199bed-9bd7-408e-9ef0-a81b0aeb3eb7"
      unitRef="usd">-16387000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtNS0xLTEtMjcyMzQ_8635b489-3139-41ae-8d54-6c0744c7b50e"
      unitRef="usd">-79455000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTMtNy0xLTEtMjcyMzQ_2119bbe3-fd4c-4e5e-bb2e-cf5c03c07508"
      unitRef="usd">-32201000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMS0xLTEtMjcyMzQ_5de68f6a-3263-445e-b414-676586554d46"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMS0xLTEtMjcyMzQ_c674fd95-db47-467d-bc9c-1bf40ff70be2"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMy0xLTEtMjcyMzQ_4a6b08c0-4c17-4cc2-a8b6-ca86e2c7cb45"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtMy0xLTEtMjcyMzQ_c7b6f53c-b546-409e-86c4-5291cf42a407"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNS0xLTEtMjcyMzQ_38dbf8f1-1700-4611-a3f3-c5456db0f0d3"
      unitRef="usdPerShare">-3.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNS0xLTEtMjcyMzQ_b9c25a00-f575-45ad-82c3-1546193cbd89"
      unitRef="usdPerShare">-3.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNy0xLTEtMjcyMzQ_376d3ba4-0203-461a-8499-f4fa7531f95a"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTUtNy0xLTEtMjcyMzQ_a25499e3-f91c-4657-8e78-69dad535f0af"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMS0xLTEtMjcyMzQ_4f7aae96-d6e0-4c1f-adc1-bf4dd6ede550"
      unitRef="shares">25545167</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMS0xLTEtMjcyMzQ_9acc3572-5dbf-40ae-9598-e2b80133ce97"
      unitRef="shares">25545167</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMy0xLTEtMjcyMzQ_4b84cedc-44c1-4b67-a8d3-0a8bd6a6feab"
      unitRef="shares">22204659</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctMy0xLTEtMjcyMzQ_bc88cf0c-ca4c-47bd-9a3b-24fa48f3015b"
      unitRef="shares">22204659</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNS0xLTEtMjcyMzQ_4a79331f-b06e-4d64-96c5-2a5fcf45cbd3"
      unitRef="shares">25331000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNS0xLTEtMjcyMzQ_eada6cbd-f90e-4800-8d7d-6ad57cef350a"
      unitRef="shares">25331000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNy0xLTEtMjcyMzQ_1ba42434-8e88-4634-aee4-73149568e6f1"
      unitRef="shares">21731711</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8xOS9mcmFnOmQ1M2Q5YjY1YmY2NTRkMWRiOGQ0NDg0ODIyNjZiZWUxL3RhYmxlOjFjZmM5NjE4NDNkOTQwNTBiMjhjOWIwMmUyYWE3MzUwL3RhYmxlcmFuZ2U6MWNmYzk2MTg0M2Q5NDA1MGIyOGM5YjAyZTJhYTczNTBfMTctNy0xLTEtMjcyMzQ_f72a6827-9306-46d7-b473-39c25f63079c"
      unitRef="shares">21731711</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="id5e3e5b1d1904de1ab6caf2253008d57_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0xLTEtMS0yNzIzNA_86903754-de0c-4cfb-8b7a-318ba2e80eb0"
      unitRef="shares">25207985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5e3e5b1d1904de1ab6caf2253008d57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0zLTEtMS0yNzIzNA_2b413e5d-95c4-4de6-bc8b-06a8e06a8a53"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f5ffa4369814ee099cdeb5c269a22a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy01LTEtMS0yNzIzNA_6e8f6843-7224-431d-bef9-c077e5c0af58"
      unitRef="usd">734523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i167177dab94c4db6a7199e7c88c61883_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy03LTEtMS0yNzIzNA_0ef53696-33cb-4d5e-b27e-5c402891ef4f"
      unitRef="usd">-163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96d0e39fa84848fd83a65fbedcbd9193_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy05LTEtMS0yNzIzNA_249882b0-34dd-4c46-83dc-2d81d688f1c6"
      unitRef="usd">-140784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMy0xMS0xLTEtMjcyMzQ_56067ebe-0d76-4306-84c0-f311fa7a7229"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC0xLTEtMS0yNzIzNA_db773e2c-0476-4ac3-bf06-b35c8244e57f"
      unitRef="shares">1475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC01LTEtMS0yNzIzNA_81ddb741-0fe9-4ee4-b965-1c21c7d803d0"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNC0xMS0xLTEtMjcyMzQ_515e3eae-6ccd-4bf5-bdfc-c56f8b2db596"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="id2ca47f736d34207ba160bd9bba32196_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS0xLTEtMS0yNzIzNA_7ed19712-486b-4aa1-8ef9-78292b6d2bf8"
      unitRef="shares">10379</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS01LTEtMS0yNzIzNA_a068fbc8-6567-4e31-979d-d8567a0cf2db"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNS0xMS0xLTEtMjcyMzQ_8cf5cdf9-0957-47ef-b1fd-00b679155f53"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4776963ce5424903852057d81548f3d6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNi01LTEtMS0yNzIzNA_a6bcf233-32da-4418-8408-6fc2759c4104"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNi0xMS0xLTEtMjcyMzQ_f5e35c25-acf6-44a2-af20-f5897076ac68"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id292fcdfa2ec483991762030cda62567_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNy03LTEtMS0yNzIzNA_97201810-5b54-4966-8b3c-65c3a8e85f05"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfNy0xMS0xLTEtMjcyMzQ_ddc12498-3809-4925-9b2a-0413fd135114"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i6dd501c8dcab465e8865f8990e84b682_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOC05LTEtMS0yNzIzNA_1768c3de-dcf1-4893-a535-e56406a2d156"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie6400ac2b7ec4ac2bab44093bb5e3d51_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOC0xMS0xLTEtMjcyMzQ_a12e9fe8-8277-46ad-b3be-8e2801c09923"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic4799c83f8064ebaa62e85e4da5639e7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0xLTEtMS0yNzIzNA_fac9a8d7-e3b2-457b-b545-c76c1b00fec7"
      unitRef="shares">25199081</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic4799c83f8064ebaa62e85e4da5639e7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0zLTEtMS0yNzIzNA_cb9844bc-1082-468e-9283-e8ebe40e4f1e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icab00efeb6ef4be2900da03084a5a9d4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS01LTEtMS0yNzIzNA_b2c98c20-8c7b-4d37-b6e4-7dd5cbab9f0a"
      unitRef="usd">740500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0ebd4532229468281c822de2a5e657c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS03LTEtMS0yNzIzNA_2fa56969-eeea-4c73-9eaa-8d33b3d911e6"
      unitRef="usd">-1197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8f1e0e5c44a4cfe96d8a13d20f90db7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS05LTEtMS0yNzIzNA_f4914cad-3ade-4c1b-8f8a-7bf891746bb0"
      unitRef="usd">-190749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41f8ca7c434f4946a365bbaa9a9d8bce_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfOS0xMS0xLTEtMjcyMzQ_3102e1fb-e604-4384-ab64-578ed7b13a40"
      unitRef="usd">548554000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if22db7b29d7e4ece89a75e653bd2115f_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtMS0xLTEtMjcyMzQ_2c95d472-22e7-4dfa-90e7-6a5add46d3b4"
      unitRef="shares">472706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtNS0xLTEtMjcyMzQ_65fab164-abc1-4fcd-9563-875381621607"
      unitRef="usd">30748000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTAtMTEtMS0xLTI3MjM0_8ce94920-ca0f-4c5b-b347-170c1d1a3823"
      unitRef="usd">30748000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtMS0xLTEtMzIxNjk_40a3ec3c-09e3-4ba2-a48a-9c144fd44050"
      unitRef="shares">7500</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5cc38ce7e95c4d069d3b4c1aed32178a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtNS0xLTEtMjcyMzQ_5c1c668a-988b-46c8-a1df-34a953a24f17"
      unitRef="usd">8335000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTEtMTEtMS0xLTI3MjM0_a7055cfc-7ff0-460e-9d95-727020b4f5fa"
      unitRef="usd">8335000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id814f4669c3d4394a7130b5293e3c8a6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTItNy0xLTEtMjcyMzQ_a8e59370-47ff-4a69-a0b5-811820a1ec13"
      unitRef="usd">-348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTItMTEtMS0xLTI3MjM0_fcf2c86b-b8a8-444f-9732-9ec9a9e7a74b"
      unitRef="usd">-348000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i775cfbfdc6864e3cb405ab41f9c0eb16_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTMtOS0xLTEtMjcyMzQ_ec9187c2-bfcc-4b6b-bcef-43d15ca1b4cd"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTMtMTEtMS0xLTI3MjM0_bf07f683-81a9-4f96-aece-c6a863f4216f"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ibdb89f313eb14a259062ad4a9df63ca2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMS0xLTEtMjcyMzQ_58edbe61-a877-4625-a1d4-0ba2e3f8793b"
      unitRef="shares">25664287</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibdb89f313eb14a259062ad4a9df63ca2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMy0xLTEtMjcyMzQ_64c94db6-dd00-4610-a33c-df9d74efb53e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1c29c2ed7724e3f9034ecf0a95d902e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtNS0xLTEtMjcyMzQ_81c2387f-c732-48e1-bc95-2ee29780a0f7"
      unitRef="usd">779583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i076da2ca9712409eb1f14f99f5da94d6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtNy0xLTEtMjcyMzQ_b238aff7-828e-4eaf-bda9-90b731bc8e22"
      unitRef="usd">-1545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9dbf9c0f040d4dc69fe77d188302bf6b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtOS0xLTEtMjcyMzQ_8a788800-ac49-41c2-b693-1e91bb00927f"
      unitRef="usd">-218857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmYzYWZhNDAxZmUxYjRhN2I5OTljMzlhZGQ2NTJlYzgzL3RhYmxlcmFuZ2U6ZjNhZmE0MDFmZTFiNGE3Yjk5OWMzOWFkZDY1MmVjODNfMTQtMTEtMS0xLTI3MjM0_c2e82515-79f9-406b-a1ab-a2cdb9b9b1d0"
      unitRef="usd">559181000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0xLTEtMS0yNzIzNA_64a541f3-6fb6-42d4-8b5f-ac658edcab7d"
      unitRef="shares">19714220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0zLTEtMS0yNzIzNA_c2acbab0-944d-4faf-bdcb-a230cc863bc3"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6e05fc289824b83b4328d58ee1c1b1d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy01LTEtMS0yNzIzNA_d850e3f6-875a-4937-9e14-5bc21a27918d"
      unitRef="usd">363292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bdfa279d35d4560b16eb6696604d967_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy03LTEtMS0yNzIzNA_82ff47d6-f448-4b77-9284-df2207786e2c"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e70fa1b51374c78acd66828c63b4cee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy05LTEtMS0yNzIzNA_0eaf988c-01a9-4cc5-b02b-b52c6c38b6d3"
      unitRef="usd">-71214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5d42d81e0d64f339007558ceec6d457_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMy0xMS0xLTEtMjcyMzQ_d8fb84c7-ea08-40a4-8965-2eec03a742a6"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i025425ccecb5443b909699e65613a02c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC0xLTEtMS0yNzIzNA_0f0806b2-6849-485d-9a92-e68fc0f671b1"
      unitRef="shares">2489837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC01LTEtMS0yNzIzNA_0f08365a-40b1-4675-987a-37fdccb89dbf"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNC0xMS0xLTEtMjcyMzQ_fd6173f0-4cfa-4b49-81d3-e85b40a7a13c"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic614957070ae4613bb95dd85c650c0ef_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNS01LTEtMS0yNzIzNA_dd991763-88b2-437c-99e9-29506979f612"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNS0xMS0xLTEtMjcyMzQ_3ba92980-a28d-4363-95e6-a2b70c3edd29"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia784962b1a35445abaf692d9da0f8b7c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNi03LTEtMS0yNzIzNA_fca57710-6db4-4844-a562-20efef73b16c"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNi0xMS0xLTEtMjcyMzQ_4cb7c7fc-e4d4-4982-84ff-c82fd380fae0"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i472f7c3bc8534d648bd470f561540a57_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNy05LTEtMS0yNzIzNA_244fabfe-813d-4f21-ae42-4f53d243f7a6"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic0ed4789864342cf89740c7ac7048056_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfNy0xMS0xLTEtMjcyMzQ_c661f6d7-8332-4fc9-88aa-5a6064322116"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iaeb9d19bc36946b7a2b39686906270ce_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0xLTEtMS0yNzIzNA_614133ae-d702-4e91-b876-30907aaed1dc"
      unitRef="shares">22204057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iaeb9d19bc36946b7a2b39686906270ce_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0zLTEtMS0yNzIzNA_55ea58e5-3435-4be1-b3de-67ade619e126"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia88065ac15b8425ba0dc82f5b062b440_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC01LTEtMS0yNzIzNA_12e6c72c-d09e-465e-9b89-ca31e72f583f"
      unitRef="usd">517675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i996e16354ef64539bf61d8bc11b8baf6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC03LTEtMS0yNzIzNA_02a7dc27-66fd-44ff-a91c-d0c0e5eb3dca"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60d5bf962dba470ab3a4481875ff9d28_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC05LTEtMS0yNzIzNA_88eba687-f4f8-4ee2-906b-f046eaa3e322"
      unitRef="usd">-87026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5da18ba1fb574a9c80c2ef998e02b45b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOC0xMS0xLTEtMjcyMzQ_37883672-0751-480a-ab86-d54d92315573"
      unitRef="usd">430652000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id6eeb4e61f234a01a966fc80ccd9a356_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS0xLTEtMS0yNzIzNA_bef0822a-8f13-4077-aa0b-a9150f6c76d9"
      unitRef="shares">975</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idf7a3cc2b19144a7acff545065372722_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS01LTEtMS0yNzIzNA_2b1af034-ccfb-4c60-9b48-760311f4a58b"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfOS0xMS0xLTEtMjcyMzQ_61d20357-6d5b-4b73-83f6-1baeb78239ed"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idf7a3cc2b19144a7acff545065372722_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTAtNS0xLTEtMjcyMzQ_171ef326-6c85-43f3-9db9-fe2d982b99e6"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTAtMTEtMS0xLTI3MjM0_35716570-8406-40db-ae85-a10fd4ac5730"
      unitRef="usd">4261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i74ef1968bb10424d945aad572a1eebe8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTEtNy0xLTEtMjcyMzQ_ad3ce583-4063-4abb-948b-3b77ca1ddf52"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTEtMTEtMS0xLTI3MjM0_1d12327a-c63d-4991-b60e-0df1a25d15d8"
      unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic83b183ffa7240659fcc27d5a7aa5c0e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTItOS0xLTEtMjcyMzQ_e774e7b2-3a65-4e5a-a3a2-b50ae5db6392"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTItMTEtMS0xLTI3MjM0_8450980d-1859-4a8f-b67f-52b6c0018aec"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7c755555716244b396f922347ef2dc75_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMS0xLTEtMjcyMzQ_ac6ec3de-7743-40dc-8e96-64e032a12c77"
      unitRef="shares">22205032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7c755555716244b396f922347ef2dc75_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMy0xLTEtMjcyMzQ_77279a72-543e-449b-a4b5-61435657a59a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iab4702597e5e480a9bc82eb00ce29108_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtNS0xLTEtMjcyMzQ_4d8ac98b-e08f-4476-889d-adbe915070bf"
      unitRef="usd">521950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7198d64a2d734ca3839ec28f8cc1be55_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtNy0xLTEtMjcyMzQ_75df1a0e-327d-4fad-bf51-5e8ab5c8d9ee"
      unitRef="usd">-21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40e7fd3b4ff64b319e3403886234d050_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtOS0xLTEtMjcyMzQ_bf1c73ca-964b-4aa1-a3e3-7cfbc64ac757"
      unitRef="usd">-103389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a7496fd6b01444da889610d00b68a0e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yMi9mcmFnOjI3ZmI3MzcyMjEzMjQwNGU5MmY2MDQ1NGQzMWNjOGE4L3RhYmxlOmM3NzM0Nzk2ZjVkMTRhOTE4ZWU2ZWE1MjQ5YjYyOWFiL3RhYmxlcmFuZ2U6Yzc3MzQ3OTZmNWQxNGE5MThlZTZlYTUyNDliNjI5YWJfMTMtMTEtMS0xLTI3MjM0_f922c37f-05d0-4086-92d9-9c9da8fa0ee7"
      unitRef="usd">418540000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMy0xLTEtMS0yNzIzNA_36b613cd-1d15-4d9d-9633-90a84d68b98c"
      unitRef="usd">-78073000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMy0zLTEtMS0yNzIzNA_480bcca7-0ea2-462b-a13e-ec679035b5a6"
      unitRef="usd">-32174000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNS0xLTEtMS0yNzIzNA_8b42597d-0861-4525-b0d3-ecb4db77636f"
      unitRef="usd">1991000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNS0zLTEtMS0yNzIzNA_1c467432-6b42-4d08-984a-d18b4203195b"
      unitRef="usd">1202000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNi0xLTEtMS0yNzIzNA_a6cb7dfe-b199-4c68-a836-e5b2bae5a188"
      unitRef="usd">14619000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNi0zLTEtMS0yNzIzNA_6f7247ba-f70a-48d6-bb90-ff6a939acbd8"
      unitRef="usd">6508000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfOC0xLTEtMS0yNzIzNA_5c53806c-eaea-4f50-889a-0ca237313e1a"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfOC0zLTEtMS0yNzIzNA_aeee7faf-8d85-4896-8522-9b49d31b2102"
      unitRef="usd">1492000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTAtMS0xLTEtMjcyMzQ_bbf200c3-8a4a-4d3a-8c03-0fc206851df0"
      unitRef="usd">-166000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTAtMy0xLTEtMjcyMzQ_87de1e82-18f1-4336-b876-29473d2b333f"
      unitRef="usd">-117000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTItMS0xLTEtMjcyMzQ_2482fbc3-bc1d-4f5c-8674-d6cef692eab5"
      unitRef="usd">-848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTItMy0xLTEtMjcyMzQ_5ea7075d-6f11-44ae-a7cb-8546ddec8419"
      unitRef="usd">-1366000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTQtMS0xLTEtMjcyMzQ_b08da3fa-e42c-47e8-bb77-9f3be31b2a9a"
      unitRef="usd">-15000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTQtMy0xLTEtMjcyMzQ_d2526622-8f77-4881-8b93-6510cf2eaf37"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTUtMS0xLTEtMjcyMzQ_16666e69-d9bc-4858-9eaa-5ab305b45812"
      unitRef="usd">-286000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTUtMy0xLTEtMjcyMzQ_a938db50-713d-456d-83a6-488c4c397156"
      unitRef="usd">-175000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTYtMS0xLTEtMjcyMzQ_ff95fd99-700a-40a5-b344-411328d64c48"
      unitRef="usd">24000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTYtMy0xLTEtMjcyMzQ_432e336d-f7c9-4f3b-9fce-fc364830f2fc"
      unitRef="usd">-680000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTctMS0xLTEtMjcyMzQ_0bf143d2-2f9b-4384-9c01-3ecc90dcd467"
      unitRef="usd">2476000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTctMy0xLTEtMjcyMzQ_e263578f-89c6-42ac-a431-770e94a5f310"
      unitRef="usd">2795000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMS0xLTEtMjcyMzQ_52e8dae9-f8b9-4eb5-9b71-a59d8b51af72"
      unitRef="usd">-58552000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMy0xLTEtMjcyMzQ_799584f4-ba50-4bd1-8fe0-9194394b758d"
      unitRef="usd">-19783000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMTktMy0xLTEtMjcyMzQ_8ac0bec3-9a74-4167-87c5-ea529f83eb26"
      unitRef="usd">-19783000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjItMS0xLTEtMjcyMzQ_76d152ed-e079-42e7-babe-a8b6368c5262"
      unitRef="usd">33706000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjItMy0xLTEtMjcyMzQ_7b51a7d2-494d-4130-84f5-7eab6b08bae0"
      unitRef="usd">6462000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjMtMS0xLTEtMjcyMzQ_cffdf4e1-f77d-414c-8a98-4632a36d6a8d"
      unitRef="usd">147255000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjMtMy0xLTEtMjcyMzQ_df04bd6c-7b87-4c74-96c7-4558af4d578c"
      unitRef="usd">59561000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjQtMS0xLTEtMjcyMzQ_525c605f-7a51-49e7-aa2f-387811536fc4"
      unitRef="usd">86829000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjQtMy0xLTEtMjcyMzQ_f0879718-762e-4e28-8a08-fff05593780a"
      unitRef="usd">2959000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjYtMS0xLTEtMjcyMzQ_0d0e076b-9936-4b94-86ce-2dc12e16fa9c"
      unitRef="usd">-94132000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjYtMy0xLTEtMjcyMzQ_f629a7c5-e4eb-4265-98f8-758df428cde6"
      unitRef="usd">-63064000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjktMS0xLTEtMjcyMzQ_06832c28-f88a-44f4-9eed-7945a2df4275"
      unitRef="usd">30807000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMjktMy0xLTEtMjcyMzQ_6e1f6c99-9ed8-4292-81b3-9c1b584e4df1"
      unitRef="usd">152065000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzAtMS0xLTEtMjcyMzQ_2ca6020a-ca98-4a13-804c-a67e16eccbed"
      unitRef="usd">649000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzAtMy0xLTEtMjcyMzQ_75dc827b-b644-47c8-9b51-f47b252094b9"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <krys:PaymentsForSuitLiability
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzEtMS0xLTEtMjcyMzQ_f58cf9a4-500c-4c5a-91da-5a192d5a14ec"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzEtMy0xLTEtMjcyMzQ_c4361ec9-08b9-454e-a653-975510eae2ba"
      unitRef="usd">7960000</krys:PaymentsForSuitLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzItMS0xLTEtMjcyMzQ_e8f30e33-27c4-4d4e-999f-162849f87355"
      unitRef="usd">30158000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzItMy0xLTEtMjcyMzQ_32b12551-12a9-4242-a441-aafe6a9a38fd"
      unitRef="usd">144105000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzQtMS0xLTEtMjcyMzQ_23683422-4388-4d6a-a4cb-7b5119f8dfba"
      unitRef="usd">-122526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzQtMy0xLTEtMjcyMzQ_3f204986-899a-4c23-a4d6-a0c6d67acaf2"
      unitRef="usd">61258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzYtMS0xLTEtMjcyMzQ_161034c1-9a1e-4bc0-b2e6-9f64143ea11f"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5d42d81e0d64f339007558ceec6d457_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzYtMy0xLTEtMjcyMzQ_36c4fbbc-4b69-4dc8-b8d6-9ecfbc6f0e31"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzctMS0xLTEtMjcyMzQ_9418a574-3894-4118-9c82-bdfd9e50f426"
      unitRef="usd">218720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2a7496fd6b01444da889610d00b68a0e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfMzctMy0xLTEtMjcyMzQ_77d0c43a-0d9b-40e2-808e-a00cdf5fc6ba"
      unitRef="usd">329527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDAtMS0xLTEtMjcyMzQ_7d26f6dd-3e05-41df-973a-6eec46599c00"
      unitRef="usd">22234000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDAtMy0xLTEtMjcyMzQ_deb2b068-8595-492d-93e3-1a0e53a33e3d"
      unitRef="usd">10143000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDEtMS0xLTEtMjcyMzQ_1fc74a03-6afb-4857-8619-6e98a708c7ff"
      unitRef="usd">1394000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8yNS9mcmFnOjE5NGFjOTJlOGUzMTRhMWJhYmI0NTk5NTM3MDJjN2M1L3RhYmxlOmEyNjJmOWFmNzQ2MDQ5Mjk5Yjc3YTRkZTZmMGI2YWZiL3RhYmxlcmFuZ2U6YTI2MmY5YWY3NDYwNDkyOTliNzdhNGRlNmYwYjZhZmJfNDEtMy0xLTEtMjcyMzQ_563b341c-59f1-46b3-8ad5-6c30642574e4"
      unitRef="usd">4060000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMzQ1Mg_308241ce-3b19-48a9-86cc-793286025af4">Organization&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company had an accumulated deficit of $218.9 million. With the net proceeds raised from its public and private securities offerings, the Company believes that its cash, cash equivalents and short-term investments of approximately $425.6 million as of June&#160;30, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercialize product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMTkxNQ_3ac1cd88-c7ac-432c-beb0-99711eb5fbab"
      unitRef="usd">-218900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zMS9mcmFnOjNjYWE3Mzk2OGQ1OTRhNDliMTk4NTcyZGUzOWRiZDQ5L3RleHRyZWdpb246M2NhYTczOTY4ZDU5NGE0OWIxOTg1NzJkZTM5ZGJkNDlfMjA5NA_b78e19c8-d315-4ba5-ae60-d30917673aab"
      unitRef="usd">425600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODE_967eea93-6644-4dca-8a0f-2dc30fe45e16">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzY_328f485a-2599-4b3f-b3c3-497bb4438b64">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <krys:RisksAndUncertaintiesPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzc_7fbd237f-023e-418b-afdd-50689e2b4380">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect the Company's business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. The full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that the pandemic could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;</krys:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzg_4ad42a0d-a366-48c9-8c57-eefa1e394b62">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzM_250ee1fc-bc78-4f42-8f6c-f3ed2bc8b28d">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceutical products.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfNDE5MA_639c1add-2c4b-4bdc-b1de-ab2dff3405e1"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODI_20ce6810-a528-402d-b10b-f69aa5ab5e87">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzQ_3cee558e-c013-4f05-8e2b-3e8ed42a9eaa">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the condensed consolidated balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2Nzk_6871b56e-29fe-4c30-92fc-06461d699205">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s consolidated financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODM_6f1f2817-8c04-4511-a115-0ae1bb626b47">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODA_0fbc186f-2099-4d11-85f4-f8078c16f87f">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iab27a23368df44c0b545b31a362ffad0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMC0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjg1MzY2NTQ3MWFjMzRkNWY5YTJhYjQyNWQyNTg2Y2EzXzQ_5a738951-d691-43b3-8bff-5d6c12d07fe3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i72afdcf0cb6547a990fc6bb8f48b7521_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMC0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjg1MzY2NTQ3MWFjMzRkNWY5YTJhYjQyNWQyNTg2Y2EzXzk_fc0d5b1b-0a7b-46bf-99a7-c446f9634804">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ief5d94d6062c49e2b1db8c7414a71a7e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMS0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjk1ZTgwODgxYmEzMDQwYzk5NmE4YTZiMTJkZDYyMTI5XzQ_188fcdd4-d5b0-4c93-bf62-6698d09821d1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia69cd7bb89554aa38e45742bc5b22eb2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMS0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjk1ZTgwODgxYmEzMDQwYzk5NmE4YTZiMTJkZDYyMTI5Xzk_aa86970f-4a45-4dde-a577-f49bffb2b8dc">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ice52f49beadd49d5861085be75f4b8a0_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMi0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjRkMzZiMDBmNzQzYzRjODliZGE4ODlhZWNjOTViYzE4XzQ_ab25b0ab-a262-43b0-93de-fa8e158e19bc">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i87b630056ae3492b8a0991e9b5343757_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RhYmxlOmE3YTY1ZTVkNzAwOTQ5NDI5NDFmNjEyMjZmMGU4OThhL3RhYmxlcmFuZ2U6YTdhNjVlNWQ3MDA5NDk0Mjk0MWY2MTIyNmYwZTg5OGFfMi0xLTEtMS0yNzIzNC90ZXh0cmVnaW9uOjRkMzZiMDBmNzQzYzRjODliZGE4ODlhZWNjOTViYzE4Xzk_9fa980a5-9369-4e86-8b95-5d4225057471">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODY_d85fcb68-d599-4671-8f4a-eb836428abc0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three and six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8721aeb105fc4c238df1588239e9c101_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_d5330314-6a2f-4e3a-bde1-7c782c8dece7"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i2f2c361f936d4f35898fb47c6618dcf8_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_d863222a-0a95-4588-90a3-e39436218736"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ic39c1f1d7ae6452eabc0f676318ed72a_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_fc7af7d2-9163-4c7b-a913-fb997818ba71"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i5a0b896d15f540bd9cd89d793a7b3dd9_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTAyOTY_fe63e451-34d4-44c0-874e-4183de4a2f94"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2NzU_2ef58acd-81bd-45f2-8eae-13fbea35de1e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Right-of-use lease assets represent the right to use an underlying asset during the lease term and the lease obligations represent the commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, the Company has used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on an assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODQ_b0e75792-61ef-4ebc-9305-93717710e6d1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODU_a7cabf23-4feb-47d4-87c0-23c4e7b4e5b0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the consolidated statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and began using only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates &lt;/span&gt;&lt;/div&gt;are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODc_5281330a-80e7-4212-a56c-995c7f1a90f2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNC9mcmFnOjI1ZjQyZjI3N2ZhMzRlNDlhMTU5MzA1MGZkYTM2M2MyL3RleHRyZWdpb246MjVmNDJmMjc3ZmEzNGU0OWExNTkzMDUwZmRhMzYzYzJfMTc2ODg_a581c14d-e647-45ad-84a4-4a4af253271a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the condensed consolidated statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfOTU4_c6fec204-860a-497b-bd72-768a960ceb5b">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,686,862 and 1,688,965 common share equivalents outstanding as of June&#160;30, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,545,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,331,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,731,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfNjYz_90fb9ac4-07f2-4bdf-bd56-a29052ed064a"
      unitRef="shares">3686862</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfNjcw_9745e37e-a811-4c59-b45d-b5ba519e4a03"
      unitRef="shares">1688965</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RleHRyZWdpb246MjdkNzI4ZGZhMWUzNDg4Y2ExZGJjMTkzN2Y1MWYyZTlfOTU5_2ceadc21-3722-447a-91dc-29f72e6e05c9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.272%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,545,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,204,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,331,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,731,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC0xLTEtMS0yNzIzNA_03a89603-0a60-4faa-a59f-c43980ad74f6"
      unitRef="usd">-28108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC0zLTEtMS0yNzIzNA_5c8dcb72-6a86-4b7a-9e58-f46f38d01dda"
      unitRef="usd">-16363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC01LTEtMS0yNzIzNA_6b95216f-fdb3-4cd8-8a4a-0e80717a6312"
      unitRef="usd">-78073000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNC03LTEtMS0yNzIzNA_2ef5f6ae-e679-419c-a59c-d7b81958fa5c"
      unitRef="usd">-32174000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0xLTEtMS0yNzIzNA_740ad0de-ea71-4f88-8093-413756cfa6d7"
      unitRef="shares">25545167</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0xLTEtMS0yNzIzNA_a356ffc5-d6ce-47ad-9ee7-a2af2e71d2a0"
      unitRef="shares">25545167</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0zLTEtMS0yNzIzNA_33399eb8-4243-45cc-809a-e6e821d74328"
      unitRef="shares">22204659</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi0zLTEtMS0yNzIzNA_79e1537d-d375-48ad-87be-08f6116a0c4e"
      unitRef="shares">22204659</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi01LTEtMS0yNzIzNA_4a79331f-b06e-4d64-96c5-2a5fcf45cbd3"
      unitRef="shares">25331000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi01LTEtMS0yNzIzNA_eada6cbd-f90e-4800-8d7d-6ad57cef350a"
      unitRef="shares">25331000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi03LTEtMS0yNzIzNA_1ba42434-8e88-4634-aee4-73149568e6f1"
      unitRef="shares">21731711</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNi03LTEtMS0yNzIzNA_f72a6827-9306-46d7-b473-39c25f63079c"
      unitRef="shares">21731711</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0xLTEtMS0yNzIzNA_33b29501-6c49-47c0-af3b-448ec135804c"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0xLTEtMS0yNzIzNA_7faabc14-99ae-417d-9a8a-e756117bb333"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0zLTEtMS0yNzIzNA_5cade551-50b1-4f96-bcbd-2c95c1352c0a"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy0zLTEtMS0yNzIzNA_74d70020-3a5b-4331-bbcb-0153fa20464b"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy01LTEtMS0yNzIzNA_38dbf8f1-1700-4611-a3f3-c5456db0f0d3"
      unitRef="usdPerShare">-3.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy01LTEtMS0yNzIzNA_b9c25a00-f575-45ad-82c3-1546193cbd89"
      unitRef="usdPerShare">-3.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy03LTEtMS0yNzIzNA_376d3ba4-0203-461a-8499-f4fa7531f95a"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml8zNy9mcmFnOjI3ZDcyOGRmYTFlMzQ4OGNhMWRiYzE5MzdmNTFmMmU5L3RhYmxlOjc1YzA0NDZmNjU1NjQ2ODhhMzMxMmYyOTJjN2M2NWE4L3RhYmxlcmFuZ2U6NzVjMDQ0NmY2NTU2NDY4OGEzMzEyZjI5MmM3YzY1YThfNy03LTEtMS0yNzIzNA_a25499e3-f91c-4657-8e78-69dad535f0af"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfNTAz_122d071f-cb83-4ab5-90a1-f4de03ad6f6f">Fair Value Instruments&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of June&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfNTA0_029534b7-c749-4519-9dc9-b080b90c6047">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of June&#160;30, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;440,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC0xLTEtMS0yNzIzNA_1334620d-679e-4cc3-b522-4e5412df21cf"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4ddee5d0afdf4df5adda87c0a405ea3d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC03LTEtMS0yNzIzNA_4f943517-5f84-4b9f-baef-18d65bcb8166"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e86db60e52a433cabc5c934bf137fd1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNC05LTEtMS0yNzIzNA_57b7853f-610d-4de5-b4ef-dcd1751f8f89"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if4d892ea64f341f094f64a0244811282_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS0xLTEtMS0yNzIzNA_4f5e87ea-9981-480f-ba6c-02e86e2396fa"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if4d892ea64f341f094f64a0244811282_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS03LTEtMS0yNzIzNA_6c401d73-d379-4776-8fa1-ecb628c45403"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4680df6fdb6448fe89234b2525155c51_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfNS05LTEtMS0yNzIzNA_a4609a1b-6c36-421f-8f59-62fff16a4d81"
      unitRef="usd">218720000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xLTEtMS0yNzIzNA_07710e5c-d629-4131-9343-c63385f20f65"
      unitRef="usd">46157000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0zLTEtMS0yNzIzNA_540cdd01-0748-4a60-b144-4a50269637eb"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC01LTEtMS0yNzIzNA_835425d4-081b-49ba-89e4-36ddda7859e1"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b201c5d548540d7bff79745cf60be1d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC03LTEtMS0yNzIzNA_5f1ca193-c780-46f4-bba5-73923161f170"
      unitRef="usd">46105000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic54be4b4a31245cfa953f2ed8fcbabb1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xMS0xLTEtMjcyMzQ_cdc9c630-8057-42db-b73c-d1f8af08cf99"
      unitRef="usd">46105000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0408fc3248f94e58a9239a4ddda6b92c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOC0xMy0xLTEtMjcyMzQ_0a33e655-ebcb-449b-b39e-cbf63c23c9f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xLTEtMS0yNzIzNA_2ff65a30-7715-4468-9ee1-895a2150cf50"
      unitRef="usd">97808000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0zLTEtMS0yNzIzNA_b3666020-36f9-4654-8db8-2bf3f3186b5c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS01LTEtMS0yNzIzNA_6b05fc55-1c8a-475a-8bc7-bed9c08b07a9"
      unitRef="usd">890000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ffb971f777745b180e887cf34cc8df6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS03LTEtMS0yNzIzNA_d6b4c18f-3032-4666-b074-42ffc8bd8af6"
      unitRef="usd">96918000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc97aeb2c0514e00a399738e538f2fe7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xMS0xLTEtMjcyMzQ_57ed61ba-7e8b-42c8-bf60-528734762a2a"
      unitRef="usd">88853000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85f691466f4f4614820d160aeb87931d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfOS0xMy0xLTEtMjcyMzQ_e3199893-2211-4ace-b606-96ffda6b865f"
      unitRef="usd">8065000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMS0xLTEtMjcyMzQ_304aed95-7b32-4371-aefa-d4d91fc64b79"
      unitRef="usd">77317000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMy0xLTEtMjcyMzQ_d7f40174-4aa9-43c9-b6ce-405c20ed1ad0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtNS0xLTEtMjcyMzQ_6c372141-095c-4b3e-a3bd-a884c0e1b39d"
      unitRef="usd">593000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i940f8b3a32dc4ad795f4ee9ecc3928e9_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtNy0xLTEtMjcyMzQ_40eb5f55-84a2-4187-963f-29692e651ec0"
      unitRef="usd">76724000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia14b5c1cb46b44daa8d2c7200a170896_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMTEtMS0xLTI3MjM0_0a79ec1e-32dc-4603-a754-cd9b468ffb92"
      unitRef="usd">71887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if10ba9e6940c4bcab91bee5cdf0f1577_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTAtMTMtMS0xLTI3MjM0_99b23e73-9fe7-4ea4-a137-56b26562732b"
      unitRef="usd">4837000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMS0xLTEtMjcyMzQ_364a49a1-2320-41fd-b025-e44eb366be9c"
      unitRef="usd">221282000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMy0xLTEtMjcyMzQ_4410fe94-36a3-4f30-a665-a51711779632"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtNS0xLTEtMjcyMzQ_8b1ee511-b26d-486c-8669-0d9f070fba40"
      unitRef="usd">1536000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15568dc832834ddaaefabea39a936bcb_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtNy0xLTEtMjcyMzQ_3141040e-f6cc-40c4-9886-bf007acf18a7"
      unitRef="usd">219747000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie89e6376ee9b402191dd9c876f00ffd1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMTEtMS0xLTI3MjM0_d123887b-c0d8-44cc-81aa-21e7d33c7a4c"
      unitRef="usd">206845000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i685fdfb571504f15be2ba3d2c639db0d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTEtMTMtMS0xLTI3MjM0_02613695-e1a4-495e-b613-75dd343bc943"
      unitRef="usd">12902000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMS0xLTEtMjcyMzQ_ac477eef-df35-4de2-932b-d2f7099fb895"
      unitRef="usd">440002000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMy0xLTEtMjcyMzQ_dbf4edac-5674-4ec1-972d-140fd461eace"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItNS0xLTEtMjcyMzQ_7ec17e64-b18b-4f69-a1e3-62a0b2e6f746"
      unitRef="usd">1536000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItNy0xLTEtMjcyMzQ_625a0482-8258-465c-9a6b-041f05ed9b7e"
      unitRef="usd">438467000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i6f864a31b3d847e786f7d911b5e088ba_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItOS0xLTEtMjcyMzQ_6781f396-c1c0-4df3-97d4-560485bea11b"
      unitRef="usd">218720000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="id4792758104f47bfbfdd2f1ff6cc0f56_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMTEtMS0xLTI3MjM0_22937882-4c88-4e0e-b63d-7a4a1c6ce84e"
      unitRef="usd">206845000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="id87854e9024645be88d96e81c1d80ce7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOjZkZTg2OWZhNzNiNDQyODI4YTY0ZTRiMTNmMTQ2YjY5L3RhYmxlcmFuZ2U6NmRlODY5ZmE3M2I0NDI4MjhhNjRlNGIxM2YxNDZiNjlfMTItMTMtMS0xLTI3MjM0_6016ed13-1e3c-47fa-86c8-f86bed467f1d"
      unitRef="usd">12902000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if698ad0c6a754e11892e9ad283a72091_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy0xLTEtMS0yNzIzNA_eb88c39a-a30e-48e2-a5f9-2e6aca2cd0b6"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if698ad0c6a754e11892e9ad283a72091_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy03LTEtMS0yNzIzNA_6418878f-563b-475e-95d3-1a8ea3c39c79"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21ae7de2a25e4d8f9c91182ae7bd789a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMy05LTEtMS0yNzIzNA_138acf61-7564-4bb1-b86e-a1ba3e92635f"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS0xLTEtMS0yNzIzNA_2f08aebd-b507-4b37-9526-0fb2e9c6ca4d"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i723e3b110bfc4c0da23e8f3dd3a60931_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS03LTEtMS0yNzIzNA_185f1ea6-fb9b-453c-943b-a000287ec7ce"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ice8f78f72c5f44daa3c018883cf88bc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNS05LTEtMS0yNzIzNA_f49def10-17ff-4830-937d-23a1ec4c0ceb"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xLTEtMS0yNzIzNA_9bcb8f91-d60f-4b6e-96b8-cadd0e8107de"
      unitRef="usd">40469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0zLTEtMS0yNzIzNA_321cdb5a-62e6-4efe-a9a8-5cba71ef36c9"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy01LTEtMS0yNzIzNA_17193d64-5d54-4d30-ab41-95758b4faf77"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ea1041fd3974f6cbd157670806fb0b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy03LTEtMS0yNzIzNA_74e9818e-db5d-46bf-9147-35330ea706d6"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7652f0186854d3eb2df5a9678980d1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xMS0xLTEtMjcyMzQ_af001b7a-31d4-45a2-b756-8b98060e4ee3"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5248a77fa14049cf940a8cd1b7fef935_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfNy0xMy0xLTEtMjcyMzQ_53be8e73-f151-4076-b500-42e39cc31770"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xLTEtMS0yNzIzNA_cb6e7a25-6239-4c75-b662-d6702203d7c8"
      unitRef="usd">83300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0zLTEtMS0yNzIzNA_47615fa8-5bfa-47de-9f56-641d073cc59d"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC01LTEtMS0yNzIzNA_a146498f-866a-4314-8ad0-bbb99457bb11"
      unitRef="usd">114000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia56331706bfb4519876ce6149c9d3899_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC03LTEtMS0yNzIzNA_7aba612f-da2d-4559-8d55-f7e94e12b50f"
      unitRef="usd">83196000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ife4757de934847a3b5d4eb65e4f812c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xMS0xLTEtMjcyMzQ_dbd9518e-7ade-4742-aee1-c0b673821636"
      unitRef="usd">35768000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifef97546d258466e8f022a081bfec632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOC0xMy0xLTEtMjcyMzQ_09dd8eae-9b19-4f54-a255-4057a1e03574"
      unitRef="usd">47428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xLTEtMS0yNzIzNA_0d6e4e88-9aa5-429f-bc48-962a31a40762"
      unitRef="usd">37621000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0zLTEtMS0yNzIzNA_aa23e44e-6f1d-489f-81e1-55a383e75de0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS01LTEtMS0yNzIzNA_c86284bd-318c-4257-b758-210ca1b9c062"
      unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibbe5bfc9a91b42dd824b1ca556542e36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS03LTEtMS0yNzIzNA_20714524-6c91-4b28-9ac8-249d8ccac48a"
      unitRef="usd">37559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20ebc1166b3d48708f5ffd968b17c9cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xMS0xLTEtMjcyMzQ_8a4abffd-51db-4ea1-9e4d-f177d7a8b5fa"
      unitRef="usd">20616000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4ac529d98474127860b5706cc0a4e57_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfOS0xMy0xLTEtMjcyMzQ_8925b35a-9e7f-47be-828c-8b925f180fb3"
      unitRef="usd">16943000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMS0xLTEtMjcyMzQ_339fa566-1dd1-4cf0-a217-4fe6a88d8787"
      unitRef="usd">161390000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMy0xLTEtMjcyMzQ_9fbdf570-ab03-42e0-a5cb-ab966d606a5f"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtNS0xLTEtMjcyMzQ_1aed5e3a-95b5-40a9-a5b1-09b7656c969b"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19f873a9b5ad47d6bb38039da03ea567_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtNy0xLTEtMjcyMzQ_bc453a0f-3782-4714-901a-d578c2ad9112"
      unitRef="usd">161221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7253ed7785a94823a46ec4162da143ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMTEtMS0xLTI3MjM0_80b9585f-aec0-40e8-a671-d2dbd861f800"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb5f33620a0044aaaa5c0668e4413da8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTMtMTMtMS0xLTI3MjM0_8225ea7c-1ce8-496c-944a-ca8c9396403f"
      unitRef="usd">64371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMS0xLTEtMjcyMzQ_f6ebffd5-be49-4a05-9d78-19771be95454"
      unitRef="usd">502636000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMy0xLTEtMjcyMzQ_86d8099e-2bd7-4518-8f40-008a0bc930da"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtNS0xLTEtMjcyMzQ_81e7b3b2-6abb-4861-9d54-c4fc5426a509"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtNy0xLTEtMjcyMzQ_16b5f982-ec95-45e7-8420-fd354079b6fc"
      unitRef="usd">502467000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i075af6a44d40468781a120b2d5467942_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtOS0xLTEtMjcyMzQ_afef9856-8d9b-4dc2-ae85-ab0e554e67a0"
      unitRef="usd">341246000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i7fe24770e30b4ee5b669d117e9f452b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMTEtMS0xLTI3MjM0_f732e420-0069-416f-9fe2-71e67c7a64bd"
      unitRef="usd">96850000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i8b4223978e6e4043b43792467895392c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RhYmxlOmYzODU5MTg3ZmYyZjQ0ZWNiOWJmMzUxNTI3ZGQwYTJjL3RhYmxlcmFuZ2U6ZjM4NTkxODdmZjJmNDRlY2I5YmYzNTE1MjdkZDBhMmNfMTQtMTMtMS0xLTI3MjM0_05c1e506-da84-42dc-9ce5-676b7ce4cea1"
      unitRef="usd">64371000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ie89e6376ee9b402191dd9c876f00ffd1_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMjcy_c6b4033e-9c73-46c1-bf2d-33934a080aa1">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ia02db18a6f9842168a740bb3825c2f42_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMzQ1_f23837ab-037a-4648-b4de-55fde884d233">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ibe1d4e05d43f4749b3b95a6990387f23_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80MC9mcmFnOmQzNDQxODBkMmJjMTQ2ODZhNDNjNzg3Y2U1NTFjMmIxL3RleHRyZWdpb246ZDM0NDE4MGQyYmMxNDY4NmE0M2M3ODdjZTU1MWMyYjFfMzUy_bfcd1616-1909-4631-9656-513f835af25c">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU3_f541cc3c-6344-4fd3-8a33-a68cb6921f8f">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $494 thousand and $956 thousand for the three and six months ended June&#160;30, 2022 and $475 thousand and $914 thousand for the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU4_63b8a8a9-efd5-4491-9964-f0ee80a33792">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19dbf144cc1344bc88a90e137beec2ff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMi0xLTEtMS0yNzIzNA_4da87525-31d3-4637-a7f8-8a517036defc"
      unitRef="usd">142893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if5474e41a39a4279ada916abbc519671_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMi0zLTEtMS0yNzIzNA_19ded535-4718-487f-b17a-59488a93d72f"
      unitRef="usd">104340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5e6353eacee0474f88b8a107b02b1652_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMy0xLTEtMS0yNzIzNA_ec4aead0-86ce-4622-9e0b-ac0c804795db"
      unitRef="usd">5736000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7aa852ef45a845dda2da256ef25ae970_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfMy0zLTEtMS0yNzIzNA_bda38e2d-bef1-4dec-aa38-ff21819aad02"
      unitRef="usd">5723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e9dbd4ee4e647aeaa50ea67ae6bab6a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNC0xLTEtMS0yNzIzNA_def333c1-cdf7-42da-a7eb-fe5570f49de0"
      unitRef="usd">900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if59b699ffbf74fb6b067fb3fd3d26948_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNC0zLTEtMS0yNzIzNA_889383f8-2f7b-4acd-be14-0c24ce28675a"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f288e08976b441381de343a114c23bc_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNS0xLTEtMS0yNzIzNA_06b233eb-4227-41f6-8e76-22eccbd3bced"
      unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id831f855902e4ca8a26e06da3c94f9ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNS0zLTEtMS0yNzIzNA_8f05d137-1074-4f30-9c11-4a0c3e1ece55"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0781359c8a514003ad12a9168fd9fc32_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNi0xLTEtMS0yNzIzNA_5e168a1a-c2f5-4b49-acfd-c4ca611e6e0a"
      unitRef="usd">6740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a061e6cc0574956ae21bc486e71b175_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNi0zLTEtMS0yNzIzNA_3c8ace6f-6a04-4d00-8346-55ecf45f7ab0"
      unitRef="usd">5530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNy0xLTEtMS0yNzIzNA_938c2d37-0351-49f3-83cf-1d61e6958090"
      unitRef="usd">156365000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfNy0zLTEtMS0yNzIzNA_d6c00be4-8c0d-4ad6-86a4-3c0d629e2e35"
      unitRef="usd">116569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOC0xLTEtMS0yNzIzNA_d431b027-2287-41c9-ba36-4df22cdff04a"
      unitRef="usd">5151000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOC0zLTEtMS0yNzIzNA_f81bb09c-a101-40d4-b71e-6f8c2b57ff30"
      unitRef="usd">4214000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOS0xLTEtMS0yNzIzNA_c21bcf7b-d83f-49c8-be9d-f8cb3f431a52"
      unitRef="usd">151214000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmU1YzJkNTFiNzBmMzRmOTBiMTRkYzc3NmI2YjQ0ZGE2L3RhYmxlcmFuZ2U6ZTVjMmQ1MWI3MGYzNGY5MGIxNGRjNzc2YjZiNDRkYTZfOS0zLTEtMS0yNzIzNA_9511c73a-8ab8-4356-a7bb-3de5d2e41d23"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTU3_42ab5476-4612-4339-8142-ce4d5440f106"
      unitRef="usd">494000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE5NA_0f847a20-d22b-42db-858e-68b91ca5eafa"
      unitRef="usd">956000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE4Nw_923923f3-4699-4c36-9efb-a04388e9d338"
      unitRef="usd">475000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMTA5OTUxMTYyODE5OQ_12ef6d87-6290-422a-bcd8-8bf512d89a2e"
      unitRef="usd">914000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RleHRyZWdpb246ZmQ3OGQ1ZmYzODk3NGYzZmFlNzM0Y2FlZGZhODZhZDNfMzU2_a39c81cd-c167-44a9-8705-cd754aeebacd">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMi0xLTEtMS0yNzIzNA_d159d654-8838-470f-9de9-b82936c480a4"
      unitRef="usd">14631000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMi0zLTEtMS0yNzIzNA_703a39fa-ecfb-491d-937c-57d030725b33"
      unitRef="usd">9606000</krys:AccruedConstructionInProgressCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMy0xLTEtMS0yNzIzNA_5db30f10-9aae-4cb3-8114-317e10f8e199"
      unitRef="usd">3812000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMy0zLTEtMS0yNzIzNA_84f8a15e-ca78-4ca8-8003-8e3ae4bb22f8"
      unitRef="usd">2011000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNC0xLTEtMS0yNzIzNA_597fd132-6d85-48d3-acf7-1eb900152384"
      unitRef="usd">2896000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNC0zLTEtMS0yNzIzNA_e577367c-a058-41cb-bc8e-d459aafeb304"
      unitRef="usd">2882000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNS0xLTEtMS0yNzIzNA_421c770e-4d7a-4274-8d30-4e574de856a2"
      unitRef="usd">2094000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNS0zLTEtMS0yNzIzNA_4b0bda67-9f56-472a-a58f-93032c4b35c1"
      unitRef="usd">1602000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedFinancingFeesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNi0xLTEtMS0yNzIzNA_1893c12e-63ae-4482-a689-740acd21a042"
      unitRef="usd">29000</krys:AccruedFinancingFeesCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNi0zLTEtMS0yNzIzNA_2ef5d58d-1bcc-414a-82d4-4b16b13ab2b7"
      unitRef="usd">26000</krys:AccruedFinancingFeesCurrent>
    <us-gaap:AccruedIncomeTaxes
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNy0xLTEtMS0yNzIzNA_061b859b-d735-454d-b115-1df56b29331c"
      unitRef="usd">22000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfNy0zLTEtMS0yNzIzNA_b5774551-9726-4ebf-8ff5-821e4c8745de"
      unitRef="usd">83000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfOS0xLTEtMS0yNzIzNA_2efa4399-58ef-4f18-96a3-ac28625e5f40"
      unitRef="usd">297000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfOS0zLTEtMS0yNzIzNA_fed9b32f-32a7-4b95-a993-e8d12bd11879"
      unitRef="usd">87000</us-gaap:OtherLiabilitiesCurrent>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMTAtMS0xLTEtMjcyMzQ_4e541cc9-bc61-43af-ae0e-79d30763b06a"
      unitRef="usd">23781000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80My9mcmFnOmZkNzhkNWZmMzg5NzRmM2ZhZTczNGNhZWRmYTg2YWQzL3RhYmxlOmM0MmNjMmM5OTJkYjQ1MmVhZmFkZjFjZTBlNjllNzg2L3RhYmxlcmFuZ2U6YzQyY2MyYzk5MmRiNDUyZWFmYWRmMWNlMGU2OWU3ODZfMTAtMy0xLTEtMjcyMzQ_14685541-405b-4be4-a6ea-83807960d19e"
      unitRef="usd">16297000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMDk_359c1dfa-e6c6-4196-8ef4-4b4967a5ee43">Commitments and Contingencies&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Contracts and Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and was scheduled to expire on October 31, 2017 (the &#x201c;2016 Lease&#x201d;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the 2016 Lease expiration date was extended to October 31, 2031. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2019, the Company entered into a lease agreement for a second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of June&#160;30, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2021, the Company entered into a 3 year lease agreement for the Boston, Massachusetts office that commenced in January 2022 and expires in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2022, the Company entered into a 16 month lease agreement for the Zug, Switzerland office ("Switzerland Lease") that commences on September 1, 2022 and expires December 31, 2023. As of June 30, 2022, the Company has not recorded a right-of-use asset or corresponding lease liability, as the Company has not yet gained control over the Switzerland Lease. Future minimum operating lease payments under the Switzerland Lease are $22&#160;thousand and $89&#160;thousand for the years ending 2022 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded operating lease costs of $391 thousand and $800 thousand for the three and six months ended June&#160;30, 2022 and $278 thousand and $497 thousand for the three and six months ended June&#160;30, 2021, respectively. The Company recorded variable lease costs of $71 thousand and $120 thousand for the three and six months ended June&#160;30, 2022 and $81 thousand and $118 thousand for the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Manufacturing Organizations and Contract Research Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of June&#160;30, 2022 under these agreements is approximately $2.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.2 million and $3.0 million for each of the three and six months ended June&#160;30, 2022 and $718 thousand and $2.5 million for the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Preparedness Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $5.1 million. The Company has incurred expenses under these activities of $3.1 million and $6.2 million for the three and six months ended June&#160;30, 2022 and $974 thousand and $2.3 million for the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, the Company has entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of June&#160;30, 2022 is $17.9 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#x201c;Agreement&#x201d;) with The Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;paid by the Company is $83.0&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. The Company answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that the Company did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that the Company is the rightful and sole owner of our product candidates and STAR-D platform. In addition, the Company filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, the Company entered into a binding term sheet to settle the dispute.  On April 27, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.  Upon approval of Krystal&#x2019;s first product by the U.S. Food and Drug Administration, Krystal will pay PeriphaGen an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the $25.0&#160;million under litigation settlement expense on the condensed consolidated statements of operations for the six months ended June 30, 2022.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of June 30, 2022, and therefore no additional accrual has been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received $768&#160;thousand of insurance proceeds during the three and six months ended June&#160;30, 2022  and Company recorded an additional $369&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="ibb5217315fdc425a8f055a9896bfb0af_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMzYy_9c3fe085-e6ba-4440-a4fb-c5403bd46b34"
      unitRef="sqft">47000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="ieb2b2a6f833a41e0b4880780fe93e686_I20200121"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTEwNw_df68dd73-ae15-4899-9a52-72041b95dc99"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTcxNg_95dd0a0f-4924-4d34-ad7d-7c88817f0139"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:ConstructionInProgressGross
      contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjAxMA_26da3317-c70f-415a-9779-0866fd6b804a"
      unitRef="usd">10000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:FinanceLeaseLiability
      contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjAxMA_6bd66670-305c-4c95-90ac-20ec75fd73da"
      unitRef="usd">10000000</us-gaap:FinanceLeaseLiability>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i9992e6e26f6f4543965ca3f6dcd6c353_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjE2NA_0d24f284-dea1-4b50-849d-8ff7b6b1d600"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="i33c418ba02a84c4fb99d060f3d678141_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjM4MQ_fb93810c-f3e8-41da-a71c-f9d66243fbf3"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:EscrowDeposit
      contextRef="i119efa4588394a448de123d82168c14b_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMjQxNg_968a112c-c271-4ea6-9aa2-08093f3520f6"
      unitRef="usd">1500000</us-gaap:EscrowDeposit>
    <krys:LessorOperatingLeaseLiabilityAnnualLeasePayments
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDI3Mg_9d04c440-6ac8-4af9-beba-f471deff4aaf"
      unitRef="usd">82000</krys:LessorOperatingLeaseLiabilityAnnualLeasePayments>
    <krys:CumulativeEscalationClausePercent
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDMwOA_c38f2dfe-85ba-4479-8784-efe292073042"
      unitRef="number">0.10</krys:CumulativeEscalationClausePercent>
    <krys:CumulativeEscalationClauseTerm
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDMzNQ_3b350587-d907-4865-842d-a3f9aa10d791">P5Y</krys:CumulativeEscalationClauseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i827059c44d894d608fa87db88be3f1d6_I20211215"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI5NjA1_8eb3b3af-86eb-4c1b-a069-b7007019c7a9">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMTA_93562ba2-9335-4b67-9403-16ef80999bc7">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining six months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMS0xLTEtMS0yNzIzNA_34ee6ecd-e8bf-42ee-8a9a-0eff851b49a8"
      unitRef="usd">743000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMi0xLTEtMS0yNzIzNA_4165d688-5164-4321-91b6-e4c4ba783245"
      unitRef="usd">1510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfMy0xLTEtMS0yNzIzNA_a0b012f4-d087-4a87-ab06-238c2cd59df3"
      unitRef="usd">1539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNC0xLTEtMS0yNzIzNA_af1dad3a-93d3-4851-a71c-7a9b0d384e2c"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNS0xLTEtMS0yNzIzNA_c02ce2a9-c5f7-440b-8baf-cb2530157dba"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNi0xLTEtMS0yNzIzNA_b1a1e6c3-ddb2-4947-9363-0ab28f4eaadf"
      unitRef="usd">12063000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfNy0xLTEtMS0yNzIzNA_a7a73a9f-040e-488f-88f5-b7e1924ceadb"
      unitRef="usd">18409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfOC0xLTEtMS0yNzIzNA_7f9a004f-af58-483c-a840-89e86fa3ef0e"
      unitRef="usd">9276000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOjRiODkzNzRlMjM5NjQ2YmRhMGNiN2VkMmI3MjYwMjU3L3RhYmxlcmFuZ2U6NGI4OTM3NGUyMzk2NDZiZGEwY2I3ZWQyYjcyNjAyNTdfOS0xLTEtMS0yNzIzNA_f629727f-fb8b-47cb-939e-c8a0033f1953"
      unitRef="usd">9133000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7d8365f8ec064a42b301d193885831a0_I20220516"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MjI3_d4fb6f48-8e86-4ccb-9f8c-2362e45da75f">P16M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear
      contextRef="i26a85807415641c1bbd4c16458db46d6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MTkz_480d31e7-21da-4602-9957-5aa16640380e"
      unitRef="usd">22000</krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear>
    <krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne
      contextRef="i26a85807415641c1bbd4c16458db46d6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI4MjA3_587ebb41-ad0c-4f0c-809c-9bd6a178e278"
      unitRef="usd">89000</krys:LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTIxMDg_f2b10869-2c67-4c19-b41b-c3667ea07a6f">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfMy0xLTEtMS0yNzIzNA_69f9a43d-aad7-450b-91fc-e91cd8451243"
      unitRef="usd">8279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfMy0zLTEtMS0yNzIzNA_e4d1ea32-38e2-4f0e-8924-6fef7c6d979d"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNC0xLTEtMS0yNzIzNA_4d05d6c2-9c39-443d-a96a-5d15ab21685a"
      unitRef="usd">1417000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNC0zLTEtMS0yNzIzNA_be372e04-2e7c-4e84-952b-da9da594c807"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNS0xLTEtMS0yNzIzNA_23082fd8-a26e-4f3e-951b-da8021feb970"
      unitRef="usd">7716000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNS0zLTEtMS0yNzIzNA_edce7cdf-3f6e-4d1c-b6b6-46016d2330c9"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNi0xLTEtMS0yNzIzNA_a90159be-20e3-46e7-b2d4-c70ccf612c7b"
      unitRef="usd">9133000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNi0zLTEtMS0yNzIzNA_70dee08c-ea7c-4926-8fbe-82b68f3f6df9"
      unitRef="usd">8024000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNy0xLTEtMS0yNzIzNA_ace31ad1-ccb2-47f0-b018-0e2e9ec914b7">P12Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfNy0zLTEtMS0yNzIzNA_c3430031-8e3b-4982-9228-57a5d3d53c8c">P14Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfOC0xLTEtMS0yNzIzNA_c26778da-8f58-4c75-8a8e-622020b5e52d"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RhYmxlOmQyMDE3MmY5YTEwYjRkMzFiMmM0ODQxZGQ1Nzk0NTRlL3RhYmxlcmFuZ2U6ZDIwMTcyZjlhMTBiNGQzMWIyYzQ4NDFkZDU3OTQ1NGVfOC0zLTEtMS0yNzIzNA_3cbe6376-ab45-4a38-9473-480a29deb1a1"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDgwNA_574f5fce-f9f9-444c-90d1-dacc002cc47b"
      unitRef="usd">391000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTQ4Mw_cd65fb30-6cdf-4181-81f6-c953b3764ac3"
      unitRef="usd">800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTQ5NA_ad9afc09-a5c6-4b92-9faf-bd307f040d7d"
      unitRef="usd">278000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTUwNA_a945e34c-ca82-4c53-9d46-67eedb30a37c"
      unitRef="usd">497000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNDg5MQ_8967f348-c82d-4635-a1ad-ae026204338e"
      unitRef="usd">71000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTU5NA_3abeefcc-90b1-4ab0-a00a-209d7ea39fbe"
      unitRef="usd">120000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTU5MA_c26184a2-c3a5-47af-b9f5-9bfb183f1a35"
      unitRef="usd">81000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTYwMg_3b25a233-c3e9-47a5-a5b6-84f594f6f340"
      unitRef="usd">118000</us-gaap:VariableLeaseCost>
    <krys:RemainingCommitmentAmount
      contextRef="i2a4c19202a764797b2b092b8f85d150c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTg0Nw_9bbf357f-5142-4327-a8ca-b1a05b518ae5"
      unitRef="usd">2100000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="ibef597c9a74640cfae1769e2be78cba6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjA1Ng_c0198b1c-4d65-40a1-937e-816deb0a21ca"
      unitRef="usd">1200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i2eac4d8ff1bc4caf99aefef1cdf232b8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTY5OA_714d7ae3-313a-4071-9c86-23a3f61ee05f"
      unitRef="usd">3000000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i4c3195ecfb794e2588cdb48c9b9e1fab_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcwNw_34130380-ddbe-4a8b-bc1b-fae8c146a2be"
      unitRef="usd">718000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="if6f4b750dd5b41018b6987ded07fec01_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcxNA_754734cc-f50f-4c5b-8b3c-fd627ad78c8f"
      unitRef="usd">2500000</us-gaap:ProfessionalFees>
    <krys:RemainingCommitmentAmount
      contextRef="ia7bff06aaa0b4172b5a7fc7c324cb8d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjQ5NQ_d676ef84-7084-42b2-9c98-384a84b19163"
      unitRef="usd">5100000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="i4bbfc5ceb794438b99f03eab41975dd2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNjU1OQ_9cd35bee-9229-4fd3-9b6e-15e2f78732e0"
      unitRef="usd">3100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="icd330d2d7b434eadb065cd5a8d7e8433_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTcyMg_c368ee96-d38b-40bb-a7a4-085351a6fa6c"
      unitRef="usd">6200000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="if7a8f2da70c8489bbe7c8d73255d7a0e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTc4Nw_0f6bb598-811f-40e3-9dda-d624a98d59d4"
      unitRef="usd">974000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i88eeda34427444d59f2632f3fe3ce3c3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MTc5NQ_d4fca84b-5b6f-4351-b8ac-271616d5076a"
      unitRef="usd">2300000</us-gaap:ProfessionalFees>
    <us-gaap:ContractualObligation
      contextRef="i67fac24ea1814a04a46df8a1f2b0307d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNzA5MQ_eab09c9e-3db2-4922-ac3b-2617ed70cd1c"
      unitRef="usd">17900000</us-gaap:ContractualObligation>
    <krys:CostOfWorkPercentage
      contextRef="i67fac24ea1814a04a46df8a1f2b0307d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNzcwNw_f9ee8a0c-1da4-4ac1-b20c-cacbd0f93a40"
      unitRef="number">0.0175</krys:CostOfWorkPercentage>
    <krys:LossContingencyGuaranteedMaximumPriceToBePaid
      contextRef="ifbc1d20961ac429694a43623cb59dc7f_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA5OTUxMTY0MjA2Mw_ee4434a8-d08c-4780-b116-d0daf1435658"
      unitRef="usd">83000000</krys:LossContingencyGuaranteedMaximumPriceToBePaid>
    <us-gaap:LitigationSettlementExpense
      contextRef="i8396aa2f370f4359935ac37bbca1ca43_D20220428-20220428"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTU2NDA_6e8f2f20-c5dd-4a88-a577-6e3cdec6ba54"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzMTI_82037f85-8ca9-473e-8bc9-eed5caf81bd3"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:NumberOfMilestones
      contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzMjg_68126afd-002c-4a80-88f4-55b387a8ceb5"
      unitRef="milestone">3</krys:NumberOfMilestones>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic0a6b6780e2744a78177e645108c3643_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_4986ee11-7a23-4e2d-bbad-d6395347a04e"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="iec561b9438fc47fa9736b2ab0dfa6e25_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_818a10be-a9a8-4cbf-80d0-05268dd7f28f"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic93ab2eb0c5b47bea0598419ed1fce33_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzNDI_ab8ad28d-6293-4ed6-9eab-84ac994ba698"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i8283d8f8c4374e57ae8f04c23b4b7428_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTAzODk_09665f78-659e-45c8-aaf3-29438cd362d2"
      unitRef="usd">100000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i3c54249f9c4e49ee9c88d0b3e52be617_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA0MTk_874332d9-3be0-453f-ae11-a8419fdf5594"
      unitRef="usd">200000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="iec04e4bd030243cd8732d95021dd1a4a_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA0NTI_4cd7e8cd-71ed-41c6-870e-515f7567604b"
      unitRef="usd">300000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementTotalConsideration
      contextRef="ibb2ca34f0ed04200a5c092337ff47225_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTA4NTU_5b86a3a7-750a-4e7e-b5f0-77e778a2a9d9"
      unitRef="usd">75000000</krys:LitigationSettlementTotalConsideration>
    <us-gaap:LitigationSettlementExpense
      contextRef="i2b0a857cc9724f2a97e3a6f93c9674d2_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfNTQ5NzU1ODI2ODU5_3c5eb560-4a95-436e-8c70-2d266826499d"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE0OTE_6d8c50de-2ea8-4dd6-b458-80f7039c1b8d"
      unitRef="usd">768000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE0OTE_efd86485-84c2-4a7f-8ba4-b7f8ed3f67c3"
      unitRef="usd">768000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80Ni9mcmFnOjkzYzAyZjI4OWJmMDQ3NmJiMTViNTY2ZjIwYzRjZjJlL3RleHRyZWdpb246OTNjMDJmMjg5YmYwNDc2YmIxNWI1NjZmMjBjNGNmMmVfMTE1ODI_418e04c9-e603-43fa-a66c-7fe9efc8b293"
      unitRef="usd">369000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTc5OQ_2956dcf1-f2f5-44e8-8dfe-38d6ad8e51f1">Capitalization&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells shares of common stock from time to time pursuant to its previously executed sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program") finalized on December 31, 2020, under which Cowen acts as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of common stock having an aggregate offering price up to $150.0&#160;million ("Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Sales Agreement are made pursuant to the Company's effective "shelf" registration statement on Form S-3.  During 2021, the Company issued and sold 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting selling commissions of approximately $524&#160;thousand. During the six months ended June 30, 2022, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share for net proceeds of $29.1&#160;million after deducting selling commissions of approximately $900&#160;thousand, resulting in a remaining $102.5&#160;million available for issuance under the ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, the Company completed an underwritten public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, the Company completed an underwritten public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters pursuant to their option to purchase additional shares, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="ic988cc831aa04c98a4a7c73bda3df147_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODIyMjQ5_c8e9bab3-22f7-4e75-b4d7-3f887c808aba"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie404abea35ec4537a1e5ce4db74c5ab6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjU2Mw_228f12c7-c7de-4098-9e93-07808b1e6365"
      unitRef="shares">262500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id2c43b6d200f4a04b123151eded83516_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjYyMQ_fccd25e4-c90c-463f-86e3-f36f2b4467ff"
      unitRef="usdPerShare">66.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjY3OQ_1d3e2f80-2d82-4200-9cff-365300256401"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="idda8bc6a6eb54f9bb345709d0bb25c5e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjc1NQ_7e531641-34e9-4e45-8c32-ae1a3807f160"
      unitRef="usd">524000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id0a266617fb74011b52795116bde11a2_D20220405-20220405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDIw_226f0efd-f6c8-45a8-8307-7dd4b074b104"
      unitRef="shares">434782</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i74bd7dcda88044e8bdc02d6eb3e42a31_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDI5_cf1b7756-853b-422a-8eba-56ac4187b7f7"
      unitRef="usdPerShare">69.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="id0a266617fb74011b52795116bde11a2_D20220405-20220405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE2MDM3_b8fcf920-a3d3-4789-9e58-00fe4dcdd37a"
      unitRef="usd">29100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfMTA5OTUxMTYzMjkyOA_4ee80ddd-0272-4c1d-ae76-99c270f9ab17"
      unitRef="usd">900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="i03068b9221284f1985b0a54a47986a4b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE5MTA3_c1851f2a-9241-43c3-b235-3874a83a139c"
      unitRef="usd">102500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1Njg5_3aa77b44-4f2d-4905-a519-aa9ec1faea99"
      unitRef="shares">2866667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4eb9b132e2e8429691c1fde0ba1c9948_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzAw_c11f2eea-cf1f-4f1c-9c09-4f259388cf92"
      unitRef="shares">200000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i5e198d54f3db4e3e9cc8a6aa406b6115_I20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzA5_37f8336a-92b5-4896-9ed4-054d8d19095d"
      unitRef="usdPerShare">75.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzE3_5d4e48c6-2bec-4e19-9bca-c1f7d586fee5"
      unitRef="usd">201900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="if777d493610b46fea5b70595880f2427_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzMz_09e486cc-eba2-4566-ae0d-25b091e853fc"
      unitRef="usd">12900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTQ5NzU1ODE1NzQ4_5a4f6361-0ee5-4ad9-97d7-13359941fe05"
      unitRef="usd">227000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTEw_ff929075-5dc1-4d77-8eef-6a036b156ee9"
      unitRef="shares">2211538</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i214b57f548b54a76aea79ee58885eda6_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTUx_c5f8e928-e0a6-4d12-aab1-f11365417cb1"
      unitRef="shares">288461</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2fb77696fe7a4014a844960177bee7df_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNTk1_5fd0a587-5982-4971-a6fb-8e111dd37818"
      unitRef="usdPerShare">65.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNjYx_b0e4bda6-9489-4e53-9f8d-aae4b2fcdd2f"
      unitRef="usd">134900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i96331d22b86d4cc499d480d9d15b10a0_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNzM2_4dd5c104-1b59-4103-a2c2-7efad77455c7"
      unitRef="usd">8600000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9051ae2ee8f6429e8c5caaf5ba0b9a3b_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml80OS9mcmFnOmMxY2Y1OGEwOGI4MDQzYjA4YzBjZjY1ZTg5MTZiOTUyL3RleHRyZWdpb246YzFjZjU4YTA4YjgwNDNiMDhjMGNmNjVlODkxNmI5NTJfNzk0_f74142f9-c3a3-411d-acc0-fca5b16c9688"
      unitRef="usd">198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1NQ_28f4eba2-c7e9-46c9-a56e-c3fa5eddc541">Stock-Based Compensation&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees and non-employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTgy_bb1fc8be-f9a4-4a8f-bc53-08d908577b13"&gt;one&lt;/span&gt;-year to four-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 544,500 and 1,724,000 stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2022, respectively, and 297,500 and 799,950 stock options to employees and directors of the Company during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 45,000 stock options to non-employees during the three and six months ended June&#160;30, 2022, respectively, and zero stock options to non-employees during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,620,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June&#160;30, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three and six months ended June&#160;30, 2022 was $704&#160;thousand and $739&#160;thousand, respectively, and during the three and six months ended June&#160;30, 2021 was $64&#160;thousand and $872&#160;thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors during the three and six months ended June&#160;30, 2022 was $42.90 and $43.03, respectively, and during the three and six months ended June&#160;30, 2021 was $42.53 and $47.25, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $115.7 million of unrecognized stock-based compensation expense related to employees', non-employees', and directors&#x2019; option awards that is expected to be recognized over a weighted-average period of 3.3 years as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $146&#160;thousand and $287&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2022, respectively, and $66&#160;thousand and $103&#160;thousand of stock-based compensation that was capitalized in the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero RSAs to employees of the Company during the three and six months ended June&#160;30, 2022, respectively, and zero and 98,800 RSAs to employees of the Company during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $4.7 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.7 years as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Shares remaining available for grant under the Company&#x2019;s stock incentive plan were 530,991, with a sublimit for incentive stock options of 1,296, at June&#160;30, 2022.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1MA_4223a3a1-5b5e-49f5-b96f-74186c6d68ce">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ifa739c94f7e4421b824446b65ca0970b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Ng_264c2096-f5b0-4d40-9554-a9013d420afe">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjM0_f05ccf92-dab9-4ad4-b11b-b3fe9875fba2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6d5e85dd3f394163a17aa2a7a2882596_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjU5_064e6f6a-bb75-4389-9626-94d3a8eb4eba"
      unitRef="shares">544500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idf15c469b0c14c2b8d582745c8548a55_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM1Ng_717f680b-5fb5-4d62-b2b9-07c6c71d4530"
      unitRef="shares">1724000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9562a91cca5a4feeabc3e61cfce17db9_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM0Mw_4c926557-3ac2-4dfe-8680-d06e22147a78"
      unitRef="shares">297500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i63b754f6b02141f7aeffcecd25d8ee9f_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM1MQ_04470aae-6720-40d7-ba9b-a1f1b75a570d"
      unitRef="shares">799950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i13ecba4f425444fab5675e6879c78727_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEyOQ_65ada071-aaa5-4bb3-9283-99cc928b0257"
      unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iee3cd2503a6d4c0d87ab6c13960cd2bc_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEyOQ_d1215956-0dc7-4757-ade7-a6d113f30da5"
      unitRef="shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0801eb6aaac14234813d62b72db774ad_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEzOA_06671a2c-feb2-4d8a-9c5a-21171ea21ddc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id49480057f2645a7bdae78e27c951b23_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MzEzOA_06c80496-6c01-4a85-bb34-1ba114a7eb16"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1MQ_f07d4890-33ac-406d-abb3-65208ad820dc">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,620,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on June&#160;30, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS0xLTEtMS0yNzIzNA_b6b397c7-ceb6-4050-bc37-223b94bb252f"
      unitRef="shares">2043179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS0zLTEtMS0yNzIzNA_dbb255a1-6026-4189-9338-09d4dd6197ed"
      unitRef="usdPerShare">57.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id67d27acccab4cc7b6215d625269df36_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS01LTEtMS0yNzIzNA_f070ddce-3d68-4e5c-8220-e81c0d76ead4">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id9e4439435f24487b699ba4fbdccaff9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMS03LTEtMS0yNzIzNA_69b3db6c-dc7d-480a-9926-2b8416601c75"
      unitRef="usd">31331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMi0xLTEtMS0yNzIzNA_950560fc-706b-415c-bf72-570a43c85675"
      unitRef="shares">1769000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMi0zLTEtMS0yNzIzNA_cb967d0a-c1dc-4445-8459-b7206b910d5b"
      unitRef="usdPerShare">62.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMy0xLTEtMS0yNzIzNA_b542aabe-7043-427d-83b2-5c1a7487226f"
      unitRef="shares">39399</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfMy0zLTEtMS0yNzIzNA_8c991236-6743-4864-9f1f-1fb28c78b0f1"
      unitRef="usdPerShare">44.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNC0xLTEtMS0yNzIzNA_7f2a16c9-6eab-4145-b67f-4b9088a6cb53"
      unitRef="shares">151642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNC0zLTEtMS0yNzIzNA_4b989eef-bb7b-4972-9293-0858a6f35ef8"
      unitRef="usdPerShare">55.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNS0xLTEtMS0yNzIzNA_b98de93f-bb72-42bb-ab41-b416e9a94b9c"
      unitRef="shares">876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNS0zLTEtMS0yNzIzNA_99cfe9c6-c7f5-4e85-bdce-ba9c8f7a9303"
      unitRef="usdPerShare">74.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi0xLTEtMS0yNzIzNA_4045c32f-be6a-4434-8e60-26b177297eb8"
      unitRef="shares">3620262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi0zLTEtMS0yNzIzNA_fd4877cd-e251-4b23-a6ba-261e52daecd0"
      unitRef="usdPerShare">59.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi01LTEtMS0yNzIzNA_70650852-a4f4-44da-9cf8-d5a8e4884a42">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNi03LTEtMS0yNzIzNA_495b890e-3375-464e-a907-112c3fbedb91"
      unitRef="usd">28341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy0xLTEtMS0yNzIzNA_550abaa1-c9e1-4a65-9fd6-427c622ecf5b"
      unitRef="shares">536979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy0zLTEtMS0yNzIzNA_71c9ee4e-5d43-4418-b2d6-e1423413c7ce"
      unitRef="usdPerShare">47.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy01LTEtMS0yNzIzNA_315d5678-987e-4adb-b3d4-a45048d61a50">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia226ea26d38a4e37a6f721a29cd03d76_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjZhN2FjNTczOGY1NjQ3NjE5YWY3OWY1ODQwMmQ1OGY5L3RhYmxlcmFuZ2U6NmE3YWM1NzM4ZjU2NDc2MTlhZjc5ZjU4NDAyZDU4ZjlfNy03LTEtMS0yNzIzNA_bc52e833-812a-4dc0-a912-8e2c574c8338"
      unitRef="usd">11184000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfNzgz_0b1f4fa1-59af-45d8-b83a-3893247248b9"
      unitRef="usd">704000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjM2MA_f44ccb3e-9457-4349-ae12-6a90a8ee12ed"
      unitRef="usd">739000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjQyNg_be6a6a6f-8d75-4662-9d49-118f433c261a"
      unitRef="usd">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjQzNA_4c0f56bf-b9a5-47c9-b710-bb46e5d2435e"
      unitRef="usd">872000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfOTQ4_3a63c458-3126-453b-b1ee-e7aea6f3ab0c"
      unitRef="usdPerShare">42.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUwOQ_7bbed4cb-6943-41f9-9ae0-b16324253d29"
      unitRef="usdPerShare">43.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUxMg_e91e5ae7-4b01-415a-b73f-8748b9f1fb2a"
      unitRef="usdPerShare">42.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjUyMA_79e8d67d-992d-4940-9774-9cd4d6a413ef"
      unitRef="usdPerShare">47.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i43306d588f4a45bab466ead6783424bc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfOTgz_4f017e88-dd5d-4590-829d-5de36fa77aa0"
      unitRef="usd">115700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i97b468c91f394f3982302387c06cb4bb_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTE1NA_c57fefab-45ec-43d3-aaa9-0cd177a39176">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Mw_ef09044f-8b7e-4e8c-9a20-94041a72a336">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs in the condensed consolidated statement of operations for the three and six months ended June&#160;30, 2022 and 2021 as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy0xLTEtMS0yNzIzNA_05ff9665-ad4a-489a-985d-43ea98f37e85"
      unitRef="usd">1995000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i58302432af964373a1478c96983fa353_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy0zLTEtMS0yNzIzNA_76bbdda6-1539-4c83-b175-d7515cdb6f1e"
      unitRef="usd">1084000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idced79ac55904d99a6ebfa0dcd88778a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy01LTEtMS0yODQ0OA_4551d39f-77f6-44e4-9087-c5c36c390301"
      unitRef="usd">3363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8924a2fba7e24e789eae274f8598c078_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfMy03LTEtMS0yODQ0OA_cd64df7d-40ad-41a7-9213-72447114916b"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65f7d144aaf64425a30d562e60e9c259_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC0xLTEtMS0yNzIzNA_f522d3f8-ae09-4597-af18-32f5895dd49c"
      unitRef="usd">5776000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i218c57c0818b4e67b3e40d185226720b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC0zLTEtMS0yNzIzNA_050c29bc-e9ac-4676-b382-df086a5ee20e"
      unitRef="usd">2625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia77dada28a724687b986b05a7dc8d862_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC01LTEtMS0yODQ0OA_47dd75ea-5861-4386-a333-e4e0e5062e12"
      unitRef="usd">10357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0203af48a23c4ada819dd5d73122c9e4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNC03LTEtMS0yODQ0OA_56c4b667-4f2f-456b-b4dc-2d431ad67aa4"
      unitRef="usd">4240000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS0xLTEtMS0yNzIzNA_4f092a22-4dfa-4b22-8da8-de33fbc21b9b"
      unitRef="usd">7771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS0zLTEtMS0yNzIzNA_d74a8914-d6dc-4bbe-8a46-21a1211b5857"
      unitRef="usd">3709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS01LTEtMS0yODQ0OA_84dc79fa-715b-4de1-bda1-b07f9ff456e2"
      unitRef="usd">13720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhmZTY2NGRmOGZiOTQyNGI4YzY4ZGQzMzVkYzdiY2E3L3RhYmxlcmFuZ2U6OGZlNjY0ZGY4ZmI5NDI0YjhjNjhkZDMzNWRjN2JjYTdfNS03LTEtMS0yODQ0OA_dea073b5-4bde-4996-ba55-e0713b3f2380"
      unitRef="usd">5840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMTUzMw_315a620a-1310-44c3-962d-ba6df568dfbc"
      unitRef="usd">146000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg0OQ_d3f7bf21-23f7-4261-9fb2-7bcc34d42209"
      unitRef="usd">287000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i85362817550643a8bb8cd6d36321dc54_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg1NQ_379e948b-593f-4d07-88e1-cc0740008460"
      unitRef="usd">66000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i4d83367f18e8471b8e783e6904f15dec_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3Mjg1OQ_8be007b8-55bc-4f67-aca9-821b4f2928dd"
      unitRef="usd">103000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Mg_bb5637db-0b58-4f53-94a5-068fab357bc1">&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three and six months ended June&#160;30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 7pt 0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi0xLTEtMS0yNzIzNA_14151d91-6a7c-4f55-a599-1f674658726b"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi0zLTEtMS0yNzIzNA_6be6fc4e-233c-48e0-8ced-5df43f4054c7"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi01LTEtMS0yOTM1OQ_1fb491c0-5a65-48cb-ad03-f5af12bf2c24"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMi03LTEtMS0yOTM1OQ_bb923309-5407-4892-a673-7eed96eff48f"
      unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy0xLTEtMS0yNzIzNA_67f2adc0-ad6d-4d30-91e1-44e4770a10e8">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy0zLTEtMS0yNzIzNA_bf9cf579-a95c-4d80-b089-fb47c3a254cc">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy01LTEtMS0yOTM1OQ_db2b9498-90b4-4e15-9a73-18276f6ce274">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfMy03LTEtMS0yOTM1OQ_bb887f65-69da-444c-8f91-b8cb7bbc1d67">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC0xLTEtMS0yNzIzNA_d743e967-97e0-49a5-9c11-3cb497551bf8"
      unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC0zLTEtMS0yNzIzNA_4d633a7c-6f4b-4e23-95d5-9162ea072ca4"
      unitRef="number">0.0105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC01LTEtMS0yOTM1OQ_4a1c5006-8b4f-41b9-9c1c-7ad5d61343cd"
      unitRef="number">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNC03LTEtMS0yOTM1OQ_11f256ee-7fe1-474d-92f3-650fe93504ad"
      unitRef="number">0.0102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS0xLTEtMS0yNzIzNA_14667385-8649-4d46-bb90-980257f87b9f"
      unitRef="usdPerShare">61.51</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS0zLTEtMS0yNzIzNA_a4af62f9-2328-4302-9d92-527e89e31b6d"
      unitRef="usdPerShare">66.58</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS01LTEtMS0yOTM1OQ_bc455d35-a434-40ab-b904-fb2244699e7c"
      unitRef="usdPerShare">62.19</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNS03LTEtMS0yOTM1OQ_ff9c54ac-a071-408d-8425-1996ab8c5a54"
      unitRef="usdPerShare">73.42</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi0xLTEtMS0yNzIzNA_94cbfc88-2bc5-41f2-97f6-f0f08e7162a7"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i8b9772f4001044bf9d8c10f227a741b2_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi0zLTEtMS0yNzIzNA_211a31e5-4644-498f-ab04-c4bc51bcb75c"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i68b372433cf844aa94cc3748fa775c76_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi01LTEtMS0yOTM1OQ_36a92f13-7d2a-4cad-99b2-2b9fe2cc9275"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i6c0bb3ee01f64c8297ccc67d92fb61d4_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjViNmU5ZjVhNDg4NDRjNTRiN2Y3NGU5MTlkOTQxZDE3L3RhYmxlcmFuZ2U6NWI2ZTlmNWE0ODg0NGM1NGI3Zjc0ZTkxOWQ5NDFkMTdfNi03LTEtMS0yOTM1OQ_35bfcd0a-1e28-4544-a187-23892e61ba1b"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if75647732fba42e284fe467cf75d3e9e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1Nw_4bab7ea1-1146-4366-81eb-97299691fedf">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjA3Nw_dc7e9792-58b9-4557-aa6d-e94e16f0d913"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjA3Nw_e39aea73-69f4-4f73-93a4-4b11b557aced"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjY0NQ_477f78b5-e4cd-43fc-95d7-6bd3f7da76a1"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0ODc3OTA3MjY1Mw_29c60634-111c-4bb4-a968-da4fdc409b86"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc1OA_2e0bcd4a-6114-4011-9e61-32346ea50962">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Surrendered or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5c44a0f0edbf4e42a4210967f72907b4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMS0xLTEtMS0yNzIzNA_45d0c171-a9d1-4798-8067-9b52b69f7751"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5c44a0f0edbf4e42a4210967f72907b4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMS0zLTEtMS0yNzIzNA_81e9eb7a-11d0-4ac8-a72c-44cc96301c39"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMi0xLTEtMS0yNzIzNA_6151d151-dd05-4001-ac27-65332875aedb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMi0zLTEtMS0yNzIzNA_c7f0d17c-0950-4a16-8062-0c2f67f84f90"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMy0xLTEtMS0yNzIzNA_b146ef70-276a-4d83-a2fb-fb95c3413816"
      unitRef="shares">14321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfMy0zLTEtMS0yNzIzNA_4d68457f-9437-4065-9fdc-a70d0bb12a25"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNC0xLTEtMS0yNzIzNA_5e9449cd-fcbf-4885-933b-bcff292c64ab"
      unitRef="shares">17879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNC0zLTEtMS0yNzIzNA_cff3ae01-f9a6-49d4-9ff4-244012e37fe0"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNS0xLTEtMS0yNzIzNA_b6ce285e-40e3-4bbd-966e-dfe19dd64b02"
      unitRef="shares">66600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjhkZGI4N2Q2ZDRmNTQ3ZTM4YmRjOTJkMDBlODY5YjMyL3RhYmxlcmFuZ2U6OGRkYjg3ZDZkNGY1NDdlMzhiZGM5MmQwMGU4NjliMzJfNS0zLTEtMS0yNzIzNA_506846ab-7471-40b4-aae5-ea4ddd9ca009"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i12dcce19b02242d3a86e91bf7df20519_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjE4NA_b446af69-4c01-4f7e-a459-69b42c424208"
      unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjMzMw_03104acd-6ffc-432b-b278-ad6aebd87413">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i973bbe15b2c641d79452fafa91f79ca3_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy0xLTEtMS0yNzIzNA_35845c9a-88ef-4ebd-bccb-fe4026dd0c42"
      unitRef="usd">418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i232a7ab61f1e47368c74babe3c12332d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy0zLTEtMS0yNzIzNA_661fd634-0570-463a-a0cc-a4a73b66fc2c"
      unitRef="usd">486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i503211a1f9354a229ff0440c90d6d24f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy01LTEtMS0yOTQzMA_806dfac9-a5a8-4f25-94c7-cba782559efa"
      unitRef="usd">899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2f7b33d629c41b8a67324d2e7bb83ff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfMy03LTEtMS0yOTQzMA_96120538-fef7-4c9b-950b-05164dfd42f1"
      unitRef="usd">668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic19088a08f7e4aa4a32a9f47b599a39b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC0xLTEtMS0yNzIzNA_6f1ee4a3-8bcb-4f33-9ebd-02e665a9477b"
      unitRef="usd">418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie455e253fcea4d5a8226cf4712b1b067_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC0zLTEtMS0yNzIzNA_76b65f66-9ea8-476c-8f92-d74a83a7725a"
      unitRef="usd">486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i953b502a78c24cafa839047b77dd0496_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC01LTEtMS0yOTQ1Mw_fbb485e9-30b8-4448-821b-1bda4157fb61"
      unitRef="usd">899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a9e2782836d4f8e9b3173907ee7e126_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RhYmxlOjQzMTJlYzYxMDZmMDRjYjdhY2MxNWY2NjE3ZDBjZTZjL3RhYmxlcmFuZ2U6NDMxMmVjNjEwNmYwNGNiN2FjYzE1ZjY2MTdkMGNlNmNfNC03LTEtMS0yOTQ1Mw_093b5af9-d11c-4ce6-a15f-d76920939167"
      unitRef="usd">668000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i34f6fa04b56749b38d5db99c77ee8cf9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjY5MA_bf4a7c53-81e9-42f7-9d48-045e019d2dd1"
      unitRef="shares">530991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic087ec71aa444b14b0f99f1a179b4d7b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81Mi9mcmFnOmU2ODhhMDBlMDVkNzQxZDRiYzAxNWNjYzA5YWVhY2FiL3RleHRyZWdpb246ZTY4OGEwMGUwNWQ3NDFkNGJjMDE1Y2NjMDlhZWFjYWJfMjc0MQ_23c45798-a2d0-4dfd-8204-6ac99f44bcfd"
      unitRef="shares">1296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="icbee1991dd3644fc8d747892be43b680_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjdlNjcyZmU3MzkxZDQ2N2Y5MjQ0NjU5MjZiNGMyNjgyL3NlYzo3ZTY3MmZlNzM5MWQ0NjdmOTI0NDY1OTI2YjRjMjY4Ml81NS9mcmFnOmU3NTZlN2YwYTcwOTQ5YWNiZDQzZGVkZTBkNDc1ZGMzL3RleHRyZWdpb246ZTc1NmU3ZjBhNzA5NDlhY2JkNDNkZWRlMGQ0NzVkYzNfNjE4_5914681d-1d55-4d1f-81e3-f83f55872520">Subsequent EventsThe Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require disclosure. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MF^'SZ"S/Z%V69S)C9IS/2FK/9>W8YX'6L)W7WB0)KV'-H1U]I'<Y,SKLZ@Q
MB)8SNE3DQE.Y/; 9MM/94U!VP&JJBN4;E#.H0OLH/1HAZZ2%8?L?0S9(.=[$
M=H$':L-V;H,YK6IFY;93*::3%W'#"(_QZV(8%L($?^"!Y?#WT-PIK#J+N4!C
MVESK8L0/W8EB!P]DA^UL]^&,9-"Y*PQQ, :H2P5QY$[@&P@.VQFNG<M3<Z@3
MEP<4[(XAZF(N"7$\@7$@.&QGN&M>%%G+O6V-RTN9E?>L3  O>OD[EPP%KXS
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MX':A'*:XHP-E _#Z3$KS/+%[AGJ/&/T!4$L#!!0    ( %8^"%5,(@=U7 4
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M/ CQU=Q<)Q<CVXR(9WRNC0L&?UM^Q;/,>()Q?*N=CIJ8QG#_^MG[KR5Y(//
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MGM8F<]!YK2P]W-(4OW.U9G-^,8)$4EQN^6CR\T\TL'_!1#VFL^DQG<V.Y.Q
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M0$43YWM$IT$9 _1%C0$W^N0:8;0Q@)HW14436&@ZH\H8H.C& !UI#-#SQ@
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MOO][!5+[WQ95ZY7YC6SIOXGDH&H>_P3 XY>NOAM>6?^E[KIZ.WS<Y)DLT?H
M^?\W==U]_]*_!?_PAQBN_P]02P,$%     @ 5CX(5<2EN""/!@  6QL  !@
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M7@\5H'P]4M]]N!N]>') R28/(;2:J7BO?VO1M]#DKY.+:5#T:\MA7ZEDP3-
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M8V*_U7PUB9**=(Z,EHM>:V3(8Y.TF- ^-17XM-)AJ]80R 1D!9XN5Q"6\-M
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M)&Y@F%=Y(A >KISW3(:GNP('V@ Y!MR=7J'(VBAW.)/= \4!2#TB[D=8J#;
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M4)[L/$3HSJ,]<T=AG"0<%"6(V3A9--'B/G&G :T@YAPF<D+!%F)TM-_>8A0
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M]H8!G'B#1HRW(R'/XZ-RC9+$Q]-+:G%+D+]B4PHJ6$_D5E+2Q*VP^DEV <:
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M XY]HD[5]V1N@WJO5]FP_,G;P7>6JD*:=. 3?@[E9*Q"H&&/HD.+H"3"YE0
MPL98/'LZS]IP\TM\P(4,LL'7CK2+8RKJ\G& PP)U0[S[</(MLA3%--TL\@D
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MZL7*9@8!2L#$GKY8N9J1V22;IFM0;1)B43 LM'%; []UBCQ@@'K;<7<3[O6
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M?Y(E(U#=F-D)1F[<:+>4A@9%MUS39([*.I!]):EM!\%^H)_UYW\!4$L#!!0
M   ( %8^"%6]88GT_P,  %4)   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;*U6VV[C-A#]E8$:% D@1'?93FT#<9)%6V3;(.FV#T4?:&ED$RN16I**
MG7Y]AY0M>PO':(N^2+R<.3IS(S7=2/59KQ$-;)M:Z)FW-J:]"0)=K+%A^EJV
M*&BGDJIAAJ9J%>A6(2N=45,'<1CF0<.X\.93M_:DYE/9F9H+?%*@NZ9AZFV!
MM=S,O,C;+SSSU=K8A6 ^;=D*7]!\:I\4S8*!I>0-"LVE (75S+N-;A:IQ3O
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M([JB57^)]Q,C6W=Q+J6A:]@-U_3?@\H":+^2TNPG]@/#G]3\+U!+ P04
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M*RR05!G0$!!:C,3-1$$4(,:(0BXU/-1F2[OH%6RN!&D3J,A&I, O, <4\DH
M/!1M02\_2BLP;&5M 5\W6JBO=0ZV!.__D#9ZJ8R8)\320APC2S__Y7(VF[X@
M B0$/4A>/)N(3QM'F(7; .FE4A!&8'. MK#J 9@O1 ,ARN)>>94:>A4)2_C(
M0F5C\;C)TPTXLS&@G&(+$D!,LZ FO1*RKHW^FD-X4?#-V6(\G4XA-+5 0*PP
M**-<0+IH,]P&2)/\)LUA;YO* A[\_O[V!)[618Y6*F75KL!*K4'%PJ>\R)OM
M6%S__>;#Q[=W$W$-]H-X:B%N(0=(D]5/HI$!V6"1^*1(27$T U9)T^IKPZH
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M^]9@79$>C^[NK]7H]/C%]? R20\NJL<O2>;>@M"[@'_-I=$PPT6>.1F4U+^
M[T%J_MR:^P@ FT\G:N/QZ\[C/\,@@ :$+2.0[<N'-YE.:/!\YF;Y<'/I?7HR
MK#Y;L+$?.6'@GPX4]ZV4*+$\O+BD3I;FFY/'1=K-UB0Q;:DGV:K7T5M/2_TT
M](9C4  R_L$Q:!B!7B.[,=L?G&S^/P:;%^83N(_Z6+JB+(&_69Z;<I;]_GAR
MG.S8Q\#)UM?;FLFY^48-/1;OAO9#[K [? :_ME]_-\?M-W3H)W.X99**S8#4
M@ROXB$C[7=H^:+$TWX*G0FM1F^6"4<@K/ #O9T+H_@$9#/\<N/H?4$L#!!0
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M4#$T&WTX283MADSG$+:QL9=(/":B6?-<!AL">+]"I*T3$@R3?OX,4$L#!!0
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M=(F!%DAPBG5L=VVD3E/(TIC[8ZQ!*0=EG[B:).#+8*)\0$YB(#/1_@H.N1G
MVV'L[R%60SE?._DB2@&$V'M4FZV#S*AC0["%) $.71:XKK7'HH1$#VO=78%H
M4;@=8R4Y$GT&U=>>WI6"B=YZ(T$?94"22LWI07Z@C*RE9;?]D)B]L]M=9$;
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M])K0WAC/EP6D@;/% AYQPW5X);IG=!9PL%V139!7B.<<URY)QQWR+@F(_,!
MH.H8MM+E=P:D%[/BHH-,7)2006!TPUN"O^IW\ 88Q-;H=+4GE^?DC=-(:8P>
MA[P.@POVV2WT>2$(:LFQC1<K3Y?O12+]O-GAI3-@WL\NS.<^7PM$E5_%KMED
M/E!^[0'C(-"\/LVQZ&@RV/WG/U! WV"!B0LP<N'D2'WH(*'ET!%;=2'VZBB]
MG!E%R <#+-=AI/9$YI7'0XHS3, >J7^9^%L$_=C7D^*.S$W$:(U[^9\'BJX
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MD>?P4!0Y:8Q]I +1P4NI-$VCPKEJ',>4%E@*.C85:K;DQI;"\=9N8JHLBBR
M2A4G@\%97 JIH]DDG"WM;&)JIZ3&I06JRU+8UP4JTTRCDVAW<"\WA?,'\6Q2
MB0VNT#U42\N[N&/)9(F:I-%@,9]&\Y/Q8N3]@\,OB0WUUN S61OSZ#??LVDT
M\()08>H\@^#?,UZB4IZ(93QM.:,NI ?VUSOVFY [Y[(6A)=&_9:9*Z;11009
MYJ)6[MXTWW";SZGG2XVB\(6F]3U-(DAK<J;<@EE!*77[%R_;>^@!+@;O )(M
M( FZVT!!Y95P8C:QI@'KO9G-+T*J <WBI/9%63G+5LDX-UNUQ0"3PTINM,QE
M*K2#>9J:6CNI-[ T2J82"3[]%&N%]'D2.P[LX7&Z#;)H@R3O!#F#.Z-=07"M
M,\S>XF,6W*E.=JH7R4'"'[4^AN'@"R2#)#G -^QN81CXAN_P[4OWSWQ-SO*K
M^;LOX99OM)_/=]*8*I'B-.)6(;3/&,T^?C@Y&WP]H';4J1T=8N_7[)J<Y*>)
M&3P0YK6"6W[CY"US(G2T3_IA\BMDQ:D4H6<D<>.EQG+5H"9_/:Y \-?B'_N1
MQT*)KC 9F&>TP8J=I+J5I':2O)5OH\+0B2""PB_0%#(M0%A_ KE1/"=H#)>F
MK&K'G/A4RXK'@ .A,R"3N\;[#N$(SN$5A26X%>N>6]]R4ULM7>VY&9S+%[^F
MMV#DIBZ,RD"6E>4T @D_="Z;5VW1SS:?>Y=/CF!LSZ \!;#8<E]UXUYWEF@W
M8081A!?7-FIWVHVY>=O=_]W;&7DG[$9JXH Y0P?'YZ<1V';NM!MGJM#K:^-X
M<H1EP:,:K7=@>VZ,VVU\@&[XS_X!4$L#!!0    ( %8^"%6:U,\HYP(  &D&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)U5VV[;, S]%<(;A@;P
MXFLNZY( 3;MA'=:B:-KU8=B#8C.Q4%OR)+G)_GZ4G&0)EN9A+S9)B8?G2"8]
M6DGUK M$ ^NJ%'KL%<;4YT&@LP(KIKNR1D$K"ZDJ9LA5RT#7"EGNDJHRB,.P
M'U2,"V\R<K$[-1G)QI1<X)T"W5054[^G6,K5V(N\;>">+PMC \%D5+,ESM \
MUG>*O&"'DO,*A>92@,+%V+N(SJ>IW>\V?.>XTGLV6"5S*9^M<YV/O= 2PA(S
M8Q$8O5[P$LO2 A&-7QM,;U?2)N[;6_3/3CMIF3.-E[)\XKDIQM[0@QP7K"G-
MO5Q]P8V>GL7+9*G=$U;MWO[ @ZS11E:;9&)0<=&^V7IS#GL)P_"5A'B3$#O>
M;2''\HH9-ADIN0)E=Q.:-9Q4ETWDN+"7,C.*5CGEF<DMW?LWJ37<H8)9P13"
MA3&*SQO#YB6"D7 IJXK.;V9D]ES(,D>EX>S!KNK.*#!$PD(%V:;@M"T8OU*P
M#S=2F$+#)Y%C?I@?$/F=@GBK8!J?!/S:B"XDH0]Q&,<G\)+=B20.+WD%[Q-3
M@HOE_HG\N)AKH^@#^GE,;PN7'H>S376N:Y;AV*.NT:A>T)N\>Q/UPX\GR*8[
MLNDI],F,FC1OZ)[D O[O*H\I.EWSH5"(![<(,[X^#-B[L(]HSSJ[%F *V6@F
M<NT#KC.L#6A'E$)0$^W6R^E+[L#9HV!-S@WFA_9M4Z%B1JIS)[FTDFUNUHIK
M(=["63STHW#8L6;4]Y-^XLS!T \'K9G$?C1(.W"%0E)KM9!/KH\Q?\]>J,H2
M;<_SS!',>=G0RD$A#7'/[Z4]/^H/(([].$S]?N^#C29)Y(=A"''D#\@<1!%,
M_\$2^PHLTVX4.G)AUU*S++M;$=UTV#GVS01[[4]'LW1#3A/-1IAV$NRBNSEZ
MT8Z/O]O;(7S#U)(+#24N*)4X]#Q0[6!K'2-K-TSFTM!H<F9!_P)4=@.M+Z0T
M6\<6V/U=)G\ 4$L#!!0    ( %8^"%581 A]DP0  'L+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;-56VV[C-A#]E8$WV,8 8^LN.1<#2?;2+;I
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M<$6W8U0V@.:74IJ]81?H[MO3?P!02P,$%     @ 5CX(59E$(&SB P  _P@
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M4J+SM,3"7+=$:RU+41 1=)6A JC)=VM0Q$S;+" \LU( 9!DM[EC5%GFP1?Y
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MJJ<TPXWZK@"N'=3S-6-R/]$!JB\5[S=02P,$%     @ 5CX(582X=>!7 P
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M,I#O-Y2*]X9RT%YCS?X!4$L#!!0    ( %8^"%7#F"_Z70D  "M0   9
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M-U6^:G[<[2ZOJGS9O'R4\;TL:@/U_4.>5]_?U+\7M_M]P,O_ U!+ P04
M" !6/@A5("F+B!0$   >%   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6RU6%V/FS@4_2L66ZU::3I@OI+,)DB=S%;;U;2*FG;W8;4/'G 2JV!3VR33
M_?5K ^$C<=B-Q+PD&.X]G'LY-@?/#XQ_$SN,)7C.4BH6UD[*_,ZV1;S#&1*W
M+,=47=DPGB&IAGQKBYQCE)1)66J[CA/:&2+4BN;EN16/YJR0*:%XQ8$HL@SQ
M'_<X98>%!:WCB<]DNY/ZA!W-<[3%:RR_YBNN1G:#DI ,4T$8!1QO%M8[>+=T
M'9U01OQ!\$%TCH$NY8FQ;WKP(5E8CF:$4QQ+#8'4WQXO<9IJ),7C>PUJ-??4
MB=WC(_K[LGA5S!,2>,G2/TDB=PMK:H$$;U"1RL_L\!NN"PHT7LQ24?Z"0QWK
M6" NA&19G:P89(16_^BY;D0G ?H7$MPZP?V_"5Z=X)6%5LS*LAZ01-&<LP/@
M.EJAZ8.R-V6VJH90_1C7DJNK1.7)Z!ZEB,88K$O-+%F6,XJI%. M6"O))$6*
M =N %5?"X?('0#0!OWXO2*X>I;P!GU32ZP<L$4G?J)2OZP?P^M4;\ H0"K[L
M6"%4O)C;4C'5][/CFM5]Q<J]P.KW@MX"S[D!KN.ZAO3E</H#CE4Z+--A/]U6
M_6F:Y#9-<DL\[P+>L?H;L%+=DOTF@+\>53CX('$F_C:56F'[9FP]3>]$CF*\
ML-0\%)COL17]_!,,G5],A8\$UFN#U[3!&T*/OC")4I!WI8"/73 57J&%)9I>
M3O81#$(O#.;VOEN2(0R&03AKPGID_8:L/TCV71P769$BB1,UK54W8H*JA4/1
M1AGCDOQ3GC QKZ"##J6W 0S@"7%#E.]"W\P[:'@'@[Q7QO;> (J-/0[.."B>
M71(554,8=+T@,',-&Z[A(-<EHT+RHEJ0U8Q7TM@JV1DG_"#2M;-@)+!>T9.F
MZ,D++@:3,=LP$EBO#=.F#=-1%X/IN0)]=SKS3H1J"'-\SW?,0ITU9&>#9!^Q
M>M/O6)H DBG*>ZQ9&F4ZB'/M\QD)K%<R=-HWN_."0JW!1^K$6&C]5G1,#AQ5
MK#5<5X;!Q M/M&J,<CVS5&%K-N#@2SQZ7W!*9,%QR7-#GO6QV42-:BW&0NN7
MW9H+Z+VD7 >MR]6M& FMWXK6NL!A[W*U7,^=R,QQ3M5Z'C2=P0MB;=T*'+8K
M^HNAD)BW!$NZ@FWD 7%L9#N(>/6C&@FM7W_K@&#XDJH=U16-A=9O1>N+X*#?
MN%ZUDW/5GBVQYS'3"Z85MLX%#EN71_3$.)*,5R0S1(L-BM4J2^CV/R@/ E_]
MO$9"Z[>A]41P]I+2'=4IC876_[QOK9([Z#^NEFX-U_UF#2?^Z8IKB H"[]3*
MVIW-&[US]A'Q+:$"I'BCTIS;B1(_KS:CJH%D>;F?\\2D9%EYN,,HP5P'J.L;
MQN1QH+>(FBW!Z%]02P,$%     @ 5CX(52-F!YND @  Y@<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S N>&ULK55M;]HP$/XK5E9-K;0U+P2ZLA )"-,Z
MJ5)5UNW#M \F.8A5Q\YL!]B_G^V$%+H4H:U?$OMRSW.ON8LV7#S*'$"A;4&9
M'#FY4N70=66:0X'E)2^!Z2]++@JL]%6L7%D*P)D%%=0-/&_@%I@P)XZL[$[$
M$:\4)0SN!))546#Q>P*4;T:.[^P$]V25*R-PXZC$*YB#>BCOA+ZY+4M&"F"2
M<(8$+$?.V!_.0J-O%;X1V,B],S*1+#A_-)>;;.1XQB&@D"K#@/5K#5.@U!!I
M-WXUG$YKT@#WSSOV3S9V'<L"2YAR^IUD*A\Y'QR4P1)75-WSS6=HXND;OI13
M:9]HT^AZ#DHKJ7C1@+4'!6'U&V^;/.P!-$\W(&@ P7- ^ *@UP!ZIUH(&T!X
MJH5^ ["ANW7L-G$)5CB.!-\@8;0UFSG8[%NTSA=AID_F2NBO1.-4/,$4LQ30
MW#;EE!<E9\"41._1.,N(*2:FZ(;5'6E*>YZ PH1>:(V'>8+.SR[0&2(,?<UY
M)3'+9.0J[9BA=]/&B4GM1/""$SUTRYG*)9JQ#+(.?'(</SB"=W5"VJP$NZQ,
M@J.$7RIVB7K>.Q1X0=#AS_1TN-\5SO]9G_VS]8-D]-H6Z5F^WDDM<@\4*\A0
M0F1*N:P$2/1CO)!*Z'_^9U?M:_:PF]W,P:$L<0HC1P\Z"6(-3OSVC3_P/G8E
M_C7)DM<DF[T2V4&)PK9$X3'V. %-FI+Z!X6M7B(2NDI1LPPLB]D@ZSB\#B-W
MO9_A#IVK_J%.\K?.=7]PJ#/KT/&?;-5ANGN#JP"QLAM#HI173-4-VDK;I32V
ML_B9?.(/IWZ'/-%+K-XY3_3U!KS%8D681!26VI1W>:7GJJBW2GU1O+1C<\&5
M'L+VF.M%#,(HZ.]+SM7N8@RTJSW^ U!+ P04    " !6/@A5; J'DSP#  #2
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RMEMUNVS@0A5^%4(M%
M"W2C/UN6L[: Q-ZB+5IL$+>[%T4O:&ED$Z5(+4G%Z=MW*"FJ8S&!+WICB^*<
MHV]&0U*+@U3?]1[ D/N*"[WT]L;4E[ZO\SU45%_(&@3.E%)5U.!0[7Q=*Z!%
M*ZJX'P5!XE>4"2];M/=N5+:0C>%,P(TBNJDJJGY< Y>'I1=Z#S=NV6YO[ T_
M6]1T!QLP7^H;A2-_<"E8!4(S*8B"<NE=A9>K,+""-N)?!@=]=$UL*ELIO]O!
M^V+I!98(..3&6E#\NX,5<&Z=D./_WM0;GFF%Q]</[F_;Y#&9+=6PDOP_5IC]
MTDL]4D!)&VYNY>$=] E-K5\NN6Y_R:&/#3R2-]K(JA<C0<5$]T_O^T(<"<+)
M$X*H%T3G"N)>$+>)=F1M6FMJ:+90\D"4C48W>]'6IE5C-DS8U[@Q"F<9ZDQV
M33D5.9!-VS,K6=52@#":_$DVV#)%PX'(DESEN6J@('_?8_]HT.1*%.0?LP=%
M5HU2J" ?&=TRS@S#V5=K,)3QU^CR9;,FKUZ^)B\)$^3S7C::BD(O?(/P%L'/
M>]#K#C1Z O1#(RY('+PA41!%#OGJ>?D:<I2'K3Q\+/>Q9$/=HJ%N4>L7GU6W
M6^#48'G63.=<ZD9A#;Y>;;51V*;?7,EV[A.WNUV[E[JF.2P]7)P:U!UXV1\O
MPB3XRY7Z;S)[5(AX*$3\G'OVT!FY%)ANTRU.?-6UDCM\FO--=XY)ZVCWF;LL
MG"0QOI:[XZS&4?,D2(:@1[23@79R%BW2E0B'K)23$L")V5E-CP#B-(Q.*,=!
M41"&;LKI0#D]CY+^4))S@BN&;$% R8P3=#IF2.?)":@K*(W<H,D FIQ93LAQ
MCN6T@QT&T.\7+NK$4;GYY(1Z'(1]^P3U;*">G45=,H%KF(D=-J]V5W8V9IR?
M$#I"GFC2=.!+S^(S]-Y=N73\R-.V'(>DL9MJ/E#-GZ7J=ON\W^WYK]W>13AW
MU&UV@CB.26=NQ##X=9H%ST)^EH9RY^$2C':3*)ZEIWN.(RQ,CM$[+O_HP+5?
M.Y^HVC&A"8<2=<'%#+-2W0=$-S"R;L_@K31XHK>7>_SH F4#<+Z4TCP,[+$^
M?,9E/P%02P,$%     @ 5CX(53<;7)'L#P  @>,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&ULM=UK<]K*'<?QMZ)Q.YUVQHV1 (-3QS..=;\TF9/3
M]D&G#V18&_4 HI(XKCM]\5V!@A"2%TB_?A+'6/M9<?FOI.4GZ?8ES7[)9T(4
MVK\7\V7^Z6)6%*N/5U?Y9"86<?XA78FE_,M3FBWB0OZ:/5_EJTS$TTVCQ?S*
MZ/6NKQ9QLKRXN]T\]C6[NTW7Q3Q9BJ^9EJ\7BSA[_2SFZ<NG"_WB^P,_)<^S
MHGS@ZNYV%3^+;Z+XR^IK)G^[VBG39"&6>9(NM4P\?;JXUS]&PW'98+/$7Q/Q
MDN_]7RN?RF.:_E+^XDT_7?3*-1)S,2E*(I8_?A4/8CXO);D>_ZK0BUV?9</]
M_W_7[<V3ET_F,<[%0SK_6S(M9I\NQA?:5#S%ZWGQ4_KBBNH)#4MODL[SS;_:
M2[5L[T*;K/,B752-Y1HLDN7V9_SOZH78:V 8;S0PJ@;&J0WZ58/^J0T&58/!
M88/K-QH,JP;#4WNXKAI<'S3HO]7#J&HP.K6'<=5@?-! [[_1X*9J<'/88/#6
M&]?[_L[U3ETI??=FG_QNZ]_?;OWD]UO__H;KFW?\:OM9W'R0S;B([VZS]$7+
MRN6E5_YG4PV;]O+SFRS+POU69/*OB6Q7W#VDBT52R$HL<BU>3K6'=%DDRV>Q
MG"0BU_ZHW4^G25EA\5SSEMMQHJRWWYNBB)/Y'[2GXG>_T4?C/VG)4OMYEJYS
MB>27VF\;O]]>%7)5RPZO)M5J6=O5,MY8K;X6R169Y9JUG(II1WM'W?Y:T?Y*
MOD2[U\GX_CI]-I3@_2K[H!GC2\WH&8;VEV^F]OO?_J%CO1[43!1+1C>.,J::
M^3(I)#/<,#T%8ZD9?[W\H/5[S;79O:4=GGVZIRM6R_E_5DO6P5S(REB*#MEE
M5M []BZ^:OKU=OTZ6OOJUJ:8[-X\O:-YH&[^3:QD\_[1YQ">\!'J'?\(14=>
MT5B^HH:N8AKUUM^-2_V-VW]K]58BB\N12 N%W"Y/M?L\%W*,^GLH%]2\0BSR
M?W2L[>>M.NA6R[V@C_DJGHA/%W(W)Q?9K^+B3GZLKGM=G_8'$C-)S"(QF\0<
M$G-)S",QG\0"$@M)+(*PQA PV T! Y5^]Q#G,VTB-^-9\K@N]SJZZEU)G%OO
M)&:2F$5B-HDY).:2F$=B/HD%)!9NL>L-5AZF_WIG#'J]VZM?]^OXR$*-^ASN
MZG.HK,^OZVPRD]MF;94E$Z&E3]HJ+>2!1"*/%5;5W[I*5JF>6[(D9@Y;K])-
MZZ6TR!YM$G-(S"4QC\1\$@M(+"2Q",(:I7V]*^UK]:8W7>9%MM[.K<DC^566
M/LM>Y(']<Y;F7<?SGY7@N55-8B:)621FDYA#8BZ)>23FDUA 8N$6&^YM/?1>
MK[4EAKILE/5H5]8C95G;R3)>RDWUO#RDOM3F2?R8S)/BM:N>E=*Y]4QB)HE9
M)&:3F$-B+HEY).:36$!BX:BU-]A5SU"7C7H>[^IYK*QG*Y^4+:9BE>9)T57%
MRO;G5C&)F>/VJSML[6N3/=HDYI"82V(>B?DD%I!82&(1A#6*^&97Q#?*(@[E
M?G6:76KI;L;[</-\J<7+Y5H>56_^H*WBU\WW=5WUKNSJW'HG,9/$+!*S2<RY
M:0UK8Z,YJ+ED?QZ)^206D%A(8A&$-:I=[]5?N/?4Q];KQ7H>EW$53>23>+[]
M0GTRC]?=TV5J[MR:1C43U2Q4LU'-J;2;O<+N?= /*AOMTD,U']4"5 M1+:*T
M9GWO!6KT'Z[O2ZT0V:*SRI7HV55.:B:J6:AFHYISY*T=:J\BSKIVO%QT/3Q4
M\U$M0+40U2)*:Y:^49>^H?Q\?&GNPFN3-._>35<[9U<[J9FH9E7:_@YQ_^9@
MNVEW+&2,QLV%G(Z%QH<3!F['0H.;47,A#WV&/JH%J!:B6D1IS>JJ$V&Z,FUR
M]]<XDT?$<W&TN- ,&*J9J&95VOY7#J-6;;67&>N'I=5>1C=:I=6QD#X^+"TT
M9(5J :J%J!916K.TZJ25KHY:A6F>;Z)6V^CWZZ7VO(ZS>%D(,2WCYLEBO:AB
M'D6J/99S4$E7*ONSNI^S:P\-9*&:A6HVJCFHYJ*:AVH^J@5Z.R8U[K>^\@G1
M3B-*:Y9^'>+2U2FN,"F2Y^TQ:BZ*8B[*N>7.TD9S6ZAFHII5:?M;NM[A5O7H
M(D['(L:P]6%RCTL>^NQ\5 M0+42UB-*:E55GJ'1UB.IKED[D]C/7GK)TH27+
M?)UMTA=UF>U_Z;,Y@U'6HNC>IT7C5:AFHIJEMV,TH^OQ8?FAR:E3NG31+CU4
M\U$M0+40U2)*:Y9TG9_2U0$J)T[*TY7G<2'WB^6>\/SDC2<:IT(U$]4L5+-1
MS:FT_4+O7]\<%CJ:E4(U']4"5 M1+:*T9J'7P2I=G:SZ*K)D-8L=T7G2D;KQ
MV=6,YJI0S4(U&]4<5'-1S4,U']4"5 M1+:*T9MG742Q]F_V@SSK6T=P5JIFH
M9J&:C6H.JKFHYJ&:CVH!JH6H%E%:\Z(?=5C+4(>U3IX=JYS&5YCMV9X'=7?G
MEC:J6:AFHYI3:<<FT]!./53S42U M1#5(DIKUFP=P#+4*9W.FKW4XD6Z7A9:
M_!)GT^W1>UK,1*:MXJS[#"AU-^=NU%'-1#4+U6Q4<RJM<:*(T3I3Q$4[]5#-
M1[4 U4)4BRBM6?EU_LI0YZ_^O%X\RHI.G^IK1.7:?Y47C/JL)L^N<C2*A6H6
MJMFHYE1:8V;NL,+)#CU4\U$M0+40U2)*:U9XG0$SU!FP-[;M15K$\S+ DB?3
MS1%\]\6"U/C9M=YO;9E&[7U2$^W40C4;U1Q4<U'-0S4?U0)4"U$MHK1FO=?!
M-$.9?MF;AY?;\>C[=ES[^27MK&\RF/. :B:J6:AFHYJ#:BZJ>:CFHUJ :B&J
M1936' ;JD)HQ?)=Y>0/-K*&:B6H6JMFHYJ":BVH>JOFH%J!:B&H1I34'A#I;
M9ZBS==@<'YJK0S43U2Q4LU'-J;2C<WQH! _5?%0+4"U$M8C2FI5?1_ ,=03O
MC<K?S?'M+H]RJ>6Q?$PK9G(U9NF\\WP5=6=GUW\[7V;TVM>,,M%>+52S4<U!
M-1?5/%3S42U M1#5(DIK#@!U-,\X-9K7G!*09=X]P8^&]5#-1#4+U6Q4<U#-
M134/U7Q4"U M1+6(TIH#01W6,]XGK&>@83U4,U'-0C4;U1Q4<U'-0S4?U0)4
M"U$MHK3F'8/JL%[_!\)Z/S IH.[FW $"U4Q4LU#-1C6GWX[\=4T*H)UZJ.:C
M6H!J(:I%E-:L_#KRU_^AR-\/3@JH.SN[_O5VM*5K4@#MU4(U&]4<5'-1S4,U
M']4"5 M1+:*TY@!0)__ZZN3?&Y,"7[HS?VKL[ )',W^H9J&:C6H.JKFHYJ&:
MCVH!JH6H%E%:<QC8NVGH.]TUE+UM*'O?4/;&H>R=0]E;A[+W#F5O'LK>/92]
M?2A[_U#V!J+OD1_LU_G!OC*8Q$T)D&FJ!U0S4<U"-1O5G$H[.B5 =NJAFH]J
M :J%J!916K/RZ\A@_P>N:_?C4P)HD+#?OM&HWCDE@$8$4<U&-0?57%3S4,U'
MM0#50E2+**TY -01P?Z1>YC*!Y))/->^K5>K^:MV_YP)\>:-D]38V06.!@%1
MS4(U&]4<5'-1S4,U']4"5 M1+:*TYC!0YP7[H_>9$D"3@:AFHIJ%:C:J.:CF
MHIJ':CZJ!:@6HEI$:<T!H<X/]H_=-+5(%IL+>&9B$<M]!#DT3-+%(BG>NK:/
M&CQ[*$ 3A*AF55HCP*P?'I;8:)_.27VZ:)\>JOFH%J!:B&H1I35+MT[\]=6W
M2OV:I?\4DT);Q,OX>;,OKY6=E+>E>.H._ZK!LTL7S?JAFE5I!_=P:95N>ZG1
MX4U<G(Z%VG=!<#N6:L_%>>B3]%$M0+40U2)*:U3:H([2#=11NB^;Z?"'=%ED
M\:0H[SW\Y7%>S:=U'C^KO7,+#=5,5+-0S48U!]5<5/-0S4>U -5"5(LHK3D2
MU-&Z@?XNQ\\#-$2':B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1936'!#JJ-U ';4[
M__A9#9X]%*!Q.U2S!NW+V W;Q\]HG\Y)?;IHGQZJ^:@6H%J(:A&E-4NWCL<-
MU%?/.__X60V>7;IH, [5K$'[]J;]CM)M7_/O9C0X.'[NH*Y;A^)N!V7T6\?/
MZ)/T42U M1#5(DIK5EJ=.QNH<V?WWW[^Z5ZSXTDR3[H396K@[,I"$V6H9J&:
MC6H.JKFHYJ&:CVH!JH6H%E%:L_3KX-G@?:Y5-T C9JAFHIJ%:C:J.:CFHIJ'
M:CZJ!:@6HEI$:<T!H0ZB#8X$T?9FT=/=+'KG$("&T%#-1#5KT''%M]%->W<;
M39>=UJF+=NJAFH]J :J%J!916K-HZ]C80'V9N8<T+\H;2;RDV2^7FMRD3^31
MLCQH[BQ;-"J&:B:J696F]_9*J/>AIX^&AX6+IL!.[=9%N_50S4>U -5"5(LH
MK5FZ=<!KH YX&3W]>KOO76>^.\L6C76AFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ
M$:4U!X Z)C9XGPO##="P&*J9J&:AFHUJ#JJYJ.:AFH]J :J%J!916F- &-9I
MMJ$ZS78_G2;E,;<\ (\S$9?[]?+'7!-Y$1="6V6I'#&*5VV^'2[^JST5LO?1
MN.NY?%;W=>XH@6HFJEG#]A78!J.#'7VT1^>$'EVT1P_5?%0+4"U$M8C2FA5=
MI]*&Z@N^?4[+D[@OM2C.\W@R6Y>G>.?;S7UGS:)A-%0S4<U"-1O5'%1S4<U#
M-1_5 E0+42VBM.8X4(?1AL:[[.H/T4@:JIFH9J&:C6H.JKFHYJ&:CVH!JH6H
M%E%:<T"H(VY#=<2M'A V._.76B&R1;G#/ZF^A>L<#="4&ZJ9J&:AFHUJ#JJY
MJ.:AFG_D,]S77D6<=9UF%:#K$:):1&G-RJ\C=T-EKN?NVTM2_$=D\W@Y51P(
MD$FC!U0S4<U"-1O5'%1S4<U#-1_5 E0+42VBM&;UUZF[X?ND[H9HZ@[53%2S
M4,U&-0?57%3S4,U'M0#50E2+**TY(-2INZ$Z=?=C!P)H  _53%2S4,U&-0?5
M7%3SCGSJ]&MM(3]?LZZ==Q]=DP#50E2+**U9^W5X;WCD'K%";OQER:>'8\#F
MA[9,"WF$56S.6A7+B9C*/R3QX^94G<OR8M"/Y=5A$_GP]@S7J<C*@>,IR<O+
M29;'9IUC!YH"1#43U:Q*:YRY9AQ^+X@& $_HT45[]%#-1[4 U4)4BRBM6?EU
M]F^HSOYAE5]6N99VWSY&O0YG5SH:'$0UJ]+VZVY\<UCI:!SPA!Y=M$</U7Q4
M"U M1+6(TK:5?I7/A"C,N(CO;A<B>Q8/8C[/9:&NET5YU+_WJ-PJ/\F10/]X
M;UQ<M1ZW](^VWO&XHW]T-X]?U?S=[2I^%E&</2?+7 X13[*KWH>1/'#)DN?9
M[I<B77VZT"^TQ[0HTL7FOS,1R[V"<@'Y]Z<T+;[_4G90GC.P>3IW_P-02P,$
M%     @ 5CX(502U)X$V P  >PL  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&ULK99=3]LP%(;_BI6A":2-?+5IR]I(T J-";2*C^UBVH6;GC86CIW9
M3@O_?K83LE)"0-%NVCCQ>_R\QW'.&6^YN)<I@$(/&65RXJ1*Y2>N*Y,4,BR/
M>0Y,/UEQD6&EAV+MREP 7EI11MW \R(WPX0Y\=C>FXMXS M%"8.Y0++(,BP>
MSX#R[<3QG:<;UV2=*G/#C<<Y7L,-J+M\+O3(K:,L209,$LZ0@-7$.?5/IKX5
MV!D_"&SESC4R5A:<WYO!Q7+B>(8(*"3*A,#Z;P-3H-1$TAQ_JJ!.O:81[EX_
M13^WYK69!98PY?0G6:ITX@P=M(05+JBZYMNO4!GJFW@)I]+^HFTUUW-04DC%
MLTJL"3+"RG_\4"5B1^#W7A$$E2!XKR"L!*$U6I)96S.L<#P6?(N$F:VCF0N;
M&ZO6;@@SVWBCA'Y*M$[%4YYE1.E]41)AMD13SA1A:V ) 8D^HQO]WBP+"HBO
MT'FA"@'HBC"2%1GZGH/ 9C*Z!)U(-,>/99S#&2A,Z)&6W]W,T.'!$3I A*';
ME!=2+R+'KM+H!L!-*LRS$C-X!?-;P8Y1Z'U"@1<$#?)INWP&B9;[5NX_E[LZ
M8776@CIK@8T7=LK:C,B$<FER]>MT(970[^KO)L_E(KWF1<P!/I$Y3F#BZ!,J
M06S B3]^\"/O2U,&_E.P9_D(ZWR$;=%CLROH4(#Y;I@70I('E.F<I/*HR7<9
M+++!S'=F$P]ZX=C=[-II7;"CG5YMI_>6G;")NU3U=[C]ON_M@;>&[@C>K\'[
M;X'WFL#[#>#A: ^\-71'\*@&C]X"[S>!1R_!@\%@#[PU=$?P00T^> L\:@(?
MO >\-71'\&$-/FP%OTU!E_V5 M&$/VS ]Z+],]JZ0D?^4<T_:N6OBE%6%2->
M%R-JBU%>%:,F<Z.7YH8];_\XM"[?T9SO_2O+7JN]2Y#R!%TPO3\@56/!]%[8
M& 6#:,]%^S)=;>QT%WZKC;D)RA3:8%K8'J+<'4KP@E"B'AN-^2_*P\@/]]^]
MAEE#^_7;[ *[.YV1:4NOL%@3)C7&2LN\XX%.GR@[O7*@>&Z;I057NO6REZGN
MCD&8"?KYBG/U-##]5]UOQW\!4$L#!!0    ( %8^"%7W"%N)4@,  "<)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;*U678_;-A#\*X0:% G@.WU:
M\EUM 3D;15-<D<,Y:1Z*/M#2VB9"D2I)V?&_[Y+2"3Y;=E*@+S8I[0QG9\FE
MIGNIONHM@"'?*B[TS-L:4]_[OBZV4%%]*VL0^&8M544-3M7&U[4"6CI0Q?TH
M"%*_HDQX^=0]>U+Y5#:&,P%/BNBFJJ@Z/ "7^YD7>B\/GMEF:^P#/Y_6= -+
M,)_K)X4SOV<I605",RF(@O7,>Q_>SR<VW@7\R6"OC\;$9K*2\JN=?"AG7F %
M 8?"6 :*?SN8 ^>6"&7\TW%Z_9(6>#Q^8?_5Y8ZYK*B&N>1?6&FV,V_BD1+6
MM.'F6>Y_@RZ?L>4K)-?NE^R[V, C1:.-K#HP*JB8:/_IM\Z'(T"470!$'2 Z
M!:07 '$'B%VBK3*7UH(:FD^5W!-EHY'-#IPW#HW9,&&KN#0*WS+$F7PNJXH9
M+(O1A(J2S*4P3&Q % PTN2%+W#9EPX'(-5DV=<W!QE)N TLL)CB(EIR5U.#D
M@7(J"B!+MP4_B':?V8(] W<11I)'0.,U>;L 0QE_A\M\7B[(VS?OR!O"!/FT
ME8U&,7KJ&TS1"O6++IV'-IWH0CJ_-^*6Q,&(1$$4#<#GU^$+*! >.GCX&NZC
ML;V[4>]NY/CB"WR/H#7 B'RL05'K:YOZB#PRNF*<F<.(/-&#M71$%@V0O]ZO
MM%&XM_\>RKU=+!E>S)[W>UW3 F8>'F@-:@=>_O-/81K\,N3$_T3VRI>X]R6^
MQIZ[9G$CUS>-!D+1(S-8ZY8D=22V'>WR293=3?W=<1[G05D43?J@5_J27E]R
M5=^\40IK0FJIW-[%S<]MX0A_J=N0W)9S?*0D3,+L1.Y 4)"$PW+'O=SQ5;F/
MW]<V/ELVR\+T1-MY4'HWB8>UI;VV]*JV3])VBQ]P+SVKXUT8QR<*SX,F090,
M*\QZA=E5A5]<J\?.1'=X2C> EY.]_NQI;64;4-7(-J8#4#6X4:\O$$8MDH0!
MJ;"_;C6)$E+2PQ#7_#M<2<>57*5Z9<2D-V+RWXPHF2YD@^< FQ<,Y=WRA>%1
M/8+;X"XYJ=J%L/%)W?RC:\Q^0OQ!U88)C558(RZXS7!GJO9:;B=&UNYF6TF#
M]Z0;;O%+!I0-P/=K*<W+Q%Z6_;=1_B]02P,$%     @ 5CX(52ADI"GN!0
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M7'QF2F_.NOJCZW960%TKVS7F;6=VK4S;M3J[R:[99.9T]I+O(=F80K,QM0)
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M07EF.I;EFSE,"V,ZEF/W9#K&6Y:E!;HG@&[S')+G6Y3A_<2PC9>!AW2U9F+
MG(XW<(7FB'W=W!-^9M8L29JC@J:X  0M)\:-?1W9@0B0B#]3M*='QT"DLL#X
M49S<)1/#$G>$,A0S00'YSP[-4)8))GX?WRI2HYY3!!X?O[#_+)/GR2P@13.<
M_94F;#TQA@9(T!)N,_: ][^B*J&!X(MQ1N5?L*^PE@'B+64XKX+Y'>1I4?["
MIVHAC@(XCSK J0*<=H!W(L"M MQS9_"J ._<&095@$S=+'.7"Q="!J=C@O>
M"#1G$P=R]64T7Z^T$(4R9X1?37D<F\X9CA\O;_E2)V"&<UY_%$H%+\&\K!V
MET"B@ (5/8EC!!Y0!AF_R#"XHW0+BQ@=XO[82.S-'I*$ E@D'$X926,144*J
M:Q]#Q&":?>*S?YV'X..'3^ #2 OP98VWE ?2L<EXTN+6S;A*\+9,T#F1H L^
MXX*M*8B*!"6*^+ _WN^)-_EBURONO*SXK=-+^-NVN *N=0$<RW$4]S,[/]Q6
MI?-]LT=OGKVQ&&Y=?J[D\TZ5WQH2=+F0A74/G[D#,7!#""Q62!Q?5+6CDKV7
M6/CK-=W &$T,;J 4D1TRIC_^8/O63ZHUUTD6ZB2+-)$UU/%J=3S)[IZA3N.Q
M/Y((+)Z!4D7Q1%\TPV:8,O#W[WP6<,=03O]1Z>KIU%4G6:B3+-)$UM!U4.LZ
MZ'WJOF &,T"E]9>JQ4<RJ40I^7S))]X]=M,@"+@![(X7NPMR VO4!(5=D.T&
MCM5$15W48.@=0(VL_3IKOS?K]C\=59Z]#*\M/IUDH4ZR2!-90X:@EB%X?Z82
MZ-15)UFHDRS21-;0=5CK.M1L*B7?X.@A]^QARU,4F*'?LI0N9CAJV4[4Q?C^
M4.TGHSKAT?_Y"8(D7LLWV@3M>-.UD57ZK[IVSWNMZ9WSM96JDRS4219I(FL(
M9UN'IL=Z?QY4W9,F:;6RA5K9(EUL376/6EI;LQ-5A,?V8(]&@Y87J5#6T&NY
MD0+ENK[;\B,5EV^=>,.QG4/J3F_JOZ "$9Z\L"28Y&F1\G<>*+[%?)\K]4_[
MZMK5R19J98MTL34%//3#MOL.G4EK+ZV5+=3*%NEB:ZI[Z*?MWK;N+<[D=7QB
M$ 1^VYFZ*,=W!FUGZJ)LRQT$;6OJPCSG5/-E'WI.N[_I[+6F<WJS?OY75ZE.
MME K6Z2+K:G4H4^V_7?H05I;;ZULH5:V2!=;4]U#^VWW=H%O\:"@\S6FVZBI
M0)U.30'JMFH*4+=7,X^V/')$5G*OB?)4M@4K/S_7H_5^UHW<Q6F-W]K7,ULQ
M'HK]+[G%<J O-\\^0[)*"PHRM.1365<!?UI)N1]5GC"\D1LN"\P8SN7A&L$$
M$0'@UY<8LY<3,4&]*SC]#U!+ P04    " !6/@A55!)R#; #  #&#   &0
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M!S_AH+W@JGBPK/GHUIE&XV8".*^5NH2V>WUK>+EY\;-Y:77V&U!+ P04
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MUZ1697/T9]WOB?DG4$L! A0#%     @ 5CX(50=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !6/@A5
M*_0!W>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !6/@A5F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %8^"%6.VU<WT04
M )X?   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !6/@A57/LM\L(%   /&   &               @($4
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 5CX(59G,
MO=P* P  +PH  !@              ("!#!0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( %8^"%5,(@=U7 4  (T6   8
M  " @4P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !6
M/@A5<"X!-ET*  "480  &               @('>'   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 5CX(5<2EN""/!@  6QL  !@
M         ("!<2<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( %8^"%5Y\;/3+P@  &42   8              " @38N  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !6/@A58'3Z!,@7  "T1P
M&               @(&;-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 5CX(5:K"^/(2!   (PH  !@              ("!F4X  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %8^"%6H\9,)Q@0
M /<+   9              " @>%2  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 5CX(5;UAB?3_ P  50D  !D              ("!
MWE<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !6/@A5
MOAR8^UX4  !R.P  &0              @($47   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( %8^"%6-"KBH[ 0  #4-   9
M      " @:EP  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 5CX(51:509>F!P  *!@  !D              ("!S'4  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !6/@A5T#P/IYD"  #U!0
M&0              @(&I?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( %8^"%4S47*]TQ<  .=+   9              " @7F   !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 5CX(50"S_1R_
M @  " 8  !D              ("!@Y@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !6/@A5FM3/*.<"  !I!@  &0
M@(%YFP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %8^
M"%581 A]DP0  'L+   9              " @9>>  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 5CX(59E$(&SB P  _P@  !D
M         ("!8:,  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !6/@A5MC-EUL #  "I"   &0              @(%ZIP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %8^"%7=@M,L)08  'T0
M   9              " @7&K  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 5CX(55LBTW%U @  ^P4  !D              ("!S;$
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !6/@A56-FN
MCA@#  "U#   &0              @(%YM   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( %8^"%6$N'7@5P,  "(0   9
M  " @<BW  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M5CX(53I4\#ZC @  )P8  !D              ("!5KL  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !6/@A5>38Z21($  #2$@  &0
M            @($PO@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( %8^"%7#F"_Z70D  "M0   9              " @7G"  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 5CX(52 IBX@4!
M'A0  !D              ("!#<P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !6/@A5(V8'FZ0"  #F!P  &0              @(%8
MT   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %8^"%5L
M"H>3/ ,  -()   9              " @3/3  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 5CX(53<;7)'L#P  @>,  !D
M     ("!IM8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8^"%7? 42W# 4  '88   9              "
M@=O\  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 5CX(
M5:T/F9"&!   (1P  !D              ("!'@(! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !6/@A55!)R#; #  #&#   &0
M        @(';!@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( %8^"%6S;G'5" 0  $86   9              " @<(* 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 5CX(57N1/04W P  UA,
M  T              ( ! 0\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !6
M/@A5EXJ[',     3 @  "P              @ %C$@$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " !6/@A5"WX,OG8#   X&P  #P              @ %,$P$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 5CX(53QA]1J- 0  3Q@  !H
M             ( ![Q8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 5CX(59C$(26B 0  IA@  !,              ( !M!@! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0  AQH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>195</ContextCount>
  <ElementCount>242</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="krys-20220630.htm">krys-20220630.htm</File>
    <File>krys-20220630.xsd</File>
    <File>krys-20220630_cal.xml</File>
    <File>krys-20220630_def.xml</File>
    <File>krys-20220630_lab.xml</File>
    <File>krys-20220630_pre.xml</File>
    <File>krys-20220630ex311.htm</File>
    <File>krys-20220630ex312.htm</File>
    <File>krys-20220630ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="562">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20220630.htm": {
   "axisCustom": 1,
   "axisStandard": 14,
   "contextCount": 195,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 367,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 32,
   "keyStandard": 210,
   "memberCustom": 18,
   "memberStandard": 25,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Instruments",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Balance Sheet Components",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Capitalization",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Subsequent Events",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Instruments (Tables)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "iab27a23368df44c0b545b31a362ffad0_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "iab27a23368df44c0b545b31a362ffad0_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedConstructionInProgressCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9992e6e26f6f4543965ca3f6dcd6c353_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9992e6e26f6f4543965ca3f6dcd6c353_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ia226ea26d38a4e37a6f721a29cd03d76_I20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Capitalization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i4230c7dd2e1041b68fd5534af97a61fc_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "id9e4439435f24487b699ba4fbdccaff9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i7c64f9e68a3641cda1e0a998c7be368a_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "ibc48c6dcb2874c569033c88aff1c332a_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i9b2826416c434b0b836617c84bedeaaa_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i5c44a0f0edbf4e42a4210967f72907b4_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i953b502a78c24cafa839047b77dd0496_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i5122f0ff5eea45fbb8d3ef9bec229dfd_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "i025425ccecb5443b909699e65613a02c_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220630.htm",
      "contextRef": "icbee1991dd3644fc8d747892be43b680_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASTRA facility.",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "ASTRA Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress current.",
        "label": "Accrued Construction In Progress Current",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedFinancingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Financing Fees, Current",
        "label": "Accrued Financing Fees, Current",
        "terseLabel": "Accrued financing costs"
       }
      }
     },
     "localname": "AccruedFinancingFeesCurrent",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AdditionalAreaOfRealEstatePropertyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of real estate property leased.",
        "label": "Additional Area Of Real Estate Property Leased",
        "terseLabel": "Additional area of real estate property leased"
       }
      }
     },
     "localname": "AdditionalAreaOfRealEstatePropertyLeased",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "krys_BostonMassachusettsLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston, Massachusetts Lease",
        "label": "Boston, Massachusetts Lease [Member]",
        "terseLabel": "Boston, Massachusetts Lease"
       }
      }
     },
     "localname": "BostonMassachusettsLeaseMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CostOfWorkPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Work, Percentage",
        "label": "Cost Of Work, Percentage",
        "terseLabel": "Cost of work, percentage"
       }
      }
     },
     "localname": "CostOfWorkPercentage",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClausePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Percent",
        "label": "Cumulative Escalation Clause, Percent",
        "terseLabel": "Cumulative escalation clause"
       }
      }
     },
     "localname": "CumulativeEscalationClausePercent",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClauseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Term",
        "label": "Cumulative Escalation Clause, Term",
        "terseLabel": "Cumulative escalation clause, term"
       }
      }
     },
     "localname": "CumulativeEscalationClauseTerm",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Remainder of Fiscal Year",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidRemainderOfFiscalYear",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One",
        "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability, To Be Paid, Year One",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, liability, to be paid, year one"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiabilityToBePaidYearOne",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "label": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "terseLabel": "Lessor, operating lease, liability, annual lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementMilestonePaymentsSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "label": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "terseLabel": "Litigation settlement, milestone payments, sales threshold"
       }
      }
     },
     "localname": "LitigationSettlementMilestonePaymentsSalesThreshold",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Total Consideration",
        "label": "Litigation Settlement, Total Consideration",
        "terseLabel": "Litigation settlement, total consideration"
       }
      }
     },
     "localname": "LitigationSettlementTotalConsideration",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LossContingencyGuaranteedMaximumPriceToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "label": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "terseLabel": "Loss contingency, guaranteed maximum price to be paid"
       }
      }
     },
     "localname": "LossContingencyGuaranteedMaximumPriceToBePaid",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones [Domain]",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Milestones",
        "label": "Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestones",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "krys_OtherContractualObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other contractual obligations.",
        "label": "Other Contractual Obligations [Member]",
        "terseLabel": "Other Contractual Obligations"
       }
      }
     },
     "localname": "OtherContractualObligationsMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PaymentToEscrowForReducingLeaseRentals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to escrow for reducing lease rentals.",
        "label": "Payment To Escrow For Reducing Lease Rentals",
        "terseLabel": "Cash contribution"
       }
      }
     },
     "localname": "PaymentToEscrowForReducingLeaseRentals",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PaymentsForSuitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Suit Liability",
        "label": "Payments For Suit Liability",
        "negatedTerseLabel": "Repayment of ASTRA build to suit liability"
       }
      }
     },
     "localname": "PaymentsForSuitLiability",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PeriphaGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PeriphaGen",
        "label": "PeriphaGen [Member]",
        "terseLabel": "PeriphaGen"
       }
      }
     },
     "localname": "PeriphaGenMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PurchasePriceOfPotentialBuildingPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Potential Building Purchase",
        "label": "Purchase Price Of Potential Building Purchase",
        "terseLabel": "Purchase price of potential purchase"
       }
      }
     },
     "localname": "PurchasePriceOfPotentialBuildingPurchase",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Sale of stock, aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Sale of stock, remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_SwitzerlandLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Switzerland Lease",
        "label": "Switzerland Lease [Member]",
        "terseLabel": "Switzerland Lease"
       }
      }
     },
     "localname": "SwitzerlandLeaseMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_TwoThousandSixteenLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen lease agreement.",
        "label": "Two Thousand Sixteen Lease Agreement [Member]",
        "terseLabel": "2016 Lease Agreement"
       }
      }
     },
     "localname": "TwoThousandSixteenLeaseAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220630",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r187",
      "r194",
      "r219",
      "r220",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r386",
      "r387",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r187",
      "r194",
      "r219",
      "r220",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r386",
      "r387",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r164",
      "r170",
      "r171",
      "r172",
      "r173",
      "r187",
      "r194",
      "r210",
      "r219",
      "r220",
      "r253",
      "r254",
      "r255",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r386",
      "r387",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r164",
      "r170",
      "r171",
      "r172",
      "r173",
      "r187",
      "r194",
      "r210",
      "r219",
      "r220",
      "r253",
      "r254",
      "r255",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r356",
      "r386",
      "r387",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r127",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r12",
      "r13",
      "r274",
      "r361",
      "r376"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due. This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r9",
      "r159"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r33",
      "r34",
      "r35",
      "r378",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r279",
      "r319",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r265",
      "r266",
      "r267",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r222",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r11",
      "r71",
      "r112",
      "r120",
      "r124",
      "r141",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r277",
      "r280",
      "r298",
      "r321",
      "r323",
      "r360",
      "r375"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r71",
      "r141",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r277",
      "r280",
      "r298",
      "r321",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r132",
      "r148"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r129",
      "r133",
      "r148",
      "r364"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r131",
      "r148"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r73",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r63"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r64",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r58",
      "r63",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r58",
      "r299"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r366",
      "r382"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r174",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at \u00a0\u00a0 June\u00a030, 2022 (unaudited) and December\u00a031, 2021; 25,664,287 \u00a0\u00a0 shares issued and outstanding at June\u00a030, 2022 \u00a0\u00a0 (unaudited); and 25,207,985 shares issued and outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r37",
      "r39",
      "r40",
      "r46",
      "r368",
      "r384"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r103",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress, gross"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r61",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r61",
      "r157"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r260",
      "r261",
      "r263",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r91",
      "r92",
      "r93",
      "r97",
      "r98",
      "r287",
      "r288",
      "r369",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r47",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r91",
      "r92",
      "r93",
      "r97",
      "r98",
      "r287",
      "r288",
      "r369",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r100",
      "r142",
      "r207",
      "r208",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r286",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r319",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r365",
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r289",
      "r290",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r188",
      "r190",
      "r191",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r290",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r188",
      "r211",
      "r212",
      "r217",
      "r218",
      "r290",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r188",
      "r190",
      "r191",
      "r211",
      "r212",
      "r217",
      "r218",
      "r290",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r188",
      "r190",
      "r191",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r309",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r149",
      "r150",
      "r151",
      "r152",
      "r189",
      "r205",
      "r284",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r61",
      "r156",
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r162",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r44",
      "r111",
      "r306",
      "r307",
      "r371"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining six months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r71",
      "r121",
      "r141",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r278",
      "r280",
      "r281",
      "r298",
      "r321",
      "r322"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r71",
      "r141",
      "r298",
      "r323",
      "r363",
      "r380"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r71",
      "r141",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r278",
      "r280",
      "r281",
      "r298",
      "r321",
      "r322",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r58",
      "r59",
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r38",
      "r43",
      "r45",
      "r62",
      "r71",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r90",
      "r112",
      "r119",
      "r122",
      "r123",
      "r125",
      "r141",
      "r176",
      "r177",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r288",
      "r298",
      "r367",
      "r383"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r112",
      "r119",
      "r122",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r312",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability",
        "totalLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities and currency translation adjustment",
        "verboseLabel": "Unrealized loss on investments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r50",
      "r52",
      "r130"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.00001 par value; 20,000,000 shares authorized at \u00a0\u00a0 June\u00a030, 2022 (unaudited) and December\u00a031, 2021; 2,061,773 \u00a0\u00a0 shares issued, and no shares outstanding at June\u00a030, 2022 \u00a0\u00a0 (unaudited) and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r56",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from insurance settlement, operating activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r8",
      "r158"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r160",
      "r323",
      "r373",
      "r381"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r160",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r273",
      "r357",
      "r406"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r208",
      "r323",
      "r379",
      "r391",
      "r393"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r142",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r286",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r314",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r229",
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Surrendered or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Surrendered or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Restricted stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r228",
      "r250",
      "r251",
      "r252",
      "r253",
      "r256",
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at June 30, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares surrendered for taxes and forfeitures (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r29",
      "r41",
      "r42",
      "r43",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r100",
      "r142",
      "r207",
      "r208",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r286",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r319",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r100",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net, (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r207",
      "r208",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r207",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r71",
      "r128",
      "r141",
      "r298",
      "r323"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r193",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r206",
      "r208",
      "r209",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r324",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r14",
      "r362",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r14",
      "r362",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r189",
      "r205",
      "r284",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r72",
      "r211",
      "r218",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r101",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r313",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r88",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r87",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r410": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r411": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r412": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r413": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r414": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r415": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r416": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r417": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r418": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r419": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001711279-22-000047-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-22-000047-xbrl.zip
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M%?D7-INF??+76FAG[P_70,^#\5M_MD+?5-+7L_#O0>/S7VLO.^T^6&]6O[J
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MQ%.C1-#81NDC01SKY<W%6")Q3#-!@EH;,+?$"8:]U(R3")Q#XRBU,[1 C+$
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M$+;69S\;]UADY)<3V='UI\"\M@&)S,F8I@NTS92U,0N:2L:YBYRPM:W#00/
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M[KGLY<DBOX;I3VO!HS3]&9O^P]WQ!I-(@(7H2"$TT,:GS;0H8X)PH"),0UP
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M389:YP"G5%//24!44I _&J%>NO6F"/7]"?6T_88G3@E(-M**")3+7",3$T9
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M190*UAGN>7#2*F),5/D0H21:LZM![HJ44?/0K@#:(H#&I@ -QR1@$Y*(,>^
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MX;C_>PDP]&+UW;JN*Y=@3!,GWVC2<31)K.J]LA?J=.PIF5[48AN[^"OJ+A&
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M#VL\NZ%^K\'8Y5P@#EXMUV-7";_CJ',I;_+#:[+S)OUN_;)60+>L"MZJF*E
MB8I2T105 QSC4B5#.0<-._?N]U1J^H7EJMLK?0*/,>QML?RPJ83CR3\?&+=?
MVW[.B1[\'?LE@+<R 'TV!FCV><N?[?[Q_GA_[\W1]OD[OOO'SN'VI_>YLPZ
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M3_P$-+I&1G)?AYPWW VH7JE/"2=_U=NOUHB#XF'(5=2_W@25+WO=>X/CU7[
M#7?SD3AY\8;6H=D[;.;SV:_'?<!RYVFK_$V+(W&%X>$RQ^LL@RUX2=Q:+=5A
M\1O^UTW>9/(-2D>_E7J%7Y9H]VP<U51R(CUGW.$\UT(2Y35W,41KK^OGC3(_
MPPO#3_-I=L,J]S>G$-PLNL/6TZ%<S7KZZLG^^4NX[^=C6 O9^?J.[FX='FZ?
M;__8/MX_V]W[\^L.W:8[GU[SV5E/.^?_^;J]!6L[SD-D/U)8&SSO]?GV^>N<
M[B>VC[?9_OD^V=\[3#NSPVA??L',:B,Q0]A*C'BR%EEA$H(MS6.<@N))@KZO
MVP3KN>#0G YX!3PMP?>WT"@;R%@/R-""2:J)$@)+#JSGG/9!!B89)<$+?DV'
M^ 8RG@ RSF<@0W@=O%,42:LEXBY'L:+0*'&9F Z8A& W7A#9AEUM(*.!C#M"
MQAV3DAK(> +((#.0(9T1E,B$4G!YTDC02%MN$8X:*Z*L9(1NO%"ZC54#&0UD
MW!4R[IBDUD#&$T &FX&,/ HB21M1E,H@3HS/AHE'03E-C-#)BCR/F+:)XH\*
M&<_>C;L5N[W2Z>+^'+GL)#<U/LV)3/?I5[MGWURSRL=?Y0,%#B=R)B>3+0E[
MFAJ/(E>?9DL07"GZL-UP:;[GRJQ]LE1KG$D[Z<-=-+I[<DOIPBU=J#VMGNZQ
M7(K\'=VB<PFV([YY6;'-3BE<V4TEQ7:P>Y&%7=)MGW4J_./J))TY9ZGBV 8<
M0">QBB">-)@QV(!!0Y@2TB<KPU4C3Y^26^H<[#FF:?CE ?G%,B%3\@(%Z2/B
MR@9D8E3(4IMH5"10BS=>4-$67+2)5-=/65P<D7TR@_AGA/<[NK ;>%\9<9UU
M;#/&C(E.(TXY@+KP/L.[!0LT:MA;Q1G5*\HM#;P_ ;\H$XE@*J  QS_B.G<Y
M42XBK),D1%KL>01XIVTXOMM2F ;>UP#>[[L&NA'8IQ/8V3 $M\HP1A)R6((^
M%B1'1H)Z1JU(/@'@N\!6E%\:=>#1N27:8"6P!$H& [=HC!%L;D#2!J%\3$Q@
M6[1W8*DV0%@#[VL [_?=OZ 1UZ<2U]F $7$VZ^T<P<Z""B_A)QLC1XH1;H34
M42:RHMS2* -/P"])42LU57EVH01^"0HYKAABQE.18">5\0#OI T,U%:$K "\
M/U+H\4GA_/=14&1APXY2N#L5C+A!(OEU\:JZ8F]!R.KR@-9OSR<)Y.')L]H*
MQ)69):->)O?KM:>7)I@L[*'20/TR4'\VYX=GS%$C8"]@NPSB>0B93<PASG7T
MA F-N;]"-5@!-J@UA(81[L8(*EGK/ &SWU@PZ0A8<\9JBZ(2DA#E'&.Y&]8F
MN8$Q=UF.T8/#Z?T:ATLGA#2':G.H/LRA>L=828.F#XRF\X4@-D0A"!+8Y70(
M(Y'+_C+JC<C'*O790;;*C-!H5_? !HH'A3'%B%D!.A5C!#G@ X2)8,F"]B.Y
MVWB!-Q?DZ3:':G.H-H?J@QZJ=XQ/-5CZH%@Z&W-B.KBD$T$$(!5Q,$J098DA
M./2$# XG?&6$<@78H-&M[H417/9"6^"!)')N29F@0SU#1 !3& 9JEC9YGL:"
MJOSF4&T.U>90?=!#]8YQP09-'QA-9V-]3('UZ"Q'8*:P?*Q:I+DQ*/%DE6 D
M&7$[2_71&*'1KNZ!#2P5L.N1H62(!S80"N4-0]($&P03"=N4W;_\.1ZJ)7C\
M[](8?L' L?$8LDN'4%\]>V#96='7##IH)EXO'!-%R$R9W<2?-Y\0Q_%X0MQJ
MC\E>N?EU_*GFU[VQG?Y_[-$I* 3C&8(K,DH#;X^&C!Z_.]_9>O=C=^OW;]O'
M>01&!O;/ASM;.U]WS@_8/@6PWWOS=?OX[8_941J?M[;AWJ_Y]A_OSO:/MW]D
M8-\Y?HVWZ3;;W0I?/^]])-N?ML_VO[Y).WLOS[\02@-6)"'O-)SHU@EDL"5P
MHH>(F0TRR30[PRY0*1C7R=$D.*'$)$J(BD[9Y%S4<G;T1B9ZJU"]];8[@-_5
M,SZ7GE%W[8,?>D;+F'U>#@9Q.'C9#7]UK.L<E6%+VV7T>@R[W?=Y %.>[ 87
M[/2Z_=$_L_(Q6*7Q+4_!<_@+I@:VT2GD54XC$,0@$[Q!#FOL#/82<W7#J;8K
M-7QPKTQB.CKJ?2_3\_(^#UJ#P][WR6&J__M_:4K4;WG4X."P7?Z<&@>5,[:N
M'C7MSHJR6T9#=X>M3IGPE$4*;C:,![W^V=5SI+:BCSE?LOZ(M!=,EFK]TIGH
MWOVO7R]5,&ZZ%P\RD.EQ1_K T;R)J^-YV9D^E&V"L73OPUST)L</,7A&L,N?
MV:RU6>OMUVKT[48:/?Y:"0@[N>V"GL]B^<UXZ_;M9QYSRI&YEV[M*S>\:?:U
M%H]3&(UI:MUPW,M=V@Q=WOQH38GWR^F=YW7\3")R_3B2Y6>1/.7VOSSNP5K.
M8P M?C"\E_>^RXBI]2+>'_W>8%#4_X]@"L-ZSNO!<7_83G?0$/-^B)D;:<:&
MFDO*]<%!/QZ U=S*GIU"Q^+>:<BX%!E?92=&=BWD'PH57U]X-%::EDLU/YSQ
M/CP!H3\<PCF$X/''5[<Z?/J5;MO^MUA<+:N^T@\7GK714N]U%6)3BQLL9$%L
M+K,R8IMD@7?*V4',=P#-E/SKFI:1C9PMS1-_];H'C9@U8C8A9O3F8G8;\V^U
M:\YO*#7QGWC4(@\_M7"E:+'V(_\::C;4;*C94+.A9D/-AIJ/3\UUF/E^,P*-
M_4"S62VK/YGV9B^XRO.?;O8&2TU_"C&*@&T*B8<DX!VM5AY;CD6T+'QY>]F<
MN.FDN<P5+[LA_S7A%GPY?&7[_3.@6O&XKL4,J-NFR]7Y^I^_?=X[H+N?X+KS
MG0Y\_VQWZRW?W]O'G_?>=[;W=H[S??:_[HNY?/WC]T>[6_OB\_%KMDWSVM[R
M[:^'ASM?WQ_M_/'VQS;=_[&S!>_V]6C1<%K"&)<4!R25B8A[SY 3E"(><QIE
M2)3XE%NTZ;:B\QU;5JS;9H,=3W?^:4KH;PT_-/S0\$/##ZNK6RRH\FCTBWO4
M+V;K 7DRG FBD$B:(^Y,0L[&A(@.4CCO-)&RT2\:_+@__*!1R^ DCH):SIBW
MS@MO&'>),)4":6R35<4.,=O\3#FE!4M($C!0>(@".0[8$7P@2I"D4V[0T6!'
M@QV-+MKPPSKSP_(9 #[&E%9@X/7-2/[AU U[0WMTJ8.<7O^N-PX5W'RHRI/1
M8PEU!FP@;6BTDB?&2<*&)\DMIIQK0JBFC3JSFNK,ASE7*T\B:A4M,D:3/.PH
MFT+2(YPUUDB9D<G>4IVYN]#<'.0JH5DNQ#6-5C<8DO13H,!-#J)F9YN=;79V
M=79V94[NQI'YL*?WK"-3>HY)4"Q/HLT#3I1$.EF"HG>2:L\%QZPYO1LD6!C2
MD!J')%-P$H0_18 %QAT55! AO&A<DBN+ K,N2<LE-I8X)#V3B%.2  6$09*F
ME(BT /FD08&?" 4:3:_9V;7<V75,+;VJMHC>I+9HB93EYM+FTML(SJBE')S[
M\>J[-U<V5RY_Y2.%BIZT5J!W?!S[OF./6B<V3R2^0]3H=DK'FJ2Z"$<Q\2((
MK@7'0;F4E%%<^"2QB^3&J7(O1TU%W_3Z'\ \W(IN>%&4/>YPE!L<E3ZUC8EY
M7R;F[GQ&/E:*X"@\"I(:Q DCR##.D)>,:9$H3E)LO."R382Z)POS40?*W)^U
MT<CVW67;^]/CTR,[C*&TC[KH')4[</T>0<[CGOW1R/1R,CTWQI-C'P(F""NN
M$;<2(T<XAY\$IM)(IJ+;>$$:<5XO<;YRKM&*R7-N M?(\RWE>79TG&:"4Q$X
MPIHXQ(VS2)O($9,A!*NT,)%LO!#L+B-M&EG^V8[F"S&>%NI&W;Y'49Z-ZXI$
MO"4&]&NE\SC0Q)%S5B#%#&5$DD04KM1M+)KS>;UD^DXN_&:75@]YO> N<L<M
M(S3CK36")1J#3MY9YVX<2&^0]RD<'=NCG%B@Q?;YNR\^>.-AKY#&0B%.@T-.
M,8\"2=HFK'TRIH'>9R_4F&.07T:Y3H9'H2T<O,;RK$E+9ZA_6*%.G1\QH//8
M[S7RO*P\GTW+,[:,12D$BLZ#501F$7+,1.1=DLQ3YDTRXT/YF0GT_8;3GRSI
MX56O?]+KYZ[GKM<-ES?HI@O?[/E!4TK.*)(4_(\+1S2.6BN?&/=>AR2; ,O*
MX]1\'0Y-20H+:H=21 !,28U,C 1I(RPE OLDP.(SJJWQ_)#B5:H:; 3RH03R
MIE&11I&X#P&=C98X)J7$%",FD\DSQ#G2P6E$76*)$2V=\+?4(QH)??! QU.+
M:!/HN(,HS@8ZI,,B>5#IB=<6<24LTLXKY&(P'FN'E0657IOY7/?+(AV-!*[K
M&=DXR1Y! &?#$T$Z[HE.B&%&X2R4$H'0<<1!B_7:!6V3!&55M@UIE-55B2DT
MI'WPVEIOE(V.>BP(CQA;9HQB.@JF$TU1-1BWPA@W%P@0*@9)G$4J:@?0YC5R
M26(DJ%:,*TDMM:!EZ+9>D%+12.*32J(621H"!U/BB4O"-<4!-@2$4RO#FF2(
M%9?$&1=^9,08;1BBE!#$K8_(22R1D2GE<(R6(H$DMK%<,B+7--2Z5P']N/EA
MLW70@^5TCV-WV+('L>O/6H.QF#0U$Y?@E>$X:<<LH\%S&Y01B<=HHO?,4!U-
MX])?==S:WGLYG-4@&.8V!B.0<ME,8HH@&Y-%@0=#DI?<*;/Q0JDV(TW11"/<
M37A@K81]1DD)*G%,LA/$6@/"[@TH*:"I<"P\Q3$0&_!SS3-X]M*^3*CAJ<6]
M"37<1:QW9LYPZ9FBA!.$C?"(.Q:192X@JS7W.!+'3-AX(4Q35;$^TKP"PMPX
M$AY%F&?.:(ZC$TD(I+D%A9QHA8QD"5$C#8U2D.CAC%:RK2AOCNCU$NJFK&(=
M=FD)Z+6$.^&)=UPZSH.U.E"O*,:6**Q-$S%>:>C=KB+& +]OV?;7;?P%6P7'
M)HDH'Z6(2\R058(C'PSLL,[I 12PE[2U_FF=(=-#=Y^E5">"G351@F+EN?/6
M&>)B%#[ JQ.AFACIBDOU]K14&^,HBXHADZ)"/%J.+&$*">FH%)(J1MW&"][6
M[.Y"/2\=36W%HPY!>49]-)= +"*$U,%K1C7C ?20F*R+EAEKF'3>-;&9U4>N
MU_.Q&<DM-Y8@RB@&4S %Y# 5*'(><ZJWB\9OO*"4M*FF2T+7$[1974;O:,3X
M <6X:5WU,.([Z\GA!*=H<G,;RQ!/#",KI4!6$$6(4D8RNGSOJD9P5S&@\M22
M.Q-0:4[E^Q/KV6B+=@2,04(06 \!<2T]TE(:A(-)6.'D+,<@UFW!Y,WC+8U4
M_T3'<>,'>!2YG3F.&8'SF..(DO0>9=<.,EI+Y!+&ROI$M%5Y HEI*[ZL(Z 1
MWY4*H33;L8)H&K6)DBD9HW$<@YR1$(S72H+\I27&RS=H^B3&S6RL)!#*M%8.
M>1PTXAPP51-K$251!<:\LCP[)[!L:[YL$ZI&?E=0?J46*20G%!&8)R)<I,ZR
M0+UD)CC<U*NLN/S.1$4PE81)(U DEB-N1"Y8(0PI$0+CS'G#&9@QM&WPNOH6
M?X*)'WN+XB+7O5^]0=6Z?V6P"Z%W"@)Y<Q!;-3+\U\.2X+D$MBVE,EHJ ].6
M1Z:L3(H22XT/F 5U;;K*M_[9H,S2G!VDV0TSCJH9C)^*'#7 ?G_ _G8N:&0]
M5PIX'(7$!.(A4F08=2C0I+ QR6F3IZ!PW,9+ _N]2-,39[DTX-B XX. 8Q-\
M>U(8G"UU<HG'8#T2,M<[14^0430@PG$*7))H?;R_P3$- #8 N)H N$P0\ZD1
ML EB/A@\S@8Q%0"BBI(C1W+CF"0-LB0R)*G%CD;8>"Z7#F(VZ-B@XWJAXSK8
MS@T0WBL0SNB)D@J+N:9(4Z%SRUR/C)4.84X2%C$8IT!/Y$RWN;ROFH\&#QL\
M7'L\E$G+/$[(L:"YBDH#'@9#B!,1:^UL@X=K@8>[L[T$E":)&8D\\1CQD!C8
MS8&#&0TH*5RTL,,Y2T:W%9WO7=S@88.'/RD>!JX,54(3S!-7+KD4 DTDY6PS
MG$2C'ZX''L[EN5!JF-*@('*O04&,.,?)64#*<DN\]%'S>-L\EP80&T!\OH"H
ME18\&DRYY* Y:!V,C)IX$C3VUW>:;@!Q10!Q)G%(8B)C( R1R#SB*EFDI=<(
M[ $7 UC)B81;)@ZM/1Z6C*-_#S,SPM^A\\^+_X8_1O<ZMOV#3K=*C*+3&.>!
MLV,?;E.^.Y-)!0\^LB>#^.OHA]]"9W!R9,]^[72+B)8O_5;?OJ:2.)G/HLK/
MJS[^[7LG# ]_-6:32I/ENDZ3JA]<?4HVB\C/[%+U&:6;!HM+/\:;Y-+/KKJM
MWN2*WNJN5W\FF&S6VJSUWM=J-K%<E[42O(E-LUA^,]2ZW]X93]MU;-&9>_%.
MYB8O51U03_-::N%K;44?CUWLMQAIMT"5))>_X9W2A%>4*+?;Z^6+&%;HE1?S
MP3BWM)632^_KU2^M WF.)"QY&/_M^O]^<9&,4?Z9<](NGXC0D/06),U)+E=,
MF6AH>H6D'QSTXT&>L?W&=OJ%FO^Q1Z>Q(>8MB)F]*BW;!=2$'PHM)WPL:T#1
M*[6L":-[D9']!.3^< BG%(+''X]I.^L>6)&5;MO^MU@\"JN^T@L78&NTU'M=
MA=C4X@8+^>VD-^AD[]:O_7ADAYU_XF^9FQ';) N<,,X.8K[#QHM?R+^F*=Q(
MVWUQQE^][D$C;(VP30@;O;FP/?]BTDND)OX3CUKDUYN<_M>XZN\78%;:D+YU
MF^6&F@TU&VHVU&RHV5"SH>;Z4O/Y1(K&/B&??XB7^X,6O-I:IVX]RP2L)(VV
M 7N99YA$0K2AT=A -;.*8E,U7".$,G)U.6?FBI?=,)N&-7QE^_TSH%KQP?X$
M25?'^^>[6["&O0/V^7C_[#.LZ?.GG<[NIS^/M\\__MC9>\L^__'N^_[>GU]G
MDZX^?]WF.WO?X'GA^//7/X]WMMX?[=.W8A_NN;/WFFQ_#=\^;_U^N'V\D\:5
M[!_PV<[YV_.=EU^BT]HS8Y%E."*N(T56)(-HE-9;Z@-V<N,%XZ1-^7R]YBJ-
M%V^P8\7'CS7\T/!#PP\_)S^LC&Z1P[M%J]CJ#/Q1;W#:;_2+^]0OV(Q^(3G1
M6NF$A&0.<24B,B(P1*R.EH'FX95I](L&/^X//RBQ485(+161!YV,-P B%'[I
M@M+&-K;)JF*'F,$.PK3U21*DA.2(.T>0TS(B2YQET5#)1&JPH\&.1A=M^&&]
M^>$:/^^H)@O@+5Y]]^;*YLKEKWQ6"2AW'_2Z=+#J><^L5I1%Y@C!+GGN<;#P
M;YU8",Q*;%CC[%]-A7K<E_%"H:8):QM=0$Y@!0HU4V",4XEP<C0:+[WEX98*
M]1V%YHD[3?RL*'"CD5?-SC8[V^SLRNSLRIS<C2O]84_O65<ZT2*1:"5*SCC$
M!?/(<.:0!7:C6D6O<M_YYO1ND& >"3S(O8+_J!>)\V M\YAHK9E/6CLO&QU^
M55%@UBF>N DQ$8R(2@EQS3 R3 5$F24QH[R/KD&!GP@%&DVOV=FUW-EU3&Z^
MJKJ-WJ2Z;8FD^>;2YM+G7R]Z2;E [_@X]GW''K5.[$GLW\5MOW[ OX1B#P8A
MR0,E C.*)^E=($))A366R6&G;ZK87S-8:7+(YN]VT/D91B@_EHX_GY1OG'<Z
M&8*"Q*#C.QF1D4XC#YR,HR98A3PY!+>Y-/>DXJ^*4M#(]J/+]L\T-O+Q9/I\
M1J89)3XX89&D42(>4T366(V$=U:1F)CTYOZF1C;B_$CBO,P0Q*>6YYDAB(T\
M+R//9-8;KXAA07(D@N"(!X:1=9P@(Y30CB>;E((S^NXC#AM1_GE.Y@LIGI;I
M1MN^1TF>C:LI'HTF.B(XG@/BTB5D"%>("<9PM K+(&MM^[X<ZHU,KX,+M=FE
MU4->KZ2@"1,MM8!#-SH:DK!&*FTT#B0TR+O"R/MC>V8DH$T8$Z<L8B2 $B4L
M14X)B;2#W90X\AA9 [W/7J@%Y=HJE2SAF!N?#,=6^P"<D6(R3#RL4*?.CQC0
M>>SW&GE>5IYG1AX+YJ*.BJ%$!$$<*YE3C3'B-#+C/2-*X?&A_,P$>AW#F9<%
M7_HGO7YNANYZW7!YQVZZ\.6>'3I9(1EP+@;#P'%!C%;21TD J$Q@VI@FQ++J
M4+7[:B[$XIV,RE*!)&4&<:\$<E)2%,"*IQ2SH+S>>*%9F^$E9Q$_?BEI(Y /
M(I!-7.0A!'$V+L*5)"+E0(A+%G$5(C()3 #)2<"*>2],GOG8".&J13.>6@J;
M:,8=I' VF@&6E^1&)Z2E!"EDA*/<A DYYXSA0CE'"$@AN7D\HY' =3T&&U?8
M(PC@7!#".BL)32A8&A 7PB =A$!)1<,CH6!&IZ*/$K/RK6Z>A2"N8)>0YT+:
M99H!1JX$Z(2&<<V594X$'IT4D2=-Z,WKEAJ,>PJ;>];='UPP(D=:E04UGRM.
MD8V1((^=5 SD3;+<;%BTE=0-R*V:)":C!)>!"LVEC#IA2BW6Q*7H):.-)*ZT
M),XXZK$)04<+MK8C!O$D.+(4U V.A;(D8B84WWC!59O3U9;$GZ 6XN/FA\W6
M00]6U#V.W6'+'L2N/VL-QJ+2%$=<@EG.1>&2-]80QREP/.6.>"N$%#DB=6OM
MH?'</QIVS3<QPD%&'K5&QEH +&H2<I[#/R6UC-@<=*2@1*BVI$TV=2/;CQ0$
M:!(*[D/69X,#-G>LX3PBF4A 7(.L:P(&@Q"6:1:5"/'9YA,\>V%?)MCPU-+>
M!!ON(-6SP0:O)=7<!<2(]G"""Y6S_C2B!'M+G/$XG^"2-K43:R/+*R#*C2/A
M$41Y-FQ!L2)<4(ZD-P1Q1[-:[D&4N0G:>PN*N2W*N!!-I?*:R713.[$.N[3,
M9!0<G2=$2L<"UPKK)%(*1FI'E#<^-<B[PL@[%TS1EEL'^X<$"0[Q: DRD0>4
MB%)!6>U$ NBEN"U)4SOQ?(4Z<.L%-<%HKCBA2DOLA,+2>VQY%*H1ZI46ZIFX
MC#94."8LB+)*B"L7D:9@)&D''R2B<7)LXP61;</9,Q/J9@9*<^437MFP7W-E
MPW[-E3_GE<^G>'&904_/J%?P,LUK3-**6>.$#5P%Z1S3F)E@,8M6R%M;#$U6
MQ*/-2MW;'LZZ Q@S"79/(A("0=PGC"PE"O$4I=4Z:*55MAQ(FYDEBZF>HI7T
M,G9_(\8/*,9-%>3#B.^,X6^2"TFHW$0.L]PO 7X2WL$_C91!8FGSK&.R;$93
M([FKF,WPU*+;9#/<171W9DY>8F,0D5EDA,L9U-: Z#J"L'%*"NF-- Y$5\^?
MNI?F,S1B^Q,=N(VG_5&D=N; =9X+9G%"3&F*N"(<&4PL"D)I3VTPL).5ODR7
MSB-NQ'>E<A2:[5A!-%54L!B4TL(:KBFS7$;/B:3!$LY\;-!TE=%TNTH# T1]
MR[:_;N,O&CLCM$C(1H]!"8H:6:D("C2XH"5)&N.-%T:VM6B\#\] ?)T3B3%)
ML<68<PO_$QY+J2/GA 7;=,!><?'=GA%?2D6TRB/B07*YD7FV++?(6^T-,Y)C
MEC9>2-YF:EV5H9^@4G1O4>#CNO>K-ZA:]Z\,-B+T3D$@6Z/E7HMCJT:&_WI8
M$CP7" \&P)H9SD2BG&OEI#'.\N2"]S:E:_L'?>N?#<I X-EIP-TPXXB:P?BI
MT% #[/<'[._FHD))QIPC*I"+W"!NL4 F*(V(48JX: 07?..%P+0MV3U/"[Z9
M-#UQ&FD#C@TX/@@X-M&U)X7!V;1:&30V)B+J@D)<$(UTXAAAK"UVH.'B8&\1
M76L0L$' ]4+ 9:*43PV!393R+A X&Z74)"K''$72.H>XE@0T0<&1Y\D+3J45
MV"P9I6S@KX&_]8*_=;".&X/X7F%P1A,DTHED-$71&P&:8%1(<XI1"DQPK(R3
MR5<&,9>J40<;/&SPL,)#K(1-TG(>..92*TTLH=A1T"&D,OS:_I\-'JX$'N[.
M3>"+ (=YY%XPH!8&GUOR:I'34*,0/$IE\<8+QDF;\L9!V.!A@X>C_)44*5<*
M1X8=CU$X*4T@1$63N*".-WBX%G@XE\B2%*,Q:X082X,XD0D9V&JD"&"A5U9R
M%VZ9R-+@88.'SQ8/M>.4,J-TE!$T1.8X4P9T!J6-8(;Z!@_7! ]G,H.P\"0*
M+%&PFB-.@T?&1X&DDD[YR'VTY):906N/AR6EZ-_#S(SP=^C\\^*_X8_1O8YM
M_Z#3K3*?*(A;?0N4 >Y7:C:I& %?IQN U7]%1)=[WZN@$WR=I-,2&"!C-^_C
M/WZ:-'*3\4R'O</8>M4[AM6<E31O]=N@-3CL]8=H&/O'+2#OMUAH/]$*'WX[
M/.W'5J?;JK%KY_08EN2GP2IJ$R53,D;C.,"2(2$8KY5,&*<42 $KBB7#L\&,
MJ[%H#Q8VA4= #_]K..U_!Y8>Q.YZ@M!1_+_OSSY_"B<.\/SSUC;<^S7?_N/=
MV?[Q]@]X#M\Y?HVWZ38#D/GZ>>\CV?ZT?;;_]4W*1N87+X'$C$6 #<40EYX@
MEVA C!G&+=;89@#I=6/K+-K^"$+J;7O1ZO5;1W$PV!R#R*R8K;98T546J_\S
M:!WUX//KY<G%X?<8KQ8JBVEP1%N9C.:42&T5Q[E(B@I/4^TA:H3JSD)U_HY\
M291IIJQ#&/X$H>(:.1XB$B*%J#4/E+$KA,IVPY5;Z2()/&(1.$M<<>.8,\)*
M8S#3"I[=;.4];>7'LR\N^4 DD8@8# :G9 09*202A"7-A$T@/ALOAM][92L'
MLWLY XPSGUZECTQB)".;XLE \D.,K9W>,+9H:]AK#0_C((*E84]#9QBSEI:7
M.*A^*NGC.5>@E3I=V_4=>P2KA5_DR3B#S%FMC'E9^81/0F?@3P>#;+GTXX'M
M9S#,]Y]3*Y+M]%M@<)S&UG&T T"\<K\%M,UBTNF>VJ+>3E*W?B-.-U4^@$YZ
M@[**7_OQ""[^)_[VO1.&AR.[:N*+M9J++[YB';SFZ?#RKRS<R4K)];#NV%^=
MO25TAH83?^8W*O*NHE0T1<5 #P.+,8'=R*4P%#0'3Z6F7SC;&'WIL']Q\!]$
MY/K1?D,VP4O_:H^^V[/!QK^G:06$FMF;I<BZB(@O_MOUX2D+7NR2NSV& J(6
MTE]L5C;8_)]7X;]W,1*3M6(F.4]>!\7!D*<N@F$O-?ZR5?"?8((N.P@^G)Z<
M'!4QLD>_VR.0U?CA,,;A%LCD42^+V& /GO?[4<]_>VK8/QO!_N=O.^>'WW8^
M?0:[^D#LG+\_WJ:?#S_O^?.=/W8./W]Z?[R_=T#W/[T[GX/]XW=L]X]WY'.Q
MU;^QG3_VSS\?O\G/Q_OTS='G/SX?YB/D\]9.AGWV)0E.O&<>2<;!KDZ!(6T9
M0U9J[Z2A).E4N5@ ;F)XF<]+I4R*QA)- X?]B [V1#GL(\XZMI4;K3CP]@1V
M8=@_C1LO:KJW"N$+Z(%& +@V=TI,<?(,RM4B>MVCGX;WRQU_[0"/=?P-I.'O
M?N\D]H=G10'*3J:3S*!M>.!PC@8/*!NC9?P-VS-\V0WCE?S$$L&_2.:TU=:@
MF L6.#>@"!G)4<(Q@I7(LC]QEL,O83JY2NK-%-/%"Z;K@DQFE:8S&+9ZJ>@E
MJ7=TU/N>M91?.EWX3>\4'AP&__KU4NNW?NE:B2C'U@0=Q"+E ,A0FWE3%7I
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M:7#?Z0MON[YW'/<R:1N8609FYK,2L"1."^-04$P@+GA CA"!2 "CQ%'#&/$
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M0!PV9GLA7Z8)^:BHFNX9,*I<E,67,W)13A^E%&IQ>MII9\PZ:O?'U[+9*/*
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MLHR-WUS0%+A3!.N5X4O5 ^^-UN*RRVBKC+3\K3;?GTFL_&.3P=WMMVP'R&#
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M1[$72[F>ADHMHS+\M?"TW_TC_F7;82O/=P-02P>H6<>4(Y9$Z1D*P5'$#5=
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MJ*GM8571' AU*QZ?=KKG,?;76S!?:.+7LANT>S!+W5[_ 3GP%:=ESG/M9?!
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MQU,0*<X==2T19> 3#R+FK?3:%0.]6?DO#S2WC8%/@.&:-/>6&Z:)\L%Y&FD
M@P?N4^*3IK(R08PZ]K0??QN]^#VT^Z<=>_Y;^Z0(0_G2[Y<?+#_(=*O0_%S5
MV_6:&KQ!,<_+6N=;UC>N5WRCK/A4.%CU'I,; I,KW\8;5[]WW64)VS"*WNFR
MU[\GR=4W7;G!<JZ;P2IUV\O.B0 <*0AL,['YY$O\Y-W+ -:[]].$>:NY8=[S
MXV_'CV6>Z6/M%^JX4U'&5V/*F#/=[U'DY-E/RP?@T7>=E-53Q)_YDS\3"-V_
MB-<*/O.U]39FGGAD,UQZZ-]O-1VWKXTV]R:WOL^SF7:RC!V@D<E&)A]9)E=O
M$VH^^22;^BUHZ0O2CE^&)W88<CO%F6X@S1S=:8Y63_!_YD_^#$7GWL=^M#U_
M5)WQQV^QTSW-)S]WS/N=5=F?J/; 30__8LH**"]Y,E%JRR0G/E@2L35&>^4B
M@[\NG'M9GT+',/^0^E5UR/FB<S_J6@%'QW ONOOF_?'>F\_MO?UWY[MOWO)/
M/S[QSV_>_=CY\??73S]"^Q-]Q:9K!<#GX;D^X<]OX+/';\7N]EO\Z<O1E]TO
M1U\_;^_\V/WG_9==^C]?/NV'W.][NAP>%BD9*06R@5O$M;'(Z!R*Q*(U.C$5
MM5C;).O&+%J _'Y:\TCEE6X>S!U+MC2(^#,@HM ,4\ZH!1WB3#%+N-+>2*-9
MLDRPA3,T&T1\=$2<J4HGG0O!2D0$,RA72T&.*(&"$D3XX&0B,2,B7G;QE-5
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M8I(;00$B%2SY:'D05E,J/> ;H8XX+-4-CN!&<E=)<B<;$'_"N^\.@.0DI9U
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M0:N51(*\3'@7N6:WF*[^E94+F'CZ$*PN5>_"SY9Q&B<LOF%) ^_@F0T\B&;
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MC%EP(SIXYM[<N'72TN)(Q%"ULB)?-N6^;"+0$/C#42&7IJH<#\20DCJ?1\6
M_*(80[5R&>$%1*&@VIVBOIF/D8^-8 Y0PI_!5M+1AS640&VWZ$11\!5&-(W1
ML\%""9RFC*T)#8(:V1@1""R0ZLAU/#:E#-)W# T/[MJ($YE3QO,2X9VG5%]H
M]3C:&P_A\@=>QN!&\R34D^@&$T\X/-*=#YP;YE" QQGGZ@T"3XX'(,4:>1(D
ME<]$K<ZG"1(,/_FQQ"JIG&:"G*?%3B<\5GCF4'3W5#B/=*Y@_5ZLX)BA&\\B
MI _:*>DV@M,/VCC"<R$\#QP#(]'9"2$5OCPZ_WA\](J_7C\+4[??3H!$G*0:
MMQ3#[\@['3SU %4./ZGX2-XA'S%%^%D,T?$1$N&X24!!4G!4W\@0"$55&/.P
M 7&I4EXW/$&"8#H!!IMD^O D!U&DSHR \-',Q!GRA4THL%[9%_AV-$N"T#!-
M01EDJR+D/Z8)41QW.4N(612KP4D=UI*?V^@EY!QVRHO5X0P.?D+1V[6AA/V3
MY< 'B$YN( ,H-N 0C Y&0H&9 C<U/@8NIG+!VH/0</DNJ2,.W&D$2:.B  WM
M@K/%4AE>D"H^I+1A_#13G7%0!3B,!X9SJJJ 1GDVB1-95;!T4,<Y9J7 @IZJ
MT,T(Q+=+@2+K5R$&_N3F+XX9-$G)!L;*9WY4R<._@LF%[<OGR<_-R$X.>?Z;
M!BE"]0UR.8@M6$!/<F@<>T@L5%U*BA_S1"8.4LG+B('>10WX2L4$Q0'N/:T
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MQF"U*. IH XJOR6!CB^D\7C"]BA4V,P!2:M$'"E %7C6])_4 <]/6.OS4Y.
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MRV']X3[!/R&7A&PZPQT$Y3H)^/=.PN0Y!.G8E%:0_$/.E5R9D8^/='X#,\,
M4>EH$K;(<8FU4O3YA;1;>7PIU1G%>>%SM);RC)]K!(G'3]*024:*O]",*<TF
MAZ4#^N5W-/&.N7I><0H8)V"<"2',8V1. J(+WZ:/5)'"\@-'& B::V!/L*_X
M$,'@NBS4]P+W>J7 KTA@7;9P:9R"SQD [3L4J:\J$A5>=VA$XI2!7BO?E8*A
M07)8$$JCO!$-$:9)58B]HB' 84]SAYL8. <M9.E<@W%(OU7"E0W%O6,D53!W
MQ$'5S.''02J,4:A2M69BK?P@23,UB_&<+GK_;M2 V:&E P^D#\D^+01O^>E\
M/:]QB/ 1<%$<X<GLG!M8]&[0=: 6@")?@+^JQ7&1"P@"29BH=#C&U_*%M=F5
MLO7G1A>#[$"/ &5:RG46B(X%(X]%)$ES%>'%Q9D%-_R1%2$,9-#@5+I"3,2)
M1E/ 1:&31\ F*P0F$?)R80@LX;IQ@C("6;-@BA4O)DT0EPB:% (HT?4OX@R#
MRU.A+*EE.>G2,O*@%=@.UQ/I#A!?<&\ [\WFA2?0 &X?9X6:QC,H["HYCD6(
M"L<,SP!^H^DD";8AXH04)U5]/I+&F4::A06@;:]SXP0A[2E, K8U)J^(S;C&
M1)\ !A+XJ U@B[C7Z,,M:/DHPT/JQ-L)B\@FH:!_'GI<>^+1U[4XCX/IPGK&
MD> Q&11$4@K4-"L.$8D 1I^J$T0ZX6/7\SN/ G8OP*$\\2)80W1$>[E_'LXY
M*18\2P4U*(Y:)4$X*,%Q1PLMLV##CHO0= 1J4IC5C=)9=BF\+)5.HZKVR2CD
MNH>5$IG4'QA%$?9^H=OG%<&U.FLGQ="4BV\6?"D=#SDT](/06M(2J6A4#>VP
M5V8&*6U=S$=I!EA"7<]-,0.!1&ZAX^A9,I$"<P<P58&_#43Y"3 89GL**3<+
M6<:J5A47654W:F/300I1$;R?L$+5E_2[)H(KFAZ/]!)'N8;*[A;!"Z7!(X9#
M1OI:D-FKK)I G)_?,$]);"&N89/&Z"!B=E1)/'*1O9E J4:/GY<%_Q31/IX$
M(M;D"Q,Y)KB#2N9(SDPTF4-"'XW[F3!,<1]PQ6@!!8_B 1I8NVZF&!JOR-'M
M#)715&B3XCU")X%N N,'^1S61XF#EO&&N0X^11X?Y["[&$!+@O2K=(A=EB"I
MDK5>C09(9FTLI-XLC7L \R13QV4Y93)+VN%J'4W7/)+*$*PUBKIR+^@;&O*<
M$>5DUR^J4)4\1B#-@=*J$WGSH [NP!2Y#?DF3I" Z42<& B8A;1U&$P#[NZ^
MWE1+B"SK)F;]BQ..$MDVG^3@8CG18H#(ZOW\? FVY=4Q;7[^0U%G> E>+<@H
M55M^_O&8_/-YX>5NG,5=[\6]]H+"VR#^&[@K4HNHG#'BP^@ZQB\^T;FN^9.U
MS!'AWD2]64^U6?!O'F;IXF[Q75JU1^#JU7OTG Q5-JEE]++>D\?=DR* 7#5B
MM$,Q/(>)C).S=VC:@J]99*ZL/(FH]^UQ]PU$&+@1/-LZ=<$@;"RP5Z-4KL&%
M(NRDE^37Z RYZ+K-2PYEAI;GDD#ILD.")4=9A>>V(H2E_"PR\7EL1<3<I>^-
M[E,T7TT]=2[4\ERHP>I<J'U,:ZHEPW=(=*50BP-HLE9O(\TS;:; N'#UA]-/
M%=4+OV$ -*B%^&-O59QG',!QF3V$QQ<K0F3UQCP)#U4#/OA-F55D3+-J.S'8
MI-PILI"+H]GB?I;4V_C(VP@K)$X/>=E223QN%L 5@>"9$]"IZX0Y(5 "B5:&
M1TB,C"70JQX>J:,5QL-\>$P7,3_(1 HAS-I)Q.UXH;B+ISGIA_.47%&<( ?3
M,=A)_,CW&BVVB!-9GDUBGM+74 =[8G!DV,&S>2T6D)D6_-=)<>;,XYH&GTP=
M+P:%M4P0F7*S4987DNC=F3!I#A2_Y&9A?@N1I<5[-?8@_X_K)!@Y> 7.. S2
MB9[*)H]<RI6:I72+THD+/G(Q669<6QJ/3H5I/OXBLFR(9&89MPZK5".=KX9,
MS)(4)K*,M:)>W'R5,[0)R=;[^\CG!I@N46%;.M7A&U+*Y\ S89G-T:!JI#PD
M0E#)'*44#]UG5Y*@WL_'W4]QWK>XH>J@?GDRT-3YRLB"T'=-L#&*>MSNB!_/
M%C:M1@T\X$>QI)3@!J@:7[=V/.9341^9N5@8ZQ:YVC2^K)P8A+>&(;PRYX>>
M,X:V!\$ZZ8>-6I8:Q:OB.=@RVG2IG(&>K8^-EZS+N:)9)6K\BJ2[:A8?GRPK
M4OAJV?2(M*PKB,65!\J<B@ %D*;(T%)I6.5" $4?LAP%#.!Z&Y]P&[6T.*4&
MA%7'XTP5+:.E#3)*]/"=&_AN67+?SWAMO7U/Z@O?BMHJQ^6Y23&*ZJ;DT941
M?-)(S)U$,)UK3 G?SZ0E7AI32J!=GYQ%*#PRKTUZ7LNRUY8F^"Z/-;2,J]C0
M]T;HL94U-3*G5Z:\2;<R%E@\9,T15B)RF5[U)[6QR/TMON)E/O%MQ!+P[V8*
MPT"%2-BW@ Z%^!LF<>AA1$&8'C*K$:%L CQ+\=31(;=(>6Y56AH,S\\5P!L@
M(;"*6,3*BIH3)F!NA';G]S@>3"[%:E2'ZPI\$3<EU@ZWA5F)<CVKZ<Y<#LGT
ML89Q2Z_B!V:XZP5HE1]\PXH9;I)H: *I$(-S+&*,PYN2BJ/AR\GBRB8!E8E2
MF :&("^A'*MJ_G$&YAP"4[E8"$'Q C+?R;5W4E%C2SY<02PX.[39ONKY893I
M"9?D":<&C[FA0W=*G JBA-4K71F83,#7,Z-AE?W%9+;5>=JXV[ M&96JX(H(
MM8#E+30(GI_K<B[5RD&0VECH8)4-G6$@U"=-"@\U97HO4(8>E2TE_-]9C2B*
M!PJ%%F,4#6T3496$1VH88J.<0J+96YSFK1RWQ]* ZSH^2\X-M,"X/%1RI^E#
M?,H4Z5A[EIXBKU N@@BX)<5Z'JE:P5:/47H(Q+T(EGY!T>(D!9L(*WC-V6QU
M-K+81ZQF=25)N &EW( \VQQ<=*?RXB]%GBBN\6>11_[622>;6B0[<PJ,Q9^\
M1HC">40":3Y%L+%_<5JYJM/@Z:TJ9QXH:AN0EI=T:,]1<=)7&^6$5AHL\/-S
M6"8Q2'E&3SC!Q':SE+V6O_P,G#T#AG\=1#1INDGB*XF#?7Q!!2:8WL>_%B?8
M0[/5Z=MXB"UZ1X@7B_/M%IUO5S"/^7>]?JMKK_ZZW3)7?K?NL6:GU1_<[['K
MO^NU#W"P=W3]6-,44>1K[!+4]AUM$8<[/ZWEO3\O07Z<<OEQK.2' :)C@P:0
M]VGULDTWS2VZ_N[X*J,8WJ2CYB8SWGSEA*A=?-1AK:SY7*0Z/$12?0F^0.YA
M_<@F'8"?LV?R-/"\D#UCAR<RQ/*4HU$613[%.?'WM.LZM*8<RZ:XX\TUNH-&
MM[O7G?%J@MLK@C.'C?Y@B_Y?.T9P][?W=U^\<[RS]>+=7>Q#N8?M)E\.[8;9
M62GV'H_8MFCON8_+VNLTVKV5/<R>>%E_*!,-CWH"CR=E%M@F6_'Q(?63!>?>
M[&[;2GS'5,WA[Y)I@QAN=_=[FP[,(E#=5%[*]ARO*$E+/WRH[-"Z1GM;A6+V
MW#Q_N'78;;9]:5I6HVOU5AKQ#[803V-\U73\8])QSVQ8=QD)^T3*A](QM "%
M&RW:K_MR\+U1\'2K(VYJ!],=M'HE,/9*SY>BD1<A54M,>T)R1_3ZRKW>EYQN
MPW%$<=2D$0<9F^H-X1 S+2%H=ZS59UAZ'Q1(=,XT!O+]M_A@50\VU7R%6I;U
M6G9I+'J/-UPD'+D[P9S_M+)Z:<HRF<JIJG66MF\KS[;N9K(E"5O#PZO@WYG%
M?6CY(-I%F</6X+[R 9M.[(A\J+!RO]5?G%2Y45)0;?%$4J;5K0B9AQ4P5J4O
MQ@&T8CM10>!#4K[+0MO;*]^AO:! 5S-7.;^5^H16J5B@;1,A-PG.G6=_4O,M
M"7J!>#CHAF/BL!%,J0Q<5J!$L%PQ0E)C2J[CBJ1,V=9+UOC.0!]QF&<-6 ?3
MKD6#C!>FW6]UC,JH5',P!'XHFJ+08^+H>J%%2F-IEV75' 978-"K"J=R.2='
M,\B*QC KNK%LE.%_T 0II'VO:N-L19"]BG3<&7KL#HNV3H](CIU6^TFH<0^D
M_GMU9' (4O^NPY#M)7^GO6 :K6:T,I&UU\L\XJ^K4VPDBYVK>!'K-TQE%PQ#
MYA*8)T591T'.+WKVL-R+G@L8.3_L*1+/L8N+\XV*:Y%I"3)!5(P0*D.I[RV2
M-?-460@3]IKAW&(/H7LVQWE.JGAW1\=,HVB&IK<7HL9CO'8H14EG=^Q&?V#)
M_F.5,B>JQ##X./ N 7<"9.%R2[0W;+7;Q@RK-":R*TBI>1IO$+X@SM&C IL:
M*R-P%E1G>HL2*1*(>7FD@$6GTX#Z9B^S58?M=IE0]D^'OM^<:<M;J1BNM-AF
MQ1KC?RC)+WEP@07W;^&VEXN\D\MF#J>]C5%<WH&N5;UUK6S$MG"R=XCH%-*X
M0UXNMP)>#*J:OR0U=5,#_^;FC^R[M(<B\#PRWK-QDF/7 %.VARQWXN-=$;S%
M%<9%L!J6:3:ZG8$F_8(L79" +WK=DI1K&6>ZB,OBTDL5JZE7\;:;9L>N-)Q\
M.#&X-'K*"SS5*%0?I\7;S>%@WZ7H7>JPVD54!ZL@9M!LE27ZTNI9C2[0P'W5
M)/@D=ZI)L_=H]-&U[,H&E]H7.F$:%VUD7YA]K3<[^DHK"$GKS5=9PCT4)INK
M87,3-=SIM=4:?H<*WK"S=N=H_4H_8^_J<]]OOA&]CB\G#(A^I&$>[1V9_*E:
M+O*V5]0]QV_*;LXIS5!'=1+8#RDU'XYXE(2*Z7/9O4U@&TC6Q2\OC]_>GQAZ
MNTL,;V/>+A$1BLZ+JOZ]HX(KZBO*^_$PK+./%4"#"KZ+^F]7FW()R"!5C:0)
MTR%UPU@>F:!]&$4YM0VCGKN@"V2'Y-^4/><'6)1OS+&A%A=5[T 43<<@JSO"
M'%)8E-@(&TDP=9-@S-]R%F?,Z!D$I-+^^2WJCZQ @,*="K"KH0L&-%UC_JQP
MZ&+< G[.$5%J *F!HM-;FL$'JNU0I<'SO>EZN#E=+SM"V_Q- VMW.>CDZOC4
MZ(CZ_\5_?_\\.KLZN1I=G?QQ;(S.WAGPP4?Y][N3R[<?SR\_7QQ?&J,WYY^O
MC-/1Q6_'5\;%R>5OSX\EL';>OU/;9]Y@$.GS=S3>Y ?O./=0!'@TQ@CO*6$N
M&A=!^K4^'M].MG7:!WX\_GPMK:F'FT=!BP8/7>#QP(T3*K&[/!1/%J5M=;7C
M _ XEL6'..*4B%*48Q1@U+*Y "-M&&,G^HJ'VDC!U(94(8[.G!GVEG;C9!93
M(^EQ3)@UU(M0PT5&W:#C&W&70A\UMW12IFF&(,)6@$+-$#:S1XTI'&KM2B84
M@24ZD?8D8P8Z!M[%)R= >@A'!>%N,G8=)X2OY(1A[&HX0?S@6T"\*U D =5(
M:X0H4S[A<<EW\5G(7I<QX;FBB!&J3QN4%E\*2-O/L$U=0KW?P9<*9@3"@SVO
M19?MU)GRMF/P?G#-@G^EPXIM]Z9,!QK&-:".T24H'I'#3%#U(-A:QJ5H*,VM
M@65K#$LK0<C$V O$'PVMEE.%>.H5ZNLI<V270$>8-/@P-%D<WJI&928D!&I#
M:TI=_G TB,JNAJ8/"%NJA]@+DCKZHM/%OCD8I6D(K&45I7+DILT%8 [",'%O
MG).(0(DJC4.!8JT:J($N*V+TI!*12QNJDQ7O)&!P<.G&SIA0D+ #"R,<,1!J
MN'N,&S:X9@V^O!F+!#2H@.ES#+3>?*!>B07'H:LX1-5=8F#E(:!.S0JXJ ET
MW"2H,GKQ#? ]H][#)=I?&(0N%7ACZ$:)RV$(F""C?4287OH(2FT8I?C AI&T
M33@0[/4HCAQA*3D@VQO>QS(J(1N7>%ZLG-[F7G8-I:TBK*6BVX[(="$O*JFT
M'I:*NH"-TO#4..X6#Q^CW)DBTC:2BB![>+;9_K_\=%LG^3T%Y)/N*Y[^H.A#
MEH)-)61[D#W4I%K^P:-<'FZ;SL0*/6ZYT*'3-Y#2LO<X^#_\="X'E9+BYHON
M[\NVELAA:P4I>E#KG>R1,7GFEN\@P!S.->08>#"?EO$GR6:M%>W]WBR&CVX>
MLCS[AFTJ"+)0"@88#5XA3BD,:2M2.]:$5!Z1<U;1GJ2GOE;:-G&QI-JV*P$N
M4.3TS"_!TR3>>*/2>PL<KJM!.6%6N(?Z#"'HQ:,?@ N^TUWK[KB[9J]TU]Z>
MGUU=G'^\)%?MT\7YV^-WZ)WMN"]V7.JY4CA?%#1(XI"3U"<,AWKHD^U=> >9
MY>TD8+YQ_(WPKX&=SRG_)U&@R?S[D4LQ>)1NXH)&@?9-9W1H""H(1!*:4XK1
MJ%B?B"-CC,7L_YQJ[4H:7*R)%C>,&S8<NQE&%(D6W\N>(8(Z7K$UKKXU,[4U
M,K+S$HPKPKKDG%^*5EY0I-+L.$VS^Y*]HB>874_\)2&BF7%9V 3'WX3N'+F4
M?6$..W8#(U!@ E.DZJ48H7ZA&,NK5WBAF!CC)Q"TFK"7L<=[KG!E3?;7_^:P
MRBP),1"/-D.CLD/;[R!?=5@PLI"\PMBX>SE)3JH=DKVZ28"#O*SV*D+7:.6#
MT@)M'A.\G,2Y3IS9Q'@Y?H5WEU98WR'4<WQW-I/,SQ@,+G35"1I6"*DJ) @U
MNS?>*^N"AT%AC_9.E)Q$XL@(/03T<Y"QZ4 :DPHI]$-)YJJ)NC$+P5X@7-W8
MSVZIT]%IX"8Q_FF\FT<P2C<UWG5Z7<5%\E/)0<1J*'UX-CP^$8T$-%^OE9>4
MS^!WCYL]Z3REY'=%A&FJ''HY:+W)5JH&A[(B=2= M2$3<,P"%Q:]19$>B9OI
M8-OW,9TC4L@:'C_B+CQ=Y:U\$0W-B%T0+ARREG>5-T3#^&J\70V_RE'D^U!G
M!C"D(M%PJ@ ?KCPFD!3IZA19V+N)I$@P)-60U.Y@]GX&'LUUABB\I><5CU"L
MCWY'G@&M\<19;:&<0CCQDR+QTLHLBU $N;0)&Y/'*H,%N,C%,[$U$&\0(9Z@
M'4-(D=,R3HNF6;10!=QOK!02!V..HR 3#E=UT<0IQXH-06O9 94CY+MRPQP<
M-[P$\9WW+Q'AO'SB BHC3Y&\G7&,C4&B6(NF;$5HG 50'WA%KH/0?JO3/$EY
M 8,M<W@;W/\S<+WCB.(<8? 5$P:R>/'ZQI9\L;!S:VW]]8Y ';%?&[$W5T?L
MMW"C!D=[$^9_'H/ET^CBRC@Y 6?ZZM?C"^/D[/WYQ>GHZN3\[+ZNZ] \VI8'
MRG+O.=U:<Z5;^_'XP^@C]V>/WYV<?=C(H:U*\><-E/&S##].IMP<P11+^ L\
MN\+AF3 >UQ)6V$=V#0+P$\\"PH,'Z5P5A^U"U45QQBV-;4[2 ^F/H+V,)I&)
MC_N$5MZ)LI;4,3O*=3Q7$(<XY$2H5@_X"-# LQ@+"BE["Z^&9][[<'YH[W ,
MAA9KU*+38.,]&$MQLF'P]OGZVXS2<D[(T26AR\]+DS@BD^IHZ02/'C:3A%P*
M/PCU#KV7QV_I>3('UQIH:>H);T^A6[,8$15X^)&PWK- ]D/ 0PD1Q56I-*)/
ME2B5*DI9]:B_UA9#>?8E&YNWZR!GYLZ<'96C1\%CGZ_DRCP="ICP/F[W9YS^
M#C,.2GEKI93_?'9Q_.'D\NKXXOB=<3GZ>'QIG+\WCG__?'+U%]+&YXN3JY-C
M'MO\?'F,7PJ5L(?ZX"R.ECDCFVTRF$$[OLNK,XK>';\???YX=6E\_G1^!MMZ
M=G)^H>WN#[>3.YQJ>\=AP^G)V3'PZ?MC8$\M%6P?=S##!/<P</'@^SOV<H<S
M96DONROW<@,/9/=W<2D?UJ[^6E??>@A7WVP/]\?7ET^#)7.;\ 1,IG[->RW-
MGZ[P_&YF[:UDUN/_^?7DS<G51I)V1[HW#5N#;N<^W9O,=JMM]1^\<Q%0FC5X
M\#9+ [LUL+L'U!!IL%&?D.-ODV <9,1T9^2=;=$NY%DA(#>;WQW]G@YE3G<!
M@=^SL<W3P??V-H*SW'@WZPD?SH3OH&VIYR*P(=<CBG[?E?LQC&5XK'UNFMVQ
MZT ZSX5D;[:V:?ZU#\##CZ5V^":M._7R_4>;%A^<AZF?=!#RFHX_\"H8D[/4
M-F?<O/CYV0=H3!+F_^?H:S)/FQB7;O<Z;?:M8YJM209$\A:7&9.%9;[))\HP
M"UP9*Q_/5^:0\4.@2T9]HHU.VU*5NTXR=B*6-L^_A6PN\]^L=ML"7]>I^CC[
M K3_P(JKGM.NS>DP-<PFC3MK#5-KF ?7,-:V&F9)%G*M8GY<<7R(<SI$%6/5
M3DRM8IY%Q5BKG)AU52\K=<TG#0W-'!B?6Y>MMRVE>\Q.MXWI/R,OGF$JF7ZU
MO&;8[M7ZZ8>1Y8<XIP/43V;[AU5/B\T.??K?MG'QN_768\W7M*A\##\S_N?-
MQ4?CY?&WC$5I@ ?!;V3*HZJ,,SXZT77N7+-7O&[+C\,POL4O9):C2F\,4H1/
M$E63BWFAOQ>(L;SD<BFHM("QA(=G(B>Y&.IKXV7PJIS27 +(H\S-WT"C94YH
MO GBC&%EUDGDMAIP9_56'4VL#/.P[B'KGT*]7=@$E_-& K#\]!);QKQ:^]B;
M]4\M*AJQD(K#;ZQZUAV/PBI]'W9P]31)I;^\@8GJ^>1WX;&M>MB5 &JA7?)B
M-^=@'S$\..+Y5I@=+, (J K(X46N\#*',H.-,>, ,(BA2Q2;.=>B)'8Z9IXG
M<H?%,W32EN]KU<9!/:==G--!&@=V;1SLM7'PEFHO/R'4](DFD-^A0'Z/ KG)
M(=+H,LSNVTXJ5T&<-V_&>;^,OV?*_KPSKW#74T([#Y(2:A:@IWN3$KHL4?(Y
M\C\O3SZ<C:XV1NY9._&G)I]/%2!\ 0&@K,6-D%WXC==!"EP4\7IS+P\%(* G
M@/*XHP&O0>@JV#,.C8+&XIA-G-#GD"Z,'WR("ZB0+(_@)GJ>DV>3.('9;=:A
M8-^3:8&;AOW57]\W[=5J6;W[I>BN'6RK9S[&6&VS\_!CA26P-QNLL/PJFLGD
M#+M=0_:]N?1A7:[G,W'W*Q%X)TYH#FE&![E-SSJIWR[^NKP:?33>G)Q?';_]
MM6&<G&F-*FK1L>/;5XN.'WJ;GG52+R^4?_#J$27&X\0-'V;C>O6D=GA2CZ&Y
MGB,T2/-[YV3LM3'*K_,TXW,5V"Q+0GK[+UL.3Z^]F;\^,/E_D$KMI_0GX[<D
M2"?&98O_$CG1<Q5I[H$5]I#3W0]JKC>XWN#]F/%WR;'#H^1]VKK#LW_J;=J7
M27U*&/91$[VB5F2?WT>4[-:1R/YOU,M/JBT=4_L3\_UYS(A,+43V8E+U-M63
M>O:HV:[%! \RT'F0DWIXHV)/&7+/E4$=^-R+25'@T\DFR3PR$'@>GQC7@<_#
MCQ+5@<]Z@P]LQM\EQPZ/DO=IZP[/_JFW:5\FM0I,HY8>^[*#M?3XH;=I5Z+Q
M19T^[^6J!,KJX/Q!%6#N4ZVE75ZQTK_CV)O#CTDV#7_Y_U!+ P04    " !6
M/@A5;-\Z4%X.   7D   $0   &MR>7,M,C R,C V,S N>'-D[1UK<^*V]OO^
M"EV^M'=F'6P@S]ELAV233F:2A4G8V_931]@"-+$M*LE)Z*^_DOS 8%NV">RZ
MA9E]@'U>TCDZ#[WX],N;YX(71!DF_F7+.C); /DV<; _O6Q]&]T:9ZU?/G_X
M\.D_AO'[U>,]^$+LP$,^!]<408X<\(KY#/SF(/8,)I1XX#="G_$+-(S/"NF:
MS!<43V<<=,Q.9_TMO8#6.720Z1CV\<0T>M <&V?')[9Q?'PR0>>G/?/DY.SC
M],+L=B9GYQ/+&#N69?2Z-C3.N\=G!G1.'.NL<P;AZ:DB^L8NF#U#'@2B83Z[
M>&.7K1GG\XMV^_7U]>BU>T3HM-TQ3:O]^\/]DP)M1; N]I]7H-_&U(WANVWY
M>@P9BL&?Z6*5N'S H3O&Y,@F7ELVV#SIFC&\I(8U]+$OL'T[H>]P:O#%'+%\
M'/&Z+5]+/J9A6D;'2G-R>(*69G/<#E^V .2<XG' T2VAWA<T@8$K4 +_KP"Z
M>(*1(RS!15+7*P"IUQS2*>)?H8?8'-JH4E]\_@" 5!+VYH1RX&>0)Y"-E;",
M<H76 J%"[XD-N;)2"<GB=F7@V\CE3'XSY+>C-^:TVM6Y!LR80CBOQ3F-$W*/
MGM21(&6=UOGY>?M-FEN^!+G6H^ -^=&P.D;7JL&VR RK\Q;?C!AO&S(LAUH]
M&6*\=\J0.[2*;*$,4WUG%<7('ZH5.R%&D*T_KL.0(?MH2E[:#L)5#'\=7'[(
M,77H^X0K?/DD>C:?8W]"P@?BD5381:RU1S2)'5C&%><,#?7?!:0V)6[).&K/
M*9DCRC%B:3>N",PHFERVI+\R8B_UIPO'1T*2&"3#8-7TY.NV0$'N_;(E,:[4
M_F6+"06X*.R;)C=\3E'=A@L4)H*$4O0_OOTV=.NV7Z#8@?OO:+Z#)G6;+U"P
MCS=HO<0>B?< .Y>M:R)RT!:0S[X]WNDR"<4T!(_IQ127HGPV18(G_@!CF; :
M0&%]:J_#KE$)&'(&_F?U>=VV(^0(1(.X9A25\59[,Q<M>AAWG[93?0?Y EE\
M8,3%CDS8KZ KH_33#"'. A\&#N8RF:O>]=6):A1D*05UA%:>1/>B1$,1<9"F
M#B+R(*0/?DXX_/>@S;R.'T(JVCE#' O)=Z+:50YZ/4M?\5X]@Y]7..Z]WI/.
M9&0R$!Y>R<B@+X \T=R90, OZ)ZPK0WQ33CJ[:)KFKUJ=K'D#<@$++D#P1ZL
M\ =2@(.#R%?;$R?V\XRX#J+LYJ\ \\4NC$/'16\0/5&V;&(0:8X_@9#GP0;R
MM7,-V>S6):\[\0LYQ/4:/S;-DTTT+AD!Q6E/]3R@4^CCOY44U16X@J713,<R
M+2O,GC&S7<("BL27-/J>]G7?<119Z-[Y$T(]]? +XA#7R+.J$M1IJ&>*/UH-
MB:]+XB!%'?P<TM^G\?(4>!ZD"Q&=\-3'$Y%#^KQOVR3P.?:G0^%F;%$C5U=A
M17KZ,=:U5 &THL&(L IK2])@21O$Q _:6^OM76FQDC8[9J^3'8_5M2D*G.C3
M85BN*V $Q^[VU1I1U2FU:QYWWZ?4D,E!I>N=OY4X^GY6^@A[TGN/?S[$W]I6
MD4#=,(X]F?=_8V@2N/>BLA?E19\QQ-ENK*0.:[W5G/;4=-?F5I,"3H0!H31
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M:K$$B2;"571,/'3*"?Z&Y 7@R.F_( JGZ.8-41LS-!1# ;4 '(M! 6U^V9I
M5UY/*2^I%=;Q_23PL:LVP%ZV. WD_9CRHNZ+.:*8."-U@Z43T&C2@PF[X9@'
M\MNOE 3SRU8(CCGR6B"\\#*YN5L245+>B;>2U/)VW&R7EUY6D.ZK4-*HJRI@
M;J&-#K^8"4AJ!V/5GKBU(2GIV?QIA79&NAJ1&V93\GI+Z*-PE7:\QO.HIKE9
MH5U412]O<'AA-8]?C<,9=-$1:(QY14V'3SSB"_=-%U6TO$VSEGFMC":B$R8(
MR\6J1Y'??I\A5<1[MX/)%B)5Z.5[Q!A"JXN'\9ZKQ8A<H2'$3G_"$?T#07I+
M EK8:9N0VMSV;(J<W1G?T(6V>J34S!Z0-T:TR*L4 .]0OP[Q(/8KM"/:83>D
MR!8Q3UX(VO>=Z^ACO.VN4*,5L9NJQ'!7(_%5TP+H#L8NGJH.+U%H!<0F*#?G
MY(S0SQ<TYLMC*<F9E=OP'$VAKC<CUM#8(8_<+M>)%[\&4'ANCI#S -_D#@65
MSL0NJ=BAU:/2T+YX>L7\;T0%*T>Y9+WI%T'_4^V][Q'*\=\RD#.^5>-?H]Q0
M[3]@5Y32 IY]4=U<I/<L7!,TOG$>%LTU]:=3BH3G1G>^3+H9ML/D+.J"PD&P
M:[9;[]N:E<7HE8QF))#3ST_X3;@T7PWVOA!;0>I]1%7L1EB0&*F#< KT$4D<
MT4')2(ZGML50#OQB[U"+1IU&?]=L2+JIP43^K-@PK Y$>5_L$'.!:_BX&FV8
M!Y6J_J^!M*K!9.FI"J7/ ]W1D,,B(9@B6L42I?W<^;(S\0L2-8-?$HD+X9LP
MKH:!R(GMP62"I,LIJ8]R89O0BMR25?[SE? _U.$I 6\C)U/&AG[ D49VBYFH
MAF1)6Z\R?@>;IA9<R7@3$4)O$GF033"(Z\!3D\XOZ$9VM^)V[<* H1&B7K&[
M+$';D?.)D:HT+*K:U0[91<5 7X+4!(7=B]P\+,V?$.?AV\2XXGWG,H"ST8PB
M)N]M*AZFF]!J;+P?!M2>P6CJ?C 9$BXC"72O NS*'RV-WQ?/'U<F\(X^^#[%
MS\ O*7OS()M@WDG\3R_BZYNB16E"F[2+,/?85\D@VV@))X7]HTNL_NAA2,F4
M0D^OKBQ<$W0D,Q9""^;R^[X?0'?EG)$V]:E'J+$.=;FMLT\1'$P>$71OF/RU
ME?AR"]62XOA2G<"V"ZVE!<C;$BNT-:ESEZ=O2HID#493T]4K(EW^ V0,VC.1
MJW'.*LR0EF$U8?A&"S?RW),0PE8YHJ_<C!B.T=4*9:L^)<A-56IJLB:9AHM+
MSY)]%.68#9WDO8?CY$H=O?'F03;!8//NDA]$=\FK?1DC],:O7*&:0O75(;'#
M)O.82Z5E*G\J"\0'2)^1NF=VN=Q0HL<*F$W0:[R[;_#>8Z2CZ!AI16/8.=^&
M6-!7XM]X<Y<L4#K=U]N.'J<)5A-%H%OL"\T([WN+4-6HE8_3U&!UYW,DHJJP
M.YMX*-I1$=_')/1$XKSY*RIN>3TBC4VO\V9?1B0<M0P[*!:JQN1-'GKCYRI8
M_PT75K_K4-O9K.A@3_XH;#B1N&&]NYS1G5%4=;9E!;9!GD=4HY2X<K?3%?+1
M!&L*7 U&4[U._VGTV+^%MJK!2V8G\D ;I*CR.^S*%%>%0E,56;SL$*W:;K!@
MD6#N: *MXFIO/!\D-]L$.%''HFRW<PY"8R/>(V;/TNZ^"5Z4"[OG\6\H+LHS
MW&K(#4E3-UX E>N= [^X9G\_X::.;3$.\7P&?T4EV7P6K@GN6>2B5*KA"PK_
MO_-79WXUR6P9X@]/X-3)("8*3 ]^_O!_4$L#!!0    ( %8^"%5A;(!UV18
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MO-#)$K56+GCI>[N]NO-YD3%Z*1TB<.G)MB/2"?/&0-3(BHN>H+]6-&^#3>2
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MXQFMO6*]M)8(,26'.B>7W"!C>;V,B3:@+U:USF]>1<O)HV1[R7>0\72K8I$
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M=CFU]0_RK>B LY+X,QJLK4ZXX09B0 '<UOFL,<LD'_1!]DOR-P/U(T9"P\8
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MQ/^9A(V#]1].+EXN+EYQ07Y!\?_EP>P 1 ]P)W!I<+ = =A%V3A$V9@]  0
MV+C8_M, _O-@8V?IR,US@)>/G_5 @PC SL;!P<[)\8_6K+M1K/L IRC7P</:
M9[G%+GOP' D2UWF8]?* TKG:3HDKWTC*NK?NQ_#R24I)R\BJ'%55.W9<3]_
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M<S>4-!.(>>3[ 9G:)]OXG$2T)>DU%U >-6VE'KO-&UJ?&M6IZ.@A6R.C4?_
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M:N>8*JZ;HT8\R;G.8["[PDG[FDUDB&5N1R&$5.*WCE<+>=M+>7'MW$C(=FK
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M<"GJZK=V>7<_AEW:;NHQ?7X%W;5QPP+.R"9LGDC?QQ\_=3GZV5N,::LL0$E
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M@+G.L:[&(S3E>=)SZ\2V %?.J%=32NKU3Z8_RM_<F-UVFF+A[&<6RC*!6TQ
M#(DA[L6C-9$C1,6W9/Z>/&A^\.L1B8T,P;*#_4=T5#.S3HEP_;3Q,KI_WZI:
MS)'5TONLZ/JXGR&%99$K7+Y!I<&2+:*#'6]WV;DY\[6'%^IS3W</\7UXNV71
M,>.DD6E-?90"_+7KA[__.EQER JR*%*+8+X<W:Z,%#N?:!K;,[E_T2ESSJ7,
M_?I!G!75VNB^SB_!Y</OR]Q8<99>80(2#'XDH@O7WQOEM]HO*]1:J%Q/;IA-
MN]\\6V'4T2#PIA8 G;N!%J=L'>'Q'7N>TZ0]LRF:X4*;ZD6R9;)K'_104VK
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MI>Z_IQ_X:)J)5VO?B#GXY7%?V$J;$3R\HWJ./=_+"425$(^[..%*@FL[34+
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M$"9?E8Y"SE%X6'G%G?')ROBM?KY$<8VIN,3=3:9VTKF^6/19M0R;G0>0H>A
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MFQDZ[?34J)FB9@)W*GJX5Z'%W%MU_:5%=-HT!13 A['5^/7A,_HM''2'"!L
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M;"K_W;)H?L?5_@1"?'^+1B/=V3M%QL?\]VO*S;EA@'L5L;7K6AK:0Y**-U
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MQ@'<!VAJ&9$-@2?QC/)GH@4ZO-H,T\:3X0H7H38;U1H8UG,'$0JD0XZ!S<7
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M35R8*VT"IHYFV[ !.4[C*^!K29_R6D@_H.(:B;)Z &5J:B*:OA&]WYG*?RE
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MIQK_)RC3W^$;I]^WC"QDS]%4AK"* PF.48 $+X@9E=!EE]7V7R9HL0C<)+*
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MW#$K5A+-O6>06>D%HT_WT,'LN6M*OBZ(W*?J-FA"8$J JVA$?UZ>(4I[QMQ
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MDLIB%\77-$N!.?MNGLNS&1/6SHCPT0S^%-&BS/[>9[:&LHJ?2 $-BM%)RF2
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MJ'!)J[HZ)2BN4$.>1%*@-(^A$\L^("H&F<PA1[+4X\UOEH+/*^ 7<QV%O;>
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MG=J4@3BJASX=*]DS"Y\:KAO.&6"1E21:@V]"/*MH@2^EX;U#[5=;A.6&F?R
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M5*8>8YY;H=;\^/[ZGE.'C<F\T)1;8WG89IZG8>UNB6%+=2+$>0FC=[1A+:R
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ME3A7L*>'4<&LKK8N4F55$)3*T%:533@.E32F4<8H8] C\!'"QI0+>L8WS;1
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ML,A4A.TH<WJ*04L,#:?I!<NI"2>E.V?K>2QT$9]@]E2VC<VYVT=W\]$K@[2
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M]1"0IE3,TPM5/;C;D\#]0^#;@ED4Z2LARK#7-<6["6LYGX>3OG0_9F6LJM*
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MM=U#GQK7)42?K<D_EQ*S+,[Q"!RD.X"K^GG@IKZ9+\)CM?J<&;T#S%DH*K+
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MK'3ZT%'GZO=[?R6)UO-2?Z_*'<O,7>ZC@(Z@TP%,89:UWZN#5Y%N*$"T ;&
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M8@4_6G^3U&^Z'_]T/4"C^Q6!/'OD.!_:%H7/W-0VJ- [ON!R?4R%<<'U1SP
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M<\\-+RQD*@\*1@$MQGXCF2@@AA,Y+'<I0'KUS.A,#07 ^==H]_KF"!K6C5!
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MI,!Q;[<>7Z688F_DVLLJ!WY@:'OC%9ZKP1M&R=RTQ[.=51>J,BZ&TY&B BC
MO2<[YC ZZRN"3_CG"XOM PS[N]R9IUNTR33G(683+1KIK=U13^EFQW;&=%OT
M4Z3C1R.8Q9Y]A0@-ZP'6EZ=/OXQ>8X'M"O3U&RO$NP(<-9?EU4RV8T?IFN93
MF- :#7\(#K&/[0T>B-+Y%,[> E=VT>FI%.&X.>CA=Y.J>4F:O)B9! ''9[E]
M=X,3L+!HX_]SQ75=C4EJV0_O([ TQMUGQ,?]!)(W>EJU!9/)C[L)@L[+ZRO]
M/59S$"^OV0/*;E)A.5:S5SD\ XN-D^)G!-S-8B(JF*>_EDQPP@[#7#+2WQ8-
M;9KB=/QT,=D@L^'9@+$F*$H+!)?182,*D?>+ZF2ON&8#NXH4S>-X F_=:3J)
M%]%;A1)Z .BOCL?_@ -EBJ!T-6=_F-1&CVO6?Q@FG=6" O#0&J=\:CL0&@J0
M8??]\[V\\V@HPZW,6T2WJB9NJ.EK78)@_@*9&W'0<SGT(_#<CR/^.A0 ^S#L
ME$:][TIV]I%M"WC>"T8!<7:Y4$%O$0)RA(75-MN.6\#G>JBC/CAW .CI%[1B
M-,;X"&&&3/WG \=MXW<4-[9$O%@$AP/K'']YI@BQ\K)O(DH)*A^A !&NVS [
M*VC[GNAOU$1B0D/<A@XF[9&>B%4)@IM4D9.? 6<Y/ 4,LS6.$M1;</#N_]MP
M:?IN\:=CUZS4]W<;\*V=>/;)\/%B<.Y+TEJ\?0VY9SKP@=VHT8G,P.Z<,B7G
MLRWE8'D4W[JZ4+8^4V/&.C<*4$I!7('G:BQ669@)?,VF_EH?9*1\S%W*C"U
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MLS;L ZZOPI]J.&JR">#%OXOL@T.@0T?M-5MA2N.@6H<ZALK@"399!G,",CP
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MUB:Z,V3+6'%&,JE\7/@6L!;M-LU/M3++O2_\>9QN7V;T>B#D)X/]!_\I^^.
M=CU :RYB=<E@(J%[Y_S2O48_H'H&"HGD?(R'9HG378[+J=G9\$.P/*'R,;PA
M<16?2_U**["KL,]TPP<$<GOEM25J/K#S;KJ"I/V?DPBR'QVQ;S^.]I7)+\$(
M'V2MD>N$O!--B1]YT'&AD0C[/H0!98^5((UYP<F4(4M+XR I32%B< \-[^$'
M 8>U' /U%EOX-/+^C3[,R<WBB*]B]@UE;#87AFB"Q3M.#%?J8SE[F)%@CU01
MXKXBSXNLE:_ /G"+X.5+*6HL]S*RQZ'WUM>H?/:F@A@F6P)HSJ)*)%-\4Q+=
M.%-=?,SYQLH"?=E<=^JB6*D^K'0VT,=^;5QII^[Q?53=5#E1=A#XC8O>K^BM
M@&HYNC!;C;BK]H:EUD48R<OI;\*AQ;;4Z?7E-4T[:CMG)?6!ZB\9-?&.K]=%
M@DK$5=Z]ZQ6UM0N\ZR"S"[6<**BU<4\[J3S;JY>TX,[ATY=@I356#FQ1N3M(
MUU-:8C=<L&";.J>X%'_V<>Q$^FKFW.%IFW[;,[GO]G0?7:8IVDGJQ+QDX XW
M9^]=@-8<9<^5^;JW+3PTU21CN&NK!"D< <.8-=<\\-AIF4G: YA[Q$I"3YEE
M3?48Z1Q%4G7]!9H7=(EUR%N('#US%Y'Q;6E._$$C_"ST$A2VSYF?P!K/>[-+
MTLM(0G.GP3_SA@6] /@6/RVKZYD&M).7LQ==E(6">09O6C!;/%2@+?;J]81[
M']A^[L:LB9@TG>2JAU]NYM%:Z%R@Z6$,!6_&WB&^@>UT4R1X?:2%Z5PY MQO
M043QL/F#+%W/A&>YA#Q"O,F^H?JF4+'!+XO3\%EYVA=<C<=GJUJTYJ2!!*[.
MWA"A[YA)*,#]Y+**-Y3\^?BK.X=%>M*>\<QSY@9WOOFD 4C5-,_J"=],Z(&B
MG4ZY$*\.K!N:*U-5@JT#A,S>]HP286%(I/O7#7FNKY_8>X 5VC' FY]LG<_M
M[].P.7#DZUR8/H[C)/#N31W'JC!BHZ'OT$ZQ[E+T*^YROWS2=Y_< >^EADV(
M'?9S?G)SAEC"W%R\5JS5I&E:BO$Z?'6IMMC-2UC9<NRDF2EO6J+C"",#GFRP
M3M"]X<4^RK55DDQ?ST(W-_, :_$<4<^?.C^JTJ*^/QC K>NO7UU&;Z; &BO>
M:2=T+',X*97WT"FH'3ME:JO7K&5G&F/\X0@UQ4">'P+$#Y6\P_3@94V%/6)L
M1QA]A3W LZC)8Q3 3;2JBG2Y7OPXU7/MJA0F23:_*IUN*%R?5<R8I)UCDJ%J
M\^'%P_DS0&! -RF; %LR5:A<1\\B<T^7P40YQ_Y)\U9ML ]'CBH3,7;\/;SF
M-]G6>-SG8I=N!I#4Y4%U'3*XX5*&(4U=,1=MOX($M*\Z8*=:\1OV3$EBDIE/
M%UXTL'<9F.9O2MKLYE$HRZ TV*X\'M/ZHU^CI)<7HO63"(_:@;HDFSL24)J'
M@'=]VBYET$L-Y\.7@M&JOW!XJ,R<^AC_JQ-V$'H'Q[O8QD>T^5U-I^T1M>$>
MN)H)@NM/"X22V"&[/8;D=V2D6+$P8H73(2/^N#>A[E)GAQ)7?)RI-UI+/$/.
M2U!!"/>2^&3ABC$A"M#)\[DN=4Y\/",C*H[':OBT1O0C1%D1,>QO'0F8^:=2
M,\+0.ML5&&? RTLIDC)!Z(J"^=.'SF+?2R?[_'6J,E017N52=PX^O&3H$+Q0
M39X_45=DKPTYT>9K7^$<:=_F*P0M:X#69*\9Y\AN,&L/KW'BKH&KD>Q3E]&@
MCS^1M5=TP%L;##^!1H!**,"W(A0 $H=0J.6ZQ+==0I#0(:9['JJ>DJ, SP)L
MS\2G48"0YI<H0.Y4%@KP5A4%B*&#I]H8GU".M\/9)(XJ(EGR=[F1)I?C^P$5
M*, ]S_<HP NP" IP)_^WNEF_M\?XH:KLA/EUQVGAS)4Q\CX,%_E.SPMY5Q;)
M"_IK8]I8\N**>B_>[2E7G65F"\+7.>J5B6Q=ZGE"6Z/I;G#2;M6<ATILFX^!
MX,)<2+8VKKR<6[F=EQ/-=#:@SH"5N$ORDYQK@B@4(++H*9+16^_(DK5BY^C"
ME==ZJ/%5'PU$F7XD%M_?09I.->XGUM27F2LIY(-#/-!([V<48-G=^%J3#I[C
M;8X,%6-& =#S4(#5TM5+EM\&3[R.LW?NCS_>FAQRU45WPKTC@:"Y]5U(C,E&
M_[FCQ9[B(W_\4?::&7H[MI_BY&][N]V.*$&T18KGTVT2@A6J9JZ-VNHGVNB!
M9/Q>Q(;S<J/[Z5@$,>$?J(D[UBF;EY=B:!_#XU)Q%6\*35H"TK<3-'S93XTG
M_+31I;W\!+^RR!OU<HDF9::$307B(P97#LGMPX:1@^V.XH.>+P\D]AMDD(&3
MB].=?(<@3#-$2)OL1T\;:O^F(L9Z%&#\\7F3^_" D:7_4Y/&/-BNEUJWD+A6
MG%M>)/L/D4@!O4%P=K%E8?^&8P7Z1VW;1_L4CGXNVJ694[S TF$*;S^5"'2]
MV2_?TAH ,B=HWH>#[NY_7NG)058E['55]O%&Y(L[%#1!S#C"1UI YIYT_[F*
M4 \1$4M"T;-#2M9'EN%KB9*4_ VJT+DN%^+%A]^K'T.>?[;0J%-X59<P(%W9
MD.200N6]YI*Y$AQD!_ME&KNJ@]6DQY>QJ)SZ6CK;>[5K5K#&8:4ZW\8^7F !
MXAUI"5% A/NXO;'S$ K X\D]_>475O_ZL?"N,?XME*1K.KTP_BRGYKVXUDU&
M=8?O\EK%%P!PU. @9XW<@VI^2R.6YOYD"+I&NG,$'^2F+!Q[XT7GP3#'<9"S
MHHUM-M/H:5%!HO*DO=-:B&,RS%'M!?E6"IN2,&U;:!!O45G84>@[F@UP_IZO
MZZ(A6VL+OA>Y3W+;CO20#NW,GL8)7;@>5@3#Q-BP6KW5^+I[)L6:H";$<B7N
MX.*JEP8?X.ZNS;I*2*,GO;PHJS?B5,;G5)VL N]G"N>VO"LOLQ<ZQ+.@K?U?
M^F3 1;;0'JHU-H=OW9VXM+2HP$#J:\ __4#02DW&*KI$FG:ECPW@*+_:/+=V
M;6TNMA3.BS5^6FI(IQZB_"0@K^? ?SO(F%N)0;+X_!YSYOL.FDL6ON%#A]LE
M-9HY$W*3M=:6D_[SI;_$%)U:@!)5U(VC_IZVSF;5- =L-85 'Z_ME5TY^%TH
MWC?8&O5D^U\'"'V$TTP>AO.!%;0JC[222]*RB5T+I;*QB(H829],TSEOS!KC
MW;,2>F3BCOP#5_.KU7S=^9H=H%];^%8A,QO.S52#$O(\T:K@]\S,^G/GUSZ%
M-^YTWZ?P?;;R MT04LN9[60<@0)&-C_.H-RWWERDL<KH@:G@A^_52H-$$C '
M<K$TC9-!3SJR-@'F7JZ9'-7VK\K,W<(.-UD%50X-3JG//N C]BLF?*DK[*[R
M(K?/F@JF($;#"@;7<$2$UZV\5:\P<;H=$$:M]SHBV=K+[B?41N]5BLP"-OR0
MMTV/]69SO&6+2F?=ZVS1:_D08LBU)ALI_L@FM0UK$O_T8U6M\$\CGY24W#MJ
MO!%WBAFHKP=S[-,O(R.5*BS$I7[&+3<$^3L<T9_)(-[E[<!W&BAEY_4VQZ!H
MK!.,K1'+\>-8ZRSF!BQT_+L[XH_]-:H1%W#F;^TXUQQ 4,":9TK_O%HEOUK%
M# :+*E26[2%>D"LANA"$_3"2]<K!R=1/C,-MI2)RW(92&T9\DW;4</52(C3=
M,9G:B"9:BD='@26&)"L$W<7_(GL-AP"3O?$F;&WR<<O1OJ_UV2>$X5F/$SY_
M6>SG8NO%]<,M*_ZM)9H![<DDC:;4.([03^#.2)8_*71370=VMQ70,ZR6VEK8
M)7N"/=(V M#R<G7V9<L6R23@29\LE^KN'T6@ !TUW#<= A_6J'UBB"Q1@%[5
M;70%E:.8V(Q5(#[!JZQR1\BKJB+N5W*N;X=<<7V<&MYE%18^]$Z$\(N3-8WG
M-LFO^\V^,O^NTLGXM'A37*X3TQTC^F;%@.G32ON#O3G/UC)]!2=+WG.075UU
M8^6'1;/9*FS"S?+%*UR33[WIOIME!C9-6]WL8+LS_CCIZJ\UBL(L'HK\6A\_
MO:#_GM,2_0EZY8/U\6TN0:K6T<2<4HU304.HAU]$>;9T?0)9[2Q_ST*W8R81
M]_ /-# -5[<B" S=29SC2^XFDG*-8(C\,?J=W!4+4$K/VF'Z36BS,0ISDN_V
M,$0S@LXL]+C=663<\=9]Y8K]^KZK(-ZWY9-'T5JY5AFKS=A=]@VC89E^EEL7
M6-/K"4'"<_].H-Z3IHS]L[&!&*@>Z7RF-3J?5.?E]#5#-M78J1/S/@K@6!>[
MU;?8;'6*WR!( ?%=UGZPYL")6T%F,%"ZW: W6)9NUO7E)GMRBVC!"<2#ET_4
M>#-ZGUN2_V;EG4&&MQT*<"71)5\ZPY#N[GNWKDDJ('?!+A@W2,)7M"A+CQDR
M_#%NY1L]^2/:JE+OR-WQ;CW'>$MSFH5I;GF7IXE*9CIY,M(,IE1N]]=PORT?
ML\O*3J  ];PS3N)]'N:;UN=D\1>NY??HGJ^O"0Z/1*[4&F-UW (*X]"*BJ?3
MFMGX-.]VI[4PA?0TO?WK Y:KY1L\T6FZ-L_+%/ IP"<Y.#$@V::VD16R4A<S
M>XO&69'7;]3D[Y3RX#=_$Y&[^W;MT0A6">AVJ^C>NI+83S7>%44!ZGQ 7Z_F
M/9V&EPZCW4OK-GU#XXL& WALM+33?9SP%)PLK/IKU=+08G#O>U:2+V?&V6L1
MA*WLT(^?JEN3S3([D'HS5=;!!R?#YJB+YBR2%U-T'Z[?>:YTUO$D2*PD\MBO
M @NZ??Y"E,^<*<O#9V4@*665CWW3\!U9DN6'T\3-1+Q>+^9L-@OX07P)0N_(
M7R)W<;LIIN79(D,JJ9H>9F/XH61'\$7<!RE!K% )[B$6](FB<JZ5Z,.*&:AW
M@0U#?:)^O&4D12@MN[MA?/'E2@X2R_#+OXV9?K<&-N6EN[=+5JWW9=^N),[I
M<6=3,\8CN'>7UJF%=T77WFK6G3T%GYBFX8;G; ?TP-"='#O +3[$F>[,.>&Z
M!9T$[2NRU^S&.*"1UENL*(P"O'>OU;R2/V=.$8L%(DDJWDML&]WB31I09QQ"
MJ^WA+7SR^PTL>MR*V+')GU/^ZMI;-0CJK(,7WN#.>2'1*Q"J?RW=D..AG_PY
M@<Z94,4?!4BLZ"'4D>]AMY@5;?J:_4M>G*WXR@!M+]]_8)\JC'E!R'QF*Q_A
MM^*MC;NR^#1Z:[,F)FZ7%06 !R',D>\';Q$BP.QV_P;Z1@IM_-;X]DT+P;I%
M@YRV$@CT6S3X0 =*/N+/MXI]2NJ$:TL4D'"F_R)*,';YXT7;(<7P:]@>?5<;
MG3%A;V I=P[,*\$PLYP_M7=@.M,<3'U\0%VU_P(%P":\A<(&MU 8DPO)%(>0
M].=& 5YNWIZ$0=R@([Y6Z7]N:'(+^-%O@3$9;\XUVNU>$)&/)**[1;R-OR%>
M/.-K12=56='FL*=^Y!)_L-WFCR;K3Z@.<_XV0-^-R<H<:I?"YWKJLEJT4D9K
M_1Z_O?-DDX$9X"S$5(X06&X/]S?<^'&+@*UT!"1LF]1P"365P)>$OI?"$H!M
MX*H"V%/A8>/$EJ4Y+PH@^(9%M986"[W"V'>[M'6-,CB:^'ME7U\CM4 PD@ !
MZF@SV,$Z"\UMN2G9QF0+T/3E^GE>OAG)'JR6M+A^X %A8^N[Q2TJJE'%WF_+
M1!7R=UX2[076<*=ZXMBK^)IG;M:7TJO +Y<08:\GW_10=EBJDBZ$07,]ALE[
M@']>F$X7^6B2(.+3DG&9F;H#[FMZ9JI*GNBI]ZK3O%7@[?,4_,?A!MVC%("A
MA6CKAVA,J=X>^,_'MLN[1%E9#;:HDJ@#Z^Q*;>O-E<=A#E).1*^J,"$\M6@Y
M8V6_K(*'R>[]-A5R+\^''JA+U2[B)438X,A].35I(1 VV:*1OI3IQ9%6>^QY
M%'S58"WQY1=&_^HQ6.IVH-SJIL6=Y-V3NSO8T\E6]D8#\V(B/N61.Q;8/4D%
MZZ,=%&^*'GZ0OV+S-%5UY'I/MXQF/>[<.2K$EF.!FP+G4V0F=46_#_IS_S=C
M!RA 0^WWDQX5Z".I?".80UGE3^9TL=>//H*^]?@:2C%F/C"0<F$@;H&'$O=_
MQV4Z;*T]I?AVN[6\;QKS,.3JWK@6*=SE5U7DO;-1X*<UOBFM*>/:_&.W\]E#
M!YQ[FM_I&:8SY(_N9N>L#K ;T@^E;*D*3$W?YR6DKJJ*>TPR'Z'!3@+]),"R
M_D\U2[YG=(HS3/ >4E# *KZDJH6..LA\X<C-^F$__\Z'/,:9.[:1?$N4T/"_
M1D5!LHD"D-?7M>;-=_CQYW(<9+7U>M;G[YMJP] 6XY'J5U7O#6<AV!U\.R0;
M.40MZBM99KMK2I,2]>[S0#*@K;^T-;F"GP^-N+>>5.8!N1K.\_6BE:K8'T\"
M)WDKS,/(IZMLFPUV_)_7NR":M6*IO((UQ\L\69S-=21\B35?1IN^VV+8HB]\
M7;4Z?$'HS87L/ ;MW%VT\G\6.B);O* WOU=-\<5PKKR5/%:A#@ ['M^PC'FQ
M[&,C[L@S:/O7P7W:'.Q\ZRC 2;R4'NOYK>/_^E>\0$&'?U.$?BFH0-_.#,V-
M+FW]34VW% G+WD@PX81?\(OER9+_6R@W9<X0G'6ZL:Z:W-C,8O6AAA^6CP-@
M#L(R?9N@K&:W^+>[6!K:6E5+>H-.SS@>?C=W+M-(IL>*_WX9F1()".X?HA$>
MPM6WZ=:"/^FA!HYJX*%=X&3_:?K;JDRQ1QZ"2[6U^F.'&UUJM30@/NTA;5OW
MM*+&:8#PL-;X1NT$O:X# ^3$\Q$UD>RCR[>29+^,V4R#<Q9[E$B5U4U S#&+
M18G7T>H>1G/1II6G%^\T>62G-]P9XHM6Y%'DG&)^+@!ESJY%<_U5&K>UWB0G
MV-]AI9FE@!7HGLID W]VI4)R'>,^J;2F5/-U LRY&:-WO"#X=H!(XUF7B74V
MVY\S[Y+$K>'.UA[B[C9HC9$7ABXN4@,\*ZEI@69_=JT=]'C$D:%IY&1GP^&X
MSXFJV;=*1;YTDN1/KK9_&1ZP:3')F;HJJN?\\2:BMD8H#)WJ>L%QV"AY7).G
M4#=+URD:>'9$F,"PX.7C5Q-M7?"?Y@O^#XK3N<G=NFTAQG''?$KEMG3'1%%'
M2)D_, /]O-%?V6SP(_ABZU"^ [<]3P_>%3>X5!]X4AG/@-MBP$+/(A'BK.A[
MEP0L7/WYD&[OD+OX-8EFX47=!84O1UL-5M8-&&0>D.D#,JOR<VAU:W8?<X2-
MDW?LS0O\!ZF4Y1FN&4XUUVE\3_(Q4CTN_OKZN3P;.0P;"3_?[W(<XIF9)/PM
MPVMG#06@1@'VIH5&S$?UZ>!Q*,!X+U((!9C.1Q*C )?>MZZ)Q.4)6IRT/:A3
M @50ID-LH0!&<;__[PBF&$G5+1)  6Y$06LY-[X2*W0H0&'<M1L*4"%)?J+5
M>TU_NP$<H0"QH-/MV_,<A,R6.!I&M@+^H?(?*O\_4SG]^,B64CGLLB0OQ7S#
MA*4/!=!+_JU"S%_,*#LDXDA]?^(7HZS28E.V/-\Z]:3;T20_R&WB]MB(G/F=
MM-\;GXOGRV[^^P[\WO@@[FWP7W5@]/?& WKSZG_? =G?&X].^U]5N?<!X1R=
M<HG<8,\R6X^.MK#TJ9#]G21KFU++58QF(#OD@]Y"Z^?F//:(!U1AS-FM-G=P
M_LYZ\N^J_!E'1"_0K7RO4DU3[9"9FG Q<F_7KZ>Z:HKWAA,(T1\XHI<,?B*%
M0>'H]K;C4$_B[WO*<'M?ZW<TC:C(\U>;$)X#ZWXG1F.R#'QBR+^)/-C^4M=B
MI4O^2AX'4_Z;Z @F5FB',<&.230QD%3V&J"5;#-KJVI'ZFSXPJV)8DU7-=J[
MO_*[X/"G8A3@[WEA_GLJM^[3@SIGWI]EM<_L"YA'7RRR5Q3/VJ=VX^9E0) C
M0'-/^N-8T=9YM\RU"KO1O^>._$/EWY_*T[\ 0K??R3SERXX[TP])'5IL$'7H
MM?<=P4S^-V%E?ZAJ/*UH,!PEL2ZVW'Z%>WNP?";S:*6+N)3H^SB%T"ZY'AU7
ME29Y6_F?NR+Z[S_:K$?*DJU'LD&G8CS*,98M.?TST1TOYMFXUX]&*'?W<H[.
M(^DZLA^T3:DM.J;/#W0_G9=RC%<O)SRO0:A@O?CE)X'"KL4[YUUGE[M02%4&
MV&CU@*.,BKO1L# V2UA;VP %>'>M@F0)T_)JT =5[O+H!(&;O>/H!)1XLI/0
M1GYA*EH_<.XN[#SNFJ-$BK(N*]CPZ8'.G2]K:,["V;)VMY9.MJA<.D75TCS4
M+XLJ!G=11)GT;N0Z?MP2*@_^<U>S^Z@^U07L+:M362MY+D!:+4V9 '@J ^C;
MT?=(7;T="I&5105UG1"8+?H/>HZ@&0J(GPI&-DU-JC(<F084AJ7CZN1Y8 E:
M2F(/3VB]5Q\]'"K.GX$F'0_^(/ZA0@U;R%V3B#'X=94M-<4[IVVL4F#LZ2LQ
M]W<V%@L\FQ0-YC2^7N7EC>='4A5Q]/##V8G\'<@5C*KQ>Z+5@OG1$##W;\N:
M_^\\?TR(+_AC@1=H7/<-W?H/H#_[9*#-3E%>Y+>9ORWRNY'PP9+!/.*JP_/(
M0(&FM0MZ+T_V,<,\IK;SMK,/Q8XD30#)YC22NQD^'=[BYCDZ7")E?9->J1-Q
M%F39GY71ILGPP>^.+(-'\4$@"]26>T]KKB""6G@P;E8T2D1_25@DT7534/N'
MS;@MM(QJ0Q"=GA=M6T,[;$^O+=\![/^B>9+#<NQ@>9RW)89>5<AT:_@=->29
MI%!'/WH7P4?SQ<$C3-,U"'S=<\ZAF5X&ZRSEL\.!HV:JBY^W?\%/#;SH0[KG
ME8(0.2R@M*LO730?%['=?7G+?)G+.X8#5D[IYP]2HJM%PCW-!Z!?W#8=UT2
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MO_C"_X[XKX)0,2LX%%Q4I+_;'5A1NLEU?ZVZXEF&>+?0\;\V(>B_.X$HJWB
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M+,WDBQ5%]E>R5!75KG7T=AL3+W+/XP,SN"WIV)*0-E1_/( K.4,WQSI<3"'
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MVPD Q8)*VWM;S. C7U3:V.P#>25'3*25,SLN?Z5!U8RVE2N?M/<*7A%/XS/
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M#JERX=B%ME^:"1608/CD(H+! ]#7M22.Y)S_4[=HWK7$2V9+>C8T<71C9\=
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MXA]5;9'.]LZ,"@**BJ-<Y)&]I.D2&AB_#VD3$].&&QXVH:5CTW9BW5/VWYL
M2_01]*\^M"$NB'-GV6:XV7#$<^NN#9.Q"\>0WR:^+6]T"?+T,>M!SZH/SY M
M2%G6/\]2\]AY?H)LS* '/=7"[HD5XD@+R24.$Y+OU06L<^<A8"WQ7/[L[V6@
MVH/[E5R]G\K+E:]$T_?T-9MGK6WHQ"*I:B1=YV6>/V)$Y+E../A],:D(N2 >
M:X,4]Y'+=)&;E&-1H(&>/.W=HI3'5H".C$3;@)^KDX7?ZEW;37/8&XS<T#.9
MO8DH "F6Q;/,?$&,"\2YNK--ZG\[W5>[K/WS7=#7.P^3FL(H5  [W'D,(,OO
MEO&*"=X(*P^78.Q8["-H[FHC+<^5%PYR7N99<P<[FF+AM!8^+%$DP\Y)X">>
M(9\U=]?NB!@S3%:$'+#(6!#K!G6.EF8[P3<7:&JT+JSO2FN)Z'V7IMG;(Y_U
M"GGS(3KY+FGP/=$<I0QR<XC4)]\8OK-A8&*+\K4+YEP7H2#[#VMRC$/_1?+U
MOR1@'[ $[E($8\[,*JO6[H4?D;;@" !1.;J_"P'NK)$D +C4,!1GS;W7"( U
MEUJ#7(.7J-XC*;L .);3[=S@5BU=!ZSO@!=VX<>KLSTU"PO 9A8EU';<=[VU
MOHF?AW%=-K>J%%]19TLR:3NV>,BLX'T@!( ^T]%H@,\0L:N_UWT1);Q:VJ++
M$6-M36PH2/&U2LQ+M_*<(]%HNKL//J;39?=M@*F<I7<":9-OHFMKTQ>@9WN:
M556:)N7A;#S5VEXX67R$-+-Q!X:L36JE69 2!V\J.P8$*T\TE'(D2K\G=;(V
MY^K3-&ST],.98FY"T69%-)E#RQ)ENHD?5JI)[U^;[F@X%K*?TC2+G,,L $-G
M9,JE>A!I 8W"WCPK'2(FW$UH!YG<-=2'QF=)CRL$'FMHA,3;Q>^&+MDE*#N!
M5C2_#^G:;JN)E>8EIV2O@BE\N*P,0&B#M"SH:L=IN;%P&0P,-M%X#)"\[G'=
MPW&P0"PPQ^L))N4=_OE7;5S:TWZS'R.<N\8V'.DBBJ[<*W ].V:B7H2Y%\GP
M395"C*N_@ !B8< IH9>37$,F8D?@YQ>!^WPJ^5<Z%BE4ZG%)J$%T9G,R/>9B
M;+GGO"HVI1,JXZ)0'5&@WU]&9/!&1)(DS/-YYKM& L!2LZ'*:@#)<UA:(X#@
M/2GK7R^I_:Q2"LEM+1"MFK7%3F:OR7+C?//UW#;.*(%7=+0AV?)VV(1JA'JB
M_-7$UV\2HQS.W982&73R11S"/7]MALU?<X#%>8>B4#5!YAZ#%]ZV[=/W%?9L
M^HY-QU[FPX^S)Q+83Y@7KFY!JAO4GC8K<<_8VH&'7?!9SB2TZQDGD*:.S<IE
M:UF[M+.Q*/NBS@?Q-Y[[I["H,@IR")G8YFCUT\2CTFH'J_73I(ER549%A/(+
M2(*[,K2#$4AQQNOFWP*D*@526!WS,?+=T#G-YN\PJ]#[C/6WF72G2+0A>2.M
ME:<5?.[1/0UO 6+)(*>79FHS:O3FDWB<+:6$U#4^<IA.Y]9N]]3PI7-W?9GI
M_OI+;COI![]3VI>W.:$6[%^:/H6J4C**E@%ZKWZ-\G[;D6\.P<6E6L5_&T2,
M:L):3+3"U&BQ8%[7:0'=&S> FK?L]5^Z]V+UCD>#ZMBT)V;4,J<A,).(:6B[
M^CS\+O8'6_)U;H;5(2U_M07]YRT&#"->#VFVSF)H4U@R/O=/VEV/,W*2>'*3
M1%(OY_KU-TTD5%>M#&Y5E1=BM/"W)UIF"M,>VIATNXWNZA^)E.0)B#_U:M5[
M0//YVN9)@](;/L\8HUE<F](  5 J.^BZ!#?-4W,]R935CMYV8EZ9O+^C%]>8
M<"0H1JXMGV?I$?:9BE,5)GBC*Z^#!"ED9LDNUYEW :7,QM-LS/D#Y$X B"F=
M55@B1R*T#Q+TC7KV-&H'40G>TQ$AO:PC3!+OM:*$'(C6M& AZ%[\IP(F>.5K
M B!UYD>^&(P+@RVP*]@XC'^Y+Z'9E3;6X($._,:3Z? @\V9L]$_-J8*W%?.?
M6;_I->#>90KL3$U[557T0]J1&V&R=K6'DANC$S5+!VL9%9&MY1YU,FJN[?J4
M=NQDV-?VY4"3GB;*LM.5>*WL:>3]YEUXE]T)T)@ &+][O:U8W8 FQVU""=.2
MJS.C3#, ZQ]7M;-'=-J2<$+XRRW7DS6:Y8],C*,_66_?>N[D;0"YX24?UKFG
M65<\A!H58'T4W7SA\G+I@WENS6ZNZ]=)S"_=KKC0\EF<C";<-;6&A]Q3.Z7E
M\(HCPG+"K)2UQ#AH5AW#/+(YTO@LEW',W0?J'X!'1*F*;XW3,VI!/&'7XM<W
M&--FN()B6^[ QF5[RK9<[EC@\S9?E_:079!OO0P 7 PW/K> ;OS%_3,,8A]*
M16^G3H#(''..KO$;FUW->"#T/4JNGHLK^7TI]U<*X6!4?B;*LX!L:FVB+BTO
M]-YID*IGI%50[(# .(-*:XC*C] S,R.7Y(QB$.6<C:%R=!-6JL3@UA<G\\BT
M6(E!G_KNPJ$(.>C[?'ITDZ1=POUI@SC2X!)IA.E^@#-"5E_G"KDQRY"-5(2(
M([VT'VDI[)ETLB'JE-C0;X0 4"PM&BK9N5Z6=.^&+BQ*5UJ>S9[J 79[\]F%
MAIJ!MH\-&YHUTJA3E6TX,21KU4%'/-A4K*9Q;2ZB33"&BO>;DNUUY@N2K0Z7
M8/TYH=A2\XP92VRYJ+OC;&??I,"(]!2;) ,Q\9(B:"&=R+$C#4T7L%_AQ-3.
MAO3=/T$\$RO[A#5#&2>CDKD@)<2TXH#+[:^ 8?.EUGC!; M#=,#,^)INZ:Z.
M@4&7,\Q=+'ZZ;<7_J$Y)VV5;<@(106\_YJ$?>EJ6:14G[DJI/RGKHD;LK]C0
MT,#,*@_TY4@_+24 DK"P %O0%T8&KSCRPK87UDZOD^67(_3V5,,OPS2+.K($
MXD=G33&/XG/&^ K]*M^E[@Y_*KYX+;W\;8O/BG'0SKXR5[1:E.L W>.*F,7H
MS:C'OH'LJ.\6N]\2LAML:]6LU)]0W*Y VV9F63'6SL2A*FL$RCWTAR1&D%;^
M[4,")GJ*[9&5>A^J12H4;_LI<5'"&XD+UNHH,'3^ UTG&JJKJ97!+]R-;G9Q
M+DU?:XZ,>NL5DF9;3_=>$BO%399L.=]+/+ON8=?L:).IQ+]=0&(_+KO:I%IV
M$6#+M=2TPE3XH;?6XY%<WF.F'0!19O]?_)SW_RG<:II:=?=3KGDIN^<J4:T#
M)R=%R6X"(Q?O%!BXVLXF?Z#?,4@QX,70H6R1!6[GNN-YH1_#5KY7;5K/U:XR
ML><1]E.L7PI@=T.OS+O;BZB02\^J8K76$"GM"RV260;QU15(=%\<</]B, %P
M@8( N*F$O\?1=DID1 #4?R  FD?%"("KYBV&>PO ,Q*NO^0O_5MM=,);Z_8.
M$'^% /BRY/G$+F6:  "LP5'?!,"K9'1G), SSG"<A6KX\846 N =*0$0F \[
MH^X-0JZT@O&7(9BTWU36*RG<"( Y"+YIPMCK; ='JDH D%^Q)P#DM)'H6P0
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MW]ZK4N$F_M]NZP61?AV;P(%5@YNVL$D,1BUY,Q8V7=$]$ -'Z/F T\'WN@@
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MC%_R;0E2W1OP=._L<M7_6%HM*F\6WU#KF)[>*EM^@=A<,.T_)XXVX]\=GW)
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M#0+@(O4,XG QFP"8>DL S.2/$ !:F$DC&(XX8777$YUEB8A#37_Z$6TMO4L
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MN@E.&@JF.C\#K/&;R3=@72XU6K>JB:+-O!H#$S XN"':?/"5M]E.BRZHAI\
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M$P V%:<J]C9LRCR\7!^&=@-NEA@]@#7$;2%PAZ=[Q6NJO^&Y_[;URQ. ?WO
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MC??5TT&:_UN/+Z-/5Y4=UJ 8NO,T?%V6K1@K:L-TQ>[-_I C--PCX]'"W*2
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MQ%;6%Q#*QT=KLPK);K[^?D,:%,C.]8T @%:@R\!J0]&;R#T8ZRVOBW_E;G"
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M_8,Y7*GK;[@?:>N"M%WS.3U6]C87=X2R,UCA$-&_I-S4\]\QW-_2-%;:VNS
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MA+X9^2L0S1(U3F1K=XAVW[<;[(2LB%^AA]MQ^D(SXN+F>03%WY_G&WGR34;
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MSQA-W_FHZ>@@BZ 9>D./,@'VL-=O@HK>D[_\?,A^)IU>-I/1+2+?:5Q(9S3
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M3LDVEO.UQN%S/!.M:HIXKQ#NE.KN]T2-YJ;0+':7GS0OY9F_^BO5[4MU(=N
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MED8>]9JG4 U,-E#'Q'X'BJ.,YZ!/FK8P\:;H0CI;-KLA*4<.2#PE]4=['I)
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MO7B,2FC^_I*2_*Y(E%TFYUF +Z 38.5P CUMF2-PV9*FNP8T&2S@UHOC3H5
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M\^'YONLJ3,Y'ZAKP-+6BE$"ZOCY8?H>:BXG40@PO!XOJB/#.A?68X*/(N6M
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MN9_LSE!HZ)HAGMLNH+@*8G@^]>-OMAOO[R;D59B2P2N#E]L(GNS)3/1[6U8
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M[%&;->;$Z/M@2GF+UY&/.QCCX9H:XYE7R#KB+;<2-)3KG/VHGN6!^<OJ*HO
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M-NH#PCG%@K+(ZH1I7+&GQNS;T.@F%KU)=0)/1MRKNHB,_$)8K""3G.8Q3J;
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M1*:0 ,-(:-,CBM- ,!5AJ_(!EN--S1C9Y'[LR=S* -E(#HSHKFDSW;AW<]4
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M?5%9RA&D42 @BK, DLQ$!R@>HYA&68*%BW%]><BI6=55 E[92L"C>PEX996
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MAHF *DLQ1 1E$..(PD"FB8Q5@BF/GNGT<%_2J9'K[?U]426I@+R1$WPU@MZ
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MW[)R55"^FC$12,H8@US2!"))%<0J"F :<)5E642)7:WQ2P--C=,:.4W(=5U
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M@.]$!_-<2?#SWR4MRE]N@-SIW6.#-?)+X[#_FNZK,.(:>FW/MQ82)[K-;-$
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M*T]:&+M6Y247S]2FO'AI/ZK[J,O->BXWS2-;/>I"48GMO,<.]@P0S0Q@F.5
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M-(*_3P=A"0&W]=PYXN47I[-G_W('C]_YPD6\MV>"BA84*0($Y P0#!'@*33
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MU! A,L"4T(#HW*[&M*:@H#HW@DA"4=_2J4T305.4T8JEMG5P%J$5ASJP]&.
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M+!T\J,?6Z\=Y^8_2+N7_:GU<;_A\Z0(\:UT=)ZM3J>K,6.&(2RF0ZTJ^6U+
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M$M(WGN<; R$^]"E$ _:G&NSW6[!KXY/[+=B/'F"'GP[T0"W6'GY(T^/NM/<
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MK&U@L$^BXH9N[]:R+Q_63I]N\_S!CJ'-JV5UOO_-O>N5^M(L530K.,6 (HX
ML9,(P"A&(--:()Q#1C/4K^Y+=\-3FR.TUMXEE;T5^V\M;H3)>I=[N=('G@NJ
M 9 =F*EO _6&,B]^"$6O\W*EV1<J].('QN5*+Y[W]SWID6LG#O=:UW_?+[>B
M<4T^ZO9 DY-,9Q!+('*H 2&& I9C^[W/"#)2BYRRH.6/?]-3(ZM?O[@HKM+M
M0NQD8GE9ZF;:NFB4]KQK)?3H#=]SI"$P'OR(J38V^:DU^V<']4["LC%]D./G
M<,2B'5!Y-SSRV54H(*?'6L%/Z$=F'^WB<3V7&ZU^Y>47%U=C_W)T^=TN1Y8N
MP_[<?VTR=K2$BHH\!1EF$) T5X";S!(=(MJ1F^$X:,O[%F,F1WC6R%KWS/VP
M9VX8O=W4/WZ$-Q;J U/@1<"3WU^OOMJE3$3&BP%9) Z\R91163$&:,<\&>69
M/86FJJCS[>2"I33CR.0 Z=1)6Z26"PEF0.=,T,QPD=&@9*S#QT^-W=K:ESVC
M (^P\^.I_H@,?>KO#4:X -)9GV/I%AT^?%RYH;..G:@$G;^J1VJ&70G**HFD
M/D)K/I"%1K)0!0<J$QD@>:& *S4 ,,XQY';D(N6UE72YB:D-W*V1S>EP0%+
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M3.?,WU\FG?U]S^SNN@J''=U&EZ6=6/+%6ZVW=6!XFC$ME0$%=JD3C"! F5$
M&[N($JC@61Y4%Z.[N:D-S+9&S+<]<Q.C@U.PNS'VFS;$0V[@\=R"MF]IXDR]
MNUJL*#Q%V@N46%G0W8V-F^CLY?A)+K/?73=J8K^;+_6]_;&<95@6F6 29!S9
M=8G *6 ZST$F["\P3"4I@M8EITU,C3&V%B:_.QN3RLC0#*A3(#T/V&Z"9^@C
ML#!D^DM=GS@?6]]ZU\#+B%J?.'A1R?KTRGY#^S>]M)/]Q:NE>J6^SI?SL@IB
M^*[?_' G.WHF.!9$&&IGYE@#DNL4")-1H#)D*$]YS@L6,LZOM#>U0=^86\4N
M\0.#PP;^-9C]6" B> -3PCYNA[8FC;'QZ,$3E4A<<:VU48G#T_5C%O&]K>>Z
MHRSU9K=UEE-E.$$I2+., +OLYX!!HH!FF#&80:U-D"#]X>.G1ABU=8&+B$/
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MUU?=[K5?QVG+@T79# K_\O,=&;ZA;QSR7)\LWGR%F;Y8+6;37/LR/ ^SVG*
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MM_Y"P<MU,4Z2E,;D^M SU:!#VLH-<6B9884GPR6V]ANW(&N<=B[# :VU)CH
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M2I<I05R0WY2##$YGAK'Y<Z8#[BX',Y9=H["!ZCH X$4_VBK<BPZC/B5I;8[
M=&VUKHN 4.JX7*V%]T(J5UH?^O>0,6XY7-?0.U1IO>#N'OE<)$LN$R@3SI3V
MVBEPR9#[P^M3(*N(Q>(3"XE$Q5L?RUL3-V[17/\8;:[@#I![-S5\R>5Y%N12
M?B5X;Y6@LX#5Q[')U/1'K<I7*CL1L[&I=?'&]M2-:U^/' <-I+0NX?A^B5_#
M-+\\I^=6[_EGJQ6N5Q,9;,J:"<B;$4ZJ9 @L*$#C%.=)91%:6]7]*!T[T3D,
M;GX(S^9*/+1F;BC;>>'*G"ZK/LX9TR87G@,#J:.B@\<[<(7BN:*"\$9'*9MW
MK-J2M-Z>!1T)CH>K:?R:S?.Y'+=9>U/_\V8:XG16KUY9#(HQ+8 703Y/*20R
M)&>:R]I3GY4<RJW0^\$Q*(^OU-MSGZ9(:B_K+H_:9RDM3LG]?A^^;]ZC1R<9
MN:L&K"$I*:T*^((97+ Q8/*2-4\A_I"HWA[V',EB':*:7K&V/"4ZSG=/]8S/
MO8%+B5[[V<2(.E7(<5"AE-KN(D!,%,6%J(TPLKC(6M]B'TIS;^]\CH?4H13;
M 9"W#_0F/"27+&-0^Z"3.VM4[4AF02NI57)<^.9]W[:G;EPS>OQ+\2&4UL&4
MC <X.RMHN5^0F0OEI%)U<&FJG6'C>3%>L,RB1>%SZ[+:W:D<.R[IH!ZHE0X[
M,)KDM%R\&DK_=3I=(O%*>V_]_?TL4/0US[5.=#/GO6YSRU)MT& "G0D:)?DU
MM-<Y(@^2BZR:#Y7=GKHN*XF:X61Q%*5UD;BYP]NS;V$ZJXYU?=$99GCU,N<E
MQO6$!<D2XQZXKX=/T70^%!V@H-<Y,$[G4NL:\AU)[+(,Z&C0;*B^/O"Y7"3$
MO'I%DJ[\_!K6E9_OM.M>+&8SW)P^=?C)8KDF,WUR=6"1!V.EU%J2.-'6QH">
MMB7*>H>:<C267.W0>C;( >1V>6TS&&Z/I-8.COSM)3O1Y%-GJP+ARI%$-9TC
MGC@%5EQ.)>64;>NNM-M3UV6<-!0^!U):OW'2J^D\S-/]@@RL'A266-(E@B(?
M!Z(3%K*RVN@0@C2MDY^[4SEVUKV#.*F5#CLPFM?/A]JWB?C"=^5:K_L)BT:6
MVA<GI!Q Q2C.LB 6L^(LRNA5<T?T1T1U&14U0\4C1_CA*NH!<^>^],X=;H03
M.81H(54!*B,81$_'@(V>"2DL<M&ZK')?6KL,C@9#Z#$4VLGU]P6OE:G3Z?KJ
M*E9KE)8G21+C]2H_<"#N$KDGS'GAF8N&WP3G ]?>#ZW09=S2&E+M9#P^7G87
MW80,N24_MH#D&<F5+@F"E1J$<%QQYUANWMMR>^JZ#$R&LFD#*:V#P*2R5?^_
M)E._A=F9X2:)31.AOO[@V3S?_,:UWSQK%'3W"C;-3JNI_^6/]"7,/^,'VD&_
ME(*D!%0R%\89R!0E[=D4P%O4X)*2''V11;9.#AV7P['+0XX9$'6,G:>^LR;:
M!E68EJ"39_6Z.4 ,SH%S*.F4TU(WOR4]B."QBTV>#.YWTFPWS> /8[EH[9.3
M')#5_CLF.PC9DJ?F=&#&&QM*ZPX,PX-YP!:S3P?,NVBVDQ9=%V^[+I/*\WSI
MQVT>?%V*56H665$>G(VT4Z.4X)2A/VPJTK)LI6_];'AKXL;N^GK4Q.L@&NL@
M]W4NM<UKE#Q=GY(67Y^]"<C/3]=O%^O_Q'7M;DNQ2]$"25PVZ4)\*3HS<K$0
MF#6B<A5*Z^K3;6D;.?LZ##3NV,@!]-0!_CY,/W]9ORL4S&Y>H+R+9Y/^7L\O
MO.]7BVM%LS<?&QB9*,R-&72V=<"[%Q 4<M \N<"ELBXWG[>X/[DC9V"/@M)C
M:;,9<)MW1WRW_!SF%PU?;E"[7=O#&_^^43_#AVEJU*CP_&5&[=N\F$W3]927
M)Z<,96+DDV'-1=6&FMEIX(8)"I^3H!\VWJ,/4W.HL7I^NB(XKU8O<966TZ_G
MW6J>A]5T]:Z\OZ:A3R38Y[-Z%>9E9-IK 3HF2_P+ YYY0K7G13L3I/6M^=^=
MRI$[$[5!SVU;-+"RGH8)NAI1\'I>%LN3S3=?UG&ZLT.MTV,?/8#AVIJ3X6T:
MBJ!8;41OL)Y4BF4(%B5H9-QD850R \P0'\BFW9ZM?&UH]TLLM-1Z$H)+7NH
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M581H@P'C0@"E&8=0B)E$48:*L1CI6Y=IW*1@Y![%P]B; X3< 40^XN<:@7[
MK[4K_$/&,J2BC7$(C%=CJ;(%,I$6R'2$XH7C*)LW6-^&L)$;"@\#J/8JZ0!G
M+Q9D5^?KY=FX7K*U+XB&Z;I^-1')!86>0W*Z]AH3&0*OYS'+6DL7K'/-R\<>
M)F?<2L>!,-5*_#T@Z:QF[4<U;;?+D3?;9\)Y*<B+!T[!,*A84KV$0I ED..7
M7)3-YX,?0N^XA8I#8?%8"NP K*_"=+F9/?ZNG%>$U"LVXO3TY!I3MCC)-'/
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M[N5J'V?N #KL"9GG<MP$F'?Y.^_AI WGRJ$'&[T"I;RF@R(E8!B5R=H5UWQ
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MZZ)><F/\D"C=U.O&[ 344:D0<LTO)G)M2$Y2N^:5=O>3LA4X])_3>VBII0[
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MJ0^XB33OZZU8@N&\\ 3&,[(5EFL((CA@TF8NDZ3CI[4QWHZR@U\PGGXE=5?
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MRTHHST.H5[7!^@B**P$AD+TH/NAB-=K$6T_=:<O!N%>D7>R(HP.AOVT0;QN
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M:( BNRPAUD%(017+F=72YQ9!\?U/[0@F+06[;L+EJ1V<9Y^XM#32)%& 1<%
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MT='1[>YL<:*QCHU"V,0#QJ?5K/Z@<\[Z=&U_?EY?[+Y4?XXOO/7>Q<2@%J.
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M0-,"L9G8]X/3$3+H %#DD2$=X.-/J_P*O^"G]1^5IIU7]_^X[4%V0<J@:PU
M3D229AR<$PJ"(Z*BMQB:ETKO<:PNP74,"-;#2J0#D/V"*[P(GXBBG_+GY6I9
M79+-\@O>)TJ%Q+@3!= 4BEX=!HB&R$,9$I+!=[FT3F_L=;!I6]&& UI[J70
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M,TS5ODCWV6=QAU.<#HW 02C^X3+ +[,O"6%R=!&2-MN](A$\4^0*\23K&LO
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MXX=?)['[1OVK-D7_[7_^"U!+ P04    " !7/@A54^G=@]@'  "K*0  %@
M &MR>7,M,C R,C V,S!E>#,Q,2YH=&WM6FU3&SD2_GZ_0FOJLJ3*+V,;!S"$
M*C!.Q74YR()SV?UTI9G1V"K&HUE)8^/[]?>T-,8&PX;;)(OADJJ8&4G=ZE8_
M\W1K-(<_G9[WAK]][+.QG:3LXZ>3#X,>J]0:C<_M7J-Q.CQE[X?__,!VZD&3
M#37/C+1293QM-/IG%5896YMW&XW9;%:?M>M*CQK#BP:IVFFD2AE1CVU<.3JD
M%OP*'A_][?"G6HV=JJB8B,RR2 MN1<P*([,1^QP+<\5JM7)43^5S+4=CRUI!
MJ\4^*WTEI]SW6VE3<;30<]CP]X<--\EAJ.+YT6$LITS&;RMRK],,PW80=7BR
MOY.$^WO)?CODT5[TIAGP=M3Z=Q-&-C#<RQ@[3\7;RD1FM;&@^;L[K?IN)[<'
M,QG;<;<9!'^ON*%'AXG*+.;3D/>77LV:,BNN;8VG<I1UG4L5+[KHCE2J='<K
M</\.J*>6\(E,Y]V?AW(B##L3,W:A)CS[N6H0AIH16B9^H)'_$; )YKG;66DR
M]*0R$PL7FBTRNG\]EJ&TK-VL-V];O.HXUR/X;E4.*:A=L3W"8@O]W8W?O=?X
M7O]B.'@WZ!T/!^=G[/P=Z[T?]-^Q_J_]WJ?AX%]]-*&W?_&@8YOBR,=/%Y>?
MCL^&;'C.+OL]YTX[:)%+P_=]=GE\<7)\UK^LG?_ZH?\;.^X-J:<5!*W'ANR)
MT#6HLG]H:<;LLNXO,IY5622TE<F<V3&WK[8Z>P>/\6(?$^8\CD$+M50DMMM^
MLT"BS&($KUNCEB=RM%E?^/#7SWY[65I[]0XMPX"-^50P+:92S$"H=BP-^Z7@
M&BA/Y^Q"Y$I;IC+V3NG)JZWFF^"@&=1^\5<J0;CFQO*4G4AE132NLD$6U1&M
M_1<0K=;&1>N$&\0(T9C,V56F9JF(1Z+J@Z9]J&(%$S*%%(D9N,P8S^:LR*PN
M!#Q TG3Y$Y'C;(([+1&\A$=HTDQ-0/%6^7%K S(1"6.XGM.0";\2F'=%IT%;
M#&,P9>J2+^:@ 9'42+88ED$<EL1"L]E81F-F"OI9RL^$%J42<F B38JL3 E^
M)NT8#II<1,Y TIO#-!7#S2G$8A;.5Y?AA2"P_7P0*%!VT8)1=R)!X!$!9QG=
M*H (00S4*_TR2\ KG(I#7$=I$4,<"%H)917HD\1%.0! V"5,I^D2G"4NC#-B
MJ1KXCUW56:4118H!0*0";-QTQMD3<62=)%4SLX"K%B-I+$I6RS@U>KMA974%
M=69AS)JU+P1X.QL'O.&MV+S:VFLU=P],":BR5""J4$DB<;MM7KO #1C7PD$$
M(9=A*BB43 "788I"@R1HV 1,26Q)][$T4:I, 3GB4*U2CY5<JTC$:#9L&]"(
M!;#FX]^_CL8\&PEV#'JZ*%)ARDS9YK5F9UN\]K=04K9W8M]>=I!)=[&'"2DS
M__G"9[>U07CBFX.G_7JP2^MP*@P*>@30I:$O![U*&3+BA7F\"*6J4  IY4P^
M^:E"0P&(9"J-HR>, F^2'BIUE\2V2HY:I+@ .LOLMX1*M21.ZI0@.=AB5"IC
MMS\V16AD++F6Y(#T.=H1=T::"D-YTSU#QB591V;8@,,@[(R=4(Y:4$9%RHF#
MX98S8IE_(>&S^6H1@JM0T$#0).1%_.=I<:-@'&X.C$M:[$]Y6KA04TQ$DB 3
MRJG(4*FM9[0;UGP$=/WM_4G.01B"@)WQJ314A7W8@L<\7/QFM* Z(?ERC<?"
M12WB'D?A5P+V.+#1!,\?<-'F .Z&-WTPUT%!&XTR#[J>>Y$GZ?5)YLLS @*C
MT*Y4;5Z7YQAPH8JB0E/H5XCG'JT392S:Z>4,=)D(BG[W>UBV_8!( @QC4W%G
M=&DXRD+A]DBT?<J*&[M>>ZO&W-RP-$B1.\R+V&4(MQ[<J P%QAP[H2N1EANF
M.^.K7[U$7X?SC:HW.YN#\Z^M-]W[E'CQD%27+$6DN0K4)6$1U!X=]>IZ"7!C
M'4<98)7V[$IC7 -43K"SMT+\04H(%=>.=V,)^YR2;< 9#&R(X?&7BI'%,RA^
M+R3,=\];D45N0_7Z1ZWZO3CW&/M=JB$EL$:[ ]I[1%( &66FOJD99X)?4>H5
M9L%EOOITKW<6>]__"6]E>>>W4?<0&X\A:,0-KSV(S5"FTCH1 $QI/!HN_QLD
M?U-,  ^LDG.FS"?WOB5X0;E]\XK)8V3P1(,SJ@BZ<$P'V+AW<26^JCX!RFRJ
MTJF@+)CQ4?E*49?D*"9YJN8"O;.Q\G3(;Z$7:/LF)4+]4<<:.R[ M-\7B^X0
MZ!.ZAJ5.>6Y$=W%Q -K.4S[ORLPMF!,Z*)6%REHUZ=)QWI3H'V5#>2;D .6[
MRY.^_?WZ;K!+AWU6XW^\F+@\!ZR[<\"&C=?[.NUZ$'0>[ [JS0?[_DCM]]&Z
M$]3?[#_<O:JVX1;"+P:6V^0\>UMI5Q8")1R[K?R:-6\?'1)"UU9<Y:L'J7_A
ML^..<$_Q-+ADQXZ+46&L?XNS5W7GS7<.=,N%^58^/X6[)_/;F?V;N>2?F2?R
MZM76#MC&_:Z?/M[R]7M@]VD\)IB^N# ^TJF2]%U.R&$FO2-C"_N>D\<_P/KR
MP?J<G/JHL<.@:MH5[[VQ% GK7XNHH-> [-SOCW]@]+F$\__%*0?"ABOQO[B+
MK#SXP=Z*R)UO_G+E/WKL^J.;J5C["G"9F=S.(EB*\!#IJ;#K(E_X<+#\]9\Q
MN@\JC_X+4$L#!!0    ( %<^"%4G2\80QP<  (8I   6    :W)Y<RTR,#(R
M,#8S,&5X,S$R+FAT;>U:;6_;.!+^?K^"Z^"Z*> 7^:V)G32 X[A78WM)-W71
MVT\'6J0L(I*H)2F[OE]_#TDY=N)DF]NV&R?7 G4DD3.<X3Q\9BCJ^*>SB^'D
MM_<C$ILT(>\_GKX;#TFEUFA\:@\;C;/)&7D[^><[TJD'33)1--/"")G1I-$8
MG5=()38F[S<:B\6BOFC7I9HU)I<-JZK32*34O,X,JYP<VR?XY92=_.WXIUJ-
MG,FP2'EF2*@X-9R10HML1CXQKJ](K5;V&LI\J<0L-J05M%KDDU178DY]NQ$F
MX2<K/<<-?W_<<(,<3R5;GAPS,2>"O:Z(SF&OQU@S.&@&K-,^;![2+NL=='M=
M]BIH1]W@WTT8V4!W+Z/-,N&O*ZG(:C&WX_<[K?I!-S='"\%,W&\&P=\KKNO)
M<20S@_$4Y/VE5[.ES/#/ID83,<OZSJ6*%UTUAS*1JK\7N']'MJ46T50DR_[/
M$Y%R3<[Y@ES*E&8_5S7"4--<B<AWU.(_'#;!/'>[*$V&GD1D?.5"LV6-'GV.
MQ508TF[66S<MWG2<JAE\-S*'%-1NV!YBLKGZ[L8?W&G\<'0Y&;\9#P>3\<4Y
MN7A#AF_'HS=D,!Q>?#R?C,__@6=H'EW>Z]FN>/+^X^6'CX/S"9E<D ^CH?.G
M';2L3Y.W(_)A<'DZ.!]]J%W\Z]WH-S@XL2VM('APS!X)7N,J^86:6"TS,JA[
MA;)*0JZ,B);$Q-2\V.L>'CW$BQX&S"ECX(5:PB/3;[]:05%D#,'KU^R31W*T
M65_Y\->/?G-:6H?UKIV&,8GIG!/%YX(OP*@F%IK\6E %E"=+<LESJ0R1&7DC
M5?IBK_DJ.&H&M5_]E8S(+VJI#4W(J9"&AW&5C+.PCFCUGD&T6CL7K5.J$2-$
M(UV2JTPN$LYFO.J#IGRHF(0)F42.Q A49(1F2U)D1A4<'B!KN@2*R%&2XDX)
M!"^B(1XI(E-PO)&^WU:'C(=<:ZJ6MDM*KSC&W="I\8S!& R9N.R+,6R'4"AD
M6W3+( Y+&%=D$8LP)KJP/VOY!5>\5&(=2(5.D)9MAE\($\-!G?/0&6CUYC!-
M,K@YAQ@CT^7F-#P3!+:?#@(YZBX[8;8Y$AFB;8&SCFX50(0@.JJ-=I%%X!5J
MJT-<ATG!( X$;82R"O0)RT4Y &"Q:S&=)&MPEKC0SHBU:N"?N;*S:GL4"3H
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M!&L1.D5&*LRVR!>^"2Q__1>*[EO)D_\"4$L#!!0    ( %<^"%7W>TW@0 4
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M,#(R,#8S,%]D968N>&UL4$L! A0#%     @ 5CX(59:>5Q<OD0( OG\# !0
M             ( !*>(! &MR>7,M,C R,C V,S!?9S$N:G!G4$L! A0#%
M  @ 5CX(5:Q+YKD<J@  (3D' !4              ( !BG,$ &MR>7,M,C R
M,C V,S!?;&%B+GAM;%!+ 0(4 Q0    ( %8^"%4+6>/\V6$  $F !  5
M          "  =D=!0!K<GES+3(P,C(P-C,P7W!R92YX;6Q02P$"% ,4
M" !7/@A54^G=@]@'  "K*0  %@              @ 'E?P4 :W)Y<RTR,#(R
M,#8S,&5X,S$Q+FAT;5!+ 0(4 Q0    ( %<^"%4G2\80QP<  (8I   6
M          "  ?&'!0!K<GES+3(P,C(P-C,P97@S,3(N:'1M4$L! A0#%
M  @ 5SX(5?=[3>! !0  @RL  !8              ( ![(\% &MR>7,M,C R
D,C V,S!E>#,R,2YH=&U02P4&      H "@"8 @  8)4%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
